<SEC-DOCUMENT>0001731122-23-000152.txt : 20230207
<SEC-HEADER>0001731122-23-000152.hdr.sgml : 20230207
<ACCEPTANCE-DATETIME>20230207171105
ACCESSION NUMBER:		0001731122-23-000152
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		47
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230207
DATE AS OF CHANGE:		20230207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		23596033

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e4385_10-q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:avxl="http://anavex.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2022_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_avxl_anavex.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20221001_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-09-30" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0150" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0194" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0204" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-01to2022-12-31" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-10-01to2022-12-31" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-10-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_MichaelJFoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_AnavexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_AnavexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b>&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20221001__20221231_zgYoReVU9qR7"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_906_edei--DocumentQuarterlyReport_c20221001__20221231_zLrSz7uH9dn3"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></b></span><b>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_90A_edei--DocumentPeriodEndDate_c20221001__20221231_zybk4ytvhkF1"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31,
2022</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_908_edei--DocumentTransitionReport_c20221001__20221231_z7lsA00yLlWc"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span><b>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from _____to _____</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <span style="text-decoration: underline"><span id="xdx_90A_edei--EntityFileNumber_c20221001__20221231_zKWbORxJdZ08"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityRegistrantName_c20221001__20221231_zWzbbPkpjlW7"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 50%"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20221001__20221231_zUjCHNeeuMfg"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20221001__20221231_ziZsPqeqmLd4"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">incorporation or organization)</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityAddressAddressLine1_c20221001__20221231" title="Entity Address, Address Line One"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20221001__20221231" title="Entity Address, Address Line Two"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20221001__20221231" title="Entity Address, City or Town"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20221001__20221231" title="Entity Address, State or Province"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressCountry_c20221001__20221231" title="Entity Address, Country"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A
<span id="xdx_90F_edei--EntityAddressPostalZipCode_c20221001__20221231" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;(Address of principal executive offices) (Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">1-<span id="xdx_902_edei--CityAreaCode_c20221001__20221231_zCBHWifJ5STk"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_907_edei--LocalPhoneNumber_c20221001__20221231_z7jMU5RRPo46"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Registrant&#8217;s telephone number,
including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities Registered Pursuant to Section&#160;12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Title of Each Class</span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Trading Symbol</span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Name of Each Exchange on Which Registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20221001__20221231_zkGAX73dYQn4"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20221001__20221231_zNOurjCq77a5"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 34%; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--SecurityExchangeName_c20221001__20221231_zOBZGo36oku5"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9746;&#160;<b><span id="xdx_908_edei--EntityCurrentReportingStatus_c20221001__20221231_zoAJ5HMAzTke"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9744;
No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9746;
<b><span id="xdx_902_edei--EntityInteractiveDataCurrent_c20221001__20221231_zeYfdXefVM0e"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26%; text-align: justify"><span style="font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20221001__20221231_zknF22RENKb9"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></span></span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</span></td>
    <td style="width: 44%; text-align: justify">&#160;</td>
    <td style="width: 26%; text-align: justify"><span style="font-size: 10pt">Accelerated filer</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Non-accelerated filer</span></td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Smaller reporting company</span></td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_90C_edei--EntitySmallBusiness_c20221001__20221231_zjaYpNtgIcsh"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntitySmallBusiness">&#9744;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Emerging growth company</span></td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20221001__20221231_zkqMLEzVm284"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b>&#9744;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> <span id="xdx_906_edei--EntityShellCompany_c20221001__20221231" title="Entity Shell Company"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding of each
of the issuer&#8217;s classes of common stock, as of the latest practicable date: <span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_c20230207_zO215wAXtaV6" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-02-07" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,032,135</ix:nonFraction></span> shares of common stock outstanding as of
February 7, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase">
    <td style="width: 92%; text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><a href="#a_001"><b>PART I &#8211; FINANCIAL INFORMATION</b></a></td>
    <td style="width: 8%; text-align: right; padding-top: 0in; padding-bottom: 0pt">f-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_002"><b>ITEM 1. FINANCIAL STATEMENTS</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">F-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_003"><b>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_004"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_005"><b>ITEM 4. CONTROLS AND PROCEDURES</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><a href="#a_006"><b>PART II &#8211; OTHER INFORMATION</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_007"><b>ITEM 1. LEGAL PROCEEDINGS</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_008"><b>ITEM 1A. RISK FACTORS</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_009"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_010"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_011"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_012"><b>ITEM 5. OTHER INFORMATION</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><a href="#a_013"><b>ITEM 6. EXHIBIT</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><a href="#a_014"><b>SIGNATURES</b></a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0pt">21</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>ITEM 1. FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Interim Condensed Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">December 31, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
Condensed Consolidated Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at December 31, 2022 and September 30, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_zsvaZCyIUZFk" summary="xdx: Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_496_20221231" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_493_20220930" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">December 31,</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
<td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">(Unaudited)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zAhxP1UKjPjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Assets</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzIUR_zDbVoXgCfR4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">Cash and cash equivalents</td>
<td style="width: 8%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">$</td>
<td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,621,848</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,157,861</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncomeTaxesReceivable_i02I_maCzIUR_zLlPSl4ckNy" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,094,431</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,192,580</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzIUR_zPpEDAwIQ3E1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and other current assets</td>
<td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,643</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,162</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--Assets_i01TI_mtCzIUR_zbBmXVKCspFj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Total Assets</td>
<td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,371,922</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,704,603</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zwx6JAXuRe2l" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Liabilities and Stockholders' Equity</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesCurrentAbstract_i01B_zz8P15fTnh11" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_maCzkYp_zVgtaLWbwFJj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">$</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,288,261</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,824,777</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzkYp_zAvI95MU8fcb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities - Note 4</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,042,822</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,944,953</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredIncomeCurrent_i02I_pp0p0_maCzkYp_zV3e8m3qtLBd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income - Note 3</td>
<td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">916,763</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--Liabilities_i02TI_mtCzkYp_maCzsk2_zK8QVYKGEOMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities</td>
<td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,247,846</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,213,561</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_i01I_zSeg32qbA4Oa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 6</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Capital stock</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Authorized:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20221231_pdd" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_c20220930_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20221231_pdd" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220930_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_986_eus-gaap--PreferredStockValue_iI_c20221231_z4qXXTtLJpAe" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_eus-gaap--PreferredStockValue_iI_c20220930_zNspzPJeZOW9" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0097">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20220930_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20221231_pdd" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20220930_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Issued and outstanding:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_c20221231_pdd" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20221231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,032,135</ix:nonFraction></ix:nonFraction></span></span> common shares (September 30, 2022 - <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20220930_pdd" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20220930_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></ix:nonFraction></span></span>)</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--CommonStockValue_iI_maCzGGx_c20221231_zWKjbn4NjCR8" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share78,032,135 common shares (September 30, 2022 - 77,942,815)" style="color: Black; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,033</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--CommonStockValue_iI_maCzGGx_c20220930_zl2fnxgq21f3" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share78,032,135 common shares (September 30, 2022 - 77,942,815)" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzGGx_z6tvjq3UuEai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,581,544</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,976,881</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzGGx_zOhGOt2PAmge" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td>
<td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">258,535,501</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,563,783</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--StockholdersEquity_iTI_mtCzGGx_maCzsk2_zlTB3PLuO9L7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total Stockholders' Equity</td>
<td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,124,076</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,491,042</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzsk2_zcJ41fNNPZGj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 20pt; text-align: left; text-indent: -10pt">Total Liabilities and Stockholders' Equity</td>
<td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,371,922</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,704,603</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
Condensed Consolidated Statement of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended December 31, 2022 and 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_113_zSBgFGQ1q2tl" summary="xdx: Statement - Interim Condensed Consolidated Statement of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_490_20221001_20221231" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20211001_20211231" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_z3aCxI18FXlk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzgQY_zFCSx5F6Lla1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,317,036</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,066,951</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzgQY_zSBUsvfDosUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,066,919</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,656,439</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_i01T_mtCzgQY_msCzOeU_z2JYDRBpjYu1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total operating expenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,383,955</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,723,390</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_i01T_mtCzOeU_maCzY5l_zQ8aZI9QXMi6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,383,955</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,723,390</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NonOperatingIncomeFromGrants_i01_maCzSTp_z3ni1mKk3vPd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Grant income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0150">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzSTp_zaZxwZg3KL03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development incentive income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">733,590</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,730</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeExpenseNet_i01_maCzSTp_zW5P1iIqNBJb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest income, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,267,618</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_pp0p0_maCzSTp_zwiwXL9AH3Pc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange gain, net</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">365,983</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,363</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzSTp_maCzY5l_zpWAkhKaqSsb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total other income, net</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,392,191</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">871,003</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtCzY5l_maCz8Xh_zanVtK9iHaJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss before provision for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,991,764</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,852,387</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_pp0p0_di_msCz8Xh_zwCzabHel9W1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Income tax recovery (expense), current</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,046</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,980</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_mtCz8Xh_zNeImQqIQK71" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Net loss and comprehensive loss</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,971,718</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,882,367</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareAbstract_iB_zDs7QP2nmr08" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Net Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NetLossPerShareBasicAndDiluted_i01_ztKXyId1HvS6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.17</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zE0TsT8Naht7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_i01_zvpJ0GAFbZp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">77,977,112</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">75,997,738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Interim Condensed Consolidated Statement of Changes in Stockholders' Equity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the three months ended December 31, 2022 and 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_z6ZCr2EJfdRi" summary="xdx: Statement - Interim Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zcqzKE8IvZI4" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zdFVHpgpw1a6" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z06tK1ZgcQzj" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_4B3_zKxf8TEzrDha" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">Additional</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">Paid-in</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">Accumulated</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Par Value</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Capital</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_430_c20221001__20221231_eus-gaap--StockholdersEquity_iS_zHPngXzYhl8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-indent: -10pt">Balance, October 1, 2022</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3LuiXx5AErl" title="Beginning balance, shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,976,881</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,563,783</ix:nonFraction></td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,491,042</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_985_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1T0Gy7CEPhc" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,320</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">258,155</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0194">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">258,244</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0199">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,346,508</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0201">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,346,508</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0204">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,971,718</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,971,718</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_43C_c20221001__20221231_eus-gaap--StockholdersEquity_iE_zuhoIlot1Od3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt">Balance, December 31, 2022</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMEGGqmCkO01" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,032,135</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,033</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,581,544</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">258,535,501</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,124,076</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20211001__20211231_eus-gaap--StockholdersEquity_iS_zg3fZ9C87gGi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, October 1, 2021</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9uZSO3wBRP" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,920</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zPqI4sYAObPk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy1VABuj4Jlf" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">137,134</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,360</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,497</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueOther_iP3custom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_zysXHGpNhsT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement, net of share issuance costs</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_iP3us-gaap--StockIssuedDuringPeriodValueOther_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yB2W5uQ9n8" title="Shares issued under Sales Agreement, net of share issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99,588</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,149,602</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,149,701</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z1dcjht7U4Ab" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,908,771</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,908,771</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--NetIncomeLoss_zR4NtmJG4DPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,882,367</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,882,367</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_430_c20211001__20211231_eus-gaap--StockholdersEquity_iE_zzsdtz0WOIv5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt">Balance, December 31, 2021</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOXGYXALZ56e" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,155,187</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,156</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,759,781</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">208,468,231</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,367,706</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
Condensed Consolidated Statement of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended December 31, 2022 and 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zeGFWjWedAmc" summary="xdx: Statement - Interim Condensed Consolidated Statement of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 20pt; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_493_20221001__20221231_zdQpFpcy8PP6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20211001__20211231_zW43z6jHMf15" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zGmbCgBxuN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash Flows used in Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i01_maCzBEy_zDUuVVgBxs72" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,971,718</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,882,367</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z9kvGOC5Yw0g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_i02_maCzBEy_zZ9CJSiJitJi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Stock-based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,346,508</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,908,771</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in working capital balances related to operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzBEy_zXiZ3HP1XLRg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">901,851</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,764,678</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_pp0p0_di_msCzBEy_zkWvaDVTbDra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,481</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,311</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzBEy_zBuRMvFVCKuj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,463,484</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104,992</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzBEy_zgOcO7I1fXZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,097,869</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">164,734</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncreaseDecreaseInDeferredGrantIncome_i02_maCzBEy_zMr8vimHEqD6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">472,932</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzBEy_maCzEA1_zkE7Ysa7f8kh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash used in operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,794,257</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,500,955</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zJlT8y18jOce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash Flows provided by Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzpb6_zc3WCcRireZ7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Issuance of common shares</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,312,785</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msCzpb6_z8PLOT7gc8Ta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share issue costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,717</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzpb6_z9fSLm3Wcmie" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Proceeds from exercise of stock options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">258,244</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,497</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzpb6_maCzEA1_zQLcwrlThPhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">258,244</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,539,565</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0p0_mtCzEA1_zFj1x9eQE5Y9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Decrease in cash and cash equivalents during the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,536,013</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">961,390</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zlxM9xgHVw3d" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, beginning of period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,157,861</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zXD5gnt6bPl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, end of period</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,621,848</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,146,355</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zVzmoh0B6bo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Supplemental Cash Flow Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CashPaidForStateAndLocalMinimumIncomeTaxes_i01_zvBDjtwq60Da" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Cash paid for state and local minimum income taxes</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,077</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zvyA2F3wVxr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 &#9;<span id="xdx_829_zePecOAZlLx2">Business Description</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccounting"><p id="xdx_805_eus-gaap--BasisOfAccounting_zbDwoEqw09j3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#9;<span id="xdx_821_zqATGLBhz5C1">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zUQdtJi6fuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i><span id="xdx_86E_zOC3uQ5iyg6a">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited interim condensed consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three months ended December
31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="avxl:LliquidityPolicyTextBlock"><p id="xdx_841_ecustom--LliquidityPolicyTextBlock_zkX9GKxjPX1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zM92AZ1bBeL9">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div id="xdx_237_zGtamZAseuD1" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_237_z1dAOUyZat49" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zLRfc9m6fgc1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zemg6LyB7472" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zVGwCgjrxOh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zc1ErEQiL605" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zf2k5XGBPoB8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_z8LP7TreHyMd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zIAr9TQNs47" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zqMWi0gGNwKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
(as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available,
that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis,
if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_zAlWL6YlnfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_868_zWRNrnlTlPVf">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="avxl:CoronavirusDisease2019COVID19PolicyTextBlock"><p id="xdx_84E_ecustom--CoronavirusDisease2019COVID19PolicyTextBlock_zHJrC2UOD7S2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zCUIR1Nn6Pfj">Coronavirus Disease 2019 (COVID-19)</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The global pandemic resulting
from the disease known as COVID-19, caused by a novel strain of coronavirus, did not have a material impact on the Company&#8217;s result
of operations or financial condition for the quarter ended December 31, 2022. However, the future course of the pandemic could have adverse
effects in the U.S and global economies and thus negatively impact our business and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhVa66jQ8Wrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zVrH6HBuajQ8">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_234_zXmz2EzOgbz4" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23C_z3jdVTAeSgj6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zOh7sCkxjdpk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zP5ClKyR7YUe" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zLRbjGrFQpN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zgec2ZmCXkz8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zKEj3J4N34fe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zX1LTqUrUZO1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zqWqKKHRfx39" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>
<ix:exclude><p id="xdx_239_z0EOW1BErl07" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbCYyGFjyKQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_865_zdQgm5cfTk02">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - &#9;quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - &#9;assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zldoy5WGjNTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_z4OE5XqndfY2">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 loss per share excludes <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20221231_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,525,296</ix:nonFraction></span>
(December 31, 2021: <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_zbRpyyYJm8Vj" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,403,769</ix:nonFraction></span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQkq8c6YE9S9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_869_zqtvQrQwJJXk">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_801_ecustom--OtherIncomeDisclosureTextBlock_zCcWHuXVRY5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 3&#9;<span id="xdx_826_z1z3uptfurRa">Other Income</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the Company had received $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_zVuib9oqfZgb" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012022-12-31_custom_MichaelJFoxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">995,862</ix:nonFraction></span> in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.
Of the total, $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__dei--LegalEntityAxis__custom--AnavexMember_zrsyTMWdTfdh" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012022-12-31_custom_AnavexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> was received during the three months ended December 31, 2022 and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_znZ31QTl4Yi" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_custom_AnavexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> was received during the year ended September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_232_zTPBTaf8N9F9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_232_zlowMtLjMpQi" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_zbILwUL7T74i" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_z8NWAZHbx3K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_23B_zXvOyVc1KCi7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zSXCXa1S3O3c" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zrKm6UiNCXE8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zuoOAxnDCNWl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zKqzu7GcwK3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three months ended December 31, 2022, the Company recognized $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20221231_zXH3rtZoR1u7" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span> (2021: $<span id="xdx_90C_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20211231_zAkumjuyPFYk" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>) of this grant on its statements of operations as grant
income. At December 31, 2022, an amount of $<span id="xdx_90B_ecustom--DeferredGrantIncome_iI_pp0p0_c20221231_zvdiFTbpN7i3" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">916,763</ix:nonFraction></span> (September 30, 2022: $<span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span>) of this grant is recorded as deferred grant income,
representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its
statement of operations as the relating expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#8220;Tax Incentive Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three months ended
December 31, 2022 the Company recorded research and development incentive income of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231_zxLd8IKoQOJ7" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">733,590</ix:nonFraction></span> (AUD <span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__srt--CurrencyAxis__currency--AUD_z28MtqNa9oml" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012022-12-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,116,618</ix:nonFraction></span>) (2021: $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231_zr568AHCTeb6" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">810,730</ix:nonFraction></span> (AUD <span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231__srt--CurrencyAxis__currency--AUD_zPl2ZPeLN3Y6" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012021-12-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,116,362</ix:nonFraction></span>))
in respect of the Tax Incentive Credit for eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO and, the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#8217;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zNbVyOfKqtki" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 4&#9; &#9; <span id="xdx_82F_z0mGfsPdULm7">Accrued Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>The principal components of accrued liabilities consists of:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zoXLvwtMqgV8" summary="xdx: Disclosure - Accrued liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zONRZM50Hhr" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20221231_zDZvtorAVph7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220930_zTbGZwc9po0b" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">December 31,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
  <tr id="xdx_404_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_maALCze45_z8SuwlLa0FZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedClinicalSiteAndPatientVisitsCosts" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,212,464</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedClinicalSiteAndPatientVisitsCosts" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,031,105</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCze45_z3qoXFs4dbG9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,249,205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,297,337</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCze45_za88OzDbUEi9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,076,630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">417,414</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCze45_zabI6rEWisSl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,504,523</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,199,097</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCze45_zZWLwTNtRVK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; color: rgb(204,238,255); text-indent: -10pt">Total accrued liabilities&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,042,822</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,944,953</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="avxl:EquityOfferingTextBlock"><p id="xdx_80F_ecustom--EquityOfferingTextBlock_zr7a25UqgGtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 5&#9;&#9;<span id="xdx_826_zK2D03L96t57">Equity Offerings</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_231_zYyNcQTnzEL2" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23C_z15j2DJGCPvb" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zJZE0VmJ6BW" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23F_zOjLpJFMGQwk" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zdMhYEzsbrX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zK4EkWLtzEJ3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zfQ3pUh2gTKf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zx7NCg8KHzAb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zdynSbt4RwSi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents commissions
for their services of up to <span id="xdx_90F_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zIsdAuxuRkCb" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the three months ended December 31, 2022, <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zcsZs5Wq5Qo3" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span>
shares were sold pursuant to the Offering. During the three months ended December 31, 2021, <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zbbz2q791Vsj" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99,588</ix:nonFraction></span> shares were sold for gross proceeds
of $<span id="xdx_903_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zNRqfTqB0cS2" title="Gross proceeds from Issuance Public Offering"><ix:nonFraction name="avxl:GrossProceedsFromIssuancePublicOffering" contextRef="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,312,785</ix:nonFraction></span> (net proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,149,701</ix:nonFraction></span>). At December 31, 2022, an amount of $<span id="xdx_90B_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20221231_zlax5CQXnKwl" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,407,882</ix:nonFraction></span> (September 30, 2022: $<span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,407,882</ix:nonFraction></span>) was registered
pursuant to an effective registration statement and remained available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_zJipZv6cvSm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 6 &#9;<span id="xdx_826_zcNDyHoj9k54">Commitments and Contingencies</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Leases </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">During the three
months ended December 31, 2022, the Company incurred office lease expense of $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_pp0p0_c20221001__20221231_zgcKyJX4u3d5" title="Operating Leases, Rent Expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,070</ix:nonFraction></span> (2021: $<span id="xdx_909_eus-gaap--LeaseAndRentalExpense_pp0p0_c20211001__20211231_zzw6p74CFrMg" title="Operating Leases, Rent Expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,845</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three months ended December 31, 2022, the Company made $<span id="xdx_90F_eus-gaap--PensionContributions_pp0p0_c20221001__20221231_zJBfWXFu8lD7" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,646</ix:nonFraction></span> (2021: $<span id="xdx_90F_eus-gaap--PensionContributions_pp0p0_c20211001__20211231_zNPoEopIERlh" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,682</ix:nonFraction></span>) in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_233_zXncGEXCN72b" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_232_zwASj43UhaZd" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zkgBOowKXzW6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zzFLhau2K0Rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal"></span><b><i>&#160;</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zx492kzU8U6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p>

<ix:exclude><p id="xdx_239_zEs0ShjTcKxe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zMjLfgHlIvLe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_z8lNFoGOY83l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>
<ix:exclude><p id="xdx_23B_zQ5ymhGwWWak" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022 and September 30, 2022, the Company
had <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_zlk04CawYIfa" title="Warrants outstanding"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zhIEMsI6hXB9" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></ix:nonFraction></span></span> warrants outstanding at a weighted average exercise price of $<span id="xdx_90F_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20221231_zumsUQH0yL5" title="Warrants outstanding weighted average exercise"><span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_zV1GNFqym1pa" title="Warrants outstanding weighted average exercise"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.72</ix:nonFraction></ix:nonFraction></span></span> as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zkEMw855x8Nl" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"><span id="xdx_8B1_zOpUD3aiovE2" style="display: none">Schedule of share purchase warrants outstanding</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zSDYZE5etdze" title="Number" style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-12-31_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zZVw7Jr4TeZg" title="Exercise Price" style="width: 27%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="text-align: right; width: 27%"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zN6X7kmeLY59" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zWWae6epErC9" title="Number" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-12-31_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztaFdmBsUFQk" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231_zJFWTV6flmci" title="Number" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
</table>




</ix:nonNumeric><p id="xdx_8A2_zAYLWzf5lQP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOSlZDBaXjZ4" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-10-012022-12-31_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zzWmjFZgDS9g" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">406,453</ix:nonFraction></span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-10-012022-12-31_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At December
31, 2022 <span id="xdx_903_ecustom--OptionIssued_c20221001__20221231_pdd" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,378,000</ix:nonFraction></span> options had been issued under the 2022 Plan and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zQUOIFhpb1z3" title="Option available issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,078,453</ix:nonFraction></span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_236_zF6Pg2Vavlj9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_z7hPtC7IkoC3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_zFtpamaHBsV9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zdO2RqFYdtjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zKOlw7Al2mYc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zgP0Tsk3W4Aa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zh7r0UDVlHm" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zRYael6eooJ1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_z9XZi71k6Oq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of Company&#8217;s outstanding
stock options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zTAu3tAG8N06" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span id="xdx_8B1_zEYEHDimIKA" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Grant Date</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Price ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Fair Value ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2021</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIGmqyfWBAXg" title="Options Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,330,903</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmEvHEGO9uk" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1D5euBgyRqj" title="Aggregate intrinsic value Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,132,451</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znlTJdrCP7C9" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,358,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzaopvGaoRw4" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8SxfSHDOOdd" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRH818Ya5f3f" title="Options Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">118,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6iC4GRDO5A9" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW8Bn62hS3Yh" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvDKn412n8sc" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,537</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCVTRzkxVjW2" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOWzLHExnze6" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNJyCSHNH8gi" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,201,015</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAqYbkF0xjli" title="Options Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,169,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9ijs9r15TJ" title="Weighted Average Exercise Price Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.61</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuGjngGc8A4d" title="Aggregate intrinsic value Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,267,309</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMtyNht74jX9" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">325,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6jj6ISozJok" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV5yypQUZCsh" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEiC8lsFy8Ei" title="Options Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuQpsN5PXG5" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvuEUSBbals5" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGWiXIYzfi7d" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,320</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR2K9ENC4Tj4" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.89</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znUPtoy4E3ib" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.44</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4FTvMu6uaFb" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">591,993</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zirxiFmbHTw6" title="Options Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdF7afoAr8Xi" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.78</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBNzuLPvIbV5" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,676,617</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zosxorn9Xgzl" title="Options Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,795,293</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7F5WIPaVlB5" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8quZAuDlHcf" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,930,627</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A4_zu2W8MSDuOIh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at December 31, 2022 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsiXt3H6xQak" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B0_zpK3BzDEDfPe" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">price</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">Range of exercise prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">options</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">life (in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">vested options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> vested</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zBuO20econda" title="Range of exercise prices, lower range limit" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zH4oGVKNe6vk" title="Range of exercise prices, upper range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zq4ehpF8iyQa" title="Number of outstanding options" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,850,742</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDzs8Y8YN047" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.86</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zeIw6gN0uvC4" title="Weighted average exercise price" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrWdowvkqbph" title="Number of vested options" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,844,908</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5IjYWPpdkuk" title="Weighted average exercise price options vested" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zQz1haJPkYke" title="Range of exercise prices, lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zC73TrJjm9q5" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zsUQxRzkbT5j" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,042,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zV2FD0JDmzu1" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.09</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zzV1nPkAB2j5" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zWJCJcVqakTg" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,032,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zN6C30a7a4t6" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zxDZvqWMWfZ6" title="Range of exercise prices, lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zVGVUeKvA5i4" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zSBgFLrF3WUa" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,927,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zib60TXSaIkd" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.80</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zKb6hKrYHZhi" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGPGkWsDKft8" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,374,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zI83oL98Zkoc" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zaiaC91dh1W7" title="Range of exercise prices, lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zo4njVVhDqb1" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zRmacfj8iLU9" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,968,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zLAGIA1yfBD1" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.04</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zE6TrRySCt4e" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zcL1qc3udUc3" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">154,581</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z6cCMWazIU6l" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zfnrQathPpR7" title="Range of exercise prices, lower range limit" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.22</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zvtx5yGXlHbj" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.58</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z15pxktYFxth" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,577,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zoLgLTQNTCvl" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.24</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zaFaDrwX6XFj" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.51</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zhxUol2dWvhi" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">388,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT2U2lIGE4ek" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.80</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zO2h9fKfcCv7" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjafHLghoMqh" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,795,293</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A6_zTAhmxGzDRid" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of options
vested during the three months ended December 31, 2022 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231_zWQvSeJMLXV9" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.40</ix:nonFraction></span> (2021: $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231_zpYmG7iaOrJj" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></span>). At December 31, 2022, the weighted average contractual
life of options outstanding was <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231_z2Sbkm3Ajifl" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.18</ix:nonNumeric></span> years (September 30, 2022: <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zvmCefcIOHQ2" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2021-10-012022-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.40</ix:nonNumeric></span> years) and for options exercisable was <span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231_zztbpI9oVRdc" title="Options exercisable"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.83</ix:nonNumeric></span> years (September 30,
2022: <span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zdXX2tGYiuXl" title="Options exercisable"><ix:nonNumeric contextRef="From2021-10-012022-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.1</ix:nonNumeric></span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended December 31, 2022, the
Company recognized stock-based compensation expense of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20221001__20221231_zAmZXw93skO3" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,346,508</ix:nonFraction></span> (2021: $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,908,771</ix:nonFraction></span>) in connection with the issuance and vesting &#9;of
stock options and warrants in exchange for services. These amounts have been included in general and &#9;administrative expenses and research
and development expenses on the Company&#8217;s statement of &#9;operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zufc8G4hxCv6" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6l0qWPPLU81" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,742,524</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,671,725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,603,984</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,237,046</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,346,508</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,908,771</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A9_zJQZAIzAYumc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_23E_z0bdZf4ZJ7Nd" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_zhZnfpD3D2Xa" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zXjgGpiFcOVg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_z9bIi3FSlOJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zMXKX75uSBze" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zGkJSIPaiHUl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zQs50EWZN6q8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_z6JgFVFau9r" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zAmDY5ytYTVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20221231_zMRZgYaWWmS9" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,340,941</ix:nonFraction></span> in stock-based
compensation is expected to be recorded over the remaining term &#9;of such options through fiscal 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option award
granted during the three months ended December 31, 2022 and 2021 is estimated on the date of grant using the Black Scholes option pricing
model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zxDTTrptBUxk" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zrXoJrxBJCSj" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20221231_zJI6nhuMJ16g" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.07</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_z417cr702jpb" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.37</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20221231_zg2WL7FzJXZb" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.98</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znTgAn5ygB5j" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2021-10-012021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.50</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20221231_zKpcopkcddLc" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.01</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_zbX9ot5dFImk" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96.79</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20221231_ze8e1w28W1u4" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_zlkeqoxgkJij" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AE_z4KrUCUdOUU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the three months ended December 31, 2022 and 2021 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zD6IOE92BQod" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Note
                                            7&#9;<span id="xdx_822_zvxoJfasjjle">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to December 31, 2022, <span id="xdx_905_eus-gaap--SignificantPurchaseCommitmentDescription_c20221001__20221231_zW90nxNoM2sb" title="Purchase agreement, description"><ix:nonNumeric contextRef="From2022-10-01to2022-12-31" name="us-gaap:SignificantPurchaseCommitmentDescription">the Company entered
into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), whereby the Company
has the right, in its sole discretion, to sell to LPC up to $150,000,000 in value of shares of the Company&#8217;s common stock from time
to time over a 36-month period pursuant to the terms of the Purchase Agreement.</ix:nonNumeric></span></p>

</ix:nonNumeric><p id="xdx_815_zPfp3FwvxPh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_003"></span>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q includes forward-looking
statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements
regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and
objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221;
&#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221;
&#8220;potential,&#8221; &#8220;predict&#8221;, &#8220;could,&#8221; &#8220;would,&#8221; &#8220;will,&#8221; &#8220;suggest,&#8221; &#8220;plan&#8221;
and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include,
without limitation, statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">volatility in our stock price and in the markets in general;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully conduct preclinical studies and clinical trials for our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to raise additional capital on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact of the COVID-19 outbreak and its effect on us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to generate any revenue or to continue as a going concern;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to execute our research and development plan on time and on budget; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our products candidates&#8217; ability to demonstrate efficacy or an acceptable safety profile; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain the support of qualified scientific collaborators; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be approved for sale; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to identify and obtain additional product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our reliance on third parties in non-clinical studies and clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to defend against product liability claims; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to safeguard against security breaches; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and maintain sufficient intellectual property protection for our product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to comply with our intellectual property licensing agreements; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to defend against claims of intellectual property infringement; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to comply with the maintenance requirements of the government patent agencies; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to protect our intellectual property rights throughout the world; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competition; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the anticipated start dates, durations and completion dates of our ongoing and future clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the anticipated designs of our future clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to attract and retain qualified employees; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact of Fast Track designation on receipt of actual FDA approval; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our anticipated future regulatory submissions and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or Fast Track designations; and </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our anticipated future cash position and ability to obtain funding for our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements largely
on our current expectations and projections about future events, including the responses we expect from the U.S. Food and Drug Administration,
(&#8220;FDA&#8221;), and other regulatory authorities and financial trends that we believe may affect our financial condition, results
of operations, business strategy, preclinical studies and clinical trials, and financial needs. These forward-looking statements are subject
to a number of risks, uncertainties and assumptions including without limitation the risks described in &#8220;Risk Factors&#8221; in
Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 28, 2022. These risks
are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors which could adversely impact our business
and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time
to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you
that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Except as required by applicable laws including the securities laws
of the United States, we assume no obligation to update or supplement forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Quarterly Report on Form 10-Q, the
terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221;, and &#8220;Anavex&#8221; mean Anavex Life Sciences
Corp., unless the context clearly indicates otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Current Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage biopharmaceutical
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead product candidate, ANAVEX<sup>&#174;</sup>2-73,
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two seed programs.
Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img src="image_001.jpg" alt="Chart, timeline&#10;&#10;Description automatically generated" style="height: 309px; width: 625px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>* = Orphan Drug Designation by the FDA; Dashed
lines indicate planned clinical trials to-date</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying in sigma-1
receptor (SIGMAR1) binding activities. The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone protein with
important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope and restores
homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds to activate quantitatively
the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography (PET) imaging scan in
mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 target engagement or receptor occupancy with SIGMAR1 in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_002.jpg" alt="Graphical user interface, diagram&#10;&#10;Description automatically generated" style="height: 416px; width: 624px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;<i>Source: Reyes S et
al., Sci Rep. 2021 Aug 25; 11(1):17150</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused by chronic
homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile spasms, the chronic
cellular stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such as Alzheimer&#8217;s
and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular insult and hence chronic
cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons
and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy, a characteristic found in Alzheimer&#8217;s
and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking, folding, processing or degradation in cells.
The clearance of macromolecules in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in
nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, and neurofibrillary
tangles, which are aggregates of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation
of microglia. With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular
balance (i.e. homeostasis). Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental
and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of some of our clinical trials, we have incorporated
a genomic analysis to better understand potential populations for whom our clinical programs might benefit. In our clinical trials, a
full genomic analysis of Alzheimer&#8217;s disease patients treated with ANAVEX<sup>&#174;</sup>2-73 has helped us identify actionable
genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73 and COMT, a
gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific biomarker
hypothesis. We believe that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20% of the population)
in prospective studies would identify approximately 80%-90% patients that would display clinically significant improved functional and
cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73, which are considered
independent of Alzheimer&#8217;s disease pathology, as well as multiple endpoints and time-points, provides support for the potential
precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 by using genetic biomarkers identified within the trial population
itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 treatment. We may in the future utilize such an
approach in Alzheimer&#8217;s disease as well as indications like Parkinson&#8217;s disease dementia or Rett syndrome in which ANAVEX<sup>&#174;</sup>2-73
is currently being studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Trials Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the safety
and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse
the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic (&#8220;PK&#8221;)
and pharmacodynamic (&#8220;PD&#8221;) data from the Phase 2a clinical trial, which established a concentration-effect relationship between
ANAVEX<sup>&#174;</sup>2-73 and trial measurements. These measures obtained from all patients who participated in the entire 57 weeks include
exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally, the clinical trial appeared
to show that ANAVEX<sup>&#174;</sup>2-73 activity was enhanced by its active metabolite (ANAVEX19-144), which also targets the SIGMAR1
receptor and has a half-life approximately twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase 2a
trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX<sup>&#174;</sup>2-73, providing
an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing these Phase
2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian Government Department
of Health &#8211; Therapeutic Goods Administration&#8217;s compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
trial of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced in August 2018. The Phase 2b/3 trial enrolled 509 patients,
which were treated with a convenient once-daily oral formulation of ANAVEX<sup>&#174;</sup>2-73 for 48 weeks, randomized 1:1:1 to two different
ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial took place at 52 sites across North America, Europe and Australia. Primary and
secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer&#8217;s Disease Assessment
Scale &#8211; Cognitive Subscale test (&#8220;ADAS-Cog&#8221;), Alzheimer&#8217;s Disease Cooperative Study &#8211; Activities of Daily
Living (&#8220;ADCS-ADL&#8221;) and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and function (&#8220;CDR-SB&#8221;). In
addition to the primary endpoints, the ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 trial design incorporated pre-specified statistical analyses
related to potential genomic precision medicine biomarkers previously identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a clinical trial.
The trial completed in mid-2022 and, in December 2022, the Company presented positive topline results from the Phase 2b/3 clinical trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 met the co-primary endpoints
ADAS-Cog and ADCS-ADL and key secondary endpoint CDR-SB. ANAVEX<sup>&#174;</sup>2-73 treatment slowed decline of cognition and function
in patients with early Alzheimer&#8217;s disease over 48 weeks. Patients treated with ANAVEX<sup>&#174;</sup>2-73 had 1.84 times higher
odds, or likelihood, to improve cognitively compared to placebo, with a ADAS-Cog score threshold change of -0.5 points or better [Odds
Ratio = 1.84 (p = 0.015)]. At clinically significant levels of improvement in function (ADCS-ADL score threshold change of +3.5 points
or better), patients treated with ANAVEX<sup>&#174;</sup>2-73 had 2.67 times higher odds, or likelihood, to improve function compared to
placebo [Odds Ratio = 2.67 (p = 0.0255)]. Additionally, treatment with ANAVEX<sup>&#174;</sup>2-73 reduced cognitive decline at end of
treatment, measured with the ADAS-Cog, as compared to placebo, by 45%, representing a treatment difference in mean score change of -1.85
points (p=0.033). Compared to placebo, ANAVEX<sup>&#174;</sup>2-73 reduced clinical decline of cognition and function by 27% with mean
score difference of -0.42 points (p=0.040) as measured by the CDR-SB. ANAVEX<sup>&#174;</sup>2-73 was generally safe and well tolerated.
All statistical analyses were performed by outside consultancy companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2019, we initiated a long-term open label
extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD trial, for patients who have completed the 48-week Phase 2b/3
placebo-controlled trial referenced above. This trial extension for an additional two years gives patients the opportunity to continue
their treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose related and significant
improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes neurological symptoms
that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January
2017, we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter
Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This award was received in quarterly instalments
which commenced during fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase 2 clinical
trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. The clinical trials are being
conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 trial, (ANAVEX<sup>&#174;</sup>2-73-RS-001),
which took place in the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety,
tolerability, PK and efficacy trial of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with Rett syndrome
over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers. The primary endpoint
of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated dose-proportional PK. All secondary
efficacy endpoints of the trial showed statistically significant and clinically meaningful response in the Rett Syndrome Behaviour Questionnaire
(&#8220;RSBQ&#8221;) response, when compared to placebo, in the intent to treat (&#8220;ITT&#8221;) cohort (all participants, p = 0.011).
66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically significant improvement in RSBQ response as compared to 10%
of the subjects on placebo in the ITT cohort (all participants, p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained
improvement in Clinical Global Impression Improvement (CGI-I) response throughout the 7-week clinical trial, when compared to placebo
in the ITT cohort (all participants, p = 0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying
the common form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements in the prespecified efficacy
endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
second, international trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced in June
2019.</span> This trial took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 trial for Rett
syndrome. The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73
in 33 adult patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. Based
upon the input from the successful U.S. Phase 2 Rett syndrome trial (ANAVEX<sup>&#174;</sup>2-73-RS-001), we updated the endpoints for
the AVATAR trial (ANAVEX<sup>&#174;</sup>2-73-RS-002) to appropriately assess the clinically meaningful outcome following International
Conference on Harmonization (ICH) guidelines. These updates were approved by the respective regulatory authorities in the U.K. and in
Australia, respectively, where the AVATAR trial was conducted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data from the AVATAR trial was released in February
2022. The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements in primary efficacy
endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, ADAMS (p = 0.010) and CGI-I (p = 0.037) response. Efficacy endpoints
demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms. Convenient once daily oral liquid
doses of up to 30 mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication compliance. All patients who participated
in the trial were eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the third trial of ANAVEX<sup>&#174;</sup>2-73
for the treatment of Rett syndrome, called the EXCELLENCE trial. This Phase 2/3 trial in pediatric patients with Rett syndrome includes
trial sites in Australia, the United Kingdom and Canada, and will evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in approximately
84 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating ANAVEX<sup>&#174;</sup>2-73 specific precision medicine
biomarkers. This trial completed enrollment in February 2023, exceeding the original
enrollment target and topline results are expected in the second half of 2023. All patients who participate in the trial will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label
extension protocol, which is currently ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements on behavioral,
histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional data announced in
October 2017 indicated that ANAVEX<sup>&#174;</sup>2-73 induced robust neurorestoration in experimental Parkinsonism. We believe the encouraging
results we have gathered in this preclinical model, coupled with the favorable profile of this product candidate in the Alzheimer&#8217;s
disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 has the potential to treat Parkinson&#8217;s disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind, randomized,
placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia in Spain and Australia,
to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 trial enrolled
approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30 mg and 50 mg, or placebo.
The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (&#8220;CDR&#8221;) computerized assessment system analysis. Treatment with ANAVEX<sup>&#174;</sup>2-73
also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson&#8217;s disease symptom severity,
MDS-Unified Parkinson&#8217;s Disease Rating Scale total score on top of standard of care including dopaminergic therapy, levodopa and
other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential capability of slowing and
reversing symptoms that progress in Parkinson&#8217;s disease. In addition, the trial confirmed the precision medicine approach of targeting
SIGMAR1 as a genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73 may result in improved clinical outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we were awarded a research grant
of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;to develop ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Parkinson&#8217;s disease. The award will explore utilization of PET imaging biomarkers to enable measurement of target
engagement and pathway activation of the SIGMAR1 with clinically relevant doses including in people with Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Frontotemporal Dementia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human Phase
1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. ANAVEX<sup>&#174;</sup>3-71 was previously granted orphan drug designation for the treatment
of Frontotemporal Dementia (&#8220;FTD&#8221;) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally administered small molecule targeting
sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71
demonstrated disease-modifying activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Phase 1
clinical trial was a prospective double-blind, randomized, placebo-controlled trial in Australia. A total of 36 healthy male and female
subjects were included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate the safety, tolerability,
and PK of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK in healthy volunteers. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The trial met
its primary and secondary endpoints of safety, with no serious adverse events (&#8220;SAEs&#8221;) or dose-limiting toxicities observed.
ANAVEX<sup>&#174;</sup>3-71 was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging from 5 mg to
200 mg daily with no SAEs and no significant lab abnormalities in any subject. In the trial, ANAVEX<sup>&#174;</sup>3-71 exhibited linear
PK. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no
effect on the bioavailability of ANAVEX<sup>&#174;</sup>3-71. The trial also met the secondary objective of characterizing the effect of
ANAVEX<sup>&#174;</sup>3-71 on electrocardiogram (&#8220;ECG&#8221;) parameters. There were no clinically significant ECG parameters throughout
the trial. Participant QTcF measures were normal across all dose groups with no difference between ANAVEX<sup>&#174;</sup>3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71&#8217;s pre-clinical profile, we intend to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect
of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of these clinical trials and preclinical study could serve as a basis
for advancing into respective registration trials in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73
currently in three different clinical trial indications, and several other compounds in different stages of clinical and pre-clinical
development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&#8482; Discovery Platform
produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may
be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&#8217;s disease, as well
as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence the functioning
of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple viruses including SARS-CoV-2
(COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular processes, in order to ensure survival
and replication. Hence, it is possible that SIGMAR1 could play a role in modulating the cellular response to viral infection and ameliorate
pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe ANAVEX<sup>&#174;</sup>2-73 may offer a
disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. ANAVEX<sup>&#174;</sup>2-73 is
being developed in an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule
formulation for diseases such as Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73
in liquid form resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome
disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic
visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated
fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73 for four weeks significantly increased
the automatic visual response in the MECP2 Rett syndrome disease mice. Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73
starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular
coordination, balance, motor learning and muscular strengths, some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease
model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted Orphan
Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In November 2019,
the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of Rett syndrome. The RPD
designation is intended to encourage the development of treatments for rare pediatric diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted Fast Track
designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The FDA Fast Track program
is designed to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment of serious
and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&#8217;s disease, data demonstrates significant
improvements and restoration of function in a disease modifying animal model of Parkinson&#8217;s disease. Significant improvements were
seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia, to
study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 trial enrolled approximately
132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73
Phase 2 Parkinson&#8217;s disease dementia trial design incorporated genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73
Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results showed clinically meaningful, dose-dependent, and statistically
significant improvements in the CDR computerized assessment system analysis. We anticipate conducting further clinical trials of ANAVEX<sup>&#174;</sup>2-73
in Parkinson&#8217;s disease dementia after submitting the results of the trial to the FDA to obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&#8217;s disease animal models, ANAVEX<sup>&#174;</sup>2-73
has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive
therapeutic agent, due to its potent affinity to SIGMAR1 and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73
has shown a potential dual mechanism which may impact amyloid, tau pathology and inflammation. In a transgenic Alzheimer&#8217;s disease
animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a statistically significant neuroprotective effect against the development of
oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that
is apparently amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in the animals,
regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing, we initiated
and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73. In this Phase 1 SAD trial, the maximum
tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown to have positive effects in mouse
models of Alzheimer&#8217;s disease. There were no significant changes in laboratory or ECG parameters. ANAVEX<sup>&#174;</sup>2-73 was
well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed adverse events at doses above the maximum
tolerated single dose included headache and dizziness, which were moderate in severity and reversible. These side effects are often seen
with drugs that target CNS conditions, including Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease. The open-label randomized trial was designed to
assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients with mild-to-moderate Alzheimer&#8217;s disease.
The Phase 2a trial met both primary and secondary objectives of the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial. More than 33,000 genes were analyzed
using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients treated
with ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73, among
them variants related to the SIGMAR1, the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that trial participants with the common
SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved cognitive (MMSE)
and the functional (ADCS-ADL) scores. The results from this evaluation supported the continued evaluation of genomic information in subsequent
clinical trials, since these signatures can now be applied to neurological indications tested in future clinical trials with ANAVEX<sup>&#174;</sup>2-73
including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled trial. On July 2, 2018, the Human Research
Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety and
efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical trial sites in Canada, the
United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 trial design incorporates inclusion of genomic precision
medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial completed and, in December 2022, the Company
presented positive topline results from the Phase 2b/3 clinical trial. ANAVEX<sup>&#174;</sup>2-73 met the co-primary endpoints ADAS-Cog
and ADCS-ADL and key secondary endpoint CDR-SB as further described above under <i>Clinical Trials Overview &#8211; Alzheimer&#8217;s
Disease.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe preclinical data from our studies also
supports further research into the use of ANAVEX<sup>&#174;</sup>2-73 as a potential platform drug for other neurodegenerative diseases
beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X
syndrome, Angelman syndrome, multiple sclerosis, and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated
significant improvements in all of these indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a preclinical study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results
indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures in mice. In a study sponsored
by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73 restored hippocampal brain-derived
neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental and neurodegenerative
pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of
BDNF expression could be a contributing factor for the positive preclinical data observed in both neurodevelopmental and neurodegenerative
disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data to-date also indicates
that ANAVEX<sup>&#174;</sup>2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease. Further,
our data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 has the potential to provide protection for oligodendrocytes (&#8220;OL&#8217;s&#8221;)
and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system neurons in addition to helping repair
by increasing OPC proliferation and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73
in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth
of numerous benign tumors in many parts of the body with a high incidence of seizures. The preclinical data demonstrated that treatment
with ANAVEX<sup>&#174;</sup>2-73 significantly increased survival and reduced seizures in those mice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is a clinical drug candidate
with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been shown to enhance neuroprotection
and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential disease modifying treatment
for cognitive impairments. We believe it is effective in very small doses against the major Alzheimer&#8217;s hallmarks in transgenic
(3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial
dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related
diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71
in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation
with the administration of ANAVEX<sup>&#174;</sup>3-71. In April 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71
for the treatment of FTD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes.
In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional
preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 has the potential
to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to
play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase 1 clinical
trial of&#160;ANAVEX<sup>&#174;</sup>3-71. The trial took place in Australia and was a double-blind, randomized, placebo-controlled, Phase
1 trial to evaluate safety and tolerability, and PK of oral escalating doses of ANAVEX<span style="background-color: white"><sup>&#174;</sup></span>3-71
including effects of food and gender in healthy volunteers. <span style="background-color: white">The trial met its primary and secondary
endpoints of safety, respectively, with no serious adverse events (SAEs) or dose-limiting toxicities observed, </span>as more fully described
above under <i>Clinical Trials Overview &#8211; Frontotemporal Dementia</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect
of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of this clinical trial and preclinical study could serve as a basis
for advancing into respective registration trials in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist. Pre-clinical
tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of
endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41
prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus,
the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and SIGMAR1 systems through
a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that ANAVEX<sup>&#174;</sup>1-41
has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired,
are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model of neuropathic
pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive threshold in the affected paw
to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant for two hours. In
a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and
a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold to control levels in a dose-dependent manner.
Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and
a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for the treatment
of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for SIGMAR1 at nanomolar
levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical studies, this compound
revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting normal/healthy cells and
also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight the possibility that these
ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed in different
tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell
membrane reorganization and interactions with ion channels, we believe our drug candidates may play an important role in inhibiting the
processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation of
new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is currently in the pre-clinical
and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown
in human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions with
potential strategic and commercial partners to most effectively advance our programs and increase stockholder value. Further, we may acquire
or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are developing compounds with potential application
to two broad categories and several specific indications, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Alzheimer&#8217;s disease &#8211; In 2022, an estimated 6.5 million Americans were suffering from Alzheimer&#8217;s disease. The Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that by 2050, this number is expected to rise to 12.7 million Americans. Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression. We believe that there is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic treatments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Parkinson&#8217;s disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson&#8217;s disease currently is estimated to afflict more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson&#8217;s disease market is expected to reach $11.5 billion by 2029, according to GlobalData.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rett syndrome &#8211; Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain develops, including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child&#8217;s life; severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000 females.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Depression &#8211; Depression is a major cause of morbidity worldwide according to the World Health Organization. The global antidepressant drug market is projected to reach $21 Billion by 2030 according to Allied Market Research. Pharmaceutical treatment for depression has been historically dominated by blockbuster brands. However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Epilepsy &#8211; Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Neuropathic Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Malignant Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for a large majority of skin cancer deaths. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Prostate Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase to nearly $10.1 billion by the end of 2030 according to Market Research Future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pancreatic Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 62,000 new cases of pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $3.73 billion by 2027.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual Property
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to seventeen
U.S. patents, nineteen U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates, methods
associated therewith, and to our research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73
directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This patent
is expected to expire in June 2034, absent any patent term extension for regulatory delays. We own three issued U.S. patents each with
claims directed to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these three patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73,
dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease
using them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The second of these
three patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment
for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent any patent term extension
for regulatory delays. The third of these three patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73,
and methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent
any patent term extension for regulatory delays. We also own two issued U.S. patents for seizure treatment. The first of these two patents
claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either:
(i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144. The second
of these two patents further claims a combination seizure treatment involving administration of an anti-epilepsy drug combined with (i)
ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX 19-144<sup>&#174;</sup> and ANAVEX 2-73<sup>&#174;</sup>. Both patents are expected to expire
in October 2035, absent any patent term extension for regulatory delays. We also own three issued U.S. patents with claims directed to
treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder, multiple sclerosis, or
their related biochemical and functional abnormalities by administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or
ANAVEX<sup>&#174;</sup>1-41 (another sigma receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. All three patents
are expected to expire in January 2037, absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent
with claims directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected to
expire in February 2030, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims crystalline
forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
and methods of treatment for Alzheimer&#8217;s disease. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays. Further, we own one issued U.S. Patent with claims directed to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73.
This patent is expected to expire in July 2038, absent any patent term extension for regulatory delays. Additionally, we own one issued
U.S. Patent with claims directed to methods of treating insomnia or anxiety with ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41. This patent is expected to expire in September 2038, absent any patent term extension for regulatory
delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own two issued U.S. patents related to ANAVEX<sup>&#174;</sup>1066.
The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX<sup>&#174;</sup>1066 isomer. The second
patent claims methods for treating or preventing pain using (-) ANAVEX<sup>&#174;</sup>1066 isomer. Both patents are expected to expire
in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada, China,
Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71, we own
exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound and methods of
treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April 2030, and January 2030,
respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related patents or applications
that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and South Africa, which are expected
to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications directed to
enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for one or more of our
product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made with
intellectual property authorities, we protect our intellectual property and confidential information by means of carefully considered
processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements and provisions
for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide some form of recourse
in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents, see
&#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on November
28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Overview </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following discussion should be read in conjunction
with our interim condensed consolidated financial statements and related notes thereto contained elsewhere in this report. Past operating
results are not necessarily indicative of results that may occur in future periods. The discussion contains forward-looking statements,
which involve a number of risks and uncertainties. See &#8220;Forward Looking Statements&#8221; included elsewhere in this report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are in the development stage and have not earned
any revenues since our inception in 2004. We do not anticipate earning any revenues until we can establish an alliance with other companies
to develop, co-develop, license, acquire or market our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating costs consist primarily of research
and development activities including the cost of clinical trials and clinical supplies as well as clinical drug manufacturing and formulation.
Research and development expenses also include personnel related costs such as salaries and wages, and third-party contract research organization
(CRO) expenses in support of these clinical trials. Personnel costs include salaries and wages, benefits, and non-cash stock-based compensation
charges associated with options and other equity awards granted to employees and consultants who are directly engaged in support of our
research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses consist of personnel
costs, expenses for outside professional services and expenses associated with operating as a public company. Personnel costs consist
of salaries and wages, benefits and stock-based compensation for general and administrative personnel. Outside professional services and
public company expenses include expenses related to compliance and reporting, additional insurance expenses, audit and SOX compliance,
expenses associated with patent research, applications and filings, investor and stockholder relations activities and other administrative
expenses and professional services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Comparison of the three months ended December 31,
2022 and 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses for the quarter ended December
31, 2022 were $15.4 million, compared to $11.7 million for the comparable quarter ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses for the three months ended December 31,
2022 were $12.1 million, as compared to $8.7 million for the three months ended December 31, 2021. The increase in research and development
expenses is primarily related to (i) an increase in personnel costs of $0.7 million and an increase in stock based compensation expense
of $1.4 million as a result of the expansion of our team engaged in research and development activities, (ii) an increase of approximately
$0.7 million over the comparable period, relating to the manufacture of additional clinical trial supplies for both our ANAVEX<sup>&#174;</sup>2-73
and ANAVEX<sup>&#174;</sup>3-71 programs and (iii) an increase in costs associated with expanded enrollment in our EXCELLENCE trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our research and development
expenses for the quarter ended December 31, 2022 and 2021 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Cost of external service providers</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,054</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,258</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,649</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other common costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended December 31, 2022 and 2021,
external service providers cost by product candidate was as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73</span></td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,908</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>3-71</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">712</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">324</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other product candidates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other external service provider costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">102</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total external service provider costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,054</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,258</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were $3.3 million
for the three months ended December 31, 2022, as compared to $3.1 million for the same quarter of fiscal 2022, an increase of $0.2 million
mostly relating to an increase in professional and IP related costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter, we utilized cash and cash equivalents
of $5.8 million to fund our operations, compared to $3.5 million during comparable quarter in fiscal 2022. Our cash position was $143.6
million at December 31, 2022 compared to $149.2 million at our fiscal year ended September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to continue an increase in our research
and development expenditures as we advance our ANAVEX<sup>&#174;</sup>2-73 clinical trials, including planned advancement of ANAVEX<sup>&#174;</sup>2-73
for Parkinson&#8217;s disease program, planned initiation of a Fragile X clinical program, ongoing extension trials of our current clinical
programs, continued advancement of our other pipeline compounds such as ANAVEX<sup>&#174;</sup>3-71, and as we continue to add additional
staffing to manage and support these clinical initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other income (net)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net amount of other income for the three months
ended December 31, 2022 was $2.4 million as compared to $0.9 million for the comparable three months ended December 31, 2021. The increase
in other income for the quarter is primarily related to an increase in return on excess cash invested in cash equivalents as well as a
foreign exchange gain relating to the recovery of the Australian dollar relative to the US dollar during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the current quarter was $13.0 million,
or $0.17 per share, as compared to $10.9 million, or $0.14 per share in the comparative quarter of fiscal 2022. The increase in net loss
for the quarter is primarily related to increased research and development fees as discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Working Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30, 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">148,371,922</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">152,704,603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,247,846</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,213,561</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Working Capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">135,124,076</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142,491,042</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022, we had current assets of $148.4
million, a decrease of $4.3 million from September 30, 2022. The decrease in current assets relates mostly to cash used in operations
of $5.8 million for the quarter ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022, we had current liabilities of
$13.2 million, an increase of $3.0 million from September 30, 2022. A portion of this increase relates to an increase in deferred grant
income of $0.5 million relating to amounts received during the quarter for a research grant awarded by the Michael J. Fox Foundation for
Parkinson&#8217;s Research. Other increases in current liabilities relate to amounts owed at period end for manufacturing of additional
clinical trial supplies for use in future studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We intend to
continue to use our capital resources to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71, and
to perform work necessary to prepare for future development of our pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table summarizes cash flows during the three months ended December 31, 2022 and 2021: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net cash flows used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,794,257</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,500,955</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash flows from financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">258,244</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,539,565</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Decrease in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,536,013</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(961,390</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow used in operating activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities for the three
months ended December 31, 2022 was $5.8 million, compared to $3.5 million during the comparable quarter ended December 31, 2021. The principal
reason for this increase in net cash used in operating activities in the current period is due to the receipt of the Company&#8217;s annual
research and development incentive income refund in the comparable quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow provided by financing activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities for the quarter
ended December 31, 2022 was $0.3 million, attributable to the exercise of employee stock options, while <span style="background-color: white">cash
provided by financing activities for the quarter ended December 31, 2021 was </span>$2.5 million, primarily attributable to the sale of
common shares at various market prices under the Sales Agreement, described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Controlled Equity Offering Sales Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2020, we entered into an Amended and Restated
Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;),
pursuant to which we may offer and sell shares of common stock registered under an effective registration statement from time to time
through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on our instructions
and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock by methods deemed to
be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the time of sale or at prices related
to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to our prior written
consent. We are not obligated to make any sales of shares under the Sales Agreement. We or the Sales Agents may suspend or terminate the
At-the-Market Offering upon notice to the other party, subject to certain conditions. The Sales Agents will act as agents on a commercially
reasonable efforts basis consistent with their normal trading and sales practices, applicable state and federal law, and rules and regulations
and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to pay the Sales Agents&#8217; commissions
for their services of 3.0% of the gross proceeds from the sale of shares of common stock pursuant to the Sales Agreement. We have also
agreed to provide the Sales Agents with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shares were sold during the quarter ended December
31, 2022 under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended December 31 2021, 99,588
shares were sold under the Sales Agreement for gross proceeds of $2.3 million (net proceeds of $2.1 million after deducting commissions
and offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>CRITICAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We prepare our interim condensed
consolidated financial statements in accordance with accounting principles generally accepted in the United States of America and make
estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses, and the related disclosures of
contingent liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable in the circumstances.
Actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There have been no significant
changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the year ended September 30,
2022, as filed with the SEC on November 28, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Please refer to Note 2 &#8220;Recent
Accounting Pronouncements&#8221; in notes to our Interim Condensed Consolidated Financial Statements included in this Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_004"></span>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Not applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>ITEM 4. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Disclosure Controls and
Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We maintain disclosure controls
and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports
filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules
and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive
officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We carried out an evaluation,
under the supervision and with the participation of our management, including our principal executive officer and principal financial
officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a 15(e) under
the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Changes in Internal
Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the quarter ended
December 31, 2022, there were no changes to our internal control over financial reporting identified in management&#8217;s evaluation
pursuant to Rules 13a 15(d) or 15d 15 (d) of the Exchange Act that materially affected, or are reasonably likely to materially affect,
our internal controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_006"></span>PART II &#8211; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>ITEM 1. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our Company
or our subsidiaries are a party or of which any of their property is subject. There are no proceedings in which any of our directors,
officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse party or has a material
interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_008"></span>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the risk factors
discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2022,
filed with the SEC on November 28, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_009"></span>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period covered by this Quarterly Report
on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously
reported in a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_010"></span>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_012"></span>ITEM 5. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023 (the &#8220;Execution
Date&#8221;), the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights
agreement (&#8220;RRA&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), an Illinois limited liability company,
whereby the Company has the right, in its sole discretion, to sell to LPC up to $150,000,000 in shares of the Company&#8217;s common
stock, par value $0.001 per share (&#8220;Common Stock&#8221;) from time to time over a 36 month period pursuant to the terms of
the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On any business day and subject to certain customary
conditions, the Company may direct LPC to purchase up to 200,000 shares of Common Stock (such purchases, &#8220;<span style="text-decoration: underline">Regular
Purchases</span>&#8221;). The amount of a Regular Purchase may increase under certain circumstances based on the market price of the Common
Stock; provided, however, that LPC&#8217;s committed obligation under any Regular Purchase shall not exceed $4,000,000. The purchase price
of shares of Common Stock will be based on the then prevailing market prices of such shares at the time of sales as described in the Purchase
Agreement. There are no limits on the price per share that LPC may pay to purchase Common Stock under the Purchase Agreement. In addition,
if the Company has directed LPC to purchase the full amount of Common Stock available as a Regular Purchase on a given day, it may direct
LPC to purchase additional amounts as &#8220;accelerated purchases&#8221; and &#8220;additional accelerated purchases&#8221; as set forth
in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement limits the Company&#8217;s
sale shares of Common Stock to LPC to 15,606,426 shares of Common Stock, representing 19.99% of the shares of the Common Stock outstanding
on the date of the Purchase Agreement unless (i)&#160;shareholder approval is obtained to issue more than such amount or (ii)&#160;the
average price of all applicable sales of Common Stock to LPC under the Purchase Agreement equals or exceeds the lower of (A) the closing
price of the Common Stock on the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing price
of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement also prohibits the Company
from directing LPC to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock then
beneficially owned by Lincoln Park and its affiliates, would result in LPC and its affiliates having beneficial ownership, at any single
point in time, of more than 4.99% of the then total outstanding shares of Common Stock, as calculated pursuant to Section&#160;13(d) of
the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement contains customary representations,
warranties, covenants, closing conditions and indemnification and termination provisions by, among and for the benefit of the parties.
LPC has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company&#8217;s
Common Stock. The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at its sole discretion;
provided, however, that the Company shall not enter into any &#8220;Variable Rate Transaction&#8221; as defined in the Purchase Agreement,
including the issuance of any floating conversion rate or variable priced equity-like securities, but excluding any &#8220;At-the-Market&#8221;
offering with a registered broker-dealer, during the 36 month term of the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the Purchase Agreement,
the Company will issue to LPC 75,000 shares of Common Stock as a commitment fee and shall issue up to 75,000 shares pro rata as up to
$150,000,000 of shares of our common stock are purchase by LPC at our discretion from time to time, in accordance with the Purchase Agreement.
The Purchase Agreement may be terminated by the Company at any time at its discretion without any cost to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Actual sales of shares of Common Stock to LPC under
the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others,
market conditions, the trading price of the Common Stock and determinations by the Company as to the appropriate sources of funding for
the Company and its operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The net proceeds under the Purchase Agreement to the Company will depend
on the frequency and prices at which the Company sells shares of its stock to LPC. The Company expects that any proceeds received by
the Company from such sales to LPC will be used for working capital and general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_013"></span>ITEM 6. EXHIBIT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-transform: uppercase">&#160;</span></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border: black 1pt solid; width: 11%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Exhibit <br /> Number </b></span></td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 89%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b><br />Description</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(3) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Articles of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">3.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm"><span style="font-size: 10pt">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">3.2</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><span style="font-size: 10pt">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(4)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Instruments Defining the Rights of Security Holders</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">4.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4385_ex4-1.htm"><span style="font-size: 10pt">Registration Rights Agreement, dated February 3, 2023, by and between the Company and Lincoln Park Capital Fund, LLC</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(10)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Material Contracts</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">10.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4385_ex10-1.htm"><span style="font-size: 10pt">Purchase Agreement dated February 3, 2023 by and between the Company and Lincoln Park Capital Fund, LLC</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(31) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Rule 13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">31.1*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4385_ex31-1.htm"><span style="font-size: 10pt">Certification of Christopher Missling, PhD.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">31.2*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4385_ex31-2.htm"><span style="font-size: 10pt">Certification of Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(32) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Section 1350 Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">32.1**</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4385_ex32-1.htm"><span style="font-size: 10pt">Certification of Christopher Missling, PhD and Sandra Boenisch.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(101)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.INS*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.SCH*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.CAL*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.DEF*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.LAB*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.PRE*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">** Furnished herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: normal 16pt Calibri Light; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>SIGNATURES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX LIFE SCIENCES CORP. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 50%"><span style="font-size: 10pt">/s/Christopher Missling, PhD</span></td>
<td style="width: 50%">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid">&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Christopher Missling, PhD</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Chief Executive Officer</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Date: February 7, 2023</span></td>
<td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-size: 10pt">/s/Sandra Boenisch</span></td>
    <td style="width: 50%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Principal Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: February 7, 2023</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">21</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>e4385_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT 4.1</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REGISTRATION RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>REGISTRATION RIGHTS AGREEMENT</B>
(this &ldquo;<U>Agreement</U>&rdquo;), dated as of February 3, 2023 by and between <B>ANAVEX LIFE SCIENCES CORP., </B>a Nevada corporation
(the &ldquo;<U>Company</U>&rdquo;), and <B>LINCOLN PARK CAPITAL FUND, LLC,</B> an Illinois limited liability company (together with its
permitted assigns, the &ldquo;<U>Buyer</U>&rdquo;). Capitalized terms used herein and not otherwise defined herein shall have the respective
meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<U>Purchase Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company has agreed, upon the
terms and subject to the conditions of the Purchase Agreement, to sell to the Buyer up to One Hundred Fifty Million Dollars ($150,000,000)
of Purchase Shares and to induce the Buyer to enter into the Purchase Agreement, the Company has agreed to provide certain registration
rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively,
the &ldquo;<U>Securities Act</U>&rdquo;), and applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>NOW, THEREFORE,</B> in consideration
of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Company and the Buyer hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DEFINITIONS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt">As used in this Agreement,
the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Investor</U>&rdquo;
means the Buyer, any transferee or assignee thereof to whom a Buyer assigns its rights under this Agreement in accordance with <U>Section
8</U> and who agrees to become bound by the provisions of this Agreement, and any transferee or assignee thereof to whom a transferee
or assignee assigns its rights under this Agreement in accordance with <U>Section 8</U> and who agrees to become bound by the provisions
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Person</U>&rdquo;
means any individual or entity including but not limited to any corporation, a limited liability company, an association, a partnership,
an organization, a business, an individual, a governmental or political subdivision thereof or a governmental agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Register</U>,&rdquo;
&ldquo;<U>Registered</U>,&rdquo; and &ldquo;Registration&rdquo; refer to a registration effected by preparing and filing one or more registration
statements of the Company in compliance with the Securities Act and pursuant to Rule 415 under the Securities Act or any successor rule
providing for offering securities on a continuous basis (&ldquo;<U>Rule 415</U>&rdquo;), and the declaration or ordering of effectiveness
of such registration statement(s) by the United States Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Registrable
Securities</U>&rdquo; means all of the Purchase Shares which have been, or which may, from time to time be issued, including without limitation
all of the Commitment Shares which have been or which may, from time to time, be issued or become issuable to the Investor under the Purchase
Agreement (without regard to any limitation or restriction on purchases), and any and all shares of capital stock issued or issuable with
respect to the Purchase Shares or the Commitment Shares or the Purchase Agreement as a result of any stock split, stock dividend, recapitalization,
exchange or similar event or otherwise, without regard to any limitation on purchases under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Registration
Statement</U>&rdquo; means the Shelf Registration Statement and any other registration statement of the Company that Registers Registrable
Securities, including a New Registration Statement, as amended when each became effective, including all documents filed as part thereof
or incorporated by reference therein, and including any information contained in a Prospectus subsequently filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Shelf
Registration Statement</U>&rdquo; means the Company&rsquo;s existing registration statement on Form S-3 ASR (File No. 333-259788) and
including any registration statement filed in connection therewith under Rule 462(b) pursuant to the Securities Act (a &ldquo;<U>462(b)
Registration Statement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>REGISTRATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Mandatory
Registration.</U> The Company agrees that it shall, within the time required under Rule 424(b) under the Securities Act, file with the
SEC the Initial Prospectus Supplement pursuant to Rule 424(b) under the Securities Act specifically relating to the transactions contemplated
by, and describing the material terms and conditions of, the Transaction Documents, containing information previously omitted at the time
of effectiveness of the Registration Statement in reliance on Rule 430B under the Securities Act, and disclosing all information relating
to the transactions contemplated hereby required to be disclosed in the Registration Statement and the Prospectus as of the date of the
Initial Prospectus Supplement, including, without limitation, information required to be disclosed in the section captioned &ldquo;Plan
of Distribution&rdquo; in the Prospectus. The Investor acknowledges that it will be identified in the Initial Prospectus Supplement as
an underwriter within the meaning of Section 2(a)(11) of the Securities Act. The Company shall permit the Investor to review and comment
upon the Initial Prospectus Supplement at least two (2) Business Days prior to their filing with the SEC, the Company shall give due consideration
to all such comments, and the Company shall not file the Initial Prospectus Supplement with the SEC in a form to which the Investor reasonably
objects. The Investor shall use its reasonable best efforts to comment upon the Initial Prospectus Supplement within one (1) Business
Day from the date the Investor receives the final pre-filing draft version thereof from the Company. The Investor shall furnish to the
Company such information regarding itself, the Securities held by it and the intended method of distribution thereof, including any arrangement
between the Investor and any other Person relating to the sale or distribution of the Securities, as shall be reasonably requested by
the Company in connection with the preparation and filing of the Initial Prospectus Supplement, and shall otherwise cooperate with the
Company as reasonably requested by the Company in connection with the preparation and filing of the Initial Prospectus Supplement with
the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Effectiveness</U>.
The Company shall use its reasonable best efforts to keep the Registration Statement effective under the Securities Act (including through
any necessary renewals), and to keep the Registration Statement and the Prospectus current and available (including through any necessary
renewals) for issuances and sales of all possible Registrable Securities by the Company to the Investor, and for the sale of all of the
Registrable Securities by the Investor, at all times until the earlier of (i) the date on which the Investor shall have sold all the Registrable
Securities and no Available Amount remains and (ii) the earlier of (A) 180 days following the Maturity Date and (B) the nine months following
the termination of the Purchase Agreement (the &ldquo;<U>Registration Period</U>&rdquo;). Without limiting the generality of the foregoing,
during the Registration Period, the Company shall (a) take all action necessary to cause the Common Stock to continue to be Registered
as a class of securities under Section 12(b) of the Exchange Act and shall not take any action or file any document (whether or not permitted
by the Exchange Act) to terminate or suspend such registration and (b) file or furnish on or before their respective due dates all reports
and other documents required to be filed or furnished by the Company pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision
of or under the Exchange Act, and shall not take any action or file any document (whether or not permitted by the Exchange Act) to terminate
or suspend its reporting and filing obligations under the Exchange Act. The Registration Statement (including any amendments or supplements
thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in the light of the circumstances then existing, not misleading. In the event that the Company
files a Rule 462(b) Registration Statement, such Rule 462(b) Registration Statement shall have been filed and automatically effective
pursuant to Rule 462 under the Securities Act prior to the filing of the Initial Prospectus Supplement under <U>Section 2(a)</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Sufficient
Number of Shares Registered</U>. In the event the number of shares available under the Shelf Registration Statement, including any 462(b)
Registration Statement, is insufficient to cover all of the Registrable Securities, the Company shall, to the extent necessary and permissible,
file a new Registration Statement (a &ldquo;<U>New Registration Statement</U>&rdquo;), so as to cover all of such Registrable Securities
as soon as practicable, but in any event not later than ten (10) Business Days after the necessity therefor arises, subject to any limits
that may be imposed by the SEC pursuant to Rule 415 under the Securities Act. The Company shall use its reasonable best efforts to cause
such New Registration Statement to become effective as soon as practicable following the filing thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Offering</U>.
If the staff of the SEC (the &ldquo;<U>Staff</U>&rdquo;) or the SEC seeks to characterize any offering pursuant to a Registration Statement
as constituting an offering of securities that does not permit such Registration Statement be used by the Investor under Rule 415 at then-prevailing
market prices (and not fixed prices), or if after the filing of the Initial Prospectus Supplement with the SEC pursuant to <U>Section
2(a)</U>, the Company is otherwise required by the Staff or the SEC to reduce the number of Registrable Securities registered under the
Shelf Registration Statement, then the Company shall reduce the number of Registrable Securities to be registered under the Shelf Registration
Statement (with the prior consent, which shall not be unreasonably withheld, of the Investor and its legal counsel as to the specific
Registrable Securities to be removed therefrom) until such time as the Staff and the SEC shall so permit such Registration Statement to
be used as aforesaid. In the event of any reduction in Registrable Securities pursuant to this paragraph, the Company shall file one or
more New Registration Statements in accordance with <U>Section 2(c)</U> until such time as all Registrable Securities have been included
in Registration Statements that have been declared effective and the prospectuses contained therein is available for use by the Investor.
Notwithstanding any provision herein or in the Purchase Agreement to the contrary, the Company&rsquo;s obligations to register Registrable
Securities (and any related conditions to the Investor&rsquo;s obligations) shall be qualified as necessary to comport with any requirement
of the SEC or the Staff as addressed in this <U>Section 2(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RELATED
OBLIGATIONS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt">With respect to the Registration
Statement and whenever any Registrable Securities are to be Registered pursuant to <U>Section 2</U> including on the Shelf Registration
Statement or any New Registration Statement, the Company shall use its reasonable best efforts to effect the registration of the Registrable
Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notifications</U>.
The Company will notify the Investor promptly of the time when any subsequent amendment to the Shelf Registration Statement or any New
Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or where
a receipt has been issued therefor or any subsequent supplement to a Prospectus has been filed and of any request by the SEC for any amendment
or supplement to the Registration Statement, any New Registration Statement or any Prospectus or for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Amendments.</U>
The Company will prepare and file with the SEC, promptly upon the Investor&rsquo;s request, any amendments or supplements to the Shelf
Registration Statement, any New Registration Statement or any Prospectus, as applicable, that, in the reasonable opinion of the Investor
and the Company, may be necessary or advisable in connection with any acquisition or sale of Registrable Securities by the Investor (provided,
however, that the failure of the Investor to make such request shall not relieve the Company of any obligation or liability hereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Investor
Review</U>. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any
Prospectus, other than documents incorporated by reference, relating to the Investor, the Registrable Securities or the transactions contemplated
hereby unless (A) the Investor shall have been advised and afforded the opportunity to review and comment thereon at least two (2) Business
Days prior to filing with the SEC, (B) the Company shall have given due consideration to any comments thereon received from the Investor
or its counsel, and (C) the Investor has not reasonably objected thereto (provided, however, that the failure of the Investor to make
such objection shall not relieve the Company of any obligation or liability hereunder), and the Company will furnish to the Investor at
the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement
or any Prospectus, except for those documents available via EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Form
S-3</U>. The Company will cause each amendment or supplement to the Prospectus, other than documents incorporated by reference, to be
filed with the SEC as required pursuant to the rules of Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Copies
Available</U>. The Company will furnish to the Investor and its counsel (at the expense of the Company) copies of the Registration Statement,
the Prospectus (including all documents incorporated by reference therein), any Prospectus Supplement, any New Registration Statement
and all amendments and supplements to the Registration Statement, the Prospectus or any New Registration Statement that are filed with
the SEC during the Registration Period (including all documents filed with or furnished to the SEC during such period that are deemed
to be incorporated by reference therein), in each case as soon as reasonably practicable upon the Investor&rsquo;s request and in such
quantities as the Investor may from time to time reasonably request and, at the Investor&rsquo;s request, will also furnish copies of
the Prospectus to each exchange or market on which sales of the Registrable Securities may be made; provided, however, that the Company
shall not be required to furnish any document (other than the Prospectus) to the Investor to the extent such document is available on
EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Qualification</U>.
The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to qualify (i) the issuance
of the Commitment Shares and the sale of the Purchase Shares to the Investor under the Purchase Agreement and (ii) any subsequent resale
of all Commitment Shares and all Purchase Shares by the Investor, in each case, under applicable securities or &ldquo;Blue Sky&rdquo;
laws of the states of the United States in such states as is reasonably requested by the Investor during the Registration Period, and
shall provide evidence of any such action so taken to the Investor.&nbsp;During the Registration Period, the Company shall promptly notify
the Investor of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of
any of the Registrable Securities for sale under the securities or &ldquo;blue sky&rdquo; laws of any jurisdiction in the United States
or its receipt of actual notice of the initiation or threat of any proceeding for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notification
of Stop Orders; Material Changes</U>. The Company shall advise the Investor promptly (but in no event later than 24 hours) and shall confirm
such advice in writing, in each case: (i) of the Company&rsquo;s receipt of notice of any request by the SEC or any other federal or state
governmental authority for amendment of or a supplement to the Registration Statement or any Prospectus or for any additional information;
(ii) of the Company&rsquo;s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop
order suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or Prospectus
Supplement, or any New Registration Statement, or of the Company&rsquo;s receipt of any notification of the suspension of qualification
of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding
for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes any statement of a material fact
made in the Registration Statement or any Prospectus untrue or which requires the making of any additions to or changes to the statements
then made in the Registration Statement or any Prospectus in order to state a material fact required by the Securities Act to be stated
therein or necessary in order to make the statements then made therein (in the case of any Prospectus, in light of the circumstances under
which they were made) not misleading, or of the necessity to amend the Registration Statement or any Prospectus to comply with the Securities
Act or any other law. The Company shall not be required to disclose to the Investor the substance or specific reasons of any of the events
set forth in clauses (i) through (iii) of the immediately preceding sentence, but rather, shall only be required to disclose that the
event has occurred. If at any time the SEC, or any other federal or state governmental authority shall issue any stop order suspending
the effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or Prospectus Supplement, the Company
shall use its reasonable best efforts to obtain the withdrawal of such order at the earliest possible time. The Company shall furnish
to the Investor, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state governmental
authority to the Company or its representatives relating to the Shelf Registration Statement, any New Registration Statement or any Prospectus,
or Prospectus Supplement as the case may be. The Company shall not deliver to the Investor any Regular Purchase Notice, Accelerated Purchase
Notice or Additional Accelerated Purchase Notice, and the Investor shall not be obligated to purchase any shares of Common Stock under
this Agreement, during the continuation or pendency of any of the foregoing events. If at any time the SEC shall issue any stop order
suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or any Prospectus Supplement,
the Company shall use its reasonable best efforts to obtain the withdrawal of such order at the earliest possible time. The Company shall
furnish to the Investor, without charge, a copy of any correspondence from the SEC or the staff of the SEC to the Company or its representatives
relating to the Registration Statement or the Prospectus, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Listing
on the Principal Market</U>. The Company shall promptly secure the listing, or conditional listing as applicable, of all of the Purchase
Shares and Commitment Shares to be issued to the Investor hereunder on the Principal Market (subject to standard listing conditions, if
any, for transactions of this nature, official notice of issuance and the Exchange Cap) and upon each other national securities exchange
or automated quotation system, if any, upon which the Common Stock are then listed, and shall maintain, so long as any Common Stock shall
be so listed, such listing of all such Registrable Securities from time to time issuable hereunder. The Company shall use commercially
reasonable efforts to maintain the listing of the Common Stock on the Principal Market and shall comply in all respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules and regulations of the Principal Market. The Company shall not take
any action that would reasonably be expected to result in the delisting or suspension of the Common Stock on the Principal Market. The
Company shall promptly, and in no event later than the following Business Day, provide to the Investor copies of any notices it receives
from any Person regarding the continued eligibility of the Common Stock for listing on the Principal Market; provided, however, that the
Company shall not provide the Investor copies of any such notice that the Company reasonably believes constitutes material non-public
information and that the Company would not be required to publicly disclose such notice in any report or statement filed with the SEC
under the Exchange Act (including on Form 8-K) or the Securities Act. The Company shall pay all fees and expenses in connection with satisfying
its obligations under this <U>Section 3(h)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delivery
of Shares</U>. The Company shall cooperate with the Investor to facilitate the timely preparation and delivery of DWAC Shares (not bearing
any restrictive legend) representing the Registrable Securities to be offered pursuant to the Shelf Registration Statement or any New
Registration Statement and enable such DWAC Shares to be in such denominations or amounts as the Investor may reasonably request and registered
in such names as the Investor may request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Transfer
Agent</U>. The Company shall at all times maintain the services of the Transfer Agent with respect to its Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Approvals</U>.
The Company shall use its reasonable best efforts to cause the Registrable Securities covered by any Registration Statement to be Registered
with or approved by such other governmental agencies or authorities in the United States as may be necessary to consummate the disposition
of such Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Confirmation
of Effectiveness</U>. If reasonably requested by the Investor at any time, the Company shall deliver to the Investor a written confirmation
from Company&rsquo;s counsel of whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason
(including, without limitation, the issuance of a stop order) and whether or not the Registration Statement is currently effective and
available to the Company for sale of all of the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">m.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Further
Assurances</U>. The Company agrees to take all other reasonable actions as necessary and reasonably requested by the Investor to expedite
and facilitate disposition by the Investor of Registrable Securities pursuant to any Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">n.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Suspension
of Sales</U>. The Investor agrees that, upon receipt of any notice from the Company of the existence of any suspension or stop order as
set forth in <U>Section 3(f)</U> or <U>3(g)</U>, the Investor will immediately discontinue disposition of Registrable Securities pursuant
to any Registration Statement covering such Registrable Securities until the Investor&rsquo;s receipt of the copies of a notice regarding
the resolution or withdrawal of the suspension or stop order as contemplated by <U>Section 3(f)</U> or <U>3(g)</U>. Notwithstanding anything
to the contrary, the Company shall cause its transfer agent to promptly deliver to the Investor DWAC Shares without any restrictive legend
in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which the
Investor has entered into a contract for sale prior to the Investor&rsquo;s receipt of a notice from the Company of the happening of any
event of the kind described in <U>Section 3(f)</U> or <U>3(g)</U> and for which the Investor has not yet settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>OBLIGATIONS
OF THE INVESTOR</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Investor
Information</U>. The Company shall notify the Investor in writing of the information the Company reasonably requires from the Investor
in connection with any registration statement hereunder. The Investor shall furnish to the Company such information regarding itself,
the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably
required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration
as the Company may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Investor
Cooperation</U>. The Investor agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation
and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>EXPENSES OF REGISTRATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt">All reasonable expenses of the
Company, other than sales or brokerage commissions, and fees and disbursements of counsel for, and other expenses of, the Investor, incurred
in connection with registrations, filings or qualifications pursuant to <U>Sections 2</U> and <U>3</U>, including, without limitation,
all registration, listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company,
shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>INDEMNIFICATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each Person,
if any, who controls the Investor, the members, the directors, officers, partners, employees, members, managers, agents, representatives
of the Investor and each Person, if any, who controls the Investor within the meaning of the Securities Act or the Securities Exchange
Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;) (each, an &ldquo;<U>Indemnified Person</U>&rdquo;), against any losses,
claims, damages, liabilities, judgments, fines, penalties, charges, costs, reasonable attorneys&rsquo; fees, amounts paid in settlement
(with the consent of the Company, such consent not to be unreasonably withheld) or reasonable expenses, joint or several, (collectively,
&ldquo;<U>Claims</U>&rdquo;) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding,
investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body
or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (&ldquo;<U>Indemnified Damages</U>&rdquo;),
to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect
thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in the Shelf Registration
Statement, any New Registration Statement or any post-effective amendment thereto or in any filing made in connection with the qualification
of the offering under the securities or other &ldquo;blue sky&rdquo; laws of any jurisdiction in which Registrable Securities are offered
(&ldquo;<U>Blue Sky Filing</U>&rdquo;), or the omission or alleged omission to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement of a material fact contained
in the final Prospectus the omission or alleged omission to state therein any material fact necessary to make the statements made therein,
in light of the circumstances under which the statements therein were made, not misleading, (iii) any violation or alleged violation by
the Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any state securities law, or any rule
or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to the Shelf Registration Statement or any
New Registration Statement or (iv) any material violation by the Company of this Agreement (the matters in the foregoing clauses (i) through
(iv) being, collectively, &ldquo;<U>Violations</U>&rdquo;). The Company shall reimburse each Indemnified Person promptly as such expenses
are incurred and are due and payable, for any reasonable out-of-pocket legal fees or other reasonable expenses incurred by them in connection
with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement
contained in this <U>Section 6(a)</U>: (i) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation
which occurs in reliance upon and in conformity with information about the Investor furnished in writing to the Company by such Indemnified
Person expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement, the Prospectus
or any such amendment thereof or supplement thereto, in each case if the foregoing was timely made available by the Company pursuant to
<U>Section 3(c)</U> or <U>Section 3(e)</U>; (ii) with respect to any superseded prospectus, shall not inure to the benefit of any such
Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit
of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected
in the revised prospectus, as then amended or supplemented, if such revised prospectus was timely made available by the Company pursuant
to <U>Section 3(c)</U> or <U>Section 3(e)</U>, and the Indemnified Person was promptly advised in writing not to use the incorrect prospectus
prior to the use giving rise to a violation and such Indemnified Person, notwithstanding such advice, used it; (iii) shall not be available
to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered the prospectus made available by
the Company, if such prospectus was timely made available by the Company pursuant to <U>Section 3(c)</U> or <U>Section 3(e)</U>; and (iv)
shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company,
which consent shall not be unreasonably withheld. Such indemnity shall remain in full force and effect regardless of any investigation
made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to
<U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
connection with the Shelf Registration Statement, any New Registration Statement or Prospectus, the Investor agrees to indemnify, hold
harmless and defend, to the same extent and in the same manner as is set forth in <U>Section 6(a)</U>, the Company, each of its directors,
each of its officers who signed the Shelf Registration Statement or signs any New Registration Statement, each Person, if any, who controls
the Company within the meaning of the Securities Act or the Exchange Act (collectively and together with an Indemnified Person, an &ldquo;<U>Indemnified
Party</U>&rdquo;), against any Claim or Indemnified Damages to which any of them may become subject, under the Securities Act, the Exchange
Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon any Violation, in each case to the extent,
and only to the extent, that such Violation occurs in reliance upon and in conformity with written information about the Investor and
furnished to the Company by the Investor expressly for use in connection with such Registration Statement; and, subject to <U>Section
6(d)</U>, the Investor will reimburse any legal or other expenses reasonably incurred by them in connection with investigating or defending
any such Claim; provided, however, that the indemnity agreement contained in this <U>Section 6(b)</U> and the agreement with respect to
contribution contained in <U>Section 7</U> shall not apply to amounts paid in settlement of any Claim if such settlement is effected without
the prior written consent of the Investor, which consent shall not be unreasonably withheld; provided, further, however, that the Investor
shall be liable under this <U>Section 6(b)</U> for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds
to the Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain
in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer
of the Registrable Securities by the Investor pursuant to <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Promptly
after receipt by an Indemnified Person or Indemnified Party under this <U>Section 6</U> of notice of the commencement of any action or
proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if
a Claim in respect thereof is to be made against any indemnifying party under this <U>Section 6</U>, deliver to the indemnifying party
a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the
indemnifying party so desires, jointly with any other indemnifying party similarly notified, to assume control of the defense thereof
with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be;
provided, however, that an Indemnified Person or Indemnified Party shall have the right to retain its own counsel with the fees and expenses
to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation
by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential
differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding.
The Indemnified Party or Indemnified Person shall cooperate fully with the indemnifying party in connection with any negotiation or defense
of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available
to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified
Party or Indemnified Person fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto.
No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided,
however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without
the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise
which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party or Indemnified
Person of a release from all liability in respect to such claim or litigation. Following indemnification as provided for hereunder, the
indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties,
firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the
Indemnified Person or Indemnified Party under this <U>Section 6</U>, except to the extent that the indemnifying party is prejudiced in
its ability to defend such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
indemnification required by this <U>Section 6</U> shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant to this <U>Section
6</U> which person is later determined to not be entitled to such payment shall return such payment to the person making it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified
Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>CONTRIBUTION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt">To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under <U>Section 6</U> to the fullest extent permitted by law; provided, however,
that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and
(ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds received by such seller
from the sale of such Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>ASSIGNMENT
OF REGISTRATION RIGHTS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt">The Company shall not assign this
Agreement or any rights or obligations hereunder without the prior written consent of the Investor; provided, however, that any transaction,
whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company remains the surviving entity
immediately after such transaction shall not be deemed an assignment. The Investor may not assign its rights under this Agreement without
the prior written consent of the Company, other than to an affiliate of the Investor controlled by Jonathan Cope or Josh Scheinfeld, in
which case the assignee must agree in writing to be bound by the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>AMENDMENT
OF REGISTRATION RIGHTS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt">No provision of this Agreement
may be amended or waived by the parties from and after the date that is one Business Day immediately preceding the initial filing of the
Initial Prospectus Supplement with the SEC. Subject to the immediately preceding sentence, no provision of this Agreement may be (i) amended
other than by a written instrument signed by both parties hereto or (ii) waived other than in a written instrument signed by the party
against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement or otherwise,
or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile
or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or
(iii) one (1) Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the
party to receive the same. The addresses for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Anavex Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">630 5th Avenue, 20th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">New York, New York 10111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Telephone: &#9;(844) 689-3939</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">E-mail: &#9;cmissling@anavexcorp.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Attention: &#9;Christopher Missling, PhD.,
CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify">With a copy to (which shall not constitute
notice or service of process):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">K&amp;L Gates LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">200 S. Biscayne Blvd., Ste. 3900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Miami, Florida 33131</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Telephone: &#9;(305) 539-3306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Facsimile: &#9;(305) 358-7095</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">E-mail: &#9;clayton.parker@klgates.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Attention: &#9;Clayton E. Parker, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify">If to the Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Lincoln Park Capital Fund, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">440 North Wells, Suite 410</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Chicago, Illinois 60654</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Telephone: &#9;(312) 822-9300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Facsimile: &#9;(312) 822-9301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">E-mail: &#9;jscheinfeld@lpcfunds.com/jcope@lpcfunds.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Attention: &#9;Josh Scheinfeld/Jonathan
Cope</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">If to the Transfer Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify; text-indent: 36pt">Nevada Agency and Transfer
Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify; text-indent: 36pt">50 West Liberty Street,
Suite 880</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify; text-indent: 36pt">Reno, NV 89501</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify; text-indent: 36pt">Tel: (775) 322-0626</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify; text-indent: 36pt">Fax: (775) 322-5623</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify; text-indent: 36pt">E-mail: tiffany@natco.org</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">Attention: Tiffany Baxter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">or at such other address and/or facsimile number and/or
to the attention of such other person as the recipient party has specified by written notice given to each other party three (3) Business
Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver
or other communication, (B) mechanically or electronically generated by the sender&rsquo;s facsimile machine or email account containing
the time, date, recipient facsimile number or email address, as applicable, and an image of the first page of such transmission or (C)
provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing
Law</U>. The corporate laws of the State of Nevada shall govern all issues concerning the relative rights of the Company and its stockholders.
All other questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal
laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting the State of Illinois, County
of Cook, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue
of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any provision of this Agreement
shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability
of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other
jurisdiction. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Integration</U>.
This Agreement and the Purchase Agreement and the exhibits and schedules hereto and thereto constitute the entire agreement among the
parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings,
other than those set forth or referred to herein and therein. This Agreement and the Purchase Agreement supersede all prior agreements
and understandings among the parties hereto with respect to the subject matter hereof and thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Survival</U>.
Subject to the requirements of <U>Section 8</U>, this Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Headings</U>.
The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Counterparts</U>.
This Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute
one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission
or by e-mail in a &ldquo;.pdf&rdquo; format data file of a copy of this Agreement bearing the signature of the party so delivering this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Further
Assurances</U>. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Strict Construction</U>. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent and no rules of strict construction will be applied against any party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 59pt"><FONT STYLE="color: #010000">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Third Party Benefits</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except with respect to <U>Section
6</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>* * * * * *</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>IN WITNESS WHEREOF,</B> the
parties have caused this Registration Rights Agreement to be duly executed as of day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>THE COMPANY</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ANAVEX LIFE SCIENCES CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Christopher Missling</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>BUYER:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>LINCOLN PARK CAPITAL FUND, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BY: LINCOLN PARK CAPITAL, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BY: ROCKLEDGE CAPITAL CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">/s/
Josh Scheinfeld</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Scheinfeld</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">11<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>e4385_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>THIS PURCHASE AGREEMENT</B>
(the &ldquo;<U>Agreement</U>&rdquo;), dated as of February 3, 2023 by and between <B>ANAVEX LIFE SCIENCES CORP.</B>, a Nevada corporation
(the &ldquo;<U>Company</U>&rdquo;), and <B>LINCOLN PARK CAPITAL FUND</B>, <B>LLC</B>, an Illinois limited liability company (the &ldquo;<U>Investor</U>&rdquo;).
Capitalized terms used herein and not otherwise defined herein are defined in <U>Section 1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Subject to the terms and conditions
set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to One Hundred
Fifty Million Dollars ($150,000,000) of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;<U>Common Stock</U>&rdquo;).
The shares of Common Stock to be purchased hereunder are referred to herein as the &ldquo;<U>Purchase Shares</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">NOW THEREFORE, in consideration
of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Company and the Investor hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>CERTAIN DEFINITIONS.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For purposes of this Agreement,
the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <FONT STYLE="font-size: 10pt">&ldquo;<U>Accelerated Purchase Date</U>&rdquo; means, with respect to any Accelerated Purchase made
pursuant to <U>Section 2(b)</U> hereof, the Business Day immediately following the applicable Purchase Date with respect to the corresponding
Regular Purchase referred to in <U>Section 2(b)</U> hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Accelerated Purchase Minimum Price Threshold</U>&rdquo; means, with respect to any Accelerated
Purchase made pursuant to <U>Section 2(b)</U> hereof, any minimum per share price threshold set forth in the applicable Accelerated Purchase
Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Accelerated Purchase Notice</U>&rdquo; means, with respect to any Accelerated Purchase
made pursuant to <U>Section 2(b)</U> hereof, an irrevocable written notice from the Company to the Investor directing the Investor to
buy a specified Accelerated Purchase Share Amount on the applicable Accelerated Purchase Date pursuant to <U>Section 2(b)</U> hereof at
the applicable Accelerated Purchase Price on the Accelerated Purchase Date for such Accelerated Purchase in accordance with this Agreement,
and specifying any Accelerated Purchase Minimum Price Threshold determined by the Company and including the Accelerated Purchase Share
Estimate.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <FONT STYLE="font-size: 10pt">&ldquo;<U>Accelerated Purchase Price</U>&rdquo; means, with respect to an Accelerated Purchase made
pursuant to <U>Section 2(b)</U> hereof, the lower of ninety-six percent (96%) of (i) the VWAP for the period beginning at 9:30:01 a.m.,
Eastern time, on the applicable Accelerated Purchase Date, or such other time publicly announced by the Principal Market as the official
open (or commencement) of trading on the Principal Market on such applicable Accelerated Purchase Date (the &ldquo;<U>Accelerated Purchase
Commencement Time</U>&rdquo;), and ending at the earliest of (A) 4:00:00 p.m., Eastern time, on such applicable Accelerated Purchase Date,
or such other time publicly announced by Principal Market as the official close of trading on the Principal Market on such applicable
Accelerated Purchase Date, (B) such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that
the total number (or volume) of shares of Common Stock traded on the Principal Market has exceeded the applicable Accelerated Purchase
Share Volume Maximum, and (C) such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that
the Sale Price has fallen below the applicable Accelerated Purchase Minimum Price Threshold (such earliest of (i)(A), (i)(B) and (i)(C)
above, the &ldquo;<U>Accelerated Purchase Termination Time</U>&rdquo;), and (ii) the Closing Sale Price of the Common Stock on such applicable
Accelerated Purchase Date (each to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split,
reverse stock split or other similar transaction).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Accelerated Purchase Share Amount</U>&rdquo; means, with respect to an Accelerated Purchase
made pursuant to <U>Section 2(b)</U> hereof, the number of Purchase Shares directed by the Company to be purchased by the Investor in
an Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i) 1,000% of the number of Purchase Shares
directed by the Company to be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular
Purchase referred to in clause (i) of the second sentence of <U>Section 2(b)</U> hereof (subject to the Purchase Share limitations contained
in <U>Section 2(b)</U> hereof) and (ii) an amount equal to (A) the Accelerated Purchase Share Percentage multiplied by (B) the total number
(or volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Accelerated Purchase Date beginning
at the Accelerated Purchase Commencement Time for such Accelerated Purchase and ending at the Accelerated Purchase Termination Time for
such Accelerated Purchase.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Accelerated Purchase Share Estimate</U>&rdquo; means, with respect to any Accelerated Purchase
made pursuant to <U>Section 2(b)</U> hereof, a good faith estimate by the Company of the number of Purchase Shares that the Investor shall
have the obligation to buy pursuant to the Accelerated Purchase Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Accelerated Purchase Share Percentage</U>&rdquo; means, with respect to any Accelerated
Purchase made pursuant to <U>Section 2(b)</U> hereof, thirty percent (30%).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Accelerated Purchase Share Volume Maximum</U>&rdquo; means, with respect to an Accelerated
Purchase made pursuant to <U>Section 2(b)</U> hereof, a number of shares of Common Stock equal to (i) the applicable Accelerated Purchase
Share Amount to be purchased by the Investor pursuant to the applicable Accelerated Purchase Notice for such Accelerated Purchase, divided
by (ii) the Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Additional Accelerated Purchase Date</U>&rdquo; means, with respect to an Additional Accelerated
Purchase made pursuant to <U>Section 2(c)</U> hereof, the Business Day (i) that is the Accelerated Purchase Date with respect to the corresponding
Accelerated Purchase referred to in <U>Section 2(b)</U> hereof and (ii) on which the Investor receives, prior to 1:00 p.m., Eastern time,
on such Business Day, a valid Additional Accelerated Purchase Notice for such Additional Accelerated Purchase in accordance with this
Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(j)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Additional Accelerated Purchase Minimum Price Threshold</U>&rdquo; means, with respect
to an Additional Accelerated Purchase made pursuant to <U>Section 2(c)</U> hereof, any minimum per share price threshold set forth in
the applicable Additional Accelerated Purchase Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(k)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <FONT STYLE="font-size: 10pt">&ldquo;<U>Additional Accelerated Purchase Notice</U>&rdquo; means, with respect to an Additional
Accelerated Purchase made pursuant to <U>Section 2(c)</U> hereof, an irrevocable written notice from the Company to the Investor directing
the Investor to purchase the applicable Additional Accelerated Purchase Share Amount at the Additional Accelerated Purchase Price for
such Additional Accelerated Purchase in accordance with this Agreement, and specifying any Additional Accelerated Purchase Minimum Price
Threshold determined by the Company and including the Accelerated Purchase Share Estimate.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(l)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Additional Accelerated Purchase Price</U>&rdquo; means, with respect to an Additional Accelerated
Purchase made pursuant to <U>Section 2(c)</U> hereof, the lower of ninety-six percent (96%) of (i) the VWAP for the period on the applicable
Additional Accelerated Purchase Date, beginning at the latest of (A) the applicable Accelerated Purchase Termination Time with respect
to the corresponding Accelerated Purchase referred to in <U>Section 2(c)</U> hereof on such Additional Accelerated Purchase Date, (B)
the applicable Additional Accelerated Purchase Termination Time with respect to the most recently completed prior Additional Accelerated
Purchase on such Additional Accelerated Purchase Date, as applicable, and (C) the time at which all Purchase Shares subject to all prior
Accelerated Purchases and Additional Accelerated Purchases (as applicable), including, without limitation, those that have been effected
on the same Business Day as the applicable Additional Accelerated Purchase Date with respect to which the applicable Additional Accelerated
Purchase relates, have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement (such latest of (i)(A),
(i)(B) and (i)(C) above, the &ldquo;<U>Additional Accelerated Purchase Commencement Time</U>&rdquo;), and ending at the earliest of (X)
4:00 p.m., Eastern time, on such Additional Accelerated Purchase Date, or such other time publicly announced by the Principal Market as
the official close of trading on the Principal Market on such Additional Accelerated Purchase Date, (Y) such time, from and after the
Additional Accelerated Purchase Commencement Time for such Additional Accelerated Purchase, that the total number (or volume) of shares
of Common Stock traded on the Principal Market has exceeded the applicable Additional Accelerated Purchase Share Volume Maximum, and (Z)
such time, from and after the Additional Accelerated Purchase Commencement Time for such Additional Accelerated Purchase, that the Sale
Price has fallen below the applicable Additional Accelerated Purchase Minimum Price Threshold (if any) (such earliest of (i)(X), (i)(Y)
and (i)(Z) above, the &ldquo;<U>Additional Accelerated Purchase Termination Time</U>&rdquo;), and (ii) the Closing Sale Price of the Common
Stock on such Additional Accelerated Purchase Date (each to be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split, reverse stock split or other similar transaction).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(m)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Additional Accelerated Purchase Share Amount</U>&rdquo; means, with respect to an Additional
Accelerated Purchase made pursuant to <U>Section 2(c)</U> hereof, the number of Purchase Shares directed by the Company to be purchased
by the Investor on an Additional Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i) 1,000%
of the number of Purchase Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Regular Purchase
Notice for the corresponding Regular Purchase referred to in <U>Section 2(c)</U> hereof (subject to the Purchase Share limitations contained
in <U>Section 2(a)</U> hereof) and (ii) an amount equal to (A) the Additional Accelerated Purchase Share Percentage multiplied by (B)
the total number (or volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Additional Accelerated
Purchase Date beginning at the Additional Accelerated Purchase Commencement Time for such Additional Accelerated Purchase and ending at
the Additional Accelerated Purchase Termination Time for such Additional Accelerated Purchase.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(n)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Additional Accelerated Purchase Share Estimate</U>&rdquo; means, with respect to any Additional
Accelerated Purchase made pursuant to <U>Section 2(c)</U> hereof, a good faith estimate by the Company of the number of Purchase Shares
that the Investor shall have the obligation to buy pursuant to the Additional Accelerated Purchase Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(o)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Additional Accelerated Purchase Share Percentage</U>&rdquo; means, with respect to an Additional
Accelerated Purchase made pursuant to <U>Section 2(c)</U> hereof, thirty percent (30%).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(p)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Additional Accelerated Purchase Share Volume Maximum</U>&rdquo; means, with respect to
an Additional Accelerated Purchase made pursuant to <U>Section 2(c)</U> hereof, a number of shares of Common Stock equal to (i) the applicable
Additional Accelerated Purchase Share Amount properly directed by the Company to be purchased by the Investor in the applicable Additional
Accelerated Purchase Notice for such Additional Accelerated Purchase, divided by (ii) the Additional Accelerated Purchase Share Percentage
(to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar
transaction).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(q)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Alternate Adjusted Regular Purchase Share Limit</U>&rdquo; means, with respect to a Regular
Purchase made pursuant to <U>Section 2(a)</U> hereof, the maximum number of Purchase Shares which, taking into account the applicable
per share Purchase Price therefor calculated in accordance with this Agreement, would enable the Company to deliver to the Investor, on
the applicable Purchase Date for such Regular Purchase, a Regular Purchase Notice for a Purchase Amount equal to, or as closely approximating
without exceeding, Four Hundred Thousand Dollars ($400,000).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(r)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Available Amount</U>&rdquo; means, initially, One Hundred Fifty Million Dollars ($150,000,000)
in the aggregate, which amount shall be reduced by the Purchase Amount each time the Investor purchases shares of Common Stock pursuant
to <U>Section 2</U> hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(s)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Average Price</U>&rdquo; means a price per Purchase Share (rounded to the nearest tenth
of a cent) equal to the quotient obtained by dividing (i) the aggregate gross purchase price paid by the Investor for all Purchase Shares
purchased pursuant to this Agreement, by (ii) the aggregate number of Purchase Shares issued pursuant to this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(t)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <FONT STYLE="font-size: 10pt">&ldquo;<U>Bankruptcy Law</U>&rdquo; means Title 11, U.S. Code, or any similar federal or state law
for the relief of debtors.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(u)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Base Price</U>&rdquo; means a price per Purchase Share equal to the sum of (i) the Signing
Market Price and (ii) $ $0.106 (subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse
stock split or other similar transaction that occurs on or after the date of this Agreement).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(v)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Base Prospectus</U>&rdquo; means the Company&rsquo;s final base prospectus, dated September
24, 2021, a preliminary form of which is included in the Registration Statement, including the documents incorporated by reference therein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(w)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <FONT STYLE="font-size: 10pt">&ldquo;<U>Business Day</U>&rdquo; means any day on which the Principal Market is open for trading,
including any day on which the Principal Market is open for trading for a period of time less than the customary time.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(x)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing Sale Price</U>&rdquo; means, for any security as of any date, the last closing
sale price for such security on the Principal Market as reported by the Principal Market.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(y)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Confidential Information</U>&rdquo; means any information disclosed by either party to
the other party, either directly or indirectly, in writing, orally or by inspection of tangible objects (including, without limitation,
documents, prototypes, samples, plant and equipment), which is designated as &ldquo;Confidential,&rdquo; &ldquo;Proprietary&rdquo; or
some similar designation. Information communicated orally shall be considered Confidential Information if such information is confirmed
in writing as being Confidential Information within ten (10) Business Days after the initial disclosure. Confidential Information may
also include information disclosed to a disclosing party by third parties. Confidential Information shall not, however, include any information
which (i) was publicly known and made generally available in the public domain prior to the time of disclosure by the disclosing party;
(ii) becomes publicly known and made generally available after disclosure by the disclosing party to the receiving party through no action
or inaction of the receiving party; (iii) is already in the possession of the receiving party without confidentiality restriction at the
time of disclosure by the disclosing party as shown by the receiving party&rsquo;s files and records immediately prior to the time of
disclosure; (iv) is obtained by the receiving party from a third party without a breach of such third party&rsquo;s obligations of confidentiality;
(v) is independently developed by the receiving party without use of or reference to the disclosing party&rsquo;s Confidential Information,
as shown by documents and other competent evidence in the receiving party&rsquo;s possession; or (vi) is required by law to be disclosed
by the receiving party, provided that the receiving party gives the disclosing party prompt written notice of such requirement prior to
such disclosure and assistance in obtaining an order protecting the information from public disclosure.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(z)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Custodian</U>&rdquo; means any receiver, trustee, assignee, liquidator or similar official
under any Bankruptcy Law.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(aa)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>DTC</U>&rdquo; means The Depository Trust Company, or any successor performing substantially
the same function for the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(bb)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>DWAC Shares</U>&rdquo; means shares of Common Stock that are (i) issued in electronic form,
(ii) freely tradable and transferable and without restriction on sale and (iii) timely credited by the Company to the Investor&rsquo;s
or its designee&rsquo;s specified Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer
(FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(cc)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Exchange Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(dd)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Fully Adjusted Regular Purchase Share Limit</U>&rdquo; means, with respect to any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction from and after the date of this Agreement,
the Regular Purchase Share Limit (as defined in <U>Section 2(a)</U> hereof) in effect on the applicable date of determination, after giving
effect to the full proportionate adjustment thereto made pursuant to <U>Section 2(a)</U> hereof for or in respect of such reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(ee)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Initial Prospectus Supplement</U>&rdquo; means the prospectus supplement of the Company
relating to the Securities, including the accompanying Base Prospectus, to be prepared and filed by the Company with the SEC pursuant
to Rule 424(b)(5) under the Securities Act and in accordance with <U>Section 5(a)</U> hereof, together with all documents and information
incorporated therein by reference.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(ff)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Material Adverse Effect</U>&rdquo; means any material adverse effect on (i) the enforceability
of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries,
taken as a whole, other than any material adverse effect that resulted exclusively from (A) any change in the United States or foreign
economies or securities or financial markets in general that does not have a disproportionate effect on the Company and its Subsidiaries,
taken as a whole, (B) any change that generally affects the industry in which the Company and its Subsidiaries operate that does not have
a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (C) any change arising in connection with earthquakes,
hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts
of war, sabotage or terrorism or military actions existing as of the date hereof, (D) any action taken by the Investor, its affiliates
or its or their successors and assigns with respect to the transactions contemplated by this Agreement, (E) the effect of any change in
applicable laws or accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole,
or (F) any change resulting from compliance with terms of this Agreement or the consummation of the transactions contemplated by this
Agreement, or (iii) the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document to be performed as of the date of determination.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(gg)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Maturity Date</U>&rdquo; means the first day of the month immediately following the thirty-six
(36) month anniversary of the Commencement Date.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(hh)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>PEA Period</U>&rdquo; means the period commencing at 9:30 a.m., Eastern time, on the fifth
(5th) Business Day immediately prior to the filing of any post-effective amendment to the Registration Statement (as defined herein) or
New Registration Statement (as such term is defined in the Registration Rights Agreement), and ending at 9:30 a.m., Eastern time, on the
Business Day immediately following, the effective date of any post-effective amendment to the Registration Statement (as defined herein)
or New Registration Statement (as such term is defined in the Registration Rights Agreement).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(ii)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Person</U>&rdquo; means an individual or entity including but not limited to any limited
liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department
or agency thereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(jj)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Principal Market</U>&rdquo; means the NASDAQ Capital Market (or any nationally recognized
successor thereto); provided, however, that in the event the Company&rsquo;s Common Stock is ever listed or traded on, the NASDAQ Global
Market, the NASDAQ Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, or the OTC Bulletin Board the
OTCQX or OTCQB operated by the OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing), then the &ldquo;Principal
Market&rdquo; shall mean such other market or exchange on which the Company&rsquo;s Common Stock is then listed or traded.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(kk)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo; means the Base Prospectus, as supplemented by any Prospectus Supplement
(including the Initial Prospectus Supplement), including the documents and information incorporated by reference therein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(ll)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Prospectus Supplement</U>&rdquo; means any prospectus supplement to the Base Prospectus
(including the Initial Prospectus Supplement) filed with the SEC pursuant to Rule 424(b) under the Securities Act in connection with the
transactions contemplated by this Agreement, including the documents and information incorporated by reference therein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(mm)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Purchase Amount</U>&rdquo; means, with respect to any Regular Purchase, any Accelerated
Purchase or any Additional Accelerated Purchase made hereunder, the portion of the Available Amount to be purchased by the Investor pursuant
to <U>Section 2</U> hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(nn)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Purchase Date</U>&rdquo; means, with respect to any Regular Purchase made pursuant to <U>Section
2(a)</U> hereof, the Business Day on which the Investor receives a valid Regular Purchase Notice for such Regular Purchase in accordance
with this Agreement; provided that if a Regular Purchase Notice is delivered by 8:30 a.m. Eastern time, the Purchase Date for such Regular
Purchase shall be the prior Business Day.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(oo)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Purchase Price</U>&rdquo; means, with respect to any Regular Purchase made pursuant to
<U>Section 2(a)</U> hereof, the lower of: (i) the lowest Sale Price on the applicable Purchase Date and (ii) the arithmetic average of
the three (3) lowest Closing Sale Prices for the Common Stock during the ten (10) consecutive Business Days ending on the Business Day
immediately preceding such Purchase Date (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split, reverse stock split or other similar transaction that occurs on or after the date of this Agreement).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(pp)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Registration Rights Agreement</U>&rdquo; means that certain Registration Rights Agreement,
of even date herewith between the Company and the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(qq)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Registration Statement</U>&rdquo; has the meaning set forth in the Registration Rights
Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(rr)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Regular Purchase Notice</U>&rdquo; means, with respect to any Regular Purchase pursuant
to <U>Section 2(a)</U> hereof, an irrevocable written notice from the Company to the Investor directing the Investor to buy such applicable
amount of Purchase Shares at the applicable Purchase Price as specified by the Company therein on the applicable Purchase Date for such
Regular Purchase.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(ss)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Sale Price</U>&rdquo; means any trade price for the shares of Common Stock on the Principal
Market as reported by the Principal Market.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(tt)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>SEC</U>&rdquo; means the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(uu)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Securities</U>&rdquo; means, collectively, the Purchase Shares and the Commitment Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(vv)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Securities Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(ww)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Signing Market Price</U>&rdquo; means $10.908, representing the consolidated closing bid
price of the Common Stock on The NASDAQ Capital Market on the date of this Agreement, representing the lower of (i) the closing price
of the Common Stock on the Nasdaq Capital Market immediately preceding the date of this Agreement or (ii) the average of the closing price
of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the signing of this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(xx)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo; means any Person the Company wholly-owns or controls, or in which
the Company, directly or indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable
pursuant to Item 601(b)(21) of Regulation S-K promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(yy)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Transaction Documents</U>&rdquo; means, collectively, this Agreement and the schedules
and exhibits hereto, the Registration Rights Agreement and the schedules and exhibits thereto, and each of the other agreements, documents,
certificates and instruments entered into or furnished by the parties hereto in connection with the transactions contemplated hereby and
thereby.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(zz)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Transfer Agent</U>&rdquo; means Nevada Agency and Transfer Company, or such other Person
who is then serving as the transfer agent for the Company in respect of the Common Stock.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(aaa)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo; means in respect of an applicable Accelerated Purchase Date and an Additional
Accelerated Purchase Date, as applicable, the volume weighted average price of the Common Stock on the Principal Market, as reported on
the Principal Market or by another reputable source such as Bloomberg, L.P.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>PURCHASE OF COMMON STOCK.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Subject to the terms and conditions
set forth in this Agreement, the Company has the right, but not the obligation, to sell to the Investor, and the Investor, in the Company&rsquo;s
sole and absolute discretion, has the obligation to purchase from the Company, Purchase Shares as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Commencement of Regular Sales of Common Stock</U>. Upon the satisfaction of the conditions set
forth in <U>Sections 7</U> and <U>8</U> hereof (the &ldquo;<U>Commencement</U>&rdquo; and the date of satisfaction of such conditions
the &ldquo;<U>Commencement Date</U>&rdquo;) and thereafter, the Company shall have the right, but not the obligation, to direct the Investor,
by its delivery to the Investor of a Regular Purchase Notice from time to time, to purchase up to Two Hundred Thousand (200,000) Purchase
Shares, subject to adjustment as set forth below in this <U>Section 2(a)</U> (such maximum number of Purchase Shares, as may be adjusted
from time to time, the &ldquo;<U>Regular Purchase Share Limit</U>&rdquo;), at the Purchase Price on the Purchase Date (each such purchase
a &ldquo;<U>Regular Purchase</U>&rdquo;); <U>provided</U>, <U>however</U>, that if, after giving effect to the full proportionate adjustment
to the Regular Purchase Share Limit therefor, the Fully Adjusted Regular Purchase Share Limit then in effect would preclude the Company
from delivering to the Investor a Regular Purchase Notice hereunder for a Purchase Amount (calculated by multiplying (X) the number of
Purchase Shares equal to the Fully Adjusted Regular Purchase Share Limit, by (Y) the Purchase Price per Purchase Share covered by such
Regular Purchase Notice on the applicable Purchase Date therefor) equal to or greater than Two Hundred Thousand Dollars ($200,000), the
Regular Purchase Share Limit for such Regular Purchase Notice shall not be fully adjusted to equal the applicable Fully Adjusted Regular
Purchase Share Limit, but rather the Regular Purchase Share Limit for such Regular Purchase Notice shall be adjusted to equal the applicable
Alternate Adjusted Regular Purchase Share Limit as of the applicable Purchase Date for such Regular Purchase Notice; and <U>provided</U>,
<U>further</U>, <U>however</U>, that the Investor&rsquo;s committed obligation under any single Regular Purchase, other than any Regular
Purchase with respect to which an Alternate Adjusted Regular Purchase Share Limit shall apply, shall not exceed Four Million Dollars ($4,000,000),
unless the parties mutually agree to increase the Regular Purchase Share Limit on any Purchase Date up to Two Million (2,000,000) Purchase
Shares. If the Company delivers any Regular Purchase Notice for a Purchase Amount in excess of the limitations contained in the immediately
preceding sentence, such Regular Purchase Notice shall be void <I>ab initio</I> to the extent of the amount by which the amount of Purchase
Shares set forth in such Regular Purchase Notice exceeds the amount of Purchase Shares which the Company is permitted to include in such
Regular Purchase Notice in accordance herewith, and the Investor shall have no obligation to purchase such excess Purchase Shares in respect
of such Regular Purchase Notice; provided that the Investor shall remain obligated to purchase the amount of Purchase Shares which the
Company is permitted to include in such Regular Purchase Notice. The Company may deliver Regular Purchase Notices to the Investor as often
as every Business Day, and upon mutual agreement of the parties may deliver multiple Purchase Notices in a Business Day, in each case
as long as the Company has not failed to deliver Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases and Additional
Accelerated Purchases, including, without limitation, those that have been effected on the same Business Day as the applicable Purchase
Date, have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement. Notwithstanding the foregoing,
the Company shall not deliver any Regular Purchase Notices during the PEA Period.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Accelerated Purchases</U>. Subject to the terms and conditions of this Agreement, beginning on
the Commencement Date, in addition to purchases of Purchase Shares as described in <U>Section 2(a)</U> above, the Company shall also have
the right, but not the obligation, to direct the Investor, by its delivery to the Investor of an Accelerated Purchase Notice from time
to time in accordance with this Agreement, to purchase the applicable Accelerated Purchase Share Amount at the Accelerated Purchase Price
on the Accelerated Purchase Date therefor in accordance with this Agreement (each such purchase, an &ldquo;<U>Accelerated Purchase</U>&rdquo;);
<U>provided</U>, <U>however</U>, that the Investor shall not be required to buy a number of Purchase Shares in an Accelerated Purchase
that exceeds the Accelerated Purchase Share Estimate. The Company may deliver an Accelerated Purchase Notice to the Investor only on a
Purchase Date on which (i) the Company also properly submitted a Regular Purchase Notice providing for a Regular Purchase of not less
than 50,000 shares and (ii) if all Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated
Purchases, including, without limitation, those that have been effected on the same Business Day as the applicable Accelerated Purchase
Date with respect to which the applicable Accelerated Purchase relates, have theretofore been received by the Investor as DWAC Shares
in accordance with this Agreement; <U>provided</U>, <U>further</U>, <U>however</U>, that the parties may mutually agree to increase the
Accelerated Purchase Share Amount on any Accelerated Purchase Date at the applicable Accelerated Purchase Price. Each Accelerated Purchase
Notice must be accompanied by the Accelerated Purchase Share Estimate for such Accelerated Purchase, and such Accelerated Purchase Notice
shall be void <I>ab initio</I> to the extent of the amount by which the number of Purchase Shares set forth in such Accelerated Purchase
Notice exceeds the number of Purchase Shares set forth in the Accelerated Purchase Share Estimate. The Investor shall immediately return
to the Company such number of Purchase Shares issued pursuant to the Accelerated Purchase Share Estimate that exceeds the Accelerated
Purchase Share Amount. Within one (1) Business Day after each Accelerated Purchase Date, the Accelerated Purchase Share Amount and the
applicable Accelerated Purchase Price shall be set forth on a confirmation of the Accelerated Purchase to be provided to the Company by
the Investor (an &ldquo;<U>Accelerated Purchase Confirmation</U>&rdquo;). Notwithstanding the foregoing, the Company shall not deliver
any Accelerated Purchase Notices during the PEA Period.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Additional Accelerated Purchases</U>. Subject to the terms and conditions of this Agreement, beginning
one (1) Business Day following the Commencement Date and thereafter, in addition to purchases of Purchase Shares as described in <U>Section
2(a)</U> and <U>Section 2(b)</U> above, the Company shall also have the right, but not the obligation, to direct the Investor, by its
timely delivery to the Investor of an Additional Accelerated Purchase Notice on an Additional Accelerated Purchase Date in accordance
with this Agreement, to purchase the applicable Additional Accelerated Purchase Share Amount at the applicable Additional Accelerated
Purchase Price therefor in accordance with this Agreement (each such purchase, an &ldquo;<U>Additional Accelerated Purchase</U>&rdquo;);
<U>provided</U>, <U>however</U>, that the Investor shall not be required to buy a number of Purchase Shares in an Additional Accelerated
Purchase that exceeds the Additional Accelerated Purchase Share Estimate. The Company may deliver multiple Additional Accelerated Purchase
Notices to the Investor on an Additional Accelerated Purchase Date; <U>provided</U>, <U>however</U>, that the Company may deliver an Additional
Accelerated Purchase Notice to the Investor only (i) on a Business Day that is also the Accelerated Purchase Date for an Accelerated Purchase
with respect to which the Company properly submitted to the Investor an Accelerated Purchase Notice in accordance with this Agreement
on the applicable Purchase Date for a Regular Purchase of a number of Purchase Shares not less than the Regular Purchase Share Limit then
in effect in accordance with this Agreement and (ii) if all Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases
and Additional Accelerated Purchases, including, without limitation, those that have been effected on the same Business Day as the applicable
Additional Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates, have theretofore been
received by the Investor as DWAC Shares in accordance with this Agreement and <U>provided</U>, <U>further</U>, <U>however</U>, that the
parties may mutually agree to increase the Additional Accelerated Purchase Share Amount applicable to any Accelerated Purchase, and all
of the Purchase Shares subject to such increased Accelerated Purchase shall be purchased by the Investor at the Accelerated Purchase Price
for such increased Accelerated Purchase in accordance with this Agreement. Each Additional Accelerated Purchase Notice must be accompanied
by the Additional Accelerated Purchase Share Estimate for such Additional Accelerated Purchase, and such Additional Accelerated Purchase
Notice shall be void <I>ab initio</I> to the extent of the amount by which the number of Purchase Shares set forth in such Additional
Accelerated Purchase Notice exceeds the number of Purchase Shares set forth in the Additional Accelerated Purchase Share Estimate. The
Investor shall immediately return to the Company such number of Purchase Shares issued pursuant to the Additional Accelerated Purchase
Share Estimate that exceeds the Accelerated Purchase Share Amount. Within one (1) Business Day after each Additional Accelerated Purchase
Date, the Additional Accelerated Purchase Share Amount and the applicable Additional Accelerated Purchase Price shall be set forth on
a confirmation of the Additional Accelerated Purchase to be provided to the Company by the Investor (an &ldquo;<U>Additional Accelerated
Purchase Confirmation</U>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Payment for Purchase Shares</U>. For each Regular Purchase, the Investor shall pay to the Company
an amount equal to the Purchase Amount with respect to such Regular Purchase as full payment for such Purchase Shares via wire transfer
of immediately available funds on the same Business Day that the Investor receives such Purchase Shares, if such Purchase Shares are received
by the Investor before 1:00 p.m., Eastern time, or, if such Purchase Shares are received by the Investor after 1:00 p.m., Eastern time,
the next Business Day. For each Accelerated Purchase and each Additional Accelerated Purchase, the Investor shall pay to the Company an
amount equal to the Purchase Amount with respect to such Accelerated Purchase and Additional Accelerated Purchase, respectively, as full
payment for such Purchase Shares via wire transfer of immediately available funds on the third Business Day following the date that the
Investor receives such Purchase Shares. The Company shall not issue any fraction of a share of Common Stock upon any Regular Purchase,
Accelerated Purchase or Additional Accelerated Purchase. If the issuance would result in the issuance of a fraction of a share of Common
Stock, the Company shall round such fraction of a share of Common Stock up or down to the nearest whole share. All payments made under
this Agreement shall be made in lawful money of the United States of America or wire transfer of immediately available funds to such account
as the Company may from time to time designate by written notice in accordance with the provisions of this Agreement. Whenever any amount
expressed to be due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the
next succeeding day that is a Business Day.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Beneficial Ownership Limitation</U>. Notwithstanding anything to the contrary contained in this
Agreement, the Company shall not issue or sell, and the Investor shall not purchase or acquire, any shares of Common Stock under this
Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Investor and its affiliates (as
calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership
by the Investor and its affiliates of more than 4.99% of the then issued and outstanding shares of Common Stock (the &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo;). Upon the written or oral request of the Investor, the Company shall promptly (but not later than 24
hours) confirm orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor and the Company
shall each cooperate in good faith in the determinations required hereby and the application hereof. The Investor&rsquo;s written certification
to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall
be conclusive with respect to the applicability thereof and such result absent manifest error.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Compliance with Principal Market Rules</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="font-size: 10pt; color: #010000">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Exchange Cap</U>. Subject to <U>Section 2(f)(ii)</U> below, the Company shall not issue or sell
any shares of Common Stock pursuant to this Agreement, and the Investor shall not purchase or acquire any shares of Common Stock pursuant
to this Agreement, to the extent that after giving effect thereto, the aggregate number of shares of Common Stock that would be issued
pursuant to this Agreement and the transactions contemplated hereby would be equal or greater to 15,606,426 shares of Common Stock, representing
19.99% of the shares of Common Stock outstanding on the date of this Agreement (which number of shares shall be reduced, on a share-for-share
basis, by the number of shares of Common Stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated
with the transactions contemplated by this Agreement under applicable rules of the Nasdaq Capital Market or any other Principal Market
on which the Common Stock may be listed or quoted) (the &ldquo;<U>Exchange Cap</U>&rdquo;), unless and until the Company elects to solicit
stockholder approval of the issuance of Common Stock as contemplated by this Agreement and the stockholders of the Company have in fact
approved such issuance in accordance with the applicable rules and regulations of the Nasdaq Capital Market, any other Principal Market
on which the Common Stock may be listed or quoted, and the Company&rsquo;s Articles of Incorporation, as amended and as in effect on the
date hereof (the &ldquo;<U>Articles of Incorporation</U>&rdquo;), and the Company&rsquo;s Bylaws, as amended and as in effect on the date
hereof (the &ldquo;<U>Bylaws</U>&rdquo;). For the avoidance of doubt, the Company may, but shall be under no obligation to, request its
stockholders to approve the issuance of Common Stock as contemplated by this Agreement; provided, that if stockholder approval is not
obtained in accordance with this <U>Section 2(f)(i)</U>, the Exchange Cap shall be applicable for all purposes of this Agreement and the
transactions contemplated hereby at all times during the term of this Agreement (except as set forth in <U>Section 2(f)(ii)</U> below).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="font-size: 10pt; color: #010000">(ii)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>At-Market Transaction</U>. Notwithstanding <U>Section 2(f)(i)</U> above and subject to the prior
approval of the Nasdaq Capital Market or any other Principal Market on which the Common Stock may be listed or quoted (to the extent required),
the Exchange Cap shall not be applicable for any purposes of this Agreement and the transactions contemplated hereby, solely to the extent
that (and only for so long as) the Average Price shall equal or exceed the Base Price and in accordance with any other applicable rules
of the Nasdaq Capital Market or any other Principal Market on which the Common Stock may be listed or quoted (it being hereby acknowledged
and agreed that the Exchange Cap shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all
other times during the term of this Agreement, unless the stockholder approval referred to in <U>Section 2(f)(i)</U> is obtained).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="font-size: 10pt; color: #010000">(iii)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>General</U>. The Company shall not issue any Securities pursuant to this Agreement if such issuance
would reasonably be expected to result in (A) a violation of the Securities Act or (B) a breach of the rules and regulations of the Principal
Market. Furthermore, the Company agrees that it shall not issue any Securities pursuant to this Agreement if, at the time of such issuance
(Y) the effectiveness of the Registration Statement registering the Securities has lapsed for any reason (including, without limitation,
the issuance of a stop order or similar order) or (Z) the Registration Statement is unavailable for the sale by the Company to the Investor
(or the resale by the Investor, as the case may be) of any or all of the Securities to be issued to the Investor under the Transaction
Documents. The provisions of this <U>Section 2(f)</U> shall be implemented in a manner otherwise than in strict conformity with the terms
hereof only if necessary to ensure compliance with the Securities Act and the rules and regulations of the Principal Market.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>INVESTOR&rsquo;S REPRESENTATIONS AND WARRANTIES.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Investor represents and warrants
to the Company that as of the date hereof and as of the Commencement Date:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Organization, Authority</U>. The Investor is an entity duly organized, validly existing and in
good standing under the laws of the jurisdiction of its organization, with the requisite power and authority to enter into and to consummate
the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Accredited Investor Status</U>. The Investor is an &ldquo;accredited investor&rdquo; as that term
is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Information</U>. The Investor understands that its investment in the Securities involves a high
degree of risk. The Investor (i) is able to bear the economic risk of an investment in the Securities including a total loss thereof,
(ii) has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the
proposed investment in the Securities and (iii) has had an opportunity to ask questions of and receive answers from the officers of the
Company concerning the financial condition and business of the Company and others matters related to an investment in the Securities.
Neither such inquiries nor any other due diligence investigations conducted by the Investor or its representatives shall modify, amend
or affect the Investor&rsquo;s right to rely on the Company&rsquo;s representations and warranties contained in <U>Section 4</U> below.
The Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with
respect to its acquisition of the Securities. The Investor acknowledges and agrees that the Company neither makes nor has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in <U>Section 4</U> hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Governmental Review</U>. The Investor understands that no U.S. federal or state agency or any
other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability
of an investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Validity; Enforcement</U>. This Agreement has been duly and validly authorized, executed and delivered
on behalf of the Investor and is a valid and binding agreement of the Investor enforceable against the Investor in accordance with its
terms, subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&rsquo; rights and remedies.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Residency</U>. The Investor is a resident of the State of Illinois.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated
hereunder, Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with Investor, directly or indirectly
executed any purchases or sales, including short sales,&nbsp;of the securities of the Company during the period commencing as of the time
that Investor first received a term sheet (written or oral) as of the Company or any other Person representing the Company setting forth
the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Other than to other
Persons party to this Agreement, Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Short Selling</U>. The Investor represents and warrants to the Company that at no time prior
to the date of this Agreement has any of the Investor, its agents, representatives or affiliates engaged in or effected, in any manner
whatsoever, directly or indirectly, any (i) &ldquo;short sale&rdquo; (as such term is defined in Rule 200 of Regulation SHO of the Exchange
Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company represents and warrants
to the Investor that as of the date hereof and as of the Commencement Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Organization and Qualification</U>. The Company and each of its Subsidiaries is an entity duly
incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or
organization, with the requisite corporate power and authority to own and use its properties and assets and to carry on its business as
currently conducted. Neither the Company, nor any of its Subsidiaries is in violation or default of any of the provisions of its respective
certificate or Articles of Incorporation, bylaws or other organizational or charter documents, except as would not reasonably be expected
to have a Material Adverse Effect. Each of the Company and its Subsidiaries is duly qualified to conduct business and is in good standing
as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes
such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably
be expected to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or
curtailing or seeking to revoke, limit or curtail such power and authority or qualification. The Company has no Subsidiaries except as
set forth in <U>Schedule 4(a)</U> hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Authorization; Enforcement; Validity</U>. (i) The Company has the requisite corporate power and
authority to enter into and perform its obligations under this Agreement and each of the other Transaction Documents, and to issue the
Securities in accordance with the terms hereof and thereof, (ii) the execution and delivery of the Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the issuance of the Commitment
Shares (as defined below in <U>Section 5(e)</U>) and the reservation for issuance and the issuance of the Purchase Shares issuable under
this Agreement, have been duly authorized by the Company&rsquo;s Board of Directors and no further consent or authorization is required
by the Company, its Board of Directors or its stockholders, (iii) this Agreement has been, and each other Transaction Document shall be
on the Commencement Date, duly executed and delivered by the Company and (iv) this Agreement constitutes, and each other Transaction Document
upon its execution on behalf of the Company, shall constitute, the valid and binding obligations of the Company enforceable against the
Company in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors&rsquo;
rights and remedies. The Board of Directors of the Company has approved resolutions (the &ldquo;<U>Signing Resolutions</U>&rdquo;) to
authorize this Agreement and the transactions contemplated hereby. The Signing Resolutions are valid, in full force and effect and have
not been modified or supplemented in any respect. Except as set forth in this Agreement, no other approvals or consents of the Company&rsquo;s
Board of Directors, any authorized committee thereof, and/or stockholders is necessary under applicable laws and the Company&rsquo;s Articles
of Incorporation and/or Bylaws to authorize the execution and delivery of this Agreement or any of the transactions contemplated hereby,
including, but not limited to, the issuance of the Commitment Shares and the issuance of the Purchase Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Capitalization</U>. As of the date hereof, the authorized capital stock of the Company is set
forth in <U>Schedule 4(c)</U> hereof. Except as disclosed in the SEC Documents (as defined below), (i) no shares of the Company&rsquo;s
capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company,
(ii) there are no outstanding debt securities, (iii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company
or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries
is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip,
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares
of capital stock of the Company or any of its Subsidiaries, (iv) there are no agreements or arrangements under which the Company or any
of its Subsidiaries is obligated to register the sale of any of their securities under the Securities Act (except the Registration Rights
Agreement), (v) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption
or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries
is or may become bound to redeem a security of the Company or any of its Subsidiaries, (vi) there are no securities or instruments containing
anti-dilution or similar provisions that will be triggered by the issuance of the Securities as described in this Agreement and (vii)
the Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
The Company has furnished to the Investor true and correct copies of the Articles of Incorporation, , and the Bylaws, , and summaries
of the terms of all securities convertible into or exercisable for Common Stock, if any, and copies of any documents containing the material
rights of the holders thereof in respect thereto.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Issuance of Securities</U>. Upon issuance and payment therefor in accordance with the terms and
conditions of this Agreement, the Purchase Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens,
charges, restrictions, rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled
to all rights accorded to a holder of Common Stock. 10,000,000 shares of Common Stock have been duly authorized and reserved for issuance
upon purchase under this Agreement as Purchase Shares. 75,000 shares of Common Stock (subject to equitable adjustment for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction) have been duly authorized and reserved
for issuance as Initial Commitment Shares (as defined below in <U>Section 5(e))</U> in accordance with this Agreement. The Initial Commitment
Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal
and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common
Stock. 75,000 shares of Common Stock (subject to equitable adjustment for any reorganization, recapitalization, non-cash dividend, stock
split, reverse stock split or other similar transaction) have been duly authorized and reserved for issuance as Additional Commitment
Shares (as defined below in <U>Section 5(e))</U> in accordance with this Agreement. When issued in accordance with this Agreement, the
Additional Commitment Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions,
rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded
to a holder of Common Stock. The Securities are being issued pursuant to the Registration Statement, and the issuance of the Securities
has been registered by the Company pursuant to the Securities Act. Upon receipt of the Purchase Shares and the Commitment Shares, the
Investor will have good and marketable title to such Securities and such Securities will be immediately freely tradable on the Principal
Market by any holder who is not an &ldquo;affiliate&rdquo; under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Conflicts</U>. The execution, delivery and performance of the Transaction Documents by the
Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the reservation
for issuance and issuance of the Purchase Shares and the Commitment Shares) will not (i) result in a violation of the <U>Articles of Incorporation</U>,
any Certificate of Designations, Preferences and Rights of any outstanding series of preferred stock of the Company or the Bylaws or (ii)
conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give
to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company
or any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including federal
and state securities laws and regulations and the rules and regulations of the Principal Market applicable to the Company or any of its
Subsidiaries) or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of
conflicts, defaults, terminations, amendments, accelerations, cancellations and violations under clause (ii), which could not reasonably
be expected to result in a Material Adverse Effect. Neither the Company nor its Subsidiaries is in violation of any term of or in default
under its Articles of Incorporation, any Certificate of Designation, preferences and rights of any outstanding series of preferred stock
of the Company or Bylaws or their organizational charter or bylaws, respectively. Neither the Company, nor any of its Subsidiaries is
in violation of any term of or is in default under any material contract, agreement, mortgage, indebtedness, indenture, instrument, judgment,
decree or order or any statute, rule or regulation applicable to the Company or its Subsidiaries, except for possible conflicts, defaults,
terminations or amendments that could not reasonably be expected to have a Material Adverse Effect. The business of the Company and its
Subsidiaries is not being conducted, and shall not be conducted, in violation of any law, ordinance, regulation of any governmental entity,
except for possible violations, the sanctions for which either individually or in the aggregate could not reasonably be expected to have
a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required under the Securities Act or applicable
state securities laws and the rules and regulations of the Principal Market and under the Corporate Financing Rule 5110 of the Financial
Industry Regulatory Authority (FINRA), the Company is not required to obtain any consent, authorization or order of, or make any filing
or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver
or perform any of its obligations under or contemplated by the Transaction Documents in accordance with the terms hereof or thereof. Except
as set forth elsewhere in this Agreement, all consents, authorizations, orders, filings and registrations which the Company is required
to obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date. Since one year prior
to the date hereof, the Company has not received nor delivered any notices or correspondence from or to the Principal Market. The Principal
Market has not commenced any delisting proceedings against the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>SEC Documents; Financial Statements</U>. The Company has filed all reports, schedules, forms,
statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to
Section 13(a) or 15(d) thereof, for the 24 months preceding the date hereof (or such shorter period as the Company was required by law
or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein, being collectively referred to herein as the &ldquo;<U>SEC Documents</U>&rdquo;) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension. As of their respective dates
and to the Company&rsquo;s knowledge, the SEC Documents complied in all material respects with the requirements of the Securities Act
and the Exchange Act, as applicable. None of the SEC Documents, when filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The financial statements of the Company included in the SEC Documents comply in all material
respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time
of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied
on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments. Except as set forth in the SEC Documents, the Company has received no notices or correspondence from the SEC
for the one year preceding the date hereof. The SEC has not commenced any enforcement proceedings against the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Absence of Certain Changes</U>. Except as disclosed in the SEC Documents, since September 30,
2022, there has been no material adverse change in the business, properties, operations, financial condition or results of operations
of the Company or its Subsidiaries. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection
pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors
intend to initiate involuntary bankruptcy or insolvency proceedings.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Absence of Litigation</U>. There is no action, suit, proceeding, inquiry or investigation before
or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or
any of its Subsidiaries, threatened against or affecting the Company, the Common Stock or any of the Company&rsquo;s or its Subsidiaries&rsquo;
officers or directors in their capacities as such, which could reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Acknowledgment Regarding Investor</U>&rsquo;<U>s Status</U>. The Company acknowledges and agrees
that the Investor is acting solely in the capacity of arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions
contemplated hereby and thereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby
and any advice given by the Investor or any of its representatives or agents in connection with the Transaction Documents and the transactions
contemplated hereby and thereby is merely incidental to the Investor&rsquo;s purchase of the Securities. The Company further represents
to the Investor that the Company&rsquo;s decision to enter into the Transaction Documents has been based solely on the independent evaluation
by the Company and its representatives and advisors.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(j)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Aggregated Offering</U>. Neither the Company, nor any of its affiliates, nor any Person acting
on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security,
under circumstances that would cause this offering of the Securities to be aggregated with prior offerings by the Company in a manner
that would require stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are
listed or designated. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal
Market.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(k)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Intellectual Property Rights</U>. Except as disclosed in the Registration Statement or the SEC
Documents, the Company and its Subsidiaries own or possess adequate rights or licenses to use all material trademarks, trade names, service
marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations,
trade secrets and rights necessary to conduct their respective businesses as now conducted. None of the Company&rsquo;s material trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals,
government authorizations, trade secrets or other intellectual property rights have expired or terminated, or, by the terms and conditions
thereof, could expire or terminate within two years from the date of this Agreement, except as would not reasonably be expected to have
a Material Adverse Effect. The Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries
of any material trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks,
service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical trade secrets
or technical information by others, and there is no claim, action or proceeding being made or brought against, or to the Company&rsquo;s
knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name, patents, patent rights, invention,
copyright, license, service names, service marks, service mark registrations, trade secret or other infringement, which could reasonably
be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(l)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Environmental Laws</U>. To the Company&rsquo;s knowledge, the Company and its Subsidiaries (i)
are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human
health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&ldquo;<U>Environmental Laws</U>&rdquo;),
(ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where, in each of
the three foregoing clauses, the failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(m)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Title</U>. Except as disclosed in the Registration Statement or SEC Documents, the Company and
its Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all
personal property owned by them that is material to the business of the Company and its Subsidiaries, in each case free and clear of all
liens, encumbrances and defects (&ldquo;<U>Liens</U>&rdquo;) and, except for Liens as do not materially affect the value of such property
and do not materially interfere with the use made and proposed to be made of such property by the Company and its Subsidiaries and Liens
for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property
and facilities held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with
which the Company and its Subsidiaries are in compliance with such exceptions as are not material and do not interfere with the use made
and proposed to be made of such property and buildings by the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(n)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Insurance</U>. The Company and each of its Subsidiaries are insured by insurers of recognized
financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary
in the businesses in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused
any insurance coverage sought or applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not
be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business at a cost that would not materially and adversely affect the condition, financial or otherwise,
or the earnings, business or operations of the Company and its Subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(o)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Regulatory Permits</U>. Except as disclosed in the Registration Statement or SEC Documents, the
Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate federal, state or
foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any such Subsidiary has received
any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit, except, in the
case of each of the two foregoing clauses, as would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(p)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Tax Status</U>. The Company and each of its Subsidiaries has made or filed all federal and state
income and all other material tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only
to the extent that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment
of all unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount,
shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside
on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports
or declarations apply, and except as would not reasonably be expected to have a Material Adverse Effect. There are no unpaid taxes in
any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for
any such claim.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(q)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Transactions With Affiliates</U>. Except as set forth in the SEC Documents, none of the officers
or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or
other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or
otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which
any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in
excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred
on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(r)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Application of Takeover Protections</U>. The Company and its Board of Directors have taken or
will take prior to the Commencement Date all necessary action, if any, in order to render inapplicable any control share acquisition,
business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under
the <U>Articles of Incorporation</U> or the laws of the state of its incorporation which is or could become applicable to the Investor
as a result of the transactions contemplated by this Agreement, including, without limitation, the Company&rsquo;s issuance of the Securities
and the Investor&rsquo;s ownership of the Securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(s)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated
by the Transaction Documents that will be timely publicly disclosed by the Company, the Company confirms that neither it nor any other
Person acting on its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might
constitute material, non-public information which is not otherwise disclosed in the Registration Statement or the SEC Documents. The Company
understands and confirms that the Investor will rely on the foregoing representation in effecting purchases and sales of securities of
the Company. All of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company, its business and the
transactions contemplated hereby, taken as a whole, including the disclosure schedules to this Agreement, is true and correct in all material
respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by
the Company during the twelve (12) months preceding the date of this Agreement taken as a whole did not as of their issue date contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and
agrees that the Investor neither makes nor has made any representations or warranties with respect to the transactions contemplated hereby
other than those specifically set forth in Section 3 hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(t)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Foreign Corrupt Practices</U>. Neither the Company, nor to the knowledge of the Company, any agent
or other Person acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment
or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company (or made by any Person acting on its behalf of which the Company is aware) which is in violation
of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(u)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Registration Statement</U>. The Company has prepared and filed with the SEC in accordance with
the provisions of the Securities Act the Registration Statement. The Registration Statement was declared effective by order of the SEC
on September 24, 2021. The Registration Statement is effective pursuant to the Securities Act and available for the issuance of the Securities
thereunder, and the Company has not received any written notice that the SEC has issued or intends to issue a stop order or other similar
order with respect to the Registration Statement or the Prospectus or that the SEC otherwise has (i)&nbsp;suspended or withdrawn the effectiveness
of the Registration Statement or (ii)&nbsp;issued any order preventing or suspending the use of the Prospectus or any Prospectus Supplement,
in either case, either temporarily or permanently or intends or has threatened in writing to do so. The &ldquo;Plan of Distribution&rdquo;
section of the Prospectus permits the issuance of the Securities hereunder. At the time the Registration Statement and any amendments
thereto became effective, at the date of this Agreement and at each deemed effective date thereof pursuant to Rule&nbsp;430B(f)(2) of
the Securities Act, the Registration Statement and any amendments thereto complied and will comply in all material respects with the requirements
of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein not misleading; and the Base Prospectus and any Prospectus Supplement
thereto, at the time such Base Prospectus or such Prospectus Supplement thereto was issued and on the Commencement Date, complied and
will comply in all material respects with the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading; provided that this representation and warranty does not apply to statements in or omissions from
any Prospectus Supplement made in reliance upon and in conformity with information relating to the Investor furnished to the Company in
writing by or on behalf of the Investor expressly for use therein. The Company meets all of the requirements for the use of a registration
statement on Form&nbsp;S-3 pursuant to the Securities Act for the offering and sale of the Securities contemplated by this Agreement without
reliance on General Instruction I.B.6. of Form S-3, and the SEC has not notified the Company of any objection to the use of the form of
the Registration Statement pursuant to Rule&nbsp;401(g)(1) of the Securities Act. The Registration Statement, as of its effective date,
meets the requirements set forth in Rule 415(a)(1)(x) pursuant to the Securities Act. At the earliest time after the filing of the Registration
Statement that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities
Act) relating to any of the Securities, the Company was not and is not an Ineligible Issuer (as defined in Rule 405 of the Securities
Act). The Company has not distributed any offering material in connection with the offering and sale of any of the Securities, and, until
the Investor does not hold any of the Securities, shall not distribute any offering material in connection with the offering and sale
of any of the Securities, to or by the Investor, in each case, other than the Registration Statement or any amendment thereto, the Prospectus
or any Prospectus Supplement required pursuant to applicable law or the Transaction Documents. The Company has not made, and agrees that
unless it obtains the prior written consent of the Investor it will not make, an offer relating to the Securities that would constitute
a &ldquo;free writing prospectus&rdquo; as defined in Rule 405 under the Securities Act. The Company shall comply with the requirements
of Rules 164 and 433 under the Securities Act applicable to any such free writing prospectus consented to by the Investor, including in
respect of timely filing with the SEC, legending and record keeping.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(v)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>DTC Eligibility</U>. The Company, through the Transfer Agent, currently participates in the DTC
Fast Automated Securities Transfer (FAST) Program and the Common Stock can be transferred electronically to third parties via the DTC
Fast Automated Securities Transfer (FAST) Program.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(w)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley</U>. The Company is in material compliance with all provisions of the Sarbanes-Oxley
Act of 2002, as amended, which are applicable to it as of the date hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(x)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Certain Fees</U>. No brokerage or finder&rsquo;s fees or commissions are or will be payable by
the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect
to the transactions contemplated by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with
respect to any claims made by or on behalf of other Persons for fees that may be due in connection with the transactions contemplated
by the Transaction Documents.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(y)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Investment Company</U>. The Company is not, and immediately after receipt of payment for the Securities
will not be, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(z)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b)
of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating
the registration of the Common Stock pursuant to the Exchange Act nor has the Company received any notification that the SEC is currently
contemplating terminating such registration. The Company has not, in the twelve (12) months preceding the date hereof, received any notice
from the Principal Market to the effect that the Company is not in compliance with the listing or maintenance requirements of the Principal
Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all
such listing and maintenance requirements.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(aa)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Accountants</U>. The Company&rsquo;s accountants are set forth in the SEC Documents and, to the
knowledge of the Company, such accountants are an independent registered public accounting firm as required by the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(bb)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Market Manipulation</U>. The Company has not, and to its knowledge no Person acting on its
behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any
compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(cc)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Shell Company Status</U>. The Company is not currently, and has never been, an issuer identified
in Rule 144(i)(1) under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">5.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>COVENANTS.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Filing of Current Report and Initial Prospectus Supplement</U>. The Company agrees that it shall,
within the time required under the Exchange Act, file with the SEC a report, which may be on Form 8-K or in a periodic report on Form
10-Q, relating to the transactions contemplated by, and describing the material terms and conditions of, the Transaction Documents (the
&ldquo;<U>Report</U>&rdquo;). The Company further agrees that it shall, within the time required under Rule 424(b) under the Securities
Act, file with the SEC the Initial Prospectus Supplement pursuant to Rule 424(b) under the Securities Act specifically relating to the
transactions contemplated by, and describing the material terms and conditions of, the Transaction Documents, containing information previously
omitted at the time of effectiveness of the Registration Statement in reliance on Rule 430B under the Securities Act, and disclosing all
information relating to the transactions contemplated hereby required to be disclosed in the Registration Statement and the Prospectus
as of the date of the Initial Prospectus Supplement, including, without limitation, information required to be disclosed in the section
captioned &ldquo;Plan of Distribution&rdquo; in the Prospectus. The Investor acknowledges that it will be identified in the Initial Prospectus
Supplement as an underwriter within the meaning of Section 2(a)(11) of the Securities Act. The Company shall permit the Investor to review
and comment upon the Report, but only such sections of the Report that relate to the transactions contemplated herein, and the Initial
Prospectus Supplement at least two (2) Business Days prior to their filing with the SEC, the Company shall give due consideration to all
such comments, and the Company shall not file the Report or the Initial Prospectus Supplement with the SEC in a form to which the Investor
reasonably objects. The Investor shall use its reasonable best efforts to comment upon the Report and the Initial Prospectus Supplement
within one (1) Business Day from the date the Investor receives the final pre-filing draft version thereof from the Company. The Investor
shall furnish to the Company such information regarding itself, the Securities held by it and the intended method of distribution thereof,
including any arrangement between the Investor and any other Person relating to the sale or distribution of the Securities, as shall be
reasonably requested by the Company in connection with the preparation and filing of the Current Report and the Initial Prospectus Supplement,
and shall otherwise cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of
the Current Report and the Initial Prospectus Supplement with the SEC.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Blue Sky</U>. The Company shall take all such action, if any, as is reasonably necessary in order
to obtain an exemption for or to register or qualify (i) the issuance of the Commitment Shares and the sale of the Purchase Shares to
the Investor under this Agreement and (ii) any subsequent resale of all Commitment Shares and all Purchase Shares by the Investor, in
each case, under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States in such states as is reasonably
requested by the Investor from time to time, and shall provide evidence of any such action so taken to the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Listing/DTC</U>. The Company shall promptly secure the listing of all of the Purchase Shares and
Commitment Shares to be issued to the Investor hereunder on the Principal Market (subject to official notice of issuance) and upon each
other national securities exchange or automated quotation system, if any, upon which the Common Stock is then listed, and shall maintain,
so long as any shares of Common Stock shall be so listed, such listing of all such Securities from time to time issuable hereunder. The
Company shall maintain the listing of the Common Stock on the Principal Market and shall comply in all respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules and regulations of the Principal Market. Neither the Company, nor any
of its Subsidiaries shall take any action that would reasonably be expected to result in the delisting or suspension of the Common Stock
on the Principal Market. The Company shall promptly, and in no event later than the following Business Day, provide to the Investor copies
of any notices it receives from any Person regarding the continued eligibility of the Common Stock for listing on the Principal Market;
provided, however, that the Company shall not provide the Investor copies of any such notice that the Company reasonably believes constitutes
material non-public information, and the Company would not be required to publicly disclose such notice in any report or statement filed
with the SEC under the Exchange Act (including on Form 8-K) or the Securities Act. The Company shall pay all fees and expenses in connection
with satisfying its obligations under this <U>Section 5(c)</U>. The Company shall take all action necessary to ensure that its Common
Stock can be transferred electronically as DWAC Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Prohibition of Short Sales and Hedging Transactions</U>. The Investor agrees that beginning on
the date of this Agreement and ending on the date of termination of this Agreement as provided in <U>Section 11</U>, the Investor and
its agents, representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i) &ldquo;short
sale&rdquo; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction,
which establishes a net short position with respect to the Common Stock.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Issuance of Commitment Shares</U>. In consideration for the Investor&rsquo;s execution and delivery
of this Agreement, the Company shall cause the Transfer Agent to issue no later than the date of the filing of the Initial Prospectus
Supplement 75,000 shares of Common Stock (the &ldquo;<U>Initial Commitment Shares</U>&rdquo;) directly to the Investor and shall deliver
to the Transfer Agent the Irrevocable Transfer Agent Instructions in the form as set forth in <U>Section 6</U> hereto. For the avoidance
of doubt, all of the Initial Commitment Shares shall be fully earned as of the date of this Agreement, whether or not the Commencement
shall occur or any Purchase Shares are purchased by the Investor under this Agreement and irrespective of any termination of this Agreement.
In connection with each Regular Purchase and each Accelerated Purchase of Purchase Shares hereunder, the Company shall issue to the Investor
a number of shares of Common Stock (the &ldquo;<U>Additional Commitment Shares</U>&rdquo; and, together with the Initial Commitment Shares,
the &ldquo;<U>Commitment Shares</U>&rdquo;) equal to the product of (x) 75,000 and (y) the Purchase Amount Fraction. The &ldquo;<U>Purchase
Amount Fraction</U>&rdquo; shall mean a fraction, the numerator of which is the Purchase Amount purchased by the Investor with respect
to such Regular Purchase and Accelerated Purchase (as applicable) of Purchase Shares and the denominator of which is One Hundred Fifty
Million Dollars ($150,000,000). The Additional Commitment Shares shall be issued to the Investor on the same Business Day as Purchase
Shares are issued to the Investor in connection with the applicable Regular Purchase, Accelerated Purchase and Additional Accelerated
Purchase (as applicable) in accordance with <U>Section 2</U>. In no event shall the amount of the Additional Commitment Shares to be issued
under this Agreement exceed 75,000 shares of Common Stock, provided that such Additional Commitment Shares shall be equitably adjusted
for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Due Diligence; Non-Public Information</U>. The Investor shall have the right, from time to time
as the Investor may reasonably deem appropriate and upon reasonable notice to the Company, to perform reasonable due diligence on the
Company during normal business hours. The Company and its officers and employees shall provide information and reasonably cooperate with
the Investor in connection with any reasonable request by the Investor related to the Investor&rsquo;s due diligence of the Company; <I>provided
however</I>, that the Company will not disclose any material non-public information to the Investor. Each party hereto agrees not to disclose
any Confidential Information of the other party to any third party and shall not use the Confidential Information for any purpose other
than in connection with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges that the Confidential
Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy
of any Confidential Information disclosed by the other party. The receiving party may disclose Confidential Information to the extent
such information is required to be disclosed by law, regulation or order of a court of competent jurisdiction or regulatory authority,
provided that the receiving party shall promptly notify the disclosing party when such requirement to disclose arises, and shall cooperate
with the disclosing party so as to enable the disclosing party to: (i) seek an appropriate protective order; and (ii) make any applicable
claim of confidentiality in respect of such Confidential Information; and provided, further, that the receiving party shall disclose Confidential
Information only to the extent required by the protective order or other similar order, if such an order is obtained, and, if no such
order is obtained, the receiving party shall disclose only the minimum amount of such Confidential Information required to be disclosed
in order to comply with the applicable law, regulation or order. In addition, any such Confidential Information disclosed pursuant to
this <U>Section 5(f)</U> shall continue to be deemed Confidential Information. Notwithstanding anything in this Agreement to the contrary,
the Company and the Investor agree that neither the Company, nor any other Person acting on its behalf shall provide the Investor or its
agents or counsel with any information that constitutes or might constitute material, non-public information, unless a simultaneous public
announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant
by the Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition to
any other remedy provided herein or in the other Transaction Documents, the Investor shall have the right to make a public disclosure,
in the form of a press release, public advertisement or otherwise, of such material, non-public information without the prior approval
by the Company; provided the Investor shall have first provided notice to the Company that it believes it has received information that
constitutes material, non-public information, the Company shall have at least 24 hours to publicly disclose such material, non-public
information prior to any such disclosure by the Investor, and the Company shall have failed to publicly disclose such material, non-public
information within such time period. The Investor shall not have any liability to the Company, any of its Subsidiaries, or any of their
respective directors, officers, employees, stockholders or agents, for any such disclosure. The Company understands and confirms that
the Investor shall be relying on the foregoing covenants in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Purchase Records</U>. The Investor and the Company shall each maintain records showing the remaining
Available Amount at any given time and the dates and Purchase Amounts for each Regular Purchase, Accelerated Purchase and Additional Accelerated
Purchase or shall use such other method, reasonably satisfactory to the Investor and the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Taxes</U>. The Company shall pay any and all transfer, stamp or similar taxes that may be payable
with respect to the issuance and delivery of any shares of Common Stock to the Investor made under this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Effective Registration Statement; Current Prospectuses</U>. The Company shall use its reasonable
best efforts to keep the Registration Statement effective pursuant to Rule 415 promulgated under the Securities Act, and to keep the Registration
Statement and the Prospectus current and available for issuances and sales of all of the Securities by the Company to the Investor, and
for the resale by the Investor as prescribed by Registration Rights Agreement, the Company shall comply with all applicable federal, state
and foreign securities laws in connection with the offer, issuance and sale of the Securities contemplated by the Transaction Documents.
Without limiting the generality of the foregoing, neither the Company, nor any of its officers, directors or affiliates will take, directly
or indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company, or which would reasonably
be expected to cause or result in, stabilization or manipulation of the price of any security of the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(j)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Stop Orders</U>. The Company shall advise the Investor promptly (but in no event later than 24
hours) and shall confirm such advice in writing: (i) of the Company&rsquo;s receipt of notice of any request by the SEC for amendment
of or a supplement to the Registration Statement, the Prospectus, any Prospectus Supplement or for any additional information with respect
thereto; (ii) of the Company&rsquo;s receipt of notice of the issuance by the SEC of any stop order suspending the effectiveness of the
Registration Statement or prohibiting or suspending the use of the Prospectus or any Prospectus Supplement, or of the Company&rsquo;s
receipt of any notification of the suspension of qualification of the Securities for offering or sale in any jurisdiction or the initiation
or contemplated initiation of any proceeding for such purpose; and (iii) of the Company becoming aware of the happening of any event,
which makes any statement of a material fact made in the Registration Statement, the Prospectus or any Prospectus Supplement untrue or
which requires the making of any additions to or changes to the statements then made in the Registration Statement, the Prospectus or
any Prospectus Supplement in order to state a material fact required by the Securities Act to be stated therein or necessary in order
to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in light of the circumstances under
which they were made) not misleading, or of the necessity to amend the Registration Statement or supplement the Prospectus or any Prospectus
Supplement to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investor the substance
or specific reasons of any of the events set forth in clauses (i) through (iii) of the immediately preceding sentence, but rather, shall
only be required to disclose that the event has occurred. The Company shall not deliver to the Investor any Regular Purchase Notice, Accelerated
Purchase Notice or Additional Accelerated Purchase Notice, and the Investor shall not be obligated to purchase any shares of Common Stock
under this Agreement, during the continuation or pendency of any of the foregoing events. If at any time the SEC shall issue any stop
order suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or any Prospectus
Supplement, the Company shall use its reasonable best efforts to obtain the withdrawal of such order at the earliest possible time. The
Company shall furnish to the Investor, without charge, a copy of any correspondence from the SEC or the staff of the SEC to the Company
or its representatives relating to the Registration Statement or the Prospectus, as the case may be.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(k)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Amendments to Registration Statement; Prospectus Supplements</U>. Except as provided in this Agreement
and other than periodic and current reports required to be filed pursuant to the Exchange Act, the Company shall not file with the SEC
any amendment to the Registration Statement or any supplement to the Base Prospectus that refers to the Investor, the Transaction Documents
or the transactions contemplated thereby (including, without limitation, any Prospectus Supplement filed in connection with the transactions
contemplated by the Transaction Documents), in each case with respect to which (a) the Investor shall not previously have been advised
and afforded the opportunity to review and comment thereon at least two (2) Business Days prior to filing with the SEC, as the case may
be, (b) the Company shall not have given due consideration to any comments thereon received from the Investor or its counsel, or (c) the
Investor shall reasonably object, unless the Company reasonably has determined that it is necessary to amend the Registration Statement
or make any supplement to the Prospectus to comply with the Securities Act or any other applicable law or regulation, in which case the
Company shall promptly (but in no event later than 24 hours) so inform the Investor, the Investor shall be provided with a reasonable
opportunity to review and comment upon any disclosure referring to the Investor, the Transaction Documents or the transactions contemplated
thereby, as applicable, and the Company shall promptly furnish to the Investor a copy thereof. In addition, for so long as, in the reasonable
opinion of counsel for the Investor, the Prospectus is required to be delivered in connection with any acquisition or sale of Securities
by the Investor, the Company shall not file any Prospectus Supplement with respect to the Securities without furnishing to the Investor
as many copies of such Prospectus Supplement, together with the Prospectus, as the Investor may reasonably request.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(l)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Prospectus Delivery</U>. The Company consents to the use of the Prospectus (and of each Prospectus
Supplement thereto) in accordance with the provisions of the Securities Act and with the securities or &ldquo;blue sky&rdquo; laws of
the jurisdictions in which the Securities may be sold by the Investor, in connection with the offering and sale of the Securities and
for such period of time thereafter as the Prospectus is required by the Securities Act to be delivered in connection with sales of the
Securities. The Company will make available to the Investor upon request, and thereafter from time to time will furnish to the Investor,
as many copies of the Prospectus (and each Prospectus Supplement thereto) as the Investor may reasonably request for the purposes contemplated
by the Securities Act within the time during which the Prospectus is required by the Securities Act to be delivered in connection with
sales of the Securities. If during such period of time any event shall occur that in the reasonable judgment of the Company and its counsel,
or in the reasonable judgment of the Investor and its counsel, is required to be set forth in the Registration Statement, the Prospectus
or any Prospectus Supplement or should be set forth therein in order to make the statements made therein (in the case of the Prospectus
or any Prospectus Supplement, in light of the circumstances under which they were made) not misleading, or if in the reasonable judgment
of the Company and its counsel, or in the reasonable judgment of the Investor and its counsel, it is otherwise necessary to amend the
Registration Statement or supplement the Prospectus or any Prospectus Supplement to comply with the Securities Act or any other applicable
law or regulation, the Company shall forthwith prepare and, subject to <U>Section 5(k)</U> above, file with the SEC an appropriate amendment
to the Registration Statement or an appropriate Prospectus Supplement and in each case shall expeditiously furnish to the Investor, at
the Company&rsquo;s expense, such amendment to the Registration Statement or such Prospectus Supplement, as applicable, as may be necessary
to reflect any such change or to effect such compliance. The Company shall have no obligation to separately advise the Investor of, or
deliver copies to the Investor of, the SEC Documents, all of which the Investor shall be deemed to have notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(m)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Aggregation</U>. From and after the date of this Agreement, neither the Company, nor or any of
its affiliates will, and the Company shall use its reasonable best efforts to ensure that no Person acting on their behalf will, directly
or indirectly, make any offers or sales of any security or solicit any offers to buy any security, under circumstances that would cause
this offering of the Securities by the Company to the Investor to be aggregated with other offerings by the Company in a manner that would
require stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed or
designated, unless stockholder approval is obtained before the closing of such subsequent transaction in accordance with the rules of
such Principal Market.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(n)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Use of Proceeds</U>. The Company will use the net proceeds from the offering as described in the
Prospectus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(o)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Other Transactions</U>. The Company shall not enter into, announce or recommend to its stockholders
any agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair
the ability or right of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation
of the Company to deliver the Purchase Shares and the Commitment Shares to the Investor in accordance with the terms of the Transaction
Documents.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(p)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Required Filings Relating to Purchases</U>. To the extent required under the Securities Act or
under interpretations by the SEC thereof, as promptly as practicable after the close of each of the Company&rsquo;s fiscal quarters (or
on such other dates as required under the Securities Act or under interpretations by the SEC thereof), the Company shall prepare a Prospectus
Supplement, which will set forth the number of Purchase Shares sold to the Investor during such quarterly period (or other relevant period),
the purchase price for such Purchase Shares and the net proceeds received by the Company from such sales, and shall file such Prospectus
Supplement with the SEC pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule
430B under the Securities Act). If any such quarterly Prospectus Supplement is not required to be filed under the Securities Act or under
interpretations by the SEC thereof, the Company shall disclose the information referenced in the immediately preceding sentence in its
annual report on Form 10-K or its quarterly report on Form 10-Q (as applicable) in respect of the quarterly period that ended immediately
before the filing of such report in which sales of Purchase Shares were made to the Investor under this Agreement, and file such report
with the SEC within the applicable time period required by the Exchange Act. The Company shall not file any Prospectus Supplement pursuant
to this <U>Section 5(p)</U>, and shall not file any report containing disclosure relating to such sales of Purchase Shares, unless a copy
of such Prospectus Supplement or disclosure has been submitted to the Investor a reasonable period of time before the filing and the Investor
has not reasonably objected thereto (it being acknowledged and agreed that the Company shall not submit any portion of any Form 10-K or
Form 10-Q other than the specific disclosure relating to any sales of Purchase Shares). The Company shall also furnish copies of all such
Prospectus Supplements to each exchange or market in the United States on which sales of the Purchase Shares may be made as may be required
by the rules or regulations of such exchange or market, if applicable.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(q)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Limitation on Variable Rate Transactions</U>. From and after the date of this Agreement until
the Maturity Date (irrespective of any earlier termination of this Agreement), the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction other than with the Investor. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means
an &ldquo;equity line of credit&rdquo; or substantially similar transaction whereby an investor is irrevocably bound to purchase securities
over a period of time from the Company at a price based on the market price of the Company&rsquo;s Common Stock at the time of each such
purchase, provided, however, that this Section 5(q) shall not be deemed to prohibit the issuance and sale of Common Stock pursuant to
an &ldquo;at-the-market offering&rdquo; by the Company exclusively through a registered broker-dealer acting as agent of the Company pursuant
to a written agreement between the Company and such registered broker-dealer.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">6.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>TRANSFER AGENT INSTRUCTIONS.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On the Commencement Date, the Company
shall issue to the Transfer Agent (and any subsequent transfer agent) irrevocable instructions, in the form substantially similar to those
used by the Investor in substantially similar transactions, to issue the Purchase Shares and the Commitment Shares in accordance with
the terms of this Agreement (the &ldquo;<U>Irrevocable Transfer Agent Instructions</U>&rdquo;). All Securities to be issued to or for
the benefit of the Investor pursuant to this Agreement shall be issued as DWAC Shares. The Company warrants to the Investor that no instruction
other than the Irrevocable Transfer Agent Instructions referred to in this <U>Section 6</U> will be given by the Company to the Transfer
Agent with respect to the Securities, and the Securities shall otherwise be freely transferable on the books and records of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">7.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>CONDITIONS TO THE COMPANY&rsquo;S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK</B>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The right of the Company hereunder
to commence sales of the Purchase Shares on the Commencement Date is subject to the satisfaction or waiver of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Investor shall have executed each of the Transaction Documents and delivered the same to the
Company;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">No stop order with respect to the Registration Statement shall be pending or threatened by the SEC;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">All federal, state, local and foreign governmental laws, rules and regulations applicable to the
transactions contemplated by the Transaction Documents and necessary for the execution, delivery and performance of the Transaction Documents
and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been complied with, and
all consents, authorizations and orders of, and all filings and registrations with, all federal, state, local and foreign courts or governmental
agencies and all federal, state, local and foreign regulatory or self-regulatory agencies necessary for the execution, delivery and performance
of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall
have been obtained or made, including, without limitation, in each case those required prior to the commencement of sales of Purchase
Shares under the Securities Act, the Exchange Act, applicable state securities or &ldquo;Blue Sky&rdquo; laws or applicable rules and
regulations of the Principal Market or otherwise required by the SEC, the Principal Market, or any state securities regulators;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered,
promulgated, threatened or endorsed by any federal, state or local court or governmental authority of competent jurisdiction which prohibits
the consummation of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">All Securities to be issued by the Company to the Investor under the Transaction Documents shall
have been approved for listing on the Principal Market in accordance with the applicable rules and regulations of the Principal Market,
subject only to official notice of issuance; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The representations and warranties of the Investor shall be true and correct in all material respects
as of the date hereof and as of the Commencement Date as though made at that time.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">8.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>CONDITIONS TO THE INVESTOR&rsquo;S OBLIGATION TO PURCHASE SHARES OF COMMON STOCK.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The obligation of the Investor
to buy Purchase Shares under this Agreement is subject to the satisfaction or waiver of each of the following conditions on or prior to
the Commencement Date and, once such conditions have been initially satisfied, there shall not be any ongoing obligation to satisfy such
conditions after the Commencement has occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Company shall have executed each of the Transaction Documents and delivered the same to the Investor;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Common Stock shall be listed or quoted on the Principal Market, trading in the Common Stock shall
not have been within the last 365 days suspended by the SEC or the Principal Market for one or more Business Days, and all Securities
to be issued by the Company to the Investor pursuant to this Agreement shall have been approved for listing or quotation on the Principal
Market in accordance with the applicable rules and regulations of the Principal Market, subject only to official notice of issuance;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Investor shall have received the opinion letter of the Company&rsquo;s corporate legal counsel
dated as of the Commencement Date substantially in the form agreed to prior to the date of this Agreement by the Company&rsquo;s legal
counsel and the Investor&rsquo;s legal counsel;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The representations and warranties of the Company shall be true and correct in all material respects
(except to the extent that any of such representations and warranties is already qualified as to materiality in <U>Section 4</U> above,
in which case, such representations and warranties shall be true and correct without further qualification) as of the date hereof and
as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date, which
shall be true and correct as of such date) and the Company shall have performed, satisfied and complied with the covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement
Date. The Investor shall have received a certificate, executed by the CEO, President or CFO of the Company, dated as of the Commencement
Date, to the foregoing effect in the form attached hereto as <U>Exhibit A</U>;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Board of Directors of the Company shall have adopted the Signing Resolutions, which shall be
in full force and effect without any amendment or supplement thereto as of the Commencement Date;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">As of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common
Stock, (i) solely for the purpose of effecting purchases of Purchase Shares hereunder, 10,000,000 shares of Common Stock; and (ii) solely
for the purpose of effecting the issuance of Additional Commitment Shares hereunder 75,000 shares of Common Stock;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Irrevocable Transfer Agent Instructions shall have been delivered to and acknowledged in writing
by the Company and the Company&rsquo;s Transfer Agent (or any successor transfer agent), and the Commitment Shares required to be issued
on the Commencement Date in accordance with <U>Section 5(e)</U> hereof shall have been issued directly to the Investor electronically
as DWAC Shares;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Company shall have delivered to the Investor a certificate evidencing the incorporation and good
standing of the Company in the State of Nevada issued by the Secretary of State of the State of Nevada as of a date within ten (10) Business
Days of the Commencement Date;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Company shall have delivered to the Investor a certified copy of the Articles of Incorporation
as certified by the Secretary of State of the State of Nevada within ten (10) Business Days of the Commencement Date;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(j)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Company shall have delivered to the Investor a secretary&rsquo;s certificate executed by the
Secretary of the Company, dated as of the Commencement Date, in the form attached hereto as <U>Exhibit B</U>;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(k)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Registration Statement shall continue to be effective and no stop order with respect to the Registration
Statement shall be pending or threatened by the SEC. The Company shall have a maximum dollar amount of Common Stock registered under the
Registration Statement which is sufficient to issue to the Investor not less than (i) the full Available Amount worth of Purchase Shares
plus (ii) all of the Commitment Shares. The Current Report and the Initial Prospectus Supplement each shall have been filed with the SEC,
as required pursuant to <U>Section 5(a)</U>, and copies of the Prospectus shall have been delivered to the Investor in accordance with
<U>Section 5(l)</U> hereof. The Prospectus shall be current and available for issuances and sales of all of the Securities by the Company
to the Investor, and for the resale of all of the Securities by the Investor. Any other Prospectus Supplements required to have been filed
by the Company with the SEC under the Securities Act at or prior to the Commencement Date shall have been filed with the SEC within the
applicable time periods prescribed for such filings under the Securities Act. All reports, schedules, registrations, forms, statements,
information and other documents required to have been filed by the Company with the SEC at or prior to the Commencement Date pursuant
to the reporting requirements of the Exchange Act shall have been filed with the SEC within the applicable time periods prescribed for
such filings under the Exchange Act;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(l)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">No Suspension Event has occurred, or any event which, after notice and/or lapse of time, would become
a Suspension Event has occurred;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(m)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">All federal, state and local governmental laws, rules and regulations applicable to the transactions
contemplated by the Transaction Documents and necessary for the execution, delivery and performance of the Transaction Documents and the
consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been complied with, and all consents,
authorizations and orders of, and all filings and registrations with, all federal, state and local courts or governmental agencies and
all federal, state and local regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction
Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained
or made, including, without limitation, in each case those required under the Securities Act, the Exchange Act, applicable state securities
or &ldquo;Blue Sky&rdquo; laws or applicable rules and regulations of the Principal Market, or otherwise required by the SEC, the Principal
Market or any state securities regulators;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(n)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered,
promulgated, threatened or endorsed by any federal, state, local or foreign court or governmental authority of competent jurisdiction
which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by the Transaction
Documents; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(o)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">No action, suit or proceeding before any federal, state, local or foreign arbitrator or any court
or governmental authority of competent jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal,
state, local or foreign governmental authority of competent jurisdiction shall have been commenced or threatened, against the Company,
or any of the officers, directors or affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by
the Transaction Documents, or seeking material damages in connection with such transactions.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">9.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>INDEMNIFICATION.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In consideration of the Investor&rsquo;s
execution and delivery of the Transaction Documents and acquiring the Securities hereunder and in addition to all of the Company&rsquo;s
other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Investor and all
of its affiliates, stockholders, officers, directors, members, managers, employees and direct or indirect investors and any of the foregoing
Person&rsquo;s agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated
by this Agreement) (collectively, the &ldquo;<U>Indemnitees</U>&rdquo;) from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such
Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys&rsquo; fees and
disbursements (the &ldquo;<U>Indemnified Liabilities</U>&rdquo;), incurred by any Indemnitee as a result of, or arising out of, or relating
to (a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other
certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of the Company
contained in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, or (c) any cause
of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution, delivery, performance
or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, other than,
in the case of clause (c), with respect to Indemnified Liabilities which directly and primarily result from the fraud, gross negligence
or willful misconduct of an Indemnitee. The indemnity in this <U>Section 9</U> shall not apply to amounts paid in settlement of any claim
if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned
or delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the
maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law.
Payment under this indemnification shall be made within thirty (30) days from the date the Investor makes written request for it. A certificate
containing reasonable detail as to the amount of such indemnification submitted to the Company by the Investor shall be conclusive evidence,
absent manifest error, of the amount due from the Company to the Investor. If any action shall be brought against any Indemnitee in respect
of which indemnity may be sought pursuant to this Agreement, such Indemnitee shall promptly notify the Company in writing, and the Company
shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee. Any Indemnitee
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of
such counsel shall be at the expense of such Indemnitee, except to the extent that (i) the employment thereof has been specifically authorized
by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel
or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material conflict on any material issue between
the position of the Company and the position of such Indemnitee, in which case the Company shall be responsible for the reasonable fees
and expenses of no more than one such separate counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">10.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>SUSPENSION EVENTS.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A &ldquo;<U>Suspension Event</U>&rdquo;
shall be deemed to have occurred at any time as any of the following events occurs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">the effectiveness of the Registration Statement registering the Securities lapses for any reason
(including, without limitation, the issuance of a stop order or similar order) or the Registration Statement or the Prospectus is unavailable
for the sale by the Company to the Investor (or the resale by the Investor) of any or all of the Securities to be issued to the Investor
under the Transaction Documents (including, without limitation, as a result of any failure of the Company to satisfy all of the requirements
for the use of a registration statement on Form S-3 pursuant to the Securities Act for the offering and sale of the Securities contemplated
by this Agreement), and such lapse or unavailability continues for a period of ten (10) consecutive Business Days or for more than an
aggregate of thirty (30) Business Days in any 365-day period;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">the suspension of the Common Stock from trading on the Principal Market for a period of three (3)
consecutive Business Days, provided that the Company may not direct the Investor to purchase any shares of Common Stock during any such
suspension;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">the delisting of the Common Stock from the NASDAQ Capital Market; provided, however, that the Common
Stock is not immediately thereafter trading on the New York Stock Exchange, the NASDAQ Global Market, he NASDAQ Global Select Market,
the NYSE American, the NYSE Arca or the OTC Bulletin Board, OTCQX or OTCQB operated by the OTC Markets Group, Inc. (or nationally recognized
successor to any of the foregoing). If at any time after the Commencement Date, the Exchange Cap is reached unless and until stockholder
approval is obtained pursuant to <U>Section 2(f)</U> hereof. The Exchange Cap shall be deemed to be reached at such time if, upon submission
of a Regular Purchase Notice or Accelerated Purchase Notice under this Agreement, the issuance of such shares of Common Stock would exceed
that number of shares of Common Stock which the Company may issue under this Agreement without breaching the Company&rsquo;s obligations
under the rules or regulations of the Principal Market;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">the failure for any reason by the Transfer Agent to issue (i) the Additional Commitment Shares to
the Investor within three (3) Business Days after the date on which the Investor is entitled to receive such Additional Commitment Shares
pursuant to <U>Section 5(e)</U> hereof and (ii) Purchase Shares to the Investor within three (3) Business Days after the applicable Purchase
Date, Accelerated Purchase Date or Additional Accelerated Purchase Date (as applicable) on which the Investor is entitled to receive such
Securities;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">the Company breaches any representation, warranty, covenant or other term or condition under any
Transaction Document if such breach could have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably
curable, only if such breach continues for a period of at least five (5) Business Days;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">if any Person commences a proceeding against the Company pursuant to or within the meaning of any
Bankruptcy Law;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">if the Company, pursuant to or within the meaning of any Bankruptcy Law, (i) commences a voluntary
case, (ii) consents to the entry of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian
of it or for all or substantially all of its property, or (iv) makes a general assignment for the benefit of its creditors or is generally
unable to pay its debts as the same become due;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is
for relief against the Company in an involuntary case, (ii) appoints a Custodian of the Company or for all or substantially all of its
property, or (iii) orders the liquidation of the Company or any Subsidiary; or</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">if at any time the Company is not eligible to transfer its Common Stock electronically as DWAC Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In addition to any other rights
and remedies under applicable law and this Agreement, so long as a Suspension Event has occurred and is continuing, or if any event which,
after notice and/or lapse of time, would become a Suspension Event, has occurred and is continuing, the Company shall not deliver to the
Investor any Regular Purchase Notice or Accelerated Purchase Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">11.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>TERMINATION</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">This Agreement may be terminated
only as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">If pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case
or any Person commences a proceeding against the Company, a Custodian is appointed for the Company or for all or substantially all of
its property, or the Company makes a general assignment for the benefit of its creditors (any of which would be a Suspension Event as
described in <U>Sections 10(f)</U>, <U>10(g)</U> and <U>10(h)</U> hereof), this Agreement shall automatically terminate without any liability
or payment to the Company (except as set forth below) without further action or notice by any Person.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">In the event that the Commencement shall not have occurred on or before March 20, 2023 due to the
failure to satisfy the conditions set forth in <U>Sections 7</U> and <U>8</U> above with respect to the Commencement, either the Company
or the Investor shall have the option to terminate this Agreement at the close of business on such date or thereafter without liability
of any party to any other party (except as set forth below); provided, however, that the right to terminate this Agreement under this
<U>Section 11(b)</U> shall not be available to any party if such party is then in breach of any covenant or agreement contained in this
Agreement or any representation or warranty of such party contained in this Agreement fails to be true and correct such that the conditions
set forth in <U>Section 7(c)</U> or <U>Section 8(e)</U>, as applicable, could not then be satisfied.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">At any time after the Commencement Date, the Company shall have the option to terminate this Agreement
for any reason or for no reason by delivering notice (a &ldquo;<U>Company Termination Notice</U>&rdquo;) to the Investor electing to terminate
this Agreement without any liability whatsoever of any party to any other party under this Agreement (except as set forth below). The
Company Termination Notice shall not be effective until one (1) Business Day after it has been received by the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">This Agreement shall automatically terminate on the date that the Company sells and the Investor
purchases the full Available Amount as provided herein, without any action or notice on the part of any party and without any liability
whatsoever of any party to any other party under this Agreement (except as set forth below).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">If, for any reason or for no reason, the full Available Amount has not been purchased in accordance
with <U>Section 2</U> of this Agreement by the Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without
any action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement
(except as set forth below).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Except as set forth in <U>Sections
11(a)</U> (in respect of a Suspension Event under <U>Sections 10(f)</U>, <U>10(g)</U> and 10(h)), <U>11(d)</U> and <U>11(e)</U>, any termination
of this Agreement pursuant to this <U>Section 11</U> shall be effected by written notice from the Company to the Investor, or the Investor
to the Company, as the case may be, setting forth the basis for the termination hereof. The representations and warranties and covenants
of the Company and the Investor contained in <U>Sections 3</U>, <U>4</U>, <U>5</U>, and <U>6</U> hereof, the indemnification provisions
set forth in <U>Section 9</U> hereof and the agreements and covenants set forth in <U>Sections 10</U>, <U>11</U> and <U>12</U> shall survive
the Commencement and any termination of this Agreement. No termination of this Agreement shall (i) affect the Company&rsquo;s or the Investor&rsquo;s
rights or obligations under (A) this Agreement with respect to pending Regular Purchases, Accelerated Purchases and Additional Accelerated
Purchases, and the Company and the Investor shall complete their respective obligations with respect to any pending Regular Purchases,
Accelerated Purchases and Additional Accelerated Purchases under this Agreement and (B) the Registration Rights Agreement, which shall
survive any such termination, or (ii) be deemed to release the Company or the Investor from any liability for intentional misrepresentation
or willful breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">12.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><B>MISCELLANEOUS.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Governing Law; Jurisdiction; Jury Trial</U>. The corporate laws of the State of Nevada shall govern
all issues concerning the relative rights of the Company and its stockholders. All other questions concerning the construction, validity,
enforcement and interpretation of this Agreement and the other Transaction Documents shall be governed by the internal laws of the State
of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any
other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Illinois, County of Cook, for
the adjudication of any dispute hereunder or under the other Transaction Documents or in connection herewith or therewith, or with any
transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in
an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party
at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of
process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by law. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE</B>, <B>AND AGREES NOT TO REQUEST</B>, <B>A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY</B>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Counterparts</U>. This Agreement may be executed in two or more identical counterparts, all of
which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to the other party; provided that a facsimile signature or signature delivered by e-mail in a &ldquo;.pdf&rdquo; format data file shall
be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an
original signature.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Headings</U>. The headings of this Agreement are for convenience of reference and shall not form
part of, or affect the interpretation of, this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Severability</U>. If any provision of this Agreement shall be invalid or unenforceable in any
jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in
that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Entire Agreement</U>. The Transaction Documents supersede all other prior oral or written agreements
between the Investor, the Company, their affiliates and Persons acting on their behalf with respect to the subject matter thereof, and
this Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor
the Investor makes any representation, warranty, covenant or undertaking with respect to such matters. The Company acknowledges and agrees
that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth
in the Transaction Documents.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Notices</U>. Any notices, consents or other communications required or permitted to be given under
the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt when delivered personally;
(ii) upon receipt when sent by facsimile or email (provided confirmation of transmission is mechanically or electronically generated and
kept on file by the sending party); or (iii) one Business Day after deposit with a nationally recognized overnight delivery service, in
each case properly addressed to the party to receive the same. The addresses for such communications shall be:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">630
5th Avenue, 20th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10111</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(844) 689-3939</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
cmissling@anavexcorp.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Christopher Missling, PhD., CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute notice or service of process):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K&amp;L
Gates, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200
S. Biscayne Blvd., Ste. 3900</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miami,
Florida 33131</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(305) 539-3306</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
(305) 358-7095</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
clayton.parker@klgates.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Clayton E. Parker, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Investor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
Park Capital Fund, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">440
North Wells, Suite 410</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chicago,
IL 60654</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(312) 822-9300</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
(312) 822-9301</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
jscheinfeld@lpcfunds.com/jcope@lpcfunds.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Josh Scheinfeld/Jonathan Cope</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Transfer Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada
Agency and Transfer Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50
West Liberty Street, Suite 880</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reno,
NV 89501</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(775) 322-0626</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:
(775) 322-5623</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
tiffany@natco.org</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Tiffany Baxter</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">or at such other address and/or facsimile number and/or
to the attention of such other Person as the recipient party has specified by written notice given to each other party three (3) Business
Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent or
other communication, (B) mechanically or electronically generated by the sender&rsquo;s facsimile machine or email account containing
the time, date, and recipient facsimile number or email address, as applicable, and an image of the first page of such transmission or
(C) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the
parties and their respective successors and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder
without the prior written consent of the Investor, including by merger or consolidation. The Investor may not assign its rights or obligations
under this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Third Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto
and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any
other Person.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Publicity</U>. The Company shall afford the Investor and its counsel with the opportunity to review
and comment upon, shall consult with the Investor and its counsel on the form and substance of, and shall give due consideration to all
such comments from the Investor or its counsel on, any press release, SEC filing or any other public disclosure by or on behalf of the
Company relating to the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated
thereby, not less than 24 hours prior to the issuance, filing or public disclosure thereof. The Investor must be provided with a final
version of any such press release, SEC filing or other public disclosure at least 24 hours prior to any release, filing or use by the
Company thereof; provided, however, that the Company&rsquo;s obligations pursuant to this <U>Section 12(i)</U> shall not apply if the
form and substance of such press release, SEC filing, or other public disclosure relating to the Investor, its purchases hereunder or
any aspect of the Transaction Documents or the transactions contemplated thereby previously have been publicly disclosed by the Company
in compliance with this <U>Section 12(i)</U>. The Company agrees and acknowledges that its failure to fully comply with this provision
constitutes a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(j)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Further Assurances</U>. Each party shall do and perform, or cause to be done and performed, all
such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the
other party may reasonably request in order to consummate and make effective, as soon as reasonably possible, the Commencement, and to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(k)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Financial Advisor, Placement Agent</U>, <U>Broker or Finder</U>. The Company represents and
warrants to the Investor that it has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions
contemplated hereby. The Investor represents and warrants to the Company that it has not engaged any financial advisor, placement agent,
broker or finder in connection with the transactions contemplated hereby. The Company shall be responsible for the payment of any fees
or commissions, if any, of any financial advisor, placement agent, broker or finder relating to or arising out of the transactions contemplated
hereby. The Company shall pay, and hold the Investor harmless against, any liability, loss or expense (including, without limitation,
attorneys&rsquo; fees and out of pocket expenses) arising in connection with any such claim.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(l)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Strict Construction</U>. The language used in this Agreement will be deemed to be the language
chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(m)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Remedies</U>, <U>Other Obligations, Breaches and Injunctive Relief</U>. The Investor&rsquo;s remedies
provided in this Agreement, including, without limitation, the Investor&rsquo;s remedies provided in <U>Section 9</U>, shall be cumulative
and in addition to all other remedies available to the Investor under this Agreement, at law or in equity (including a decree of specific
performance and/or other injunctive relief), no remedy of the Investor contained herein shall be deemed a waiver of compliance with the
provisions giving rise to such remedy and nothing herein shall limit the Investor&rsquo;s right to pursue actual damages for any failure
by the Company to comply with the terms of this Agreement. The Company acknowledges that a breach by it of its obligations hereunder will
cause irreparable harm to the Investor and that the remedy at law for any such breach may be inadequate. The Company therefore agrees
that, in the event of any such breach or threatened breach, the Investor shall be entitled, in addition to all other available remedies,
to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(n)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Enforcement Costs</U>. In the event of a dispute arising out of or relating to this Agreement,
if a court of competent jurisdiction determines in a final, non-appealable order that a party has breached this Agreement, then in addition
to any other available remedies, the non-breaching party shall be entitled to (in addition to all other available remedies), and the breaching
party shall be liable for, the reasonable legal fees and expenses incurred by the non-breaching party in connection with such dispute,
including any appeals in connection therewith.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt; color: #010000">(o)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #010000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Waivers</U>. No provision of this Agreement may be waived other than in a written instrument signed
by the party against whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>** Signature Page Follows **</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>IN WITNESS WHEREOF,</B> the
Investor and the Company have caused this Purchase Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>THE COMPANY:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ANAVEX
LIFE SCIENCES CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Christopher Missling</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>INVESTOR:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LINCOLN PARK CAPITAL FUND, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BY: LINCOLN PARK CAPITAL, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BY: ROCKLEDGE CAPITAL CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">/s/
Josh Scheinfeld</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Scheinfeld</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULES</B></FONT></TD>
<TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 4(a)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AnavexAustralia Pty Limited</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AnavexGermany GmbH</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AnavexCanada Ltd.</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 4(c)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See attached.</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS</B></FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit A</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Officer&rsquo;s Certificate</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit B</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Secretary&rsquo;s Certificate</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 112.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM OF OFFICER&rsquo;S CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Officer&rsquo;s Certificate (&ldquo;<U>Certificate</U>&rdquo;)
is being delivered pursuant to <U>Section 8(e)</U> of that certain Purchase Agreement dated as of February 3, 2023 (&ldquo;<U>Purchase
Agreement</U>&rdquo;), by and between <B>ANAVEX LIFE SCIENCES CORP. </B>, a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), and
<B>LINCOLN PARK CAPITAL FUND, LLC </B>(the &ldquo;<U>Investor</U>&rdquo;). Terms used herein and not otherwise defined shall have the
meanings ascribed to them in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The undersigned, ___________, ______________
of the Company, hereby certifies as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">I am the _____________ of the Company and make the statements contained in this Certificate;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The representations and warranties of the Company are true and correct in all material respects (except
to the extent that any of such representations and warranties is already qualified as to materiality in Section 4 of the Purchase Agreement,
in which case, such representations and warranties are true and correct without further qualification) as of the date when made and as
of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date, in which
case such representations and warranties are true and correct as of such date);</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Company has performed, satisfied and complied in all material respects with covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement
Date.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Company has not taken any steps, and does not currently expect to take any steps, to seek protection
pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors
intend to initiate involuntary bankruptcy or insolvency proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">IN WITNESS WHEREOF, I have hereunder signed my name
on this ___ day of ___________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%">&nbsp;</TD>
  <TD STYLE="width: 60%">Name:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned as Secretary of <B>ANAVEX LIFE SCIENCES
CORP.</B>, a Nevada corporation, hereby certifies that ___________ is the duly elected, appointed, qualified and acting ________ of _________
and that the signature appearing above is his genuine signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%">&nbsp;</TD>
  <TD STYLE="width: 60%">Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM OF SECRETARY&rsquo;S CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Secretary&rsquo;s Certificate (&ldquo;<U>Certificate</U>&rdquo;)
is being delivered pursuant to <U>Section 8(k)</U> of that certain Purchase Agreement dated as of February 3, 2023 (&ldquo;<U>Purchase
Agreement</U>&rdquo;), by and between <B>ANAVEX LIFE SCIENCES CORP. </B>, a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;) and
<B>LINCOLN PARK CAPITAL FUND, LLC</B> (the &ldquo;<U>Investor</U>&rdquo;), pursuant to which the Company may sell to the Investor up to
One Hundred Fifty Million Dollars ($150,000,000) of the Company&rsquo;s Common Stock, $0.001 par value per share (the &ldquo;<U>Common
Stock</U>&rdquo;). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned, ____________, Secretary of the Company,
hereby certifies as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">I am the Secretary of the Company and make the statements contained in this Secretary&rsquo;s Certificate.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Attached hereto as <U>Exhibit A</U> and <U>Exhibit B</U> are true, correct and complete copies of
the Company&rsquo;s Bylaws (&ldquo;<U>Bylaws</U>&rdquo;) and Articles of Incorporation (&ldquo;<U>Charter</U>&rdquo;), in each case, as
amended through the date hereof, and no action has been taken by the Company, its directors, officers or stockholders, in contemplation
of the filing of any further amendment relating to or affecting the Bylaws or Charter.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Attached hereto as <U>Exhibit C</U> are true, correct and complete copies of the resolutions duly
adopted by the Board of Directors of the Company on _____________, at which a quorum was present and acting throughout. Such resolutions
have not been amended, modified or rescinded and remain in full force and effect and such resolutions are the only resolutions adopted
by the Company&rsquo;s Board of Directors, or any committee thereof, or the stockholders of the Company relating to or affecting (i) the
entering into and performance of the Purchase Agreement, or the issuance, offering and sale of the Purchase Shares and the Commitment
Shares and (ii) and the performance of the Company of its obligation under the Transaction Documents as contemplated therein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">As of the date hereof, the authorized, issued and reserved capital stock of the Company is as set
forth on <U>Exhibit D</U> hereto.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, I have hereunder signed
my name on this ___ day of ____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%">&nbsp;</TD>
  <TD STYLE="width: 60%">Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned as ___________ of <B>ANAVEX LIFE SCIENCES
CORP.</B>, a Nevada corporation, hereby certifies that ____________ is the duly elected, appointed, qualified and acting Secretary of
_________, and that the signature appearing above is his genuine signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 60%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">35</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-align: justify; text-indent: 468pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>e4385_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;<B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the three months ended December 31, 2022 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: February 7, 2023</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Christopher Missling, PhD</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer, President and Secretary</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>e4385_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;<B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the three months ended December 31, 2022 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: February 7, 2023</FONT></TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Sandra Boenisch</FONT></TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>e4385_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of Anavex
Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended December 31, 2022 as filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the date indicated below,
hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the
best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(1) the Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(2) the information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: February 7, 2023</FONT></TD>
<TD STYLE="border-bottom: black 1pt solid; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/Christopher Missling, PhD </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer, President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer) </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/Sandra Boenisch</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished solely
to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic
version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U G$# 2(  A$! Q$!_\0
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MLJOC@L,@?AD57\N__P"?FW_[\-_\70!:HJKY=_\ \_-O_P!^&_\ BZ/+O_\
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M_P"?FW_[\-_\71Y=_P#\_-O_ -^&_P#BZ +5%5?+O_\ GYM_^_#?_%T>7?\
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M_P#OPW_Q= %JBJOEW_\ S\V__?AO_BZ/+O\ _GYM_P#OPW_Q= %JBJOEW_\
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M_P"^Z ,Z/Q S:?I]VUN@%W.L102Y*!C@'ISC(S6[5(6UV,8EM!@Y'^C'@_\
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MQ3C&"JC8QQR=QYW9K2T6VU,Z??\ GZ?=0VT\TCM97,[-*J; %6-PYY8@DY(
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MK1)N3B/A<8YY)VX X/>E3Q'XP?RA_;#*TC.JJRKGY<[OX?8^]7'\)>,W(?\
ML^W64*RB19ER Q).!NQW/:E'A3QDKLXTRUW.V^0^<OSG!&3\W!Y/(Q2YL/\
MW?P'RXC^]^)C2>-O$\<C(=9E)4XR$7'ZK3?^$Y\3_P#08F_[X3_XFK<GP[\4
MR2,_]G1+N.<"X3 _,TW_ (5QXI_Y\(__  (3_&M.;!_W?P,^7&?WOQ*W_"<^
M)_\ H,3?]\)_\31_PG/B?_H,3?\ ?"?_ !-6?^%<>*?^?"/_ ,"$_P :/^%<
M>*?^?"/_ ,"$_P :.;!_W?P#EQG][\2M_P )SXG_ .@Q-_WPG_Q-'_"<^)_^
M@Q-_WPG_ ,35G_A7'BG_ )\(_P#P(3_&C_A7'BG_ )\(_P#P(3_&CFP?]W\
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M?_$T?\)SXG_Z#$W_ 'PG_P 35G_A7/BG_GPC_P# A/\ &C_A7/BG_GPC_P#
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MG_F3CPII(\TBVU(F7B0#4I?F&<\_/ZUYMXDC:QUV[TZ"YO%M;:4B*,W4AVY
M)YW9KT6"_P#&<222)X3LHV&!M^VKEQ[<XX]ZY+5O"'BO5=5DOWTF)'NFWNBW
M2$1=L')YZ9XS7H8!JG-O$335O)]?0X,>G.*5"+3OYKIZG,?;;PW#3F]NS*X(
M9_M#Y((P>_I2">X\@P?:[KRBV_;]HDQG&,]:WAX!\4;Y5_LU,("5;[2F'Y[<
M]_?%!\">*!$KC2U+$D%!<QY'OUQ^M>I[?!]X_A_D>9[#&=I?C_F8HO+OSHIO
MMMWYD0 1OM#_ "@=.]"SW"QR(+JZ"RXWC[0_S8.1WK>_X0'Q-]H\O^SX]F,^
M;]H3;TSCKGVZ4T>!O%'DESI0#!@!']ICR1Z]<?K1[?!]X_A_D+V&,[2_'_,Q
M3/<,L2FZNBL7W!]H?Y><^OK3_M-R999?M=UYDH(D;[0_S ]>];?_  @GB;S(
ME_LY,. 6;[0F(\]CSGCVS0/ _B8B3.F*-GW1]IC^?GMS^/.*7M\)WC^'^0>P
MQG:7X_YF)YDQ@$!N;GR@V\+]H?&>F>M2BZNOM*W'VNZ\Y0 '^T/D#&/7TK7/
M@GQ,L<;#2P2V<J+F/*?7G'Y9J3_A!_$@G=/[.3:H)$GVA,-CL.<\^X%+V^$[
MQ_#_ "'[#%]I?C_F8:/*L+PK<7(C<@LOVA^2.G?WI_FS%H6-S<YA $9^T/\
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M?_?0_P */^$P\1_]!J[_ .^A_A5__A7/BG_H'Q_^!"?XT?\ "N?%/_0/C_\
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M7&>">34:75I&Q*>#==4$DX$9X[<<UYK53I"/W1_^2/5O0_GE][_^1-#S/&X
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M]Y?C_D;G_"S?$O\ SUM?^_'_ ->C_A9OB7_GK:_]^/\ Z]8?_"-:]_T!;_\
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M[]G_  H^SS_\\)O^_9_PH^I8;^5?U\P^NXG^9_U\CO/^%M:M_P! VR_[Z?\
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M/!?J>P./6U#XS46/VJ[L3!&$SN:4 %Q")2.>G!P,]?2GIXM^V:;K5S:VNT6
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M4]XG6,'[/!. @(QYBG(_-2?H10 NB7]S/&(+]9Q>%3(X>#8J= 5!'!&2<'N
M:V*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M.UW5DT/1;G4GB:58 "44X)R0/ZUQ'_"W;3_H#W/_ ']6NC^(!QX&U3/]Q?\
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M/_?U:\IWK_>'YT;U_O#\Z/[-P_\ +^+#^TL1_-^"/5O^%NVG_0'N?^_JT?\
M"W;3_H#W/_?U:\IWK_>'YT;U_O#\Z/[-P_\ +^+#^TL1_-^"/5O^%NVG_0'N
M?^_JT?\ "W;3_H#W/_?U:\IWK_>'YT;U_O#\Z/[-P_\ +^+#^TL1_-^"/5O^
M%NVG_0'N?^_JT?\ "W;3_H#W/_?U:\IWK_>'YT;U_O#\Z/[-P_\ +^+#^TL1
M_-^"/5O^%NVG_0'N?^_JT?\ "W;3_H#W/_?U:\IWK_>'YT;U_O#\Z/[-P_\
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MDMAY?D3.ADR@)P#G@]J]? 8:%6DY26M^[1Y&/Q,Z551B]+=DST#_ (63X?\
M^A<;_OB.E_X63X?_ .A<;_OB.N336-.WJS*0T93:P3[R^86(/T['W(J"WU.P
M\H"<2"1IEG9S\^UE(PN3R?E!_P"^O:NOZG2_E?WLX_KM7^9?<CL_^%D^'_\
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MQO\ OB.C_A9/A_\ Z%QO^^(Z\QR/6C(]:/[/H=G][#^T*_=?<CT[_A9/A_\
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MT\."?.CP.IWCBH6FB !\V/!Z?,.:I8&AV_$EXZOW_ ZS_A85T$DW:/%O&/+
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MRRVXI]G3!/KC'6G?V1IOF1R?V?:;X@!&WDKE .@!QQBKE% %$:-I:K(HTVS
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MXQS][I3^H_W_ ,/^"+Z]_<_'_@'OOV6?_J'_ /?@_P#Q5'V6?_J'_P#?@_\
MQ5>#CPZJRNLEW*5,Q$)4@;XMK$.2>!DKC\#Z57.E6Y(6*ZN)!(DDD<J_ZL!.
MH8]SP1D<=/6E]1_O_A_P1_7O[GX_\ ^@/LL__4/_ ._!_P#BJ/LL_P#U#_\
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M!$:AN#CG.:?U#^_^'_!%]?\ [GX_\ ^@OLL__4/_ ._!_P#BJ/LL_P#U#_\
MOP?_ (JOG;4+%;2!9(Y9CEPI#G! 9%< CL1D@_A6=N;^^W_?1IK+V_M_A_P1
M/,$OL?U]Q]-?99_^H?\ ]^#_ /%4?99_^H?_ -^#_P#%5\R[F_OM_P!]&C<W
M]]O^^C3_ +.?\_\ 7WA_:"_D_K[CZ:^RS_\ 4/\ ^_!_^*H^RS_]0_\ [\'_
M .*KYEW-_?;_ +Z-6],M&U"_C@:61(\%I'4\J@&2>3C_ /72>7M:\_\ 7W@L
MP3^Q_7W'T?\ 99_^H?\ ]^#_ /%4JP729V/8KD8.(2,_^/5X"WAZ46\I$\C7
M$0DWQ#V;:A'J"?YCUIT_A\0W#QBZE*(JRN^1_JQD2$8/\+#\B*GZBOY_P_X)
M7UY_R?C_ , ]^\N\QCS;+'IY)_\ BJ-E[NW>;9Y]?*/_ ,57S^NBPRW1MTN+
MG*P"=CN#9X!*XXPQS@#G)HCT_2;F:PAM;^Y=YH_W^3CRW)&!R/<\=_6E]07\
MWX#^OO\ E_$^@/+O,8\VRQZ>2?\ XJCR[S(/FV>1T_<GC_QZOG*"S417+73S
M*8HO,#1R*1GHJD<\D]LCO4PTH/?I%'--]G,*RL68"0@IOP%SR>,=Z?\ 9Z_F
M_ 7]H/\ E_$^A_+O.?WMGSU_<GG_ ,>H\N\( \VRP.G[D_\ Q5?/L^D0PVWG
M>?=#=#]H7(!VKE05/JWS>W;UK-U"#['J%Q;I)*5C<JI<X)'O0LO3VE^ /,&O
ML_B?2FR]R3YMGD]_*/\ \54'VAOG7[=IO[OEQM^[VY^;BOFG<W]]O^^C75^%
MM32<G3KBUCD8J=LHB!)7KA^.1[FB67-*_-^ +,4_L_B>UF[8*LAO],"GA6*\
M''H=U.\Z42-%]LT[>.638<^O(W5Y?<6EL4"&V@*+DJOEK@?08K.G@A\PR>3'
MO/!?8,G\:S^I?WOP-/KW]W\3U_[4QC\S[?IFP'&[;P#Z9W4[[1+YBK]MT[?(
M,J-IRP/_  +FO"YK:W"%/(BV9SM\L8SZXK.GAB#!A$FY>%.T9'T]*7U+S#Z[
M_=_$^@Q<N4;%]II5/O?+POU^:E-S(-CF_P!-&_[K;>O;CYJ^:9H8@& BC ;[
MP"CGZ^M9\T46 /+3"_=&T<?2CZGYC6,OT/J?SY SQ_;=.RN2R[#QCU&ZD^U/
ML$AO]-VYP&V\9],[J^2Y$3S"VU=S=3CD_6I8HHR@7RTVYSC:,9I?4_,KZUY'
MU@)Y?,\L7NG>8PSMV')[]-U-%RS1EA?::44X)V\#/_ J^78HTWA]B[QT;'(_
M&K44$(4J(H]IZC:,&J6!O]K\#-XZWV?Q/IDW,FY";[3MTGW?EY;MQ\W-'VA_
MG7[;IOR<N-OW>W/S<5\YQ0Q'83%'E?N_*/E^GI5V*"'+'R8\O]X[!\WU]:M9
M?_>_ EYA_=_$]^-TP19#?Z:%/"L5X./0[J=Y\OF-%]LT[?C)38<^O3=7AD=M
M;E0A@B*CD*4&!^%7HH(?,\SR8]Y&"^P9].M4LMO]K\"7F7]W\3VF,7<T:O'/
M9.A^ZRQ$C\/FIWE7^2?,M,GK^Y;_ .*KSGPQK,^BWMM9V\<9L[F<(]N!@[FP
M-R>XQDCH1D\&O4ZXJ]!T9\K.VA7C6AS(I>3?8QYEICT\EO\ XJE\J_SGS+3/
MKY+?_%5<HK$V*7DWV,>99X/;R6_^*H\J^X_>6G'3]RW'_CU7:* *7E7W/[RT
MYZ_N6Y_\>H\F^P!OL\#MY+?_ !57:* *?E7^[=YEIGU\EO\ XJD$5\.DEH.<
M_P"I;_XJKM% %3;J/_/:U_[]-_\ %4;=1_Y[6O\ WZ;_ .*JW10!7B6\$@\Z
M2!D]$C(/ZDU8HHH **** "N,^)")+I.DQR*KHVK6ZLK#(().0:[.N.^(O_(-
MT?\ [#%M_,UMA_XJ_KN8U_X;_KL;7_"*^'_^@)IW_@,G^%'_  BOA_\ Z FG
M?^ R?X5KT5'M)]W]Y?LX=E]QD?\ "*^'_P#H":=_X#)_A1_PBOA__H":=_X#
M)_A6O7G;0>-+J[G.;FU2[O8[JW83!A;HC,/+=>,*RB,E1G)+\T>TGW?WA[.'
M9?<=;_PBOA__ * FG?\ @,G^%'_"*^'_ /H":=_X#)_A7&V<'C6\-FUQ'>6<
M+0/:W"FY!>-Y2[>8 /O>6?* ;(X#\'-3Q)XBGU'3]0U6WU&-)UF:>T@=V6$C
MRU11L=0"0KMDY'S'BCVD^[^\/9P[+[CJ_P#A%?#_ /T!-._\!D_PH_X17P__
M - 33O\ P&3_  KD].\,>(=4_LVYU76M4LKK3KLS21K)N2YC*KL7@@9"C:W!
MRV\]P:T=$CUD6VIK=6UT]B\[L@FFD2?R_+7Y8P69L[@>2X&22,"CVD^[^\/9
MP[+[C;_X17P__P! 33O_  &3_"C_ (17P_\ ] 33O_ 9/\*PM*M=6T[5M!CN
M'U.97M9S>9D:2&-W8,JDDY)7YE!.> /6NTH]I/N_O#V<.R^XR/\ A%?#_P#T
M!-._\!D_PJ.Y\+Z MK*PT33P0A((MD]/I6W45U_QZ3?]<V_E0JD[[O[P=.%M
ME]QS/PU_Y)_I7^Z__HQJZNN4^&O_ "3_ $K_ '7_ /1C5U=57_BR]630_A1]
M$%%%%9&IS'CGPU+XHTB"SBNXK9HYQ*7E4D'Y2,?K7!K\)-07&W7[0;3N&$;@
M^O7K71_%M$D\/Z<DA94:_0,47<0-K9P.YKRZ71H87CRMTZSRA(C&P8*N%.YC
MCONZ8& *]7"*I[)<LK+7I<\K%RI^U?-&[TZG8K\*=41&1/$=NJLNUE < CTZ
M].3^=-_X5-J0Z>(;7J&^ZW4< ]>HKDQH$>#LE>X;S"@6%L#[^WDD<8')XIAT
MBT<XA:[*2+))'*P&U0AQAN.IQ[=5XKHY:O\ /^".?FI?R?BSL/\ A4^I>1Y'
M_"0VWDYSY>UMN?7&<4Y?A5JRJZKXDMP'.6 #_,?4_-S7)/H-FUZ8(;W&VX2%
MPS@X)+# (&"V%!QVSB@:#:>5#(9I2#"9) &'!VHV"=IV_>Z8/ S1:K_/_P"2
MAS4OY/Q.K_X5/J?_ $,5MTQ]UNG/O[G\S0OPGU-(3"OB*V6)CDH%8*3],UR<
M/A^":WBG6>7:4C,B\91F)P/<$#@^H-(OA]%^RB5Y2\T6"BD#$W!"9YV\-W[@
MCBBU7^?\$'-2_D_%G6GX3ZDP /B&U(5MXRK<-Z]>OO3C\*]6+QN?$L!>/[C?
M/E?I\W%>9$$$@Y!!P:*KV5;^?\$3[2C_ "?BSTT?"O5@' \2P .VYA\_S'U/
MS<FD3X4ZI&RLGB.W4KC! <8QG'?W/YUYG11[*M_/^"#VE'^3\6>EM\)]3<L7
M\0VS%AALJQR,YP>?7FD;X2ZBZ,C>(+5E<Y8%6(8^IYYZ"O-:*/9UOY_P0>TH
M_P GXL]-'PJU0)(H\0VF)&#,=C9) (SG/H2/QIL?PFU*%E,7B&U0J25*JPQG
MKCFO-**/95OY_P $'M*/\GXL]+?X3ZE+&(W\06;*&+\QL26.,DG/)X%1_P#"
MH+W_ *#EE_W[/^-><44>SK?S_@@]I1_D_%GH_P#PJ"]_Z#EE_P!^S_C1_P *
M@O?^@Y9?]^S_ (UYQ13]G6_G_ /:4?Y/Q9Z/_P *@O?^@Y9?]^S_ (TH^$5\
M P&NV8### 1MR/0\UYO11[.M_/\ @@]I1_D_%GI@^%.J!@P\1VX8#:" ^0/3
MKTX%,'PDU!4V#Q!:!<$8"-C!ZCKWQ7FU%+V=;^?\$'M*/\GXL]-;X5ZLZJK>
M)8"$QM!W_+CICYN,4V+X3ZG"S-%XBMHV88)16!(_ UYI11[*M_/^"#VE'^3\
M6>D#X17P4J->LPI()&QL''3O4C_"G59)4E?Q';M(GW78.2OT.>*\SHH]G6_G
M_!![2C_)^+/33\*]6((/B2 AGWGA^6]?O=?>F2_"749Y#)-X@M9'/5G5B3^)
M->:T4>RK?S_@@]I1_D_%GH__  J"]_Z#EE_W[/\ C6QH_@Z+2[:YMXM;TEI5
M4L[A3NR#U?Y^ /;'->05U/A34\N-,EM4D5E.R18QE1U(;U6HJ4J[7Q_@7"K1
M3^#\3O)O#C-:1RCQ#I +,RLY4[#TP%^?KZ_A39/!JO?O /$&GA=I*1[/WGW<
MC(W]._3I6//;6^W;]GAV@Y"^6,9^E9T\,6_?Y4>_^]M&?SK#V57^?\#;VM+^
M3\3;;P.LEH\O_"3:5N5P"P3Y ".A^?K44GPYB>XMU_X2C3PDBJ2/+&YL_P!S
MY^F>E<K/;P %1#%M)R1L&*SIX8L@^5'E?NG:./I2]G5_G_ ?M:7\GXG8'X7Q
MR)<;O%>G;X^FV+A><'=^\_R:@E^$\!AA?_A+]. ?.YC$-IP?X?WE<)/#%\W[
MI.>ORCGZUG30Q8QY28'0;1Q2=.K_ #_@4JE+^3\3TAO@U;FZFC/B^S!4,53R
M1O&/[P\SIZTB_"&!;42#QAIQ._:6\H;.G3_6=:\JEC3S-VQ<GJ<<FGQ0Q8QY
M28SG&T8I>SJ?S_@7ST_Y?Q/6T^$L NXX_P#A++(HZ@A?)&]LCM\_3/Z4L7PO
MC%O*_P#PEFFED(Y$7RKG^]^\_*O+XXH]P;RTR.AVC(JW%#%@CRH\'J-HYK14
MJO\ /^!C*K2_D_$]-'PVB3[.?^$JT[;(/F)C^]S@[/G_ ,FIT^'B++<)_P )
M-IV8P2J^7RN#_'\_3'7I7G$4,1"CRH^.GRCCZ5>BABR3Y29;J=HY^M6J5;_G
MY^!FZU'_ )]_B=Y_P@X2UCE7Q-I62Q5G9/D/3 'S]?7\*N+X*5;XPKXAT\J5
MRJ;/WA^7(_CZ=^G2N#BMX"H7R8MN<XV#&:OQ0Q;P_E1[_P"]M&?SJU1K_P#/
MS\"'6H?\^_Q/4_"WARVTV!;R2>WOKMBVRYB3"HIP-J\GTY.?\*Z6O*_#&KW&
MC7]O:6L<;6UW.%>W VDLV!N3L" ,D=" >G6O5*\O%4YPJ/G=WW/5PM2$Z:Y%
M9+H%%%%<YT!1110 4444 %%%% !1110 4444 %%%% !7'?$7_D&Z/_V&+;^9
MKL:XWXC$+I>CLQ  U>V)). .36U#^*OZ[F5?^&_Z['9455_M/3_^?ZV_[_+_
M (T?VGI__/\ 6W_?Y?\ &LN5]C3F7<M455_M/3_^?ZV_[_+_ (T?VGI__/\
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MC"'EU8'ZC.5(KU,+&HZ:Y96WZ'EXJ5-5'S1OMU.V3X1:C&<IXBC4]<K$P_\
M9J5OA)J;JRMXC1@YW,#&Y#'U/S<FN)?2(69S!>R;$,JD._S,R1ACM]1G(SZ<
MU*NBVS:A);F]G2.)@KR;@V/E<Y/3'W1Q]:Z.6K_/^!S\U+^3\3KO^%/WP.1K
M\.2=V?);KZ_>ZTY/A'J4;;H_$2(WJL; ^G][TKC1H(AM]UY<RI,D;O+&'VA2
M&0*,G/4/G\JBN--MK:VM99+JY/GJH(4[MC%5;G'3 8\=3@4<M7^?\ YJ7\GX
MG;?\*@U $G_A((LGJ?*;_P"*I4^$6I1EC'XB1"_WBL;#=]?FYKA'L(X[RX1W
MNF@C@$R>6X9I%) !';'/IFK$NB+#YL8NIY)P"453M! 9@3SZ!1E>O7THY:O\
M_P" <]+^3\3K_P#A3=W_ -!NW_[\'_XJC_A3=W_T'+?_ +\'_P"*KD6T(O<:
MA';SS,+92L9+@^9)R=O;'"GCDY(J.32X$MI;E;BX:%8U:-S(%WL20>,9&"/N
MGGWI\M;_ )^?@'-1_P"??XG9?\*;N_\ H.6__?@__%4?\*;N_P#H.6__ 'X/
M_P 57F>]_P"^_P#WT:-[_P!]_P#OHU7LZ_\ /^!/M*'\GXGIG_"F[O\ Z#EO
M_P!^#_\ %4?\*;N_^@Y;_P#?@_\ Q5>9[W_OO_WT:-[_ -]_^^C1[.O_ #_@
M'M*'\GXGIG_"F[O_ *#EO_WX/_Q5'_"F[O\ Z#EO_P!^#_\ %5YGO?\ OO\
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M?\*;N_\ H.6__?@__%5KZ1X%CTFTN88M:T]IARTAB.1S_'\_0=.,<UXYO?\
MOO\ ]]&NK\+:FDY.G7%I'(Q4XE$0)*]<.<<CW-14I5VOC_ N%6@G\'XGH$OA
M5V@A?^W].4L2&8PG:V#_  _O/3KUJ.3P/ONIH_[>M  I*)Y/SJ<9&[Y^GKP*
MP+BTM2@0VT!122JF)<#/H,5GSP0^8TGDQ^8>"^P;C^-8>RJ_S_@;>UH_R?B=
M&_P^\RU\S_A)+'=OP7\CY,8Z?ZSK^-1O\,8WNHU/B2WV.H.T0#>V1V^?IGIQ
M7&36UN$*"WBV9SM\L8SZXK/GABW!O*3<HPK;1E?3'I2]E5_G_ ?M:7\GXG;G
MX4))#*6\4VF]<8*VXVKSSN_>?X5#)\'H6$+'Q5;A7^\?LX^;GG;^\_QYKSN:
M"(!@(HP&^\ HY^OK6?-%%@#RTPOW1M''T]*GV=7^?\!JI2_D_$]/;X)P--,I
M\5PC:"57[,,KC^]\_P"?2D'P8A2W5QXMML[B"QMAM/L/WG7\:\CE1/,+;5W-
M]XXY/U]:DBBC*A?+3;G.W:,9^E+V=7^?\#3VE/\ E/85^#D NQ&/%$)0C*I]
MG&\\?[_X].E+'\)HQ;N__"56A96 W"W&T#W_ 'G7\:\ICC3>'V+O'1L<C\:M
M100A2HBCVGJ-HP?PK14JW\_X&,JM'K#\3U0?"R))(!_PDUML<#<# ,N<\[?G
M_+K4J?#15\\?\)+:%D^[^X^YSSN_>?X<UYG'#$=A\J/Y?N_*/E^GI5V*"'+'
MR8\O]X[!\WU]:T5&M_S\_ S=:A_S[_$]#_X5\(X(G'B2Q!)(9F@^4_[O[S\^
MM6AX#VW<D8U^TVA240P_..,C/S]/7@<5Y]';6Y14-O"5'(4QC _"K\4$/F>9
MY,?F$8+[!D]NM4J-?_GY^!#KT/\ GW^)ZOX9\-6VE0BZ>6&\O&W 72)M 0_P
MKR<#CDYYKHJ\K\+ZS/HE[;6=O'&;.YG"/ !@[FP-R>XQDCH1D\&O5*\S$TYP
MJ/G=WW/4PM2%2FN162Z!1117.= 4444 %%%% !1110 4444 %%%% !1110 '
M@9K'U2+1]:L_LFI6KW,&X/L>"3&1T/ ]ZV*YCQS=WEKI-DME=R6LEQ?10-+'
MC(5LYZ_A6E*+E-1B[,SJR48.35T5/^$-\$_] -?^_,M'_"&^"?\ H!K_ -^9
M:E_X1/6?^AQU+_OVE'_")ZS_ -#CJ7_?M*Z+_P#3[_THPM_TZ_\ 22+_ (0W
MP3_T U_[\RT?\(;X)_Z :_\ ?F6I?^$3UG_H<=2_[]I1_P (GK/_ $..I?\
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M'PA875Y,TT[JVYVZG#D#]!705S5(N,W%[IG13DI04ELT5/[2MO\ IM_WX?\
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MU%._X5QJQ+$^(9"6783]FGY7T^E<Q_;VL?\ 06O_ /P)?_&C^WM8_P"@M?\
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M?%(5L-T?EBV_U"[-Y3EOEW9Y^]C.-W&:->[_ *^0:=E_7S#R/"G_ $$=8_\
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MV?>7WL5_*/W(H_V3X<_Z!4'_ (#C_P"+H_LGPY_T"H/_  ''_P 76D&LO+0
MKN12&ROWB>>/7!XJ&]>W<(T 4$LY90,8Y&/P[_C0E=VO+[V#=E>T?N13_LGP
MY_T"H/\ P''_ ,71_9/AS_H%0?\ @./_ (NEHJ_9_P!Y_>R/:?W5]R$_LGPY
M_P! J#_P''_Q=']D^'/^@5!_X#C_ .+I:*/9_P!Y_>P]I_=7W(3^R?#G_0*@
M_P# <?\ Q=']D^'/^@5!_P" X_\ BZ6BCV?]Y_>P]I_=7W(3^R?#G_0*@_\
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M_?@?XU<HH I_9[[_ )_E_P"_ _QH^SWW_/\ +_WX'^-7** *?V>^_P"?Y?\
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M_/\ +_WX'^-7** *?V>^_P"?Y?\ OP/\:/L]]_S_ "_]^!_C5RB@"G]GOO\
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M^0MLQLV_Q;<]Z]*HH \_O=&U[1[#6[^/7M7OC>7,4MI;11,SP*&R4QSQC@X
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M]&_YXWG_ 'T*SJ*/9^;^\/:>2^XZ/1GTK[61 DBS$?*9B#]<>]=!7GJ!BZA
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M%% #G?8!QFE5]V..HS110 I;!'O31)D$XZ#UHHH 4OA"V.V:<.1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &@ G # 2(  A$! Q$!_\0
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M:VZ1F"&(,0H=64F0D#)Y'7 QBNTGNS/;3P:=>6;:@(V\L.VY5?IEE!SC/44
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M6>6.3[9J<]XFP'Y5D((!SW%)!H<\7CF]UTRQF"XL(;41\[@R.[$^F/G%;M%
M'#6/AKQ9H%N^D:%JFE+H_FNUO)=0.\]JC,6*  A7 )."<>^<5T*Z!8Z=]JO=
M(TO38-6DC;%P;<)O<\_.5&<%L$UL44 <#I'@_695URQ\2?V5<:7K,[W-PEF\
MR2!RJ+M!./EPGUY]*?;?#.PM?%DNI)-<FQ?3C:"*2\FD?>2P8G<Q!7:V IR
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MHH ]/_X7[XZ_Y^+'_P !11_POWQU_P _%C_X"BO,** /3_\ A?OCK_GXL?\
MP%%'_"_?'7_/Q8_^ HKS"B@#T_\ X7[XZ_Y^+'_P%%'_  OWQU_S\6/_ ("B
MO,** /3_ /A?OCK_ )^+'_P%%'_"_?'7_/Q8_P#@**\PHH ]/_X7[XZ_Y^+'
M_P !11_POWQU_P _%C_X"BO,** /3_\ A?OCK_GXL?\ P%%'_"_?'7_/Q8_^
M HKS"B@#T_\ X7[XZ_Y^+'_P%%'_  OWQU_S\6/_ ("BO,** /3_ /A?OCK_
M )^+'_P%%'_"_?'7_/Q8_P#@**\PHH ]/_X7[XZ_Y^+'_P !11_POWQU_P _
M%C_X"BO,** /3_\ A?OCK_GXL?\ P%%'_"_?'7_/Q8_^ HKS"B@#T_\ X7[X
MZ_Y^+'_P%%'_  OWQU_S\6/_ ("BO,** /3_ /A?OCK_ )^+'_P%%'_"_?'7
M_/Q8_P#@**\PHH ]/_X7[XZ_Y^+'_P !11_POWQU_P _%C_X"BO,** /3_\
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M'_"_?'7_ #\6/_@**\PHK(9Z?_POWQU_S\6/_@**/^%^^.O^?BQ_\!17F%%
M'I__  OWQU_S\6/_ ("BC_A?OCK_ )^+'_P%%>844 >G_P#"_?'7_/Q8_P#@
M**/^%^^.O^?BQ_\  45YA10!Z?\ \+]\=?\ /Q8_^ HH_P"%^^.O^?BQ_P#
M45YA10!Z?_POWQU_S\6/_@**/^%^^.O^?BQ_\!17F%% 'I__  OWQU_S\6/_
M ("BC_A?OCK_ )^+'_P%%>844 >G_P#"_?'7_/Q8_P#@**/^%^^.O^?BQ_\
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M+H4."*\_&8;D?/#X6?88+%PQ-)3B,HHHK@.P**** "BBB@ HHHH **** "E
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MJVW;N/7%>%Q3+,*N-IX7!J5HVVNE=]3YBEB<%.K7J8[7I%/?Y'&:F$LK@E0
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M1I)Z&;.I\+ZS+8W:*&(7/K7M>F:M#=6ZNLB[L<@FOG*-VC(*\&MFR\1WEH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHV.F<'Z&J]=K\2T\C5-%M3<2W$EOHUM&[RJ5?/S$94\KP1@'G&*XJ@ HHHH
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MH'_7%O\ T8U ';4444 ?!VM?\A[4?^OJ3_T(U1J]K7_(>U'_ *^I/_0C5&@
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M2/PUJ#HUQ(RLL6006/(-4O\ A67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\
MOR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[
M\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_
M^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\
MH6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A6
M7C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\
MA67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y
M2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\
MOR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[
M\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_
M^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\
MH6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A6
M7C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\
MA67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y
M2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\
MOR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[
M\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_
M^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\
MH6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A6
M7C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\
MA67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y
M2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\
MOR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[
M\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\ H6-2_P"_)H Y2BNK_P"%9>-_
M^A8U+_OR:/\ A67C?_H6-2_[\F@#E**ZO_A67C?_ *%C4O\ OR:/^%9>-_\
MH6-2_P"_)H Y2BNK_P"%9>-_^A8U+_OR:/\ A67C?_H6-2_[\F@#E*^R?A#_
M ,DIT#_KBW_HQJ^8?^%9>-_^A8U+_OR:^J/AEIMYI'PXT6QU"W>WNHH6$D3C
M#*2['G\"* .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\''? ZUA6KQIQE+=KHM6:0IN;2VN2Z+_ ,@B#_@7_H1J_7->&A?R6TBM*R0
M_(2N>><XS6[]DR<O/.W_  /;_+%9X;%/$4E4C!J_>W]?@55HJG-P<KV[%BHV
MGB3[TJ+]6 J,6-MG)B#'_:);^=/6V@7[L,8^BBM[U.R_$S]WS&F]M1UN(O\
MOL4W[?:_\]0?H":L  = !]*6BU3NON?^8>[V*B7MOO<[V.2.B-Z?2G_;8?63
M_OTW^%2K_K)/J/Y4^BU3NON_X(7CV_$K_;(?^FG_ 'Z;_"C[;#_TT_[]-_A5
MBBBU3O\ A_P0O'M^)7^W6_\ >;\4;_"D^WVW_/3_ ,=/^%6:*+5.Z^[_ ((7
MCV*AOK4R)^^0=>O%2?;;4_\ +Q%_WV*D;_6)^-/P#VHM4[K[G_F'ND/VNV/2
MXB_[[%.%Q">DT9_X$*<8XSU13^%--O >L,9_X"*/WGE^(>YY_@.#H>C+^=.Z
MU#]DMC_R[Q?]\"FFQM3_ ,N\?X+1>IV7XA[OF2R_ZL_4?SI]5)+&V"$B%1R.
MF1WI_P!AM_[K#Z.W^-%ZG9??_P  +1[EBBJ_V*$=/,'TE;_&C[(G_/2?_O\
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M+ [+/(#]G+N"@P>(R .GUS0!Z-17G-Y)'86EQID]J6LAJTD4#W4DODP)Y2N
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M3Z &>7_MO^='E_[;_G3Z* &>7_MO^='E_P"V_P"=/HH A:/]XGS/W[T_R_\
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MM!U2[ELHXKRS<M'#O)66$R%%<'ZJP([%?<5JZSXC?2]<L+)+=9+=RIO9BV#
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MD"([1\H!Y&/0]*T: "BBN*U7Q5J^D7US#)#8SL(G=88MV;?,BI"96S@[RV<
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M E_U9^H_G3ZAD<E/N-U'\Z?O/]QZ 'T4S>?[CT;S_<>@!]%,WG^X]&\_W'H
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M_P"K/U'\Z?3)?]6?J/YT^@ HHHH **** "F1?ZI:?3(O]4M #Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O,+2+4M*\2Q:B/#6M2W7VR[^W7,31LMQ"Q;R@ 9!D#]W@
M8&,'WKT^B@".WE,]M%,T4D)=0QCD #)D=#@D9'UJ2BB@ IDLL<$3RRR+'&BE
MF=S@*!U)/84^L;Q987&I>&;RUM8_-F8(PBR!Y@5U8ISQR 1SZT :5G>VNH6R
MW%G<17$+$@21.&&1UY%5KN>'^T[.$RIO#$E=W(^7BJ/AN&X^T:O?2VLMI%>W
M8EA@E #@")$+$ G!)4GZ8]:KW?ARYGU=KA9E$3ON+9^9?:N''5:].$?8PYKM
M7\D=&'A3E)\\K:'345#Y!_Y[2_F/\*/(/_/:7\Q_A7<<Y-14/D'_ )[2_F/\
M*/(/_/:7\Q_A0!-3)?\ 5GZC^=,\@_\ /:7\Q_A0;?(P9I?S'^% $U%0^0?^
M>TOYC_"CR#_SVE_,?X4 345#Y!_Y[2_F/\*/(/\ SVE_,?X4 345#Y!_Y[2_
MF/\ "CR#_P ]I?S'^% #X?\ 5"GU"+? P)I<?4?X4>0?^>TOYC_"@":BH?(/
M_/:7\Q_A1Y!_Y[2_F/\ "@":BH?(/_/:7\Q_A1Y!_P">TOYC_"@!Z?ZR3ZC^
M5/J'[/@D^=+S[C_"CR#_ ,]I?S'^% $U%0^0?^>TOYC_  H\@_\ /:7\Q_A0
M!-14/D'_ )[2_F/\*/(/_/:7\Q_A0 ]O]8GXT^H?L_(/G2Y'N/\ "CR#_P ]
MI?S'^% $U%0^0?\ GM+^8_PH\@_\]I?S'^% $U%0^0?^>TOYC_"CR#_SVE_,
M?X4 /E_U9^H_G3ZA-OD8,TOYC_"CR#_SVE_,?X4 345#Y!_Y[2_F/\*/(/\
MSVE_,?X4 345#Y!_Y[2_F/\ "CR#_P ]I?S'^% $U,B_U2TSR#_SVE_,?X4"
MWP,":7'U'^% $U%-1=@QN9O=J=0 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>avxl-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSaiGOcPtxJFziZkhv2p3ffkqbyomkFQPnyqj1UtmsdoA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:avxl="http://anavex.com/20221231" elementFormDefault="qualified" targetNamespace="http://anavex.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations" id="InterimCondensedConsolidatedStatementOfOperations">
	  <link:definition>00000004 - Statement - Interim Condensed Consolidated Statement of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows" id="InterimCondensedConsolidatedStatementOfCashFlows">
	  <link:definition>00000006 - Statement - Interim Condensed Consolidated Statement of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescription" id="BusinessDescription">
	  <link:definition>00000007 - Disclosure - Business Description</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BasisOfPresentation" id="BasisOfPresentation">
	  <link:definition>00000008 - Disclosure - Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
	  <link:definition>00000010 - Disclosure - Accrued Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
	  <link:definition>00000011 - Disclosure - Equity Offerings</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000013 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BasisOfPresentationPolicies" id="BasisOfPresentationPolicies">
	  <link:definition>00000014 - Disclosure - Basis of Presentation (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
	  <link:definition>00000015 - Disclosure - Accrued Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000016 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
	  <link:definition>00000017 - Disclosure - Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000018 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
	  <link:definition>00000019 - Disclosure - Accrued liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
	  <link:definition>00000020 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000023 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000024 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000025 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000026 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000027 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="avxl_MichaelJFoxMember" name="MichaelJFoxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AnavexMember" name="AnavexMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NetLossPerShareBasicAndDiluted" name="NetLossPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptions" name="SharesIssuedPursuantToExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" name="SharesIssuedPursuantToExerciseOfStockOptionsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncreaseDecreaseInDeferredGrantIncome" name="IncreaseDecreaseInDeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" name="CashPaidForStateAndLocalMinimumIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingTextBlock" name="EquityOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LliquidityPolicyTextBlock" name="LliquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CoronavirusDisease2019COVID19PolicyTextBlock" name="CoronavirusDisease2019COVID19PolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccruedClinicalSiteAndPatientVisitsCosts" name="AccruedClinicalSiteAndPatientVisitsCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FixedContractAccruals" name="FixedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrossProceedsFromIssuancePublicOffering" name="GrossProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SalesOfAgreementAmount" name="SalesOfAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WarrantsOutstandingWeightedAverageExercise" name="WarrantsOutstandingWeightedAverageExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>avxl-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20221231.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20221231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20221231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20221231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20221231.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20221231.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20221231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20221231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20221231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20221231.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20221231.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations" xlink:title="00000004 - Statement - Interim Condensed Consolidated Statement of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows" xlink:title="00000006 - Statement - Interim Condensed Consolidated Statement of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000014 - Disclosure - Basis of Presentation (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000015 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000016 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000017 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000018 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000019 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000020 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000027 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>avxl-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20221231.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20221231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20221231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20221231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20221231.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20221231.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20221231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20221231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20221231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20221231.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20221231.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations" xlink:title="00000004 - Statement - Interim Condensed Consolidated Statement of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows" xlink:title="00000006 - Statement - Interim Condensed Consolidated Statement of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000014 - Disclosure - Basis of Presentation (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000015 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000016 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000017 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000018 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_AnavexMember" xlink:label="loc_avxlAnavexMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlAnavexMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlDeferredGrantIncome_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000019 - Disclosure - Accrued liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000020 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="loc_avxlGrossProceedsFromIssuancePublicOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromIssuancePublicOffering_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000027 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>avxl-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_MichaelJFoxMember" xlink:label="avxl_MichaelJFoxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxMember" xlink:to="avxl_MichaelJFoxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxMember_lbl" xml:lang="en-US">Michael J Fox [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_AnavexMember" xlink:label="avxl_AnavexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AnavexMember" xlink:to="avxl_AnavexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AnavexMember_lbl" xml:lang="en-US">Anavex [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">Stock Option Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities - Note 4</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income - Note 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share78,032,135 common shares (September 30, 2022 - 77,942,815)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax recovery (expense), current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="avxl_NetLossPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossPerShareBasicAndDiluted" xlink:to="avxl_NetLossPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of share issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:to="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Decrease in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:to="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xml:lang="en-US">Cash paid for state and local minimum income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_EquityOfferingTextBlock" xlink:label="avxl_EquityOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_LliquidityPolicyTextBlock" xlink:label="avxl_LliquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LliquidityPolicyTextBlock" xlink:to="avxl_LliquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LliquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_CoronavirusDisease2019COVID19PolicyTextBlock" xlink:label="avxl_CoronavirusDisease2019COVID19PolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CoronavirusDisease2019COVID19PolicyTextBlock" xlink:to="avxl_CoronavirusDisease2019COVID19PolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CoronavirusDisease2019COVID19PolicyTextBlock_lbl" xml:lang="en-US">Coronavirus Disease 2019 (COVID-19)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share-based Payment Arrangement, Option, Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="avxl_AccruedClinicalSiteAndPatientVisitsCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:to="avxl_AccruedClinicalSiteAndPatientVisitsCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccruedClinicalSiteAndPatientVisitsCosts_lbl" xml:lang="en-US">Accrued clinical site and patient visits costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_FixedContractAccruals" xlink:label="avxl_FixedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FixedContractAccruals" xlink:to="avxl_FixedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FixedContractAccruals_lbl" xml:lang="en-US">Fixed contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued liabilities&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="avxl_GrossProceedsFromIssuancePublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrossProceedsFromIssuancePublicOffering" xlink:to="avxl_GrossProceedsFromIssuancePublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrossProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US">Gross proceeds from Issuance Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SalesOfAgreementAmount" xlink:label="avxl_SalesOfAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SalesOfAgreementAmount" xlink:to="avxl_SalesOfAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SalesOfAgreementAmount_lbl" xml:lang="en-US">Sales of agreement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contribution amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WarrantsOutstandingWeightedAverageExercise" xlink:to="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xml:lang="en-US">Warrants outstanding weighted average exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Option available issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantPurchaseCommitmentDescription" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription_lbl" xml:lang="en-US">Purchase agreement, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingTextBlock_2_lbl" xml:lang="en-US">EquityOfferingTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_2_lbl" xml:lang="en-US">NonOperatingIncomeFromGrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_2_lbl" xml:lang="en-US">DeferredGrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>avxl-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows" xlink:href="avxl-20221231.xsd#InterimCondensedConsolidatedStatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20221231.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20221231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20221231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20221231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20221231.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20221231.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20221231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20221231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20221231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20221231.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20221231.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations" xlink:title="00000004 - Statement - Interim Condensed Consolidated Statement of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="loc_avxlNetLossPerShareBasicAndDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_avxlNetLossPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows" xlink:title="00000006 - Statement - Interim Condensed Consolidated Statement of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_EquityOfferingTextBlock" xlink:label="loc_avxlEquityOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000014 - Disclosure - Basis of Presentation (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_LliquidityPolicyTextBlock" xlink:label="loc_avxlLliquidityPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlLliquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_CoronavirusDisease2019COVID19PolicyTextBlock" xlink:label="loc_avxlCoronavirusDisease2019COVID19PolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlCoronavirusDisease2019COVID19PolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000015 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000016 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000017 - Disclosure - Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000018 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_AnavexMember" xlink:label="loc_avxlAnavexMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlAnavexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000019 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000020 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="loc_avxlGrossProceedsFromIssuancePublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromIssuancePublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20221231.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000027 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="loc_us-gaapSignificantPurchaseCommitmentDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSignificantPurchaseCommitmentDescription" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577346714976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,032,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577347548416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 143,621,848<span></span>
</td>
<td class="nump">$ 149,157,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">4,094,431<span></span>
</td>
<td class="nump">3,192,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">655,643<span></span>
</td>
<td class="nump">354,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">148,371,922<span></span>
</td>
<td class="nump">152,704,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,288,261<span></span>
</td>
<td class="nump">3,824,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities - Note 4</a></td>
<td class="nump">7,042,822<span></span>
</td>
<td class="nump">5,944,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income - Note 3</a></td>
<td class="nump">916,763<span></span>
</td>
<td class="nump">443,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">13,247,846<span></span>
</td>
<td class="nump">10,213,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share78,032,135 common shares (September 30, 2022 - 77,942,815)</a></td>
<td class="nump">78,033<span></span>
</td>
<td class="nump">77,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">393,581,544<span></span>
</td>
<td class="nump">387,976,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(258,535,501)<span></span>
</td>
<td class="num">(245,563,783)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">135,124,076<span></span>
</td>
<td class="nump">142,491,042<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 148,371,922<span></span>
</td>
<td class="nump">$ 152,704,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577347796528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">78,032,135<span></span>
</td>
<td class="nump">77,942,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">78,032,135<span></span>
</td>
<td class="nump">77,942,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577346144144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statement of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 3,317,036<span></span>
</td>
<td class="nump">$ 3,066,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,066,919<span></span>
</td>
<td class="nump">8,656,439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">15,383,955<span></span>
</td>
<td class="nump">11,723,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(15,383,955)<span></span>
</td>
<td class="num">(11,723,390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">733,590<span></span>
</td>
<td class="nump">810,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,267,618<span></span>
</td>
<td class="nump">4,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain, net</a></td>
<td class="nump">365,983<span></span>
</td>
<td class="nump">55,363<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">2,392,191<span></span>
</td>
<td class="nump">871,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(12,991,764)<span></span>
</td>
<td class="num">(10,852,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax recovery (expense), current</a></td>
<td class="nump">20,046<span></span>
</td>
<td class="num">(29,980)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (12,971,718)<span></span>
</td>
<td class="num">$ (10,882,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NetLossPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">$ 77,977,112<span></span>
</td>
<td class="nump">$ 75,997,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577346419680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 75,920<span></span>
</td>
<td class="nump">$ 348,328,048<span></span>
</td>
<td class="num">$ (197,585,864)<span></span>
</td>
<td class="nump">$ 150,818,104<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2021</a></td>
<td class="nump">75,918,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">373,360<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">373,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">137,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement, net of share issuance costs</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">2,149,602<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,149,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, net of share issuance costs, shares</a></td>
<td class="nump">99,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,908,771<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,908,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,882,367)<span></span>
</td>
<td class="num">(10,882,367)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 76,156<span></span>
</td>
<td class="nump">354,759,781<span></span>
</td>
<td class="num">(208,468,231)<span></span>
</td>
<td class="nump">146,367,706<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">76,155,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 77,944<span></span>
</td>
<td class="nump">387,976,881<span></span>
</td>
<td class="num">(245,563,783)<span></span>
</td>
<td class="nump">142,491,042<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2022</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">258,155<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">258,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">89,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,346,508<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,346,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,971,718)<span></span>
</td>
<td class="num">(12,971,718)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 78,033<span></span>
</td>
<td class="nump">$ 393,581,544<span></span>
</td>
<td class="num">$ (258,535,501)<span></span>
</td>
<td class="nump">$ 135,124,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">78,032,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577347579536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,971,718)<span></span>
</td>
<td class="num">$ (10,882,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,346,508<span></span>
</td>
<td class="nump">3,908,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(901,851)<span></span>
</td>
<td class="nump">3,764,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="num">(301,481)<span></span>
</td>
<td class="num">(22,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,463,484<span></span>
</td>
<td class="num">(104,992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,097,869<span></span>
</td>
<td class="num">(164,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncreaseDecreaseInDeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">472,932<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,794,257)<span></span>
</td>
<td class="num">(3,500,955)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,312,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(146,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">258,244<span></span>
</td>
<td class="nump">373,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">258,244<span></span>
</td>
<td class="nump">2,539,565<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Decrease in cash and cash equivalents during the period</a></td>
<td class="num">(5,536,013)<span></span>
</td>
<td class="num">(961,390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">149,157,861<span></span>
</td>
<td class="nump">152,107,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">143,621,848<span></span>
</td>
<td class="nump">151,146,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes', window );">Cash paid for state and local minimum income taxes</a></td>
<td class="nump">$ 50,077<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalMinimumIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncreaseDecreaseInDeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncreaseDecreaseInDeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577350377072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zvyA2F3wVxr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_829_zePecOAZlLx2">Business Description</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577350321152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_805_eus-gaap--BasisOfAccounting_zbDwoEqw09j3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 	<span id="xdx_821_zqATGLBhz5C1">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zUQdtJi6fuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i><span id="xdx_86E_zOC3uQ5iyg6a">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited interim condensed consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three months ended December
31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_841_ecustom--LliquidityPolicyTextBlock_zkX9GKxjPX1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zM92AZ1bBeL9">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
(as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available,
that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis,
if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84D_eus-gaap--UseOfEstimates_zAlWL6YlnfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_868_zWRNrnlTlPVf">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_ecustom--CoronavirusDisease2019COVID19PolicyTextBlock_zHJrC2UOD7S2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zCUIR1Nn6Pfj">Coronavirus Disease 2019 (COVID-19)</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The global pandemic resulting
from the disease known as COVID-19, caused by a novel strain of coronavirus, did not have a material impact on the Company&#8217;s result
of operations or financial condition for the quarter ended December 31, 2022. However, the future course of the pandemic could have adverse
effects in the U.S and global economies and thus negatively impact our business and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhVa66jQ8Wrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zVrH6HBuajQ8">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbCYyGFjyKQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_865_zdQgm5cfTk02">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zldoy5WGjNTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_z4OE5XqndfY2">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 loss per share excludes <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20221231_pdd" title="Loss per share for potentially dilutive common shares">13,525,296</span>
(December 31, 2021: <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_zbRpyyYJm8Vj" title="Loss per share for potentially dilutive common shares">11,403,769</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQkq8c6YE9S9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_869_zqtvQrQwJJXk">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577351049440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_801_ecustom--OtherIncomeDisclosureTextBlock_zCcWHuXVRY5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 3	<span id="xdx_826_z1z3uptfurRa">Other Income</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the Company had received $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_zVuib9oqfZgb" title="Research and development incentive income">995,862</span> in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.
Of the total, $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__dei--LegalEntityAxis__custom--AnavexMember_zrsyTMWdTfdh" title="Research and development incentive income">497,931</span> was received during the three months ended December 31, 2022 and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_znZ31QTl4Yi" title="Research and development incentive income">497,931</span> was received during the year ended September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three months ended December 31, 2022, the Company recognized $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20221231_zXH3rtZoR1u7" title="Grant income">25,000</span> (2021: $<span id="xdx_90C_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20211231_zAkumjuyPFYk" title="Grant income">0</span>) of this grant on its statements of operations as grant
income. At December 31, 2022, an amount of $<span id="xdx_90B_ecustom--DeferredGrantIncome_iI_pp0p0_c20221231_zvdiFTbpN7i3" title="Deferred grant income">916,763</span> (September 30, 2022: $<span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income">443,831</span>) of this grant is recorded as deferred grant income,
representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its
statement of operations as the relating expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#8220;Tax Incentive Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three months ended
December 31, 2022 the Company recorded research and development incentive income of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231_zxLd8IKoQOJ7" title="Research and development incentive income">733,590</span> (AUD <span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__srt--CurrencyAxis__currency--AUD_z28MtqNa9oml" title="Research and development incentive income">1,116,618</span>) (2021: $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231_zr568AHCTeb6" title="Research and development incentive income">810,730</span> (AUD <span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231__srt--CurrencyAxis__currency--AUD_zPl2ZPeLN3Y6" title="Research and development incentive income">1,116,362</span>))
in respect of the Tax Incentive Credit for eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO and, the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#8217;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577435437008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zNbVyOfKqtki" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 4	 	 <span id="xdx_82F_z0mGfsPdULm7">Accrued Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>The principal components of accrued liabilities consists of:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zoXLvwtMqgV8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zONRZM50Hhr" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20221231_zDZvtorAVph7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220930_zTbGZwc9po0b" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">December 31,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
  <tr id="xdx_404_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_maALCze45_z8SuwlLa0FZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,212,464</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,031,105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCze45_z3qoXFs4dbG9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,249,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,297,337</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCze45_za88OzDbUEi9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,076,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">417,414</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCze45_zabI6rEWisSl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,504,523</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,199,097</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCze45_zZWLwTNtRVK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; color: rgb(204,238,255); text-indent: -10pt">Total accrued liabilities&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,042,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,944,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577350354128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EquityOfferingTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_80F_ecustom--EquityOfferingTextBlock_zr7a25UqgGtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 5		<span id="xdx_826_zK2D03L96t57">Equity Offerings</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>












<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents commissions
for their services of up to <span id="xdx_90F_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zIsdAuxuRkCb" title="Percentage of gross proceeds from sales">3.0</span>% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the three months ended December 31, 2022, <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zcsZs5Wq5Qo3" title="Number of common stock sold">no</span>
shares were sold pursuant to the Offering. During the three months ended December 31, 2021, <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zbbz2q791Vsj" title="Number of common stock sold">99,588</span> shares were sold for gross proceeds
of $<span id="xdx_903_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zNRqfTqB0cS2" title="Gross proceeds from Issuance Public Offering">2,312,785</span> (net proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering">2,149,701</span>). At December 31, 2022, an amount of $<span id="xdx_90B_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20221231_zlax5CQXnKwl" title="Sales of agreement amount">142,407,882</span> (September 30, 2022: $<span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount">142,407,882</span>) was registered
pursuant to an effective registration statement and remained available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577428548112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_zJipZv6cvSm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 6 	<span id="xdx_826_zcNDyHoj9k54">Commitments and Contingencies</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Leases </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">During the three
months ended December 31, 2022, the Company incurred office lease expense of $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_pp0p0_c20221001__20221231_zgcKyJX4u3d5" title="Operating Leases, Rent Expense">30,070</span> (2021: $<span id="xdx_909_eus-gaap--LeaseAndRentalExpense_pp0p0_c20211001__20211231_zzw6p74CFrMg" title="Operating Leases, Rent Expense">4,845</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three months ended December 31, 2022, the Company made $<span id="xdx_90F_eus-gaap--PensionContributions_pp0p0_c20221001__20221231_zJBfWXFu8lD7" title="Contribution amount">43,646</span> (2021: $<span id="xdx_90F_eus-gaap--PensionContributions_pp0p0_c20211001__20211231_zNPoEopIERlh" title="Contribution amount">22,682</span>) in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>







<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p>








<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022 and September 30, 2022, the Company
had <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_zlk04CawYIfa" title="Warrants outstanding"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zhIEMsI6hXB9" title="Warrants outstanding">160,000</span></span> warrants outstanding at a weighted average exercise price of $<span id="xdx_90F_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20221231_zumsUQH0yL5" title="Warrants outstanding weighted average exercise"><span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_zV1GNFqym1pa" title="Warrants outstanding weighted average exercise">3.72</span></span> as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zkEMw855x8Nl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"><span id="xdx_8B1_zOpUD3aiovE2" style="display: none">Schedule of share purchase warrants outstanding</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zSDYZE5etdze" style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: right; text-indent: -10pt" title="Number">150,000</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zZVw7Jr4TeZg" style="width: 27%; text-align: right" title="Exercise Price">3.17</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="text-align: right; width: 27%"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zN6X7kmeLY59" title="Expiry Date">May 6, 2024</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zWWae6epErC9" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">10,000</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">12.00</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztaFdmBsUFQk" title="Expiry Date">April 21, 2026</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231_zJFWTV6flmci" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number">160,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
</table>




<p id="xdx_8A2_zAYLWzf5lQP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOSlZDBaXjZ4" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zzWmjFZgDS9g" title="Option granted">406,453</span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance">10,000,000</span> additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At December
31, 2022 <span id="xdx_903_ecustom--OptionIssued_c20221001__20221231_pdd" title="Option issued">2,378,000</span> options had been issued under the 2022 Plan and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zQUOIFhpb1z3" title="Option available issue">8,078,453</span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of Company&#8217;s outstanding
stock options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zTAu3tAG8N06" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span id="xdx_8B1_zEYEHDimIKA" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Grant Date</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Price ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Fair Value ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2021</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIGmqyfWBAXg" style="width: 12%; text-align: right" title="Options Outstanding at beginning">11,330,903</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmEvHEGO9uk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">5.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1D5euBgyRqj" style="width: 12%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">140,132,451</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znlTJdrCP7C9" style="text-align: right" title="Options Granted">2,358,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzaopvGaoRw4" style="text-align: right" title="Weighted Average Exercise Price Granted">10.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8SxfSHDOOdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">7.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRH818Ya5f3f" style="text-align: right" title="Options Forfeited">(118,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6iC4GRDO5A9" style="text-align: right" title="Weighted Average Exercise Price Forfeited">6.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW8Bn62hS3Yh" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">5.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvDKn412n8sc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(400,537</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCVTRzkxVjW2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.52</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOWzLHExnze6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">1.88</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNJyCSHNH8gi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">4,201,015</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAqYbkF0xjli" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning">13,169,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9ijs9r15TJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">6.61</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuGjngGc8A4d" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">62,267,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMtyNht74jX9" style="text-align: right" title="Options Granted">325,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6jj6ISozJok" style="text-align: right" title="Weighted Average Exercise Price Granted">12.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV5yypQUZCsh" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">8.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEiC8lsFy8Ei" style="text-align: right" title="Options Forfeited">(40,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuQpsN5PXG5" style="text-align: right" title="Weighted Average Exercise Price Forfeited">7.51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvuEUSBbals5" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">2.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGWiXIYzfi7d" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(89,320</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR2K9ENC4Tj4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.89</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znUPtoy4E3ib" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">2.44</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4FTvMu6uaFb" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">591,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zirxiFmbHTw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending">13,365,296</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdF7afoAr8Xi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">6.78</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBNzuLPvIbV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending">50,676,617</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zosxorn9Xgzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending">8,795,293</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7F5WIPaVlB5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">4.51</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8quZAuDlHcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending">45,930,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A4_zu2W8MSDuOIh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at December 31, 2022 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsiXt3H6xQak" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B0_zpK3BzDEDfPe" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">price</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">Range of exercise prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">options</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">life (in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">vested options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> vested</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zBuO20econda" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zH4oGVKNe6vk" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">2.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zq4ehpF8iyQa" style="width: 11%; text-align: right" title="Number of outstanding options">3,850,742</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDzs8Y8YN047" title="Weighted average remaining contractual life (in years)">4.86</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zeIw6gN0uvC4" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrWdowvkqbph" style="width: 10%; text-align: right" title="Number of vested options">3,844,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5IjYWPpdkuk" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zQz1haJPkYke" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zC73TrJjm9q5" style="text-align: right" title="Range of exercise prices, upper range limit">4.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zsUQxRzkbT5j" style="text-align: right" title="Number of outstanding options">2,042,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zV2FD0JDmzu1" title="Weighted average remaining contractual life (in years)">5.09</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zzV1nPkAB2j5" style="text-align: right" title="Weighted average exercise price">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zWJCJcVqakTg" style="text-align: right" title="Number of vested options">2,032,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zN6C30a7a4t6" style="text-align: right" title="Weighted average exercise price options vested">3.29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zxDZvqWMWfZ6" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">5.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zVGVUeKvA5i4" style="text-align: right" title="Range of exercise prices, upper range limit">8.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zSBgFLrF3WUa" style="text-align: right" title="Number of outstanding options">3,927,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zib60TXSaIkd" title="Weighted average remaining contractual life (in years)">5.80</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zKb6hKrYHZhi" style="text-align: right" title="Weighted average exercise price">6.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGPGkWsDKft8" style="text-align: right" title="Number of vested options">2,374,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zI83oL98Zkoc" style="text-align: right" title="Weighted average exercise price options vested">6.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zaiaC91dh1W7" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">9.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zo4njVVhDqb1" style="text-align: right" title="Range of exercise prices, upper range limit">13.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zRmacfj8iLU9" style="text-align: right" title="Number of outstanding options">1,968,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zLAGIA1yfBD1" title="Weighted average remaining contractual life (in years)">9.04</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zE6TrRySCt4e" style="text-align: right" title="Weighted average exercise price">10.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zcL1qc3udUc3" style="text-align: right" title="Number of vested options">154,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z6cCMWazIU6l" style="text-align: right" title="Weighted average exercise price options vested">12.27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zfnrQathPpR7" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">13.22</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zvtx5yGXlHbj" style="text-align: right" title="Range of exercise prices, upper range limit">24.58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z15pxktYFxth" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,577,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zoLgLTQNTCvl" title="Weighted average remaining contractual life (in years)">8.24</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zaFaDrwX6XFj" style="text-align: right" title="Weighted average exercise price">18.51</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zhxUol2dWvhi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">388,750</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT2U2lIGE4ek" style="text-align: right" title="Weighted average exercise price options vested">18.80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zO2h9fKfcCv7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">13,365,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjafHLghoMqh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">8,795,293</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A6_zTAhmxGzDRid" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of options
vested during the three months ended December 31, 2022 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231_zWQvSeJMLXV9" title="Weighted average grant date fair value of options vested">4.40</span> (2021: $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231_zpYmG7iaOrJj" title="Weighted average grant date fair value of options vested">2.85</span>). At December 31, 2022, the weighted average contractual
life of options outstanding was <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231_z2Sbkm3Ajifl" title="Weighted average contractual life of options outstanding">6.18</span> years (September 30, 2022: <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zvmCefcIOHQ2" title="Weighted average contractual life of options outstanding">6.40</span> years) and for options exercisable was <span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231_zztbpI9oVRdc" title="Options exercisable">4.83</span> years (September 30,
2022: <span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zdXX2tGYiuXl" title="Options exercisable">5.1</span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended December 31, 2022, the
Company recognized stock-based compensation expense of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20221001__20221231_zAmZXw93skO3" title="Share based compensation">5,346,508</span> (2021: $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" title="Share based compensation">3,908,771</span>) in connection with the issuance and vesting 	of
stock options and warrants in exchange for services. These amounts have been included in general and 	administrative expenses and research
and development expenses on the Company&#8217;s statement of 	operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zufc8G4hxCv6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6l0qWPPLU81" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">1,742,524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">1,671,725</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,603,984</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,237,046</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation">5,346,508</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation">3,908,771</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A9_zJQZAIzAYumc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20221231_zMRZgYaWWmS9" title="Remaining stock based compensation">16,340,941</span> in stock-based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option award
granted during the three months ended December 31, 2022 and 2021 is estimated on the date of grant using the Black Scholes option pricing
model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zxDTTrptBUxk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zrXoJrxBJCSj" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20221231_zJI6nhuMJ16g" title="Risk-free interest rate">4.07</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_z417cr702jpb" title="Risk-free interest rate">1.37</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20221231_zg2WL7FzJXZb" title="Expected life of options (years)">4.98</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znTgAn5ygB5j" title="Expected life of options (years)">6.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20221231_zKpcopkcddLc" title="Annualized volatility">84.01</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_zbX9ot5dFImk" title="Annualized volatility">96.79</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20221231_ze8e1w28W1u4" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_zlkeqoxgkJij" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>



<p id="xdx_8AE_z4KrUCUdOUU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the three months ended December 31, 2022 and 2021 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577350354128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zD6IOE92BQod" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Note
                                            7	<span id="xdx_822_zvxoJfasjjle">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to December 31, 2022, <span id="xdx_905_eus-gaap--SignificantPurchaseCommitmentDescription_c20221001__20221231_zW90nxNoM2sb" title="Purchase agreement, description">the Company entered
into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), whereby the Company
has the right, in its sole discretion, to sell to LPC up to $150,000,000 in value of shares of the Company&#8217;s common stock from time
to time over a 36-month period pursuant to the terms of the Purchase Agreement.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577346697440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zUQdtJi6fuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i><span id="xdx_86E_zOC3uQ5iyg6a">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited interim condensed consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three months ended December
31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LliquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_841_ecustom--LliquidityPolicyTextBlock_zkX9GKxjPX1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zM92AZ1bBeL9">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
(as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available,
that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis,
if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_zAlWL6YlnfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_868_zWRNrnlTlPVf">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CoronavirusDisease2019COVID19PolicyTextBlock', window );">Coronavirus Disease 2019 (COVID-19)</a></td>
<td class="text"><p id="xdx_84E_ecustom--CoronavirusDisease2019COVID19PolicyTextBlock_zHJrC2UOD7S2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zCUIR1Nn6Pfj">Coronavirus Disease 2019 (COVID-19)</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The global pandemic resulting
from the disease known as COVID-19, caused by a novel strain of coronavirus, did not have a material impact on the Company&#8217;s result
of operations or financial condition for the quarter ended December 31, 2022. However, the future course of the pandemic could have adverse
effects in the U.S and global economies and thus negatively impact our business and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhVa66jQ8Wrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zVrH6HBuajQ8">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbCYyGFjyKQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_865_zdQgm5cfTk02">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zldoy5WGjNTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_z4OE5XqndfY2">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 loss per share excludes <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20221231_pdd" title="Loss per share for potentially dilutive common shares">13,525,296</span>
(December 31, 2021: <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_zbRpyyYJm8Vj" title="Loss per share for potentially dilutive common shares">11,403,769</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQkq8c6YE9S9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_869_zqtvQrQwJJXk">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CoronavirusDisease2019COVID19PolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CoronavirusDisease2019COVID19PolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LliquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LliquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577435437008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zoXLvwtMqgV8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zONRZM50Hhr" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20221231_zDZvtorAVph7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220930_zTbGZwc9po0b" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">December 31,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
  <tr id="xdx_404_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_maALCze45_z8SuwlLa0FZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,212,464</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,031,105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCze45_z3qoXFs4dbG9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,249,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,297,337</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCze45_za88OzDbUEi9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,076,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">417,414</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCze45_zabI6rEWisSl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,504,523</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,199,097</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCze45_zZWLwTNtRVK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; color: rgb(204,238,255); text-indent: -10pt">Total accrued liabilities&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,042,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,944,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577347701360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zkEMw855x8Nl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"><span id="xdx_8B1_zOpUD3aiovE2" style="display: none">Schedule of share purchase warrants outstanding</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zSDYZE5etdze" style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: right; text-indent: -10pt" title="Number">150,000</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zZVw7Jr4TeZg" style="width: 27%; text-align: right" title="Exercise Price">3.17</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="text-align: right; width: 27%"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zN6X7kmeLY59" title="Expiry Date">May 6, 2024</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zWWae6epErC9" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">10,000</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">12.00</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztaFdmBsUFQk" title="Expiry Date">April 21, 2026</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231_zJFWTV6flmci" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number">160,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
</table>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zTAu3tAG8N06" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span id="xdx_8B1_zEYEHDimIKA" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Grant Date</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Price ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Fair Value ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2021</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIGmqyfWBAXg" style="width: 12%; text-align: right" title="Options Outstanding at beginning">11,330,903</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmEvHEGO9uk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">5.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1D5euBgyRqj" style="width: 12%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">140,132,451</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znlTJdrCP7C9" style="text-align: right" title="Options Granted">2,358,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzaopvGaoRw4" style="text-align: right" title="Weighted Average Exercise Price Granted">10.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8SxfSHDOOdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">7.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRH818Ya5f3f" style="text-align: right" title="Options Forfeited">(118,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6iC4GRDO5A9" style="text-align: right" title="Weighted Average Exercise Price Forfeited">6.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW8Bn62hS3Yh" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">5.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvDKn412n8sc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(400,537</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCVTRzkxVjW2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.52</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOWzLHExnze6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">1.88</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNJyCSHNH8gi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">4,201,015</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAqYbkF0xjli" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning">13,169,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9ijs9r15TJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">6.61</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuGjngGc8A4d" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">62,267,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMtyNht74jX9" style="text-align: right" title="Options Granted">325,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6jj6ISozJok" style="text-align: right" title="Weighted Average Exercise Price Granted">12.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV5yypQUZCsh" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">8.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEiC8lsFy8Ei" style="text-align: right" title="Options Forfeited">(40,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuQpsN5PXG5" style="text-align: right" title="Weighted Average Exercise Price Forfeited">7.51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvuEUSBbals5" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">2.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGWiXIYzfi7d" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(89,320</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR2K9ENC4Tj4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.89</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znUPtoy4E3ib" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">2.44</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4FTvMu6uaFb" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">591,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zirxiFmbHTw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending">13,365,296</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdF7afoAr8Xi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">6.78</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBNzuLPvIbV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending">50,676,617</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zosxorn9Xgzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending">8,795,293</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7F5WIPaVlB5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">4.51</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8quZAuDlHcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending">45,930,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsiXt3H6xQak" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B0_zpK3BzDEDfPe" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">price</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">Range of exercise prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">options</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">life (in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">vested options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> vested</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zBuO20econda" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zH4oGVKNe6vk" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">2.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zq4ehpF8iyQa" style="width: 11%; text-align: right" title="Number of outstanding options">3,850,742</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDzs8Y8YN047" title="Weighted average remaining contractual life (in years)">4.86</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zeIw6gN0uvC4" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrWdowvkqbph" style="width: 10%; text-align: right" title="Number of vested options">3,844,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5IjYWPpdkuk" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zQz1haJPkYke" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zC73TrJjm9q5" style="text-align: right" title="Range of exercise prices, upper range limit">4.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zsUQxRzkbT5j" style="text-align: right" title="Number of outstanding options">2,042,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zV2FD0JDmzu1" title="Weighted average remaining contractual life (in years)">5.09</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zzV1nPkAB2j5" style="text-align: right" title="Weighted average exercise price">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zWJCJcVqakTg" style="text-align: right" title="Number of vested options">2,032,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zN6C30a7a4t6" style="text-align: right" title="Weighted average exercise price options vested">3.29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zxDZvqWMWfZ6" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">5.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zVGVUeKvA5i4" style="text-align: right" title="Range of exercise prices, upper range limit">8.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zSBgFLrF3WUa" style="text-align: right" title="Number of outstanding options">3,927,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zib60TXSaIkd" title="Weighted average remaining contractual life (in years)">5.80</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zKb6hKrYHZhi" style="text-align: right" title="Weighted average exercise price">6.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGPGkWsDKft8" style="text-align: right" title="Number of vested options">2,374,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zI83oL98Zkoc" style="text-align: right" title="Weighted average exercise price options vested">6.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zaiaC91dh1W7" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">9.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zo4njVVhDqb1" style="text-align: right" title="Range of exercise prices, upper range limit">13.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zRmacfj8iLU9" style="text-align: right" title="Number of outstanding options">1,968,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zLAGIA1yfBD1" title="Weighted average remaining contractual life (in years)">9.04</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zE6TrRySCt4e" style="text-align: right" title="Weighted average exercise price">10.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zcL1qc3udUc3" style="text-align: right" title="Number of vested options">154,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z6cCMWazIU6l" style="text-align: right" title="Weighted average exercise price options vested">12.27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zfnrQathPpR7" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit">13.22</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zvtx5yGXlHbj" style="text-align: right" title="Range of exercise prices, upper range limit">24.58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z15pxktYFxth" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,577,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zoLgLTQNTCvl" title="Weighted average remaining contractual life (in years)">8.24</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zaFaDrwX6XFj" style="text-align: right" title="Weighted average exercise price">18.51</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zhxUol2dWvhi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">388,750</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT2U2lIGE4ek" style="text-align: right" title="Weighted average exercise price options vested">18.80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zO2h9fKfcCv7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">13,365,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjafHLghoMqh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">8,795,293</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zufc8G4hxCv6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6l0qWPPLU81" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">1,742,524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">1,671,725</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,603,984</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,237,046</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation">5,346,508</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation">3,908,771</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zxDTTrptBUxk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zrXoJrxBJCSj" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20221231_zJI6nhuMJ16g" title="Risk-free interest rate">4.07</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_z417cr702jpb" title="Risk-free interest rate">1.37</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20221231_zg2WL7FzJXZb" title="Expected life of options (years)">4.98</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znTgAn5ygB5j" title="Expected life of options (years)">6.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20221231_zKpcopkcddLc" title="Annualized volatility">84.01</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_zbX9ot5dFImk" title="Annualized volatility">96.79</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20221231_ze8e1w28W1u4" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_zlkeqoxgkJij" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577351051968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">13,525,296<span></span>
</td>
<td class="nump">11,403,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577343692992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 733,590<span></span>
</td>
<td class="nump">$ 810,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">916,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">1,116,618<span></span>
</td>
<td class="nump">$ 1,116,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_AnavexMember', window );">Anavex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember', window );">Michael J Fox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 995,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_AnavexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_AnavexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577346702688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccruedClinicalSiteAndPatientVisitsCosts', window );">Accrued clinical site and patient visits costs</a></td>
<td class="nump">$ 2,212,464<span></span>
</td>
<td class="nump">$ 2,031,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,249,205<span></span>
</td>
<td class="nump">1,297,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FixedContractAccruals', window );">Fixed contract accruals</a></td>
<td class="nump">1,076,630<span></span>
</td>
<td class="nump">417,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">2,504,523<span></span>
</td>
<td class="nump">2,199,097<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities&#160;</a></td>
<td class="nump">$ 7,042,822<span></span>
</td>
<td class="nump">$ 5,944,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccruedClinicalSiteAndPatientVisitsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccruedClinicalSiteAndPatientVisitsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FixedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FixedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577343653408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SalesOfAgreementAmount', window );">Sales of agreement amount</a></td>
<td class="nump">$ 142,407,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,407,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald And Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_GrossProceedsFromIssuancePublicOffering', window );">Gross proceeds from Issuance Public Offering</a></td>
<td class="nump">$ 2,312,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Public Offering</a></td>
<td class="nump">$ 2,149,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrossProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrossProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SalesOfAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SalesOfAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577346137952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Apr. 21,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577346499440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - Equity Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning</a></td>
<td class="nump">13,169,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 62,267,309<span></span>
</td>
<td class="nump">$ 140,132,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="nump">2,358,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 12.43<span></span>
</td>
<td class="nump">$ 10.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 8.17<span></span>
</td>
<td class="nump">$ 7.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="num">(118,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 7.51<span></span>
</td>
<td class="nump">$ 6.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Forfeited</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 5.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(89,320)<span></span>
</td>
<td class="num">(400,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 2.89<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Exercised</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value Exercised</a></td>
<td class="nump">$ 591,993<span></span>
</td>
<td class="nump">$ 4,201,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">13,365,296<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 6.78<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending</a></td>
<td class="nump">$ 50,676,617<span></span>
</td>
<td class="nump">$ 62,267,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at ending</a></td>
<td class="nump">8,795,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable at ending</a></td>
<td class="nump">$ 4.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable at ending</a></td>
<td class="nump">$ 45,930,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577342114592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">13,365,296<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.78<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">8,795,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,850,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,844,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,042,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,032,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,927,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,374,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 6.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,968,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">9 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 10.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">154,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 12.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">13.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 24.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,577,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">8 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">388,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 18.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577346488704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 5,346,508<span></span>
</td>
<td class="nump">$ 3,908,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">1,742,524<span></span>
</td>
<td class="nump">1,671,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 3,603,984<span></span>
</td>
<td class="nump">$ 2,237,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577343681488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">84.01%<span></span>
</td>
<td class="nump">96.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577343402000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 30,070<span></span>
</td>
<td class="nump">$ 4,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution amount</a></td>
<td class="nump">$ 43,646<span></span>
</td>
<td class="nump">$ 22,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WarrantsOutstandingWeightedAverageExercise', window );">Warrants outstanding weighted average exercise</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="nump">2,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="nump">$ 4.40<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable</a></td>
<td class="text">4 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 5,346,508<span></span>
</td>
<td class="nump">$ 3,908,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 16,340,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">Stock Option Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Option available issue</a></td>
<td class="nump">8,078,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WarrantsOutstandingWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WarrantsOutstandingWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140577350621280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantPurchaseCommitmentDescription', window );">Purchase agreement, description</a></td>
<td class="text">the Company entered
into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), whereby the Company
has the right, in its sole discretion, to sell to LPC up to $150,000,000 in value of shares of the Company&#8217;s common stock from time
to time over a 36-month period pursuant to the terms of the Purchase Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a)(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>e4385_10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20221231"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-10-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_MichaelJFoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_AnavexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_AnavexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-10-01to2022-12-31">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-10-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-10-01to2022-12-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-10-01to2022-12-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-10-01to2022-12-31">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0150"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0194"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0204"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2022-12-31"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-10-01to2022-12-31"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-10-01to2022-12-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-10-01to2022-12-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-10-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-10-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-10-01to2022-12-31">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-10-01to2022-12-31">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-10-01to2022-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-10-01to2022-12-31">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-10-01to2022-12-31">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-10-01to2022-12-31">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-10-01to2022-12-31">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-10-01to2022-12-31">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2022-10-01to2022-12-31">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2022-10-01to2022-12-31">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-10-01to2022-12-31">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-10-01to2022-12-31">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-10-01to2022-12-31">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-10-01to2022-12-31">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-10-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-10-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-10-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-10-01to2022-12-31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-10-01to2022-12-31">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-10-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-10-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-02-07" decimals="INF" unitRef="Shares">78032135</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">143621848</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">149157861</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4094431</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3192580</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">655643</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">354162</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">148371922</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">152704603</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5288261</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3824777</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7042822</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5944953</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">916763</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredIncomeCurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13247846</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">10213561</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">78032135</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">78032135</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">77942815</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">77942815</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">78033</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">77944</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">393581544</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">387976881</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-258535501</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">-245563783</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">135124076</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142491042</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">148371922</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">152704603</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">3317036</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">3066951</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">12066919</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">8656439</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">15383955</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">11723390</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15383955</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-11723390</us-gaap:OperatingIncomeLoss>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">733590</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">810730</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">1267618</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">4910</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">365983</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">55363</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">2392191</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">871003</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12991764</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-10852387</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">-20046</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">29980</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12971718</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-10882367</us-gaap:NetIncomeLoss>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.17</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.14</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">77977112</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">75997738</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77942815</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">387976881</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-245563783</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142491042</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">89320</avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">89</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">258155</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">258244</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5346508</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">5346508</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-12971718</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12971718</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">78032135</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">78033</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">393581544</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-258535501</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">135124076</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75918465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">348328048</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-197585864</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">137134</avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">137</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">373360</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">373497</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">99588</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">99</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2149602</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">2149701</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3908771</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">3908771</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10882367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-10882367</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">76155187</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">76156</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">354759781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-208468231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">146367706</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12971718</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-10882367</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">5346508</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">3908771</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">901851</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-3764678</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">301481</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">22311</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">1463484</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-104992</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">1097869</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-164734</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">472932</avxl:IncreaseDecreaseInDeferredGrantIncome>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5794257</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-3500955</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">2312785</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">146717</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">258244</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">373497</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">258244</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">2539565</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5536013</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-961390</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">149157861</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">143621848</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">151146355</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">50077</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zvyA2F3wVxr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Note 1 	&lt;span id="xdx_829_zePecOAZlLx2"&gt;Business Description&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d; or
the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73
is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--BasisOfAccounting_zbDwoEqw09j3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 	&lt;span id="xdx_821_zqATGLBhz5C1"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zUQdtJi6fuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zOC3uQ5iyg6a"&gt;Basis of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited interim condensed consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the three months ended December
31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--LliquidityPolicyTextBlock_zkX9GKxjPX1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zM92AZ1bBeL9"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the Sales Agreement
(as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available,
that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis,
if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zAlWL6YlnfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zWRNrnlTlPVf"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--CoronavirusDisease2019COVID19PolicyTextBlock_zHJrC2UOD7S2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zCUIR1Nn6Pfj"&gt;Coronavirus Disease 2019 (COVID-19)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The global pandemic resulting
from the disease known as COVID-19, caused by a novel strain of coronavirus, did not have a material impact on the Company&#x2019;s result
of operations or financial condition for the quarter ended December 31, 2022. However, the future course of the pandemic could have adverse
effects in the U.S and global economies and thus negatively impact our business and financial results.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhVa66jQ8Wrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zVrH6HBuajQ8"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbCYyGFjyKQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zdQgm5cfTk02"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2022 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zldoy5WGjNTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z4OE5XqndfY2"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022 loss per share excludes &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20221231_pdd" title="Loss per share for potentially dilutive common shares"&gt;13,525,296&lt;/span&gt;
(December 31, 2021: &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_zbRpyyYJm8Vj" title="Loss per share for potentially dilutive common shares"&gt;11,403,769&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQkq8c6YE9S9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zqtvQrQwJJXk"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2021, the FASB
issued ASU 2021-10, &#x201c;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#x201d; (&#x201c;ASU&#160;2021-10&#x201d;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#x2019;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#x201c;ATO&#x201d;) for its clinical trials in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zUQdtJi6fuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zOC3uQ5iyg6a"&gt;Basis of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited interim condensed consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the three months ended December
31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <avxl:LliquidityPolicyTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_841_ecustom--LliquidityPolicyTextBlock_zkX9GKxjPX1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zM92AZ1bBeL9"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the Sales Agreement
(as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available,
that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis,
if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:LliquidityPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zAlWL6YlnfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zWRNrnlTlPVf"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <avxl:CoronavirusDisease2019COVID19PolicyTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_84E_ecustom--CoronavirusDisease2019COVID19PolicyTextBlock_zHJrC2UOD7S2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zCUIR1Nn6Pfj"&gt;Coronavirus Disease 2019 (COVID-19)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The global pandemic resulting
from the disease known as COVID-19, caused by a novel strain of coronavirus, did not have a material impact on the Company&#x2019;s result
of operations or financial condition for the quarter ended December 31, 2022. However, the future course of the pandemic could have adverse
effects in the U.S and global economies and thus negatively impact our business and financial results.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:CoronavirusDisease2019COVID19PolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhVa66jQ8Wrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zVrH6HBuajQ8"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbCYyGFjyKQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zdQgm5cfTk02"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2022 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zldoy5WGjNTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z4OE5XqndfY2"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022 loss per share excludes &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20221231_pdd" title="Loss per share for potentially dilutive common shares"&gt;13,525,296&lt;/span&gt;
(December 31, 2021: &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_zbRpyyYJm8Vj" title="Loss per share for potentially dilutive common shares"&gt;11,403,769&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">13525296</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="Shares">11403769</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQkq8c6YE9S9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zqtvQrQwJJXk"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2021, the FASB
issued ASU 2021-10, &#x201c;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#x201d; (&#x201c;ASU&#160;2021-10&#x201d;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#x2019;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#x201c;ATO&#x201d;) for its clinical trials in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_801_ecustom--OtherIncomeDisclosureTextBlock_zCcWHuXVRY5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 3	&lt;span id="xdx_826_z1z3uptfurRa"&gt;Other Income&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Grant Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of December 31, 2022,
the Company had received $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_zVuib9oqfZgb" title="Research and development incentive income"&gt;995,862&lt;/span&gt; in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#x2019;s Research. The grant
will be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to Parkinson&#x2019;s disease.
Of the total, $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__dei--LegalEntityAxis__custom--AnavexMember_zrsyTMWdTfdh" title="Research and development incentive income"&gt;497,931&lt;/span&gt; was received during the three months ended December 31, 2022 and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_znZ31QTl4Yi" title="Research and development incentive income"&gt;497,931&lt;/span&gt; was received during the year ended September
30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three months ended December 31, 2022, the Company recognized $&lt;span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20221231_zXH3rtZoR1u7" title="Grant income"&gt;25,000&lt;/span&gt; (2021: $&lt;span id="xdx_90C_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20211231_zAkumjuyPFYk" title="Grant income"&gt;0&lt;/span&gt;) of this grant on its statements of operations as grant
income. At December 31, 2022, an amount of $&lt;span id="xdx_90B_ecustom--DeferredGrantIncome_iI_pp0p0_c20221231_zvdiFTbpN7i3" title="Deferred grant income"&gt;916,763&lt;/span&gt; (September 30, 2022: $&lt;span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income"&gt;443,831&lt;/span&gt;) of this grant is recorded as deferred grant income,
representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its
statement of operations as the relating expenditures are incurred to offset the income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research and development
incentive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#x201c;Tax Incentive Credit&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the three months ended
December 31, 2022 the Company recorded research and development incentive income of $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231_zxLd8IKoQOJ7" title="Research and development incentive income"&gt;733,590&lt;/span&gt; (AUD &lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20221001__20221231__srt--CurrencyAxis__currency--AUD_z28MtqNa9oml" title="Research and development incentive income"&gt;1,116,618&lt;/span&gt;) (2021: $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231_zr568AHCTeb6" title="Research and development incentive income"&gt;810,730&lt;/span&gt; (AUD &lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231__srt--CurrencyAxis__currency--AUD_zPl2ZPeLN3Y6" title="Research and development incentive income"&gt;1,116,362&lt;/span&gt;))
in respect of the Tax Incentive Credit for eligible research and development expenses incurred during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO and, the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#x2019;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012022-12-31_custom_MichaelJFoxMember"
      decimals="0"
      unitRef="USD">995862</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012022-12-31_custom_AnavexMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_custom_AnavexMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">916763</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">443831</avxl:DeferredGrantIncome>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">733590</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012022-12-31_currency_AUD"
      decimals="0"
      unitRef="USD">1116618</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">810730</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012021-12-31_currency_AUD"
      decimals="0"
      unitRef="USD">1116362</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zNbVyOfKqtki" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 4	 	 &lt;span id="xdx_82F_z0mGfsPdULm7"&gt;Accrued Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;The principal components of accrued liabilities consists of:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zoXLvwtMqgV8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zONRZM50Hhr" style="display: none"&gt;Schedule of Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20221231_zDZvtorAVph7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220930_zTbGZwc9po0b" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;September 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_maALCze45_z8SuwlLa0FZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued clinical site and patient visits costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,212,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,031,105&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCze45_z3qoXFs4dbG9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,249,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,297,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCze45_za88OzDbUEi9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,076,630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;417,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCze45_zabI6rEWisSl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,504,523&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,199,097&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCze45_zZWLwTNtRVK8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; color: rgb(204,238,255); text-indent: -10pt"&gt;Total accrued liabilities&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,042,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,944,953&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2022-10-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zoXLvwtMqgV8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zONRZM50Hhr" style="display: none"&gt;Schedule of Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20221231_zDZvtorAVph7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220930_zTbGZwc9po0b" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;September 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_maALCze45_z8SuwlLa0FZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued clinical site and patient visits costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,212,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,031,105&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCze45_z3qoXFs4dbG9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,249,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,297,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCze45_za88OzDbUEi9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,076,630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;417,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCze45_zabI6rEWisSl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,504,523&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,199,097&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCze45_zZWLwTNtRVK8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; color: rgb(204,238,255); text-indent: -10pt"&gt;Total accrued liabilities&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,042,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,944,953&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:AccruedClinicalSiteAndPatientVisitsCosts contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2212464</avxl:AccruedClinicalSiteAndPatientVisitsCosts>
    <avxl:AccruedClinicalSiteAndPatientVisitsCosts contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2031105</avxl:AccruedClinicalSiteAndPatientVisitsCosts>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1249205</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">1297337</us-gaap:AccruedBonusesCurrent>
    <avxl:FixedContractAccruals contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1076630</avxl:FixedContractAccruals>
    <avxl:FixedContractAccruals contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">417414</avxl:FixedContractAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2504523</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2199097</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7042822</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5944953</us-gaap:AccruedLiabilitiesCurrent>
    <avxl:EquityOfferingTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_80F_ecustom--EquityOfferingTextBlock_zr7a25UqgGtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 5		&lt;span id="xdx_826_zK2D03L96t57"&gt;Equity Offerings&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#x201c;Board&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;












&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp;
Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon delivery of a placement notice based on the Company&#x2019;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#x201c;at the market offering&#x201d; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has agreed to pay the Sales Agents commissions
for their services of up to &lt;span id="xdx_90F_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zIsdAuxuRkCb" title="Percentage of gross proceeds from sales"&gt;3.0&lt;/span&gt;% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the three months ended December 31, 2022, &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zcsZs5Wq5Qo3" title="Number of common stock sold"&gt;no&lt;/span&gt;
shares were sold pursuant to the Offering. During the three months ended December 31, 2021, &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zbbz2q791Vsj" title="Number of common stock sold"&gt;99,588&lt;/span&gt; shares were sold for gross proceeds
of $&lt;span id="xdx_903_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zNRqfTqB0cS2" title="Gross proceeds from Issuance Public Offering"&gt;2,312,785&lt;/span&gt; (net proceeds of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering"&gt;2,149,701&lt;/span&gt;). At December 31, 2022, an amount of $&lt;span id="xdx_90B_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20221231_zlax5CQXnKwl" title="Sales of agreement amount"&gt;142,407,882&lt;/span&gt; (September 30, 2022: $&lt;span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount"&gt;142,407,882&lt;/span&gt;) was registered
pursuant to an effective registration statement and remained available to be sold under the Sales Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:EquityOfferingTextBlock>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">99588</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:GrossProceedsFromIssuancePublicOffering
      contextRef="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">2312785</avxl:GrossProceedsFromIssuancePublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-10-012022-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">2149701</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">142407882</avxl:SalesOfAgreementAmount>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142407882</avxl:SalesOfAgreementAmount>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_zJipZv6cvSm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 6 	&lt;span id="xdx_826_zcNDyHoj9k54"&gt;Commitments and Contingencies&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;Leases &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;During the three
months ended December 31, 2022, the Company incurred office lease expense of $&lt;span id="xdx_907_eus-gaap--LeaseAndRentalExpense_pp0p0_c20221001__20221231_zgcKyJX4u3d5" title="Operating Leases, Rent Expense"&gt;30,070&lt;/span&gt; (2021: $&lt;span id="xdx_909_eus-gaap--LeaseAndRentalExpense_pp0p0_c20211001__20211231_zzw6p74CFrMg" title="Operating Leases, Rent Expense"&gt;4,845&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Employee 401(k) Benefit Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three months ended December 31, 2022, the Company made $&lt;span id="xdx_90F_eus-gaap--PensionContributions_pp0p0_c20221001__20221231_zJBfWXFu8lD7" title="Contribution amount"&gt;43,646&lt;/span&gt; (2021: $&lt;span id="xdx_90F_eus-gaap--PensionContributions_pp0p0_c20211001__20211231_zNPoEopIERlh" title="Contribution amount"&gt;22,682&lt;/span&gt;) in matching contributions under the 401(k) plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anavex
Life Sciences Corp.&lt;/span&gt;&lt;/p&gt;








&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;Share Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2022 and September 30, 2022, the Company
had &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_zlk04CawYIfa" title="Warrants outstanding"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930_zhIEMsI6hXB9" title="Warrants outstanding"&gt;160,000&lt;/span&gt;&lt;/span&gt; warrants outstanding at a weighted average exercise price of $&lt;span id="xdx_90F_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20221231_zumsUQH0yL5" title="Warrants outstanding weighted average exercise"&gt;&lt;span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_zV1GNFqym1pa" title="Warrants outstanding weighted average exercise"&gt;3.72&lt;/span&gt;&lt;/span&gt; as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zkEMw855x8Nl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"&gt;&lt;span id="xdx_8B1_zOpUD3aiovE2" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zSDYZE5etdze" style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: right; text-indent: -10pt" title="Number"&gt;150,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zZVw7Jr4TeZg" style="width: 27%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 27%"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zN6X7kmeLY59" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zWWae6epErC9" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;10,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztaFdmBsUFQk" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231_zJFWTV6flmci" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;160,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p id="xdx_8A2_zAYLWzf5lQP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;Stock&#x2013;based Compensation
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;2015 Stock Option Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s Board approved
a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOSlZDBaXjZ4" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zzWmjFZgDS9g" title="Option granted"&gt;406,453&lt;/span&gt;
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2022 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance"&gt;10,000,000&lt;/span&gt; additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At December
31, 2022 &lt;span id="xdx_903_ecustom--OptionIssued_c20221001__20221231_pdd" title="Option issued"&gt;2,378,000&lt;/span&gt; options had been issued under the 2022 Plan and &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zQUOIFhpb1z3" title="Option available issue"&gt;8,078,453&lt;/span&gt; options were available for issue under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the status of Company&#x2019;s outstanding
stock options is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zTAu3tAG8N06" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_8B1_zEYEHDimIKA" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Grant Date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;intrinsic value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fair Value ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIGmqyfWBAXg" style="width: 12%; text-align: right" title="Options Outstanding at beginning"&gt;11,330,903&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmEvHEGO9uk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;5.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1D5euBgyRqj" style="width: 12%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;140,132,451&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znlTJdrCP7C9" style="text-align: right" title="Options Granted"&gt;2,358,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzaopvGaoRw4" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;10.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8SxfSHDOOdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;7.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRH818Ya5f3f" style="text-align: right" title="Options Forfeited"&gt;(118,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6iC4GRDO5A9" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;6.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW8Bn62hS3Yh" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;5.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvDKn412n8sc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(400,537&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCVTRzkxVjW2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.52&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOWzLHExnze6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;1.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNJyCSHNH8gi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;4,201,015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAqYbkF0xjli" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning"&gt;13,169,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9ijs9r15TJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;6.61&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuGjngGc8A4d" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;62,267,309&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMtyNht74jX9" style="text-align: right" title="Options Granted"&gt;325,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6jj6ISozJok" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;12.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV5yypQUZCsh" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;8.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEiC8lsFy8Ei" style="text-align: right" title="Options Forfeited"&gt;(40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuQpsN5PXG5" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;7.51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvuEUSBbals5" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;2.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGWiXIYzfi7d" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(89,320&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR2K9ENC4Tj4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znUPtoy4E3ib" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;2.44&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4FTvMu6uaFb" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;591,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zirxiFmbHTw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;13,365,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdF7afoAr8Xi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;6.78&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBNzuLPvIbV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;50,676,617&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zosxorn9Xgzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;8,795,293&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7F5WIPaVlB5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;4.51&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8quZAuDlHcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;45,930,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A4_zu2W8MSDuOIh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock options
at December 31, 2022 by a range of exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsiXt3H6xQak" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B0_zpK3BzDEDfPe" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;Range of exercise prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;contractual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;options&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;vested options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt; vested&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zBuO20econda" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zH4oGVKNe6vk" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;2.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zq4ehpF8iyQa" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,850,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDzs8Y8YN047" title="Weighted average remaining contractual life (in years)"&gt;4.86&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zeIw6gN0uvC4" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrWdowvkqbph" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,844,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5IjYWPpdkuk" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zQz1haJPkYke" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zC73TrJjm9q5" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;4.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zsUQxRzkbT5j" style="text-align: right" title="Number of outstanding options"&gt;2,042,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zV2FD0JDmzu1" title="Weighted average remaining contractual life (in years)"&gt;5.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zzV1nPkAB2j5" style="text-align: right" title="Weighted average exercise price"&gt;3.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zWJCJcVqakTg" style="text-align: right" title="Number of vested options"&gt;2,032,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zN6C30a7a4t6" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zxDZvqWMWfZ6" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;5.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zVGVUeKvA5i4" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;8.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zSBgFLrF3WUa" style="text-align: right" title="Number of outstanding options"&gt;3,927,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zib60TXSaIkd" title="Weighted average remaining contractual life (in years)"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zKb6hKrYHZhi" style="text-align: right" title="Weighted average exercise price"&gt;6.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGPGkWsDKft8" style="text-align: right" title="Number of vested options"&gt;2,374,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zI83oL98Zkoc" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zaiaC91dh1W7" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;9.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zo4njVVhDqb1" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zRmacfj8iLU9" style="text-align: right" title="Number of outstanding options"&gt;1,968,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zLAGIA1yfBD1" title="Weighted average remaining contractual life (in years)"&gt;9.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zE6TrRySCt4e" style="text-align: right" title="Weighted average exercise price"&gt;10.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zcL1qc3udUc3" style="text-align: right" title="Number of vested options"&gt;154,581&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z6cCMWazIU6l" style="text-align: right" title="Weighted average exercise price options vested"&gt;12.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zfnrQathPpR7" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;13.22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zvtx5yGXlHbj" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;24.58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z15pxktYFxth" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,577,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zoLgLTQNTCvl" title="Weighted average remaining contractual life (in years)"&gt;8.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zaFaDrwX6XFj" style="text-align: right" title="Weighted average exercise price"&gt;18.51&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zhxUol2dWvhi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;388,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT2U2lIGE4ek" style="text-align: right" title="Weighted average exercise price options vested"&gt;18.80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zO2h9fKfcCv7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;13,365,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjafHLghoMqh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;8,795,293&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A6_zTAhmxGzDRid" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average grant date fair value of options
vested during the three months ended December 31, 2022 was $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231_zWQvSeJMLXV9" title="Weighted average grant date fair value of options vested"&gt;4.40&lt;/span&gt; (2021: $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231_zpYmG7iaOrJj" title="Weighted average grant date fair value of options vested"&gt;2.85&lt;/span&gt;). At December 31, 2022, the weighted average contractual
life of options outstanding was &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231_z2Sbkm3Ajifl" title="Weighted average contractual life of options outstanding"&gt;6.18&lt;/span&gt; years (September 30, 2022: &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zvmCefcIOHQ2" title="Weighted average contractual life of options outstanding"&gt;6.40&lt;/span&gt; years) and for options exercisable was &lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231_zztbpI9oVRdc" title="Options exercisable"&gt;4.83&lt;/span&gt; years (September 30,
2022: &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zdXX2tGYiuXl" title="Options exercisable"&gt;5.1&lt;/span&gt; years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the options
that were in-the-money at December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended December 31, 2022, the
Company recognized stock-based compensation expense of $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20221001__20221231_zAmZXw93skO3" title="Share based compensation"&gt;5,346,508&lt;/span&gt; (2021: $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" title="Share based compensation"&gt;3,908,771&lt;/span&gt;) in connection with the issuance and vesting 	of
stock options and warrants in exchange for services. These amounts have been included in general and 	administrative expenses and research
and development expenses on the Company&#x2019;s statement of 	operations as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zufc8G4hxCv6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_z6l0qWPPLU81" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;1,742,524&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;1,671,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,603,984&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,237,046&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;5,346,508&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;3,908,771&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A9_zJQZAIzAYumc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20221231_zMRZgYaWWmS9" title="Remaining stock based compensation"&gt;16,340,941&lt;/span&gt; in stock-based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of each option award
granted during the three months ended December 31, 2022 and 2021 is estimated on the date of grant using the Black Scholes option pricing
model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zxDTTrptBUxk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zrXoJrxBJCSj" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20221231_zJI6nhuMJ16g" title="Risk-free interest rate"&gt;4.07&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_z417cr702jpb" title="Risk-free interest rate"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20221231_zg2WL7FzJXZb" title="Expected life of options (years)"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znTgAn5ygB5j" title="Expected life of options (years)"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20221231_zKpcopkcddLc" title="Annualized volatility"&gt;84.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_zbX9ot5dFImk" title="Annualized volatility"&gt;96.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20221231_ze8e1w28W1u4" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_zlkeqoxgkJij" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AE_z4KrUCUdOUU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock compensation charges recognized
during the three months ended December 31, 2022 and 2021 was determined with reference to the quoted market price of the Company&#x2019;s
shares on the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">30070</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">4845</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PensionContributions
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">43646</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">22682</us-gaap:PensionContributions>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">160000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">160000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:WarrantsOutstandingWeightedAverageExercise>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:WarrantsOutstandingWeightedAverageExercise>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2022-10-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zkEMw855x8Nl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"&gt;&lt;span id="xdx_8B1_zOpUD3aiovE2" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zSDYZE5etdze" style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: right; text-indent: -10pt" title="Number"&gt;150,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zZVw7Jr4TeZg" style="width: 27%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 27%"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zN6X7kmeLY59" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zWWae6epErC9" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;10,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztaFdmBsUFQk" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221231_zJFWTV6flmci" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;160,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-12-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-12-31_custom_PurchaseWarrants1Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-12-31_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-12-31_custom_PurchaseWarrants2Member">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-10-012022-12-31_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-10-012022-12-31_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:OptionIssued
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">2378000</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">8078453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2022-10-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zTAu3tAG8N06" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_8B1_zEYEHDimIKA" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Grant Date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;intrinsic value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fair Value ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIGmqyfWBAXg" style="width: 12%; text-align: right" title="Options Outstanding at beginning"&gt;11,330,903&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmEvHEGO9uk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;5.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1D5euBgyRqj" style="width: 12%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;140,132,451&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znlTJdrCP7C9" style="text-align: right" title="Options Granted"&gt;2,358,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzaopvGaoRw4" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;10.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8SxfSHDOOdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;7.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRH818Ya5f3f" style="text-align: right" title="Options Forfeited"&gt;(118,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6iC4GRDO5A9" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;6.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW8Bn62hS3Yh" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;5.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvDKn412n8sc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(400,537&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCVTRzkxVjW2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.52&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOWzLHExnze6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;1.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNJyCSHNH8gi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;4,201,015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAqYbkF0xjli" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning"&gt;13,169,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9ijs9r15TJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;6.61&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuGjngGc8A4d" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;62,267,309&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMtyNht74jX9" style="text-align: right" title="Options Granted"&gt;325,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6jj6ISozJok" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;12.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV5yypQUZCsh" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;8.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEiC8lsFy8Ei" style="text-align: right" title="Options Forfeited"&gt;(40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuQpsN5PXG5" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;7.51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvuEUSBbals5" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;2.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGWiXIYzfi7d" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(89,320&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zR2K9ENC4Tj4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znUPtoy4E3ib" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;2.44&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4FTvMu6uaFb" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;591,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zirxiFmbHTw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;13,365,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdF7afoAr8Xi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;6.78&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBNzuLPvIbV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;50,676,617&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zosxorn9Xgzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;8,795,293&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7F5WIPaVlB5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;4.51&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8quZAuDlHcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;45,930,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">11330903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">140132451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2358000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">10.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">118750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.23</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">400537</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.88</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">4201015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13169616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">62267309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">12.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">8.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.52</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">89320</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.44</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">591993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13365296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">50676617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">8795293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">45930627</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-10-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsiXt3H6xQak" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B0_zpK3BzDEDfPe" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;Range of exercise prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;contractual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;options&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;vested options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt; vested&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zBuO20econda" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zH4oGVKNe6vk" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;2.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zq4ehpF8iyQa" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,850,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDzs8Y8YN047" title="Weighted average remaining contractual life (in years)"&gt;4.86&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zeIw6gN0uvC4" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrWdowvkqbph" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,844,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5IjYWPpdkuk" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zQz1haJPkYke" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zC73TrJjm9q5" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;4.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zsUQxRzkbT5j" style="text-align: right" title="Number of outstanding options"&gt;2,042,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zV2FD0JDmzu1" title="Weighted average remaining contractual life (in years)"&gt;5.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zzV1nPkAB2j5" style="text-align: right" title="Weighted average exercise price"&gt;3.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zWJCJcVqakTg" style="text-align: right" title="Number of vested options"&gt;2,032,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zN6C30a7a4t6" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zxDZvqWMWfZ6" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;5.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zVGVUeKvA5i4" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;8.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zSBgFLrF3WUa" style="text-align: right" title="Number of outstanding options"&gt;3,927,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zib60TXSaIkd" title="Weighted average remaining contractual life (in years)"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zKb6hKrYHZhi" style="text-align: right" title="Weighted average exercise price"&gt;6.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGPGkWsDKft8" style="text-align: right" title="Number of vested options"&gt;2,374,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zI83oL98Zkoc" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zaiaC91dh1W7" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;9.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zo4njVVhDqb1" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zRmacfj8iLU9" style="text-align: right" title="Number of outstanding options"&gt;1,968,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zLAGIA1yfBD1" title="Weighted average remaining contractual life (in years)"&gt;9.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zE6TrRySCt4e" style="text-align: right" title="Weighted average exercise price"&gt;10.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zcL1qc3udUc3" style="text-align: right" title="Number of vested options"&gt;154,581&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z6cCMWazIU6l" style="text-align: right" title="Weighted average exercise price options vested"&gt;12.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zfnrQathPpR7" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;13.22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zvtx5yGXlHbj" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;24.58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z15pxktYFxth" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,577,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zoLgLTQNTCvl" title="Weighted average remaining contractual life (in years)"&gt;8.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zaFaDrwX6XFj" style="text-align: right" title="Weighted average exercise price"&gt;18.51&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zhxUol2dWvhi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;388,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT2U2lIGE4ek" style="text-align: right" title="Weighted average exercise price options vested"&gt;18.80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zO2h9fKfcCv7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;13,365,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjafHLghoMqh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;8,795,293&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3850742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">P4Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3844908</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">4.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2042500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2032500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">5.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">8.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">3927054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">2374554</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">9.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">1968000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">P9Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">10.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">154581</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">12.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">13.22</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">24.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">1577000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">P8Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">388750</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13365296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">8795293</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">4.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-01to2022-12-31">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-01to2022-12-31">P4Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">5346508</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">3908771</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-10-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zufc8G4hxCv6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_z6l0qWPPLU81" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;1,742,524&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;1,671,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,603,984&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,237,046&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;5,346,508&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;3,908,771&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1742524</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1671725</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">3603984</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2237046</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      unitRef="USD">5346508</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">3908771</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16340941</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-10-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zxDTTrptBUxk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zrXoJrxBJCSj" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20221231_zJI6nhuMJ16g" title="Risk-free interest rate"&gt;4.07&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_z417cr702jpb" title="Risk-free interest rate"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20221231_zg2WL7FzJXZb" title="Expected life of options (years)"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znTgAn5ygB5j" title="Expected life of options (years)"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20221231_zKpcopkcddLc" title="Annualized volatility"&gt;84.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_zbX9ot5dFImk" title="Annualized volatility"&gt;96.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20221231_ze8e1w28W1u4" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_zlkeqoxgkJij" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-10-01to2022-12-31">P4Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-10-012021-12-31">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.8401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.9679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-10-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zD6IOE92BQod" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Note
                                            7	&lt;span id="xdx_822_zvxoJfasjjle"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to December 31, 2022, &lt;span id="xdx_905_eus-gaap--SignificantPurchaseCommitmentDescription_c20221001__20221231_zW90nxNoM2sb" title="Purchase agreement, description"&gt;the Company entered
into a Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;LPC&#x201d;), whereby the Company
has the right, in its sole discretion, to sell to LPC up to $150,000,000 in value of shares of the Company&#x2019;s common stock from time
to time over a 36-month period pursuant to the terms of the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SignificantPurchaseCommitmentDescription contextRef="From2022-10-01to2022-12-31">the Company entered
into a Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;LPC&#x201d;), whereby the Company
has the right, in its sole discretion, to sell to LPC up to $150,000,000 in value of shares of the Company&#x2019;s common stock from time
to time over a 36-month period pursuant to the terms of the Purchase Agreement.</us-gaap:SignificantPurchaseCommitmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MV@K ][4"$MH_V$M==XF?_P=02P,$%     @ 88E'5EW_.)S. @  JP@  !@
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M:;!7U<,<WR9 V0#<7TEIGB:V877O)\D_4$L#!!0    ( &&)1U;S<A95LP0
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MUEWX J$[6]NJ%N;0'?X&FD" 9'I:<@?(LSK 5MNZ$/P.)38^VF4;!6AV[*!
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MWMH+_[+5NR?W]JOQ0;B=-H%"SJ'#P=7K!%RKQ.W&VSJJW]9ZUM*X+)@NNN#
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MCS)@++%M@K.:$W(OL:/[*+#S>ZOOQ MNI,5J(G:5RBNQ0_0D! I.'7QAYV3
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MR?$X78_](M@FOB4W-N!E&C\K_"M C@5POK5X=70+-K#_YV+]+U!+ P04
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MQ[622'NT ,_)1ND+'="]A/KJOU!+ P04    " !AB4=6 N,BG,("   .!@
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ML@YXOI;2[!<VP/ +R/X"4$L#!!0    ( &&)1U9FU/X1S 4  /<.   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;+U72V_;1A"^\U<,U+BP 9;:!Y^I
M+4".D[2'-(:=)H>BAS6YD@CSU25EQ?WUG5E2E!(HLAL4/4CD<N?Q[<Y\,[OG
MF]K<MRNM._A<%E5[,5EU7?-R.FW3E2Y5Z]6-KG!F49M2=3@TRVG;&*TRJU06
M4\%8."U57DUFY_;;M9F=U^NNR"M];:!=EZ4RCY>ZJ#<7$S[9?KC)EZN./DQG
MYXU:ZEO=_=Y<&QQ-1RM97NJJS>L*C%Y<3.;\Y65,\E;@8ZXW[=X[T$KNZOJ>
M!K]F%Q-&@'2ATXXL*'P\Z%>Z*,@0POAKL#D979+B_OO6^AN[=ES+G6KUJ[KX
ME&?=ZF(23R#3"[4NNIMZ\XL>UA.0O;0N6OL/FT&632!=MUU=#LJ(H,RK_JD^
M#_OP' 4Q* B+NW=D45ZI3LW.3;T!0])HC5[L4JTV@LLK"LIM9W V1[UN]JHN
MR[S#7>Y:4%4&K^JJRZNEKM)<MW#Z0=T5NCT[GW;HBS2FZ6#WLK<KOF%7PCNT
MM&KA=97I[$O]*6(<@8HMT$MQU."53CV0W 7!A#AB3XX+E]:>_*Z%7^5M6M3M
MVFCX8W[7=@:SY\]#N] [\0\[(4:];!N5ZHL)4J;5YD%/9C_^P$/V\Y$E^.,2
M_&/69[?(T&Q=:*@7T*X48FW6)EUACL)&&:-H:<C#ML/UX=(.P3_JX##\?^G5
M^6U=WFD#KS]KD^8H=&WR5..PR<TC8,YJAP?,98S!"Y >C^"=>H30QMEW^':&
M"P^?\\;D!8@^"T(']]%.']G+8-S+X-E[N8<>D(#I_6Z%=4.UI#VTE4?M/[V5
M3SMU/MD2HS/8OCCS!VVP=,+X7"Z-7M*>#KN.AL>-?TNQL3L.>=69' MK"@^J
M6&OGEN+8#J$Y?7$&;U1NX"/-V2'^G/<[@"[<ZJ;3UH-D-A@<.'<E#A(F(? B
M'[C/7"Z%ZP?<L:X1N'!E$-N0<>9Q"9''(@>KZT+G-'W*>>Q& 8,S"+TX1#M"
M.EO\..TSY@8RPFGA!0*X%\?@NX)QE_'@"8 H+ET>)F[(0[0><@B%*\+(E2P9
M\4D1].B$YTN(,1OWT?E]MITA[(!;"/O@XL25@EEL<8)_O@]!PMTDD5\BPT(V
M .,[8#(,7)$0L"@&I$,8A0@TVMJG*GQ($W<K(44)/D'R S?!Y88B.D:)<*1$
M^#Q*O%^ 39"?J/UE<*T>J6S"G,B^U/3NPGN;HR[,J<OFW>,AAAQU]P1#O@?#
MCB<C<U1/%&=X@A[BM\<7H^DL0S0<M1KBA7-#GDABJ]1__Z+:08IMA)K%6A5;
M9["SO67R&U.7\*'>CJ'(%TBTO()'K4Q[]I4'>- MP=A*]T/G!3 O$9AIF#?2
MC3%K(E]@(B!QA"<2^N;[R,?8#AU;70.:9\A#Y@LWP&0./(:2GK3?9/]-]N(X
MY2,'DA@M)2)R68 93=HA64<J1[X;X+?0DQS%$P^SGTN/82EPD["G>4(VD.N1
M!!Z@>,R)6R)">13%#!:8N#$J!%%D%6)/H$),V2SCOAC@*&;.'DEV67\DRZ,Q
MRZ-G%W[L_ABQPIX'5(:GK9PZ/QT;,2)X#&YU?U:@]%18G.T@TP]XM&UL.FZE
M#F7_41A/]X?_#)MC*P>5;.?MMVUB?"B=W ##0>]AA&,1.#??,B_=D&&>Q#YF
MAI 83#]T/M0=6K?=;.!M6I>$0MD3.::8*_T0<RZFWD^IZD81/Q;5>(QJ_.RH
M;KXB/Z@6KR #E_!: PMJ=K816G8K7%U/-5!XHLD.!?/_\[X7KIN\O?]I8;3M
MWQH#W8&A;NYC%X43;(?8&D^P931XXT&'MJCLB@Z<#L7%)TJ'7L"<>55AG<K_
M1N&'NL"@%%0U8Y\X? ()-J,$#5YA,<TTI18Y8W0..QD>AR(UW;N,E-HL[96K
MQ<BOJZZ_EXQ?QUO=O+_,[,3[*^$[998YE4>]0%6L(GC&,OTUJQ]T=6.O-G=U
MAQ<E^[K"FZDV)(#SB[KNM@-R,-YU9_\ 4$L#!!0    ( &&)1U;G3?ZRA (
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MP^V-VGV KIZ1XZL4-_Z7[+K8)"+5QE@E.C J$$R&+[WK?-@#(,]A0-8!LJ>
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M965T,C N>&ULQ9=KCYLX%(;_RA%=5:VT.UQ";M,$:2:TW9%VVJA1=S]4_>#
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M6, +'R5),P'O".=$?Y27\ =\W/GPXK>7*U.J.;72#!K_Z]K?><1_ K>,RD3
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M71"JQT1=^I#K >I]Q)A\:.@)VFND]S]02P,$%     @ 88E'5J]DM(SJ @
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M"L*^)W\G?R-34CS%N2KNIJ6NNU*8+IMZWAWJ81?JX>2]5GXJR$_;E5KUE'^
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M<Q7UCW#M-5Q[Q]"36:73G"H/V%(C4D?8%A6>234O764?HGL<T.8($R5*)M^
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MVK:_P/2Z:7L.M+FXS-F*Y9.FJ^=3UXQLPV9M+B <(M?N"B,8QV-A!# L#^8
MXW@6EN=_FL\ G8_',&^#(#) .0.4XUDA9.(^6)XP)[-7>*99EB1IBJWH9!)T
M,,'6+4WA&U;#O $#RP.9_FRM\=W&*^3I.L#V]*D*P6:*5R(V4WRM 0FO&S"R
M++S;6!Y@8+N U0[D#^>!F@ISD@1V%?.&/<$XDF48 K48KM$T158GA4]X?["G
M)$FR+(P %G:0)!@"3R..8 [  X8DB7L/'KR/XLU[*M[^PC7^#5!+ P04
M" !AB4=6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M<',O87!P+GAM;%!+ 0(4 Q0    ( &&)1U;!>V"L[0   "L"   1
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M965T,BYX;6Q02P$"% ,4    " !AB4=67?\XG,X"  "K"   &
M    @($-$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M88E'5O-R%E6S!   IQ$  !@              ("!$18  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &&)1U:9D?U';@4  !H<   8
M          " @?H:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " !AB4=6(.D)!(P%   ^%0  &               @(&>(   >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 88E'5MX=73Q- P  &@<
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &&)1U9E[^FV=0L  .<<   9
M      " @6=%  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ 88E'5J>F)HG6 @  008  !D              ("!$U$  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !AB4=6%[!!0N .  "0*@
M&0              @($@5   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( &&)1U8"XR*<P@(   X&   9              " @3=C  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 88E'5F;4_A',
M!0  ]PX  !D              ("!,&8  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " !AB4=6YTW^LH0"  #Y!0  &0
M@($S;   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &&)
M1U9J,28NF0,  *X1   9              " @>YN  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ 88E'5MXB@B70 @  Y@<  !D
M         ("!OG(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " !AB4=6QY+>U9(#  !2#@  &0              @('%=0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &&)1U:O9+2,Z@(  &0*
M   9              " @8YY  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ 88E'5AWK]0F:!   BA,  !D              ("!KWP
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !AB4=6?.#F
M7/,'   )1   &0              @(& @0  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( &&)1U;0A>DE#0,  !X+   9
M  " @:J)  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M88E'5H,W((#/ @  X <  !D              ("![HP  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " !AB4=65_4YBJ,%  !B'P  &0
M            @('TCP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( &&)1U:SBW1KW0(  "D&   9              " @<Z5  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 88E'5E$,J*XP P
M[A(   T              ( !XI@  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !AB4=6EXJ[',     3 @  "P              @ $]G   7W)E;',O+G)E
M;'-02P$"% ,4    " !AB4=67W5W5,L"  "P$@  #P              @ $F
MG0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 88E'5G\]WVE' 0  V!
M !H              ( !'J   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 88E'5MIR6=AX 0  L1$  !,              ( !G:$
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     ", (P!L"0  1J,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>59</ContextCount>
  <ElementCount>161</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>21</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Interim Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Interim Condensed Consolidated Statement of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations</Role>
      <ShortName>Interim Condensed Consolidated Statement of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>Interim Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Interim Condensed Consolidated Statement of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows</Role>
      <ShortName>Interim Condensed Consolidated Statement of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescription</Role>
      <ShortName>Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BasisOfPresentationPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e4385_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SubsequentEvents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="e4385_10-q.htm">e4385_10-q.htm</File>
    <File>avxl-20221231.xsd</File>
    <File>avxl-20221231_cal.xml</File>
    <File>avxl-20221231_def.xml</File>
    <File>avxl-20221231_lab.xml</File>
    <File>avxl-20221231_pre.xml</File>
    <File>e4385_ex10-1.htm</File>
    <File>e4385_ex31-1.htm</File>
    <File>e4385_ex31-2.htm</File>
    <File>e4385_ex32-1.htm</File>
    <File>e4385_ex4-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="270">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e4385_10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 270,
    "http://xbrl.sec.gov/dei/2022": 31
   },
   "contextCount": 59,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "e4385_10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 264,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20221231": 5,
    "http://fasb.org/us-gaap/2022": 13,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 23
   },
   "keyCustom": 24,
   "keyStandard": 137,
   "memberCustom": 14,
   "memberStandard": 7,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Accrued Liabilities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://anavex.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Equity Offerings",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://anavex.com/role/EquityOfferings",
     "shortName": "Equity Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://anavex.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "14",
     "role": "http://anavex.com/role/BasisOfPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Basis of Presentation (Details Narrative)",
     "menuCat": "Details",
     "order": "17",
     "role": "http://anavex.com/role/BasisOfPresentationDetailsNarrative",
     "shortName": "Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Other Income (Details Narrative)",
     "menuCat": "Details",
     "order": "18",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:AccruedClinicalSiteAndPatientVisitsCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Accrued liabilities (Details)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:AccruedClinicalSiteAndPatientVisitsCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
     "shortName": "Interim Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Equity Offerings (Details Narrative)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "shortName": "Equity Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-09-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments and Contingencies (Details 1)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_StockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments and Contingencies (Details 2)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-012022-12-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Commitments and Contingencies (Details 3)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Commitments and Contingencies (Details 4)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantPurchaseCommitmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Subsequent Events (Details Narrative)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://anavex.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantPurchaseCommitmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Interim Condensed Consolidated Statement of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations",
     "shortName": "Interim Condensed Consolidated Statement of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
     "shortName": "Interim Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Interim Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows",
     "shortName": "Interim Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Business Description",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://anavex.com/role/BusinessDescription",
     "shortName": "Business Description",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://anavex.com/role/BasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4385_10-q.htm",
      "contextRef": "From2022-10-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 21,
   "tag": {
    "avxl_AccruedClinicalSiteAndPatientVisitsCosts": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical site and patient visits costs"
       }
      }
     },
     "localname": "AccruedClinicalSiteAndPatientVisitsCosts",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_AnavexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anavex [Member]"
       }
      }
     },
     "localname": "AnavexMember",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald And Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CashPaidForStateAndLocalMinimumIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local minimum income taxes"
       }
      }
     },
     "localname": "CashPaidForStateAndLocalMinimumIncomeTaxes",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CoronavirusDisease2019COVID19PolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coronavirus Disease 2019 (COVID-19)"
       }
      }
     },
     "localname": "CoronavirusDisease2019COVID19PolicyTextBlock",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_DeferredGrantIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredGrantIncome",
        "verboseLabel": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredGrantIncome",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "localname": "DisclosureEquityOfferingsAbstract",
     "nsuri": "http://anavex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_EquityOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingTextBlock",
        "verboseLabel": "Equity Offerings"
       }
      }
     },
     "localname": "EquityOfferingTextBlock",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_FixedContractAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed contract accruals"
       }
      }
     },
     "localname": "FixedContractAccruals",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_GrossProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from Issuance Public Offering"
       }
      }
     },
     "localname": "GrossProceedsFromIssuancePublicOffering",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_IncreaseDecreaseInDeferredGrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantIncome",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LliquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "localname": "LliquidityPolicyTextBlock",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_MichaelJFoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox [Member]"
       }
      }
     },
     "localname": "MichaelJFoxMember",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_NetLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "NetLossPerShareBasicAndDiluted",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonOperatingIncomeFromGrant",
        "verboseLabel": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrants",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_OptionIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "localname": "OptionIssued",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionPrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "localname": "OptionPrice1Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "localname": "OptionPrice2Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "localname": "OptionPrice3Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "localname": "OptionPrice4Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "localname": "OptionPrice5Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to percentage of gross proceeds from sales.",
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SalesOfAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of agreement amount"
       }
      }
     },
     "localname": "SalesOfAgreementAmount",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptions",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options, shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsInShares",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2019 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2022Member",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_WarrantsOutstandingWeightedAverageExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding weighted average exercise"
       }
      }
     },
     "localname": "WarrantsOutstandingWeightedAverageExercise",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "nsuri": "http://anavex.com/20221231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r233",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r221"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities - Note 4",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails",
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r246",
      "r247",
      "r248",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r53",
      "r54",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r67",
      "r74",
      "r86",
      "r93",
      "r113",
      "r115",
      "r117",
      "r119",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r175",
      "r177",
      "r181",
      "r221",
      "r253",
      "r254",
      "r287"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r28",
      "r85",
      "r216"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r23",
      "r28",
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r23",
      "r65"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Decrease in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r11",
      "r70",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r246",
      "r247",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r221"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized:200,000,000 common stock, par value $0.001 per share78,032,135 common shares (September 30, 2022 - 77,942,815)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r58",
      "r171",
      "r174",
      "r245"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax recovery (expense), current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred grant income - Note 3"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r64",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r40",
      "r83",
      "r89",
      "r90",
      "r91",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r108",
      "r120",
      "r136",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r179",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange gain, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r16",
      "r66",
      "r71",
      "r81",
      "r113",
      "r114",
      "r116",
      "r118",
      "r210",
      "r220"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r69",
      "r79",
      "r242"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r93",
      "r119",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r176",
      "r177",
      "r178",
      "r181",
      "r219",
      "r253",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r68",
      "r76",
      "r221",
      "r244",
      "r249",
      "r285"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r38",
      "r39",
      "r123",
      "r124",
      "r125",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r23",
      "r25",
      "r27"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r17",
      "r27",
      "r72",
      "r80",
      "r84",
      "r87",
      "r88",
      "r91",
      "r93",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r106",
      "r113",
      "r114",
      "r116",
      "r118",
      "r119",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r180",
      "r181",
      "r220",
      "r253"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r14",
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r113",
      "r114",
      "r116",
      "r118",
      "r220"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Business Description"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BusinessDescription"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "All other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Contribution amount"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r52"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r137",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r137",
      "r193",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r55",
      "r82",
      "r289"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r41",
      "r75",
      "r214",
      "r215",
      "r221"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r83",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r120",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r179",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Number of common stock sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share-based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted average grant date fair value of options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Option available issue"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of outstanding options",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average exercise price options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, lower range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, upper range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (in years)",
        "verboseLabel": "Weighted average contractual life of options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of vested options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantPurchaseCommitmentDescription": {
     "auth_ref": [
      "r11",
      "r70",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.",
        "label": "Purchase agreement, description"
       }
      }
     },
     "localname": "SignificantPurchaseCommitmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r13",
      "r40",
      "r83",
      "r89",
      "r90",
      "r91",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r108",
      "r120",
      "r136",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r179",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r108",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement, net of share issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r40",
      "r41",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement, net of share issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r36",
      "r221",
      "r244",
      "r249",
      "r285"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r222": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r223": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r224": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r225": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r226": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r227": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r228": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r229": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r231": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r232": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r233": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r234": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r235": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r236": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r237": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r238": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r239": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r241": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001731122-23-000152-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-23-000152-xbrl.zip
M4$L#!!0    ( &&)1U8UX9ITW0D  -]9   1    879X;"TR,#(R,3(S,2YX
M<V3M7-USVS82?[Z;N?^!U<OE'F19DIW$KMV.(T<9M4ZD1D[:Z4L'(B$)9Q"0
M 5"6^]?? OP0*7Z(E)P,YZ0\."2PN]C?+CYV04!7/Z]<:BVQD(2SZT;[Y+1A
M869SA[#9=>/+N'DS[@T&#>OGG_[U3PO^7?W0;%I]@JES:=URNSE@4_ZC]0FY
M^-+Z@!D62''QH_4544^7\#ZA6%@][BXH5A@J_)8NK?.3]AMD-9LEY'[%S.'B
MR^=!)'>NU$)>MEI/3T\GC"_1$Q</\L3F;CF!8X64)R-IIZO3X%\Y]H]$VA'S
MVU_IG_+-ZC/Y8X;96Z^'F&./$?DPM$=J]4O_;_+GPWS9672GTX?'R3-W'_J_
MC=CSXW_;7Y0K'7[C-WDE[3EVD07.8/*ZH?$%\)ZZ)US,6IW3TW;KCX]W8T/7
M\ DO5Y2PARSR]L7%1<O4AJ0IRM5$T%!TMZ6K)TCB2#+4D@)ZPJ1"S$[0.RIB
MB!.?M_S*!"G))'WMDY*0U,$;=!+;)S.^;$$%T'<Z(:$GFS.$%A'Q%,F)$2J%
M:DIO88@?NR$YE&:2)F1J5O6\P#);JJE*,#A*;# D[ ;5+5VM>4Z;I^UFIQUR
MHN6*1DR(H25>Z=YLI+<[7:##%+N8J3X7[BV>(H\"@$</43(EV&E8"HD95KI[
MR@6R<:&LL(<CQC@,!!B-08DN6RP(]'0H^,>5[A*7@E-\#TI;^@&&8)9D7=7J
M<9A$&A9QKAO^HY8!$HT4!T\)(Z:I8*2UK:8>5YX&!8^&Y:JU21P3X4GL#-E/
MYGDAL 0^H_L=% 2, 4D.DXVH[=%J/&M5,EF"@M!&.UAMP!06Q.UQYF &<N%!
M<DH<I+#S#E$]PL9SC)7T+5N>O-CZ'3"YG@1Q8/Y KA4)MN*2K4"TY<NV7GUA
MR',(U/SGZ+)\'XR0 ,1SK C@J.B_)&^Q,[LOY4SK5:+9HW.3#HIL/)P.%SK0
M 35*C,MLMF*7GE5SZ9J43ZUU(\>!6L8IO3EB,RP';*RX_3#GU($0]?VC1]1S
M)><6R2GV]OD>W@Y:M0BSXNW^V_);/G:!4JY#<MZG_*G::%YS%;OW]3[NA38L
MT\B!>_*=)PG#4MYB:0NRT"WYSLJJ*/;'&QUZ0@I'N?0$AI=0A!63<8@F1I+(
MX704 Q28.*.BV,1O4R;6(G2'C@LY0!L/(;@2 P;OV+=MO*#8IA>;-C6LEL][
M@*:\L6WA8>>.H FAT! .9N^,\D+#MD\W#1M(L&(B#M"^?@ QG$YAL6*SP+B;
MA<66;6]:-@A*(OX#-&N/NRY1>GV7-TR'%@H,@9D=]=\B@F)S=S;-'1-E(6;B
MC+6P [3]V)M(_.@!F/=+;13?X*G28BMW-ZV\YK=\ 0=HV8P08001[;I7%Q$4
MV_NL5"QAO0K%'6)TG%[S[M&$YJ^(06VQX<]+K(O6*U_4(1J]8**.6W\[6;$;
M7E>:U0_9(1ESS"U6B%#Y"0F])[;$N9-1BK#8*>D<,GM2"L1:D=Q#]$LLQ\GV
M1Q%!L1]2B68\*3J:/V=Q",R2MSJ$U<6F3^6CX?) X\M#(.L0[;Z1*V5W_6U$
MA3[HI%+7S03K. 2V+=6)L5""KM@AJ8QWRV)]P,-CNZW;99W2WN*5:HGQ>LRT
MCW[),G>GK%\Z6_R22J5+^J5S]$N6N;ME_=+=XI=4REW2+]VC7[+,?5;6+V=;
M_)+*R$OZY>SHERQS;X1B51B*_50U93_&:!F;L]E.VDI5[)E4WI[:O/W_]H;^
MHX_Y?L93RQP/OM0G4J\;DN@#VHV@;"[P]+JA#Z4VPU.C?P&TDY5+0Q(MNN!X
ML/'HIC6"AD,12-@I*:GCRR"$+[#0R60K5#X4H(C2[(D=%]T.!/.MEX!,T:0J
M9&#!]!MBO=/R7Q0D]+ZJ(#<Z[#>"VENW\J* 8>A4!9P<;=\([VW42!QN<"Z[
MM3Z8';QO'MZ^ N!<*(NESH 7'=[WKQW<<=N(*F#1;\V0KZF+FNU.L]L^64EG
MK6D5)=9FJ*9$R+>#$CE7"++:EWGD^L%TIK*-1I<&@CL*91K-Y&EAJF18LI<*
MB1L1U15Y[,8%-?VBRKILWLPHIT=X20-T" 3LVCY B%_AV,,?1DPEAVR_%Y*G
MSC9.\RYW&A V]Y@2SU4&19PE?*EDB*0T3P@(B:MI$.>)WG8;'>L+0-7ZHM\1
M='?<M=D=>F*Z\=QN&-P=,O&S7@O_^DCL.<+TESY??<3N1-_;T?I=-[(J"*7Z
MB^)U0PE/KUGZ8M@EK&6$._=FR74\$1P6])?@Z!K4I<-=1-A 85=3 C((MF&U
M\S3U!\&]Q77#%T> I$CA&Y,K)'7=**N#FLG-_#&B6-[,!#942>5+4=8!4@\Q
MQ46?J+]G6"#JF,PXB:68I X@S,GXH3G7.Z*(=4[;YTD(!00(VA3(5B& F@*Z
MV ;HHMX>Z72V (@1U ' R!,P54K\N]XD8$JVD^KG5]=1^4ZQ\O6R?- I!+'Q
MAM$S:VJF<B=7Y=I:N9NK<K>N*I_EJGQ65Y7/<U4^KY7*GS@+;ABRF7_,IB^X
M^\%,%*'R6V@JP/#K)OZ5U>N&+;!#5(C.KW0YPPJ)YQ? ]AE+C&#N@PCF%B\Q
MY0M=#PC@+UGB\-Z&#[(L<6W1?L+JCDLYPF(\1P+K$VRV!D.HI_1O"@2^W$:U
M1Z=<!$)? ,SOF,SFH-#-$OK=#'_R]) 93HUX.?24WKC2OVF2@W)W]GK ]Q4=
M2.EA!Y9OZ<%0N^?O5UC81&( L@ZGHE%:D:>V_;@*C@'SJ7>Q08RWLM-]"NFW
MMC]DF%P$A@CM%OO_#]@MAE02[&PFV>1$599X=P<[>/(-_:OOP(X0<?I<F+NQ
M,/STY@C]2!AQ/=?7_QZMUEZMQ%%7V.O/E+'CL3=!-AHBW4*T?_(:=%REMRE>
M(N")G?2-5+_'*_6.PD"+@I]M5'M,NBH4\Z(NVCC&F>^F7,+:N2JI:<I'^=4U
M<<X=): B+#S/YF;0<PI!$4%-,/2XX PMB? D="$]>>N=G-[PZ^"V?9$#JR)/
M39#JWS5S/(J#F&MS"R(6@IG[+2G4>_#7Q (%25.)O*K. 5I!;+)C).)_B%;?
M&TAPPZ%'(8Z <&),3&@Q J,"V5<BB9(]+M=Y< 7ZND+NDY7Y 12S-AD\B$;X
M\BKK"@:26)V=0X(WG (C9+6"VQ@[4@\C\Q$FV@(M0[E?ZJ?EOP"FE'8ZF='6
M''D3F.O#!3H$5IZ\KG&QL?YP&GTNNW'U=^=H'<BKK6N?#'=5]$!R%YA)8],;
MO6S-#*E\][RF&:%G@^H)"2=(2R')F6)H66>6;&0 ;>QFA.FL--N)B=3W.S=<
MH\V2?9!'N+ZOP2LW6P]S9\1@.8I'NW%5.,H/[&^(T?>0OX^4W,*/RK[?GM%5
MRS]" H__ U!+ P04    " !AB4=6*\*.+^8)  #<;P  %0   &%V>&PM,C R
M,C$R,S%?8V%L+GAM;.U=6V\;MQ)^+W#^ ZL"1?H@RY*<Y,2)6]BR'0AP8\-*
M@O-6T+N4161%JLM=6?[W'>Y%WCNYEE9D@>,'7U:<X3?SD4-RR*4__;%9>FA-
M?$$Y.^L-CXY[B#"'NY0]GO6^S?KGL\ETVD,BP,S%'F?DK,=X[X_?__,3@J]/
M/_?[Z)H2SSU%E]SI3]F<?T1?\)*<HL^$$1\'W/^(OF,OE$_X-?6(CR9\N?)(
M0."#N.)3]/9H^!ZC?E]#[W?"7.Y_NY]N]2Z"8"5.!X.GIZ<CQM?XB?L_Q)'#
MEWH*9P$.0K'5=KPY3KYB\4\>93].Y;<'+ @"?S%QNA'TK"?K3:I]&A]Q_W$P
M.CX>#O[WY\W,69 E[E,F_>:07BHEM53)#3]\^#"(/DV+EDIN'GPOK6,\2.%L
M-<.GM*%\!HF@IR*"=\,='$2T*ZM!M27D7_VT6%\^Z@]'_?'P:"/<7NK\R(,^
M]\@]F2/Y$]C;UHH97I.-I&L@/QI,.#1'P!D)+7PR/^OA]<8#W:/1<!1K_B57
M*'A>0;,45+:J'AJ\JM8I"XA/EQ/.7,($<>$7P3WJXH"X%]B3OILM" F$"EEK
M10=%?X=]PH(%":B#O;V94JFU:[MDMR5+J/=V?KN2D0::\D[L-"H\H#63!6:/
M1$S9+.#.CP7W7(B25W^'-'C>DWD:-1S27BP6UQY_VA=Y)7W[L.4B%)01(2Z)
M<'RZDFU#!;=!9"^(L*#B=G[G$P%F8RU$]2+[0'0+(<"?PNQA251(*HKN \&Y
MX_@A<6\H?J >#2A1MJEZB7W@B?O4[7P.[98]*L'4%-\'$IAS+6D@.X@X9[+G
M!% #S/0T7*0AN@^$L_!!D+]#J.9J+>M2P:HKWU'?NH-(H^,M#=%N6OI7_."]
MIKWGY3IN:WH@M15TQ/4E"3#UQ!?LRUG 6AG-6JC8<YQMBU1#M)O6F=36OGD6
M!#N(RFU]J"G><4_2=*B^AL/@'>X.>'A8Q*/=$8\.BWB\.^+Q81&?[([XY+"(
MM:/%*U1U,9MJ"UM7O@FK@STG]*+A\ ;^SDF034!@&>>F>B1HO9100 -9-,G1
M#5%?)O1"Z6#X-2G9$8[VN9T<UA$ W*Y3X?=$'=KJ0UF%*-&(8I7HS3>&0Y?"
M)[^EB;740(\[.:,\F=GCA21:FB6-\G=S+!ZB)%XH^H\8KP:2_ 'Q I$^B9I#
MU!22!W^="Y$QS<,/Q(NJ^BLID'X^,().KOIE!X,?<H!>8R_J<L$$6NPS=+DH
MNUL/7E.\:%NF:9W[#N*^2_RSWG:$PKZ3:U#E_&E28B#"Y3)2TP>&EZG\W.?+
M2A\G_N2OL2'+!53?0T^$/BZ""+89[N()Z5>\(>*>. 20/W@-7-44U^-F9(:;
M1A-MX@(6,2M,W:O-2H8D:$[1DB&V;1+Z,M%;SXR6L!Y/8S,\M3#?)M8J\E=E
M=G*%S."$]1T/F=PQ>)8=0-F@ZLJ;CL-5^4*NA=R^ME-><^O04B=B.@IK,=-L
MKTWD7)(Y 7!N/'XHB:DI;CKDJDEIM-,F0NJWS,IL5)4U-#N&52B/M_M4$^%2
M2=.QMF&3DBN@V]=\SEU8PH')V+N#:<:43?"*!MC+0&^(NAJRIL.O-EGZCK")
MOGN9!F'$O<(^D\E?&$O"I?0O<2&"48<VQ&8=6=.!6IL^?4?81%]F'(*I?9M0
MKI8T'29U;2L06;OSK6+,X,2NC7VJ(RYU9GX:5.4.#><5JP]:Y9*,XWTE&=&;
M7&V_&<FJ-I_)RAE^TL[PEZ)\CEYTFT^S)EC88Y*#:%C05Q0U$U?CL[X>],MS
M=TD9%4&\2Y#@JK= *6@ZJM:R40@SFAZP:3"\)X( $IDROB1KXO&5[ Y*RA1B
MIH<)7<*TK+>)KJUA\1+YA@N=R) M;$U?*EM0(*>>Q#(A?6.,?.&,YTU2=IX&
MD5?94-ZXE4\DLH*SKX&,SSYFE1MX4J99Q'334;HZ;4!J4_;>LVLXJ XP@ >^
MP\"0/_Q:($-3UG2L;<5**W_8%'BCB2010<["+Z1AI5\O87I]K\V8TA+[>+KF
M/D!@<>[8>?X*_5U@1_KD,Z9,CC879 YEON)-/76ME.BQ>6(-FZ_PD$T$OTP;
M9#R/CU*%8/K+ZBV&G]EKO]K /!QXH S[SU/PI0"?.2 );O8BK\7M6W78H*-*
M30^K!_!HW<RN8@YH9=KI\"Y2]VJ+^B2,!3KKD4(QT^V^$G7EB9UNB;>(R&3+
M=6M-TN8N""/SIET-E9SI_JM#M9[MBK6G+0GCEN]YYG*H;W?(H2:5(<I0MKI?
M\8J+CRBN-9==-9Q/+K\FFG/%NUU< :I1I-M\.AG:OX1SY_,U!0]>/'\3\I3%
M=AP^A_G?6G%PK(V._P]#K6)32VZ*4X7*X&;1J#);8)]<X*@7+F50S;UT7'%B
MIJ:\!:/(;DPU.\(FRJ!!^02 7I+XYY2U/YZMI\!X,F174ENZRJKD=1E[_NAS
M&WZ+DL;S(OLGMMHYEC-:.(/<AM*2J!ZG;_]-G-:XQ^Y@7']AA2:M)6D]9M_]
MRYAMO-6CRWV?,IKT;'.T ]6X[Z,IJ\?8>PL9:V&D?9VQQNQKRC!S=EM*5>HP
M]0(8=PAQHZS75(A0'@^#U;+. 64-44N77 T<EEX0TW2/32T71KCH#?3;^=;0
M"1=-+_/62UBZ%&O!H,(95DWJLLTM:EZWT45BXFI#?(>*EY18<V^L$;5T!?:Z
MWMCH'IMZHS2Y\)+V/1&!3YV N,E+W/D'F9)WQ*?<+8ZA5QO'"]WHP)03Y6'O
M<4"NYG/B-*7N#XS#=.PWX_=RRJ[MW,G*?5&;G=D4/ZPY]-]T/61N)^*]O.*$
M"L?C(O0)_)%*HIQH1[LI37=&YF#^MP132LKMD+QL1SBK;I3,X?M0Q!=)H.*:
M:L^P&E:B673#XR*Z1!!5+M7W#++NWLD<PF$18;*EEQ'K[/H?]064.:BC(M2,
M!H19M'67U=$1[MH;*G-@QT6P+V(HE3M<WR[=59G#>J+5Q]&;5$MWF[S*>RQS
MN-]J]"[T)M;0'6;]:RUSX-^U:LW=F]'FMLN<(>6!K+KU)-K05EUWMNC<AYFS
MH33*94>1@T)77Y69 UX:_M(NX&6[0*+"U UCG=Y$LDM2-ZEF B7ERY SF!I#
M%[X#&J&J[U300-0E5*2\OKCI-9+Z<A3^&K/L6X0GV"\X"X5^.RL6-[T*TZ:K
MV8Q#[8U<TTUT'BOPL1-$6+!7UV=JRII.6;7J((WVVM0;XEO.VH=?E9SIDP!M
M^X>>'^Q)(NC>19V="HQ*:\WB2NZ@\Y@6-U3GK"BM1Q73XNW4QIPAPVI+VBU7
M7\@9FK1E5&U+:36K:<O(I"WC:EM*JUU-6\8F;3FIMJ6T M:TY<2D+8HXUG9A
M?,"@IGU]=LZ@T@*YE JJ-R(9=>0W^:_8X,D_4$L#!!0    ( &&)1U;5>:]7
M/!(  &$D 0 5    879X;"TR,#(R,3(S,5]D968N>&UL[5U;<]NX%7[O3/\#
MZ\YTL@^*+-F.$^^F'<67C#J.[;&=W?9) XN0Q(8B%("4[?WU!7B1> ,)4@0!
MR=J'K"P= -^YX';. ?#;OU[FMK&$F%C(^7S0>W]X8$!GC$S+F7X^^/[0&3R<
M#X<'!G&!8P(;.?#S@8,._O7/O_[%H/_]]K=.Q[BRH&V>&1=HW!DZ$_2K<0/F
M\,SX"AV(@8OPK\;OP/;8-^C*LB$VSM%\84,7TA^"AL^,D_>]4V!T.@+U_@X=
M$^'O]\-5O3/779"S;O?Y^?F]@Y;@&>$?Y/T8S<4J?'"!ZY%5;8<OA^%_0?'?
M;,OY<<;^>0($&E1>#CE[(=;G ]9NV.SST7N$I]W^X6&O^Y]OUP_C&9R#CN4P
MN8WA052*U9)7KO?ITZ>N_VM$FJ%\><)VU,91-X*SJIG^:KJK G'BDV[P8YS4
M*J@Z!II89\3GY!J-@>M;2"DB@TO!_NI$9!WV5:?7[QSUWK\0\R#2DR]LC&QX
M#R<&^S]5]*I5X( E?&&:[;*?NN>(6B[%Z1>:83CY? "6+S:MN]_O]8.:_YX@
M<E\7U(*)Q0SPP.C6:G7HN!!;\W/DF- AT*0?"+(M$[C0_ )L)KN'&80N*4-6
MN:)6T=\!#!UW!EUK#.S&6,FM539?K(?#.6WW=G*[8(,2->6-M%-888O<G,^
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ME$6"C^STE6\Z86W&JCIIK(@<PTBPD)G;XI-'+O)]:LP^-6974F/NH<W6RG<
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M%6+0$P:F['SXGJ0XFM.S59D!>MB@.G&?3M!H#8081RQ^UF7IGWD];SQ5I:A
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MA_Z[_QU7^E+71/YYW4SVHGMJ*VBZ1^+VOQ/JBB6/BX069)0GW!2K#IX)?SM
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M9$F5FYXCS9^NZ)_HS]5/]#]P[YK^\K]02P,$%     @ 88E'5KLGGJ6/(@
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M"KR^HO:(+/I2[-9QUYF[?K]"V(8]4V%'KN(%)/?IBG7#U=8Z]%A 2W3?<"!
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M7!8IE]B&05XCNF 7[F^$>WD7&;K+O];H+C_Y.@V"G!QER=.-^V7QQM+(J-<
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M]'P[BM8\88_47VYLEG1J!HBF+/8JTW(X&#E&U_UT/UE?.:R#P%8/VXVK_6B
M(8$NL ZRVEQ,SORA.D]:( EM_BH-:MX^D,O"?BT=9S6/WW!N"^/([=>C<^,A
M#R31/ .M<#)7^BI/>)[FZ^(=F\T%PD%?HW*C &8A= @'OCM&#[S43K1-$4M]
M]C*22P!G0[&6%J%/\/ =4&YDVQ=W!4K-OB::XM^9$FA00/="J7-*FIG3WIPN
M-T]M&QJ' AB5N;H_;,NBFYOL\K)W3=0>=R9H2H7Q?AM2$=O4T%$?]1F'3?B\
M^,6,:*)\\:W96M^:0Q+*HB<L_G-&!0G\-/[(.!49:Z#-00#/&P"KCLR;EU1X
M"H69'(.?!(^BT@/@)-"^! BIB!Z.W_\IIB@U.';H1CA%31Y5?IXHM<IC\:+3
M*$K4D^ %I@UG_U:M8"_Z+L7?"1"G [FF@(H$$GKT,KD-F+?<N&A&,[@V]EV&
MZS'=$D;T@=U$ZFG(8D8"J^"7)FUX$]B7) ,,Z=: .AK/Z?HASY#+,X8V4C3-
M&Z,IC'U;XGJTFD%"C^8T!<\;/%WV:R\=6=)7X?J\;%'^*N>9;HHZ_O&I.=T!
M^()EXR[&<<@?(OM-"U#P;U>L+.@XJ,V%#=K30]OC4)O>AUI5I7I "O_:)&-3
M=F"^+JD4^SXD7&$:_5:D.Y=K3D+_,B#A.9E36W2OF][&H3F-6M]V?'?BWXVI
MLYKH<<]HYM26QK:XN%3PDN'-#)<K4VFEU_U60MI'CP!%%M+^$(&E0^S"EIG*
M:!139:D_?EQ03_YZP]5'A1RMF4G0P5ZM-078$6:];7C[VL-UE.%WH+2_43:[
M5V4>J" S>OQ(A<<B>BF89SJT(M,U^I5OO!H.$3BZWB\7$<G(E2*WF K[,XE5
MUK>G(Q(;-!3>PN@7Z*ZZU!;$+;"?[C4;4-N]B+WV-]][,:$ZY_7B[BZBL:)L
M&LE?;/[FFN+C.(?V8=K4,(AOIJP2!K ^&JJ,0V!&Y;,(9E1VOR,JV$-Z;W8:
M2O5*E Y>L>AWLQG07&O[1&3F!]W@MR9OE1E#]F8SW)EKC4-($/73RJJ)K3XS
M\G1+0+K*06[S26\HBGW\@"A:+0VIAF'TO?ZF1YX!+3#C,[58%^V>SY<04TF[
MJ-9%^HS$=4Q$O$G"F#&I(8Y-96N,)X@ZV]+X\=UK\JE<75@8,2]]HG<0W:UV
MB6V>0=369O2_>_U,\V)%IV'V %'JP>M.,QL[P_:+'5HG#8B/?_NHO=]L9,[1
MVMTG$=A>OKUK7_\2&K]6;L)R^J6RW)\0)AROS*T) 6KGNZW13C>2VGH-/>'B
MCK(X4=%/.?/NM+"Q,Z"F_?A<-,V >/L]X?ML3QC2F7H38MS[0=OZT  ,TC+>
MFA*@#O^T-3KL2%:NHJZ&8R?2Z5X:V#0\'6@YY]MJ'A(^8UFFE=T^"R\^2E0<
M8D9\%G9<?$EU2;]I%>[0%E!-WJ.KR08\OJRA:SBP5]"6=(!MV:/13Q1!C77Y
MA#+C=O%L2P54Z?!O4%#@&<O*N>%QJ\;VC<J_.]2-"*QWJ"8^F]N1-D+9>@W$
M]&SXN@_7KF=SS]&(0B^W;L?AR/>'S\2[H8W:;L\%27_8O"CSR!P<VBCLL[DS
M,:+QHJ+K?8[RA7:]]#=T!57(9W.UHH5[Z_>0!<YP%FXP 5"EVYZ[D'Y%,PY5
MO+7S>VOGMSSK[UFTSU&?4(7#OP(9  RMCHTM!'2]0RB%@!YT# '=?PD!=<[K
M2PCH2P@HFL!>0D!?0D QA/02 OH2 OH2 KK)(3?SV9@F\3T7[$_J?Y&[2%%@
M0N4DBSX^E0Y+5VHK;)X1G70VCC':9B)U D.O3^T,K$EUGKJEW-RPLW%HDL,1
MV9\>ZD%TD[8S[UKU9L[8V500>\%P.#**WB9ZC!SY(!4Z-&?H;"J('<@WO%!Z
M3LMI%\H!5"@'+87B[#9L>*$<#"V4MU"AO&TI%&?&^>&%\G9HH;R#"N5=2Z$X
M<\X>7BCOGL_)I8[ &?]&1?8;FS.#U==MK\\BI4V_(GA>>O9EL4#0LUJOV#MB
M5$73R&"DBK8=/JO?=;*8,?JM;'!7K?=IO*)JGR _7QH^$Q+<4#'?MVC:T,1@
MGRV']B[80&+CT-;OP#WZ&2:/<9;\;3OGS>P!@/+KQ.XFQN;>L TX0\]\)LS'
MH5 ;#"#-BQ+H?J6;TO6]98_I1XY;X"!XT.P@^+:C@^#!BX.@<U[/>!252+-X
M".K*C^/NM \701V'^#Z"-<IJ$Q= 7F=C\Q(T:Z!-.&=C\A,\#>5D2:\E@NFR
M<*8Z45@:G6*,E;901$9^T+T$-=39_$TLU<8A)H#ZP60U%C_!3S24^Z% 3N53
M?\Y"IN9MY7>G]E%A1&V^@\#JV,9PD$I6!-<*&?2#T)4$5'9_+\D]H@\TX O%
M*%"*H,K8%K\N,FR!"KH$IT':+O6;ST(YT7HA0NLC7X#:=UC5A\];X;(%1[BW
MS4>X=QV/<&]?CG#C-3.M,B-/HRB99[8*%5=P(JB*4J12[>(KXU.? W2-/"/T
M<:(<3$#HRT1G<VX3IRMK&15S%W'*@#ZQMX:]:9]3F8Q#[?H:8$L6?^6!;"9@
M\=. <Z"N<VSOBM%-@V8I/4^-/&(/S)>;/01]+'>-?=H:K38V26@+-OWGZKER
M93YHWOS_V''SOVKVY1#@?L+Q[JF?!#2_!.^4=-9R]=-C%^.PE_8RC?0'"OX%
M4^<Y$7 1U4?;XU";WH=:7RO3J.["E//U.9E;(L++I;X/^99Y1K\16Y)CNP*K
MEAN'L)K43(.WVPCE2MS!_IL]<U"9H3RV$U^S1I02V]N8=?7J0:W?]RU!?M\2
M9&=.:%U ?H\#\KXYNMM0'CMTM0/(56;130EG5"XN<G]ZI8 +K#=MFN+(9O3^
M=I95AR 3.NBRNY342#[3X MVFZ2V L,*VU@:VP;M3'0F<- E=QB0*+JX^TV9
M,,+X0EPI!]U"1(/!7&"MB6W,=291*&B.%JZ\7T#@B68E:], M@VT?R&V16 L
M(Y7/YSQ,U_%#LF!R%<C"0)1[C7B@_@D7)XEZ?E ]34="4V!$AZ:P@[K<C>6N
ML*(K1&=(EF%$4]]GJLJ2Y76$N0/S%J13[ .A,R4;0%3;JXZ-KYP[T$!-/]@'
MY/$IG5$@3I,49:^J:G8MY2+81VXW^Y(F&+9W9)?C5:</A 7*7BR7U%2W'*XR
MVAZQWZ0>WV@'"FE[M?#XCX3%3^N4TM%%?$_%S3T)2W&KFJ='4Q".2$Q7_A .
MU+9_$L>9MPU3SUVIP3@&QDL>'(CI<#NU'3UC3KOG\63[MSRB^(_CU7"KGIV
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MX/-F5\?PDA.BMKJ2-;GZ%\F_3%PC>]G>Q&>>DS29^R1^YG"332 B^+[Y %O
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MFH@&HI=V=U08DW!2"VQ]O#4#-(I$::!\"_R4 T#N!WYA]N#PPC2&PX4!EST
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MJZ/^P^]!HFK.<GD7>J@:O.52+HU/83IQSI3ETX4T".&@ZQ%;SA0GUF+C1H+
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M2,CA.Z\,SS)X#/#\_GTH7&NQI.6Q%!@T+R\1-*\T1H.N?J;JEE"5X[H;.TN
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M<W8E7&JY6OMA[YMG_9R] 0YWP'VB>]@7BI__$K$;="_YA=U+QE/?4?4FG!N
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M,&.>A=C<"TX]QP%3D;"]=R5U2%3<+?:V[S?GK:@6MMYL'Y6;2R!S,"JKI7.
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M0&=@=2.XMGO[PY'CC2WKC'=B0F2#Q19^.NZ=*IW',8I=+PB#<QC0:_C,!1P
M"O0:'<MQ1+R8) __#3+5D?]6T=Z=A%.WJG%]OXEZG>TW]<'U[F433D0TA#T8
MTQ#^,O;LH.-X001'NHCB,+1#"LZ0(*'I H.&6]F&+7VQ9X6F[01&[>4MXM(B
MP=(!$3)'@?67(7]Z!4>K&P[P*>4_?EL^SF(Y^ G\_832Q832W7Y=_7[3=,H_
MOYR<?/BT75$KU;6#D6.._S) G&&8<K?QH.EG>YYS;4PZUBE@]JJXC&9_\#Z9
ME6XS&D[-S!2SR=(4$S]6<HD?.[ MEG]'O,V$O!?(.V[S?W^KW2I[R4/[[6_4
MEX]A$)7[J36?PM@I]$^C^<>\9_[-Q!.;7E'Q[.T_IB<QI0K,&4%^4?SN[4R[
MR?GV0Q>,.>M,&@ ?Q.622K>+B;?<;BLQ;?$.D8)/&HSG7@A+%4PR&]-+4/WC
M%MGVN]OL.?GSN29[=U.T4MC"=N35V?S?4Z4D7ZVL2OY:RW$MGN4OZ]S<O_PU
MMT &JWEIKEO*WTH LW->O9.U]ND$^^G.$)1%;KX%N%/O4:_+I0%9VXL79@FG
M:NFXJI5H^CFFOXR00[-<*\ 6/S( U1*EM_DPM\(O(;V3[XE[D=XJ&-=;A7)]
M)7#D>S?^JZ7&@I>'D)@)H>Y9:T#ON\4QY'%VO:CM6/.:9J^7<X4L[\!,GL0]
M:?S[B\?/(06WU^3W*41[JT@=K*<0W7/V80DB="OD\<[WFW?__-LZO&E]BX:=
ME2&/]<B^=4T)CK__\_\5B\:!;3G=OXP3LP_[>V;]C# 9#&^NOS(([P<_&L6B
M%/FN?:G&7JWM?[\IM[O_]NK_OMLZZLX0I/CZYA%S9+B)RRI^(;_0I/CN2'O1
MWO>;P;]N;[17VZM^-6^Q2'E!0GT8Y9QAT/US4-172:[/*^-\/(*E:?EFV^Z\
M,HY Z'D-CSQ<K4I5_]:?\FOX)]R(__P)ZYB_I+O?;[[^Z+\9V0>=X\_]>$E]
MRX0+T((3 "\:T6;-NXSB$4I.=&66&HL^:)P-#U@3F8P(Z;L$HKS3/K1K!V?.
M\;OF2D5Y_D&]_G[S\>O[KUN-Z.SUC94WJ)9OFT[!>&LYEQ;:/C <TPV*Z3')
ME(/V@&+/'-K.^*]9\Z+/!O:-Q6_\[>^6:UY:UYL;'Q"3=]:Q43@"8]?S1R65
M3%ADD@??;]Y<O#L[/#'MMY^<1S+)(R^T$-GA4<[S$ ^=/<3D5A=U/J6Y2"$0
M(.7 =DVW V,TE-<1W&HIFM]O_@D:Y?TO_QXU?VX_DJ60J([-#0GKN-7<ZM]O
MFN_Z!Y\/S&C'?R13>_')-:.N#7OX\E9SVD$4R=ZWQCC\=O[YXIZ5Q@H2Z2U7
M0 HPQ6B.1KYW#89):#GC+%!$C^;.E7T^\EPN%R!\;$"&G?YWS$##L?MFA7%N
M6@/5!5A^K,-Y",3S\?3?_C?SRY?A65P$HV!T J^U..[D7N8SK4!X"1':)K@<
MY<).?2):!2$BFF^ZN9' 8=D!I8B1X<$ +=BV"+WE([3$ S^;U&),B@;J<2@
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M]D^=4+LG03)_L/,%_VZC.20V00(58C%EZJ]@Y%&7J2M+/$Q _>"/GTIG)>/
M\[KTY#T49;T;A><6-C<D@A$43(Q@I(-&D3O]7'&?U5 &4F*H1 A3Z8HPW!4V
MP".T D7D3)%'P=M-?1[3? ); >./'(1R4%5L#)'(8"X*\R8%"ZG!N9;558WZ
MINP0YO1!V>#B$T32--R(4+8P,M\.+N#!$>8_4-K5&NA\0_'&9//W OH)3Q%
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MEZFV.9O(Q)6-5(%D)F./(J9<-"FT2L-'\F#!C,?''K<<3#'"K]!4L;1,=&7
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MP;!RPM2XHM2>%KR>%> 7\>$"IBK16I5M=D[>DPBHS+_2+_J>SQ!:)03(%](
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M&Q0!V"Y(6[A2G6P,"]S>'0SBS8UD!$NY*7&XD.&TTOG7DE)53)1>=RQ+=7<
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M.,/BD(48[P605%$158RSN D(UZM<(QF_9+]F"@\%=A6]LGO4E'AD^8H^!H]
MHU$4(%'BW:'/H^QB^P\^!S\C3*Q;HEI.:)Q0-!M11"42@TV)\TB%2Z?7SJ0A
MF/KQYVX\]$ '1B.:((/=F@1DSNQK T90TNYIPVFYHJG)N8M50@_#<]&LL9UN
M&M^,^&'B(1/9[I)Q+*/<J4^:LJPP7L,9^R,!]PA0[YJ= =]&7?OF!MDM TG1
MP@TMY:V" Q*5TM+!Q\)@\+@D'2:UWY'[8E+Y=8CY>FIT3;,580 T(P5!TN[1
MF>;%SX6.6?.3GPKH-3-N;*;KHZ3SFL'$4\@/]TP_#$3X5&1F-\WOBPM$M/@/
MHI%23>]E'.B./>]%\RG*U'E%)7*3A\X4&FJE8BY$NF3RJPP4\CMI-Z^Y.,V5
M8*D])UAPWMO/"98'YS6/RZ61[D\G(>/$AF8+F2J&LW?4HL-\"O\K >AQU7VB
MH[RP1">USC4^<I=$$XFX"^5RF5@D)(4S.OLW1(]-Z?;(;=MHI\D +.'M"S#W
MS@##2-)*!A/?QQA2AP'"(5S_=I\DZT7K\*6,)' 3,WP!/EJ?$3U<;Y@ID _B
MTIQJJ!'Q@8A1Z,$LR8UQ"0Z?R8W1S%"X9%9W7I8,K!?V!/?_,'Z6U@M98ST0
M_!Y\K\^XJTK("Z$'>=@F(#6>V$[%3,:=!V(&$(1UL%M+C0?$V#2"0K2=AW*8
M;0NMHR@TMLM_*+'Q1A(C!1Z(T[V"Y2LD UXQ+8@*RK[X^/%L_R4;X3I,EJC+
M12_.E\P'$R3#68+SUPYT$1;<:,+ODJWJNBDIE^< '&8L[)&Q?+ - U)B8;JV
MD]"] LE+EEF?\<+8S\$%R_>*5F0T<FQ>GT0+,0WC+F+W!K4<Q0=DHERS*7[F
M CS/$PES4XV@?CFZ\ZG+3%H$32!0J#XZ4<2#E)(8!6/6Z'NHJDCK\#VIU!<\
M$*F["T)]H\PRK\6I N'NA]0):Q?.JQV&5KKA@V3)#P?*IQ5"CD"K>!CIM@PS
MLCFR[61LEFH]?V[?"F-&U^)2W!8FQ;@K^71#;-"1Y-OE93NR,-CG(!*?)/N-
MY5-!04P+;7:I)EJG!)[6QEX@Y8.4RE#I#W"0[YK_2!G<3_/\Z=D/S2WC!BN)
M'F+5@N!0PR:S8ZQ?R="IIKE_%>^[MJ%I"^6VW;]5KV*^G.;O_FT0+2HG,4"N
M.K[=MD1#5L$0_!_[;R7HYZSWC\'[IPP_G8G*JSP>T#WEL*\6E@[#DU*QVA=I
MZ'2]"#&F]$<=)LADZ! CU0%=\/$*JZHUTKRXF1@KGJ&<4KF&D:B9XM(HU%Q<
MQ#*9\@:QZ6-O>FGGY#M8--;18-5#-*,EQ38#5JV1[5BC8%S(P30=($LM_/MK
MW)NG8+3<ON7@Y:$]5E;_!!W'\K%$I\!'C]Z'60L,;\.YB^ ,(BN ^IPXJ]?&
MB_.SW1G=OY(PXFE90L0Q*#"G;A?9*G(KJTEU@4BDH=8\P$!IF6S);0)F3GE'
MQ03'=;=J=\_B#9^!/5=8XDPK7'DYIX!D9H2E]Y0M"BS[)DK;W&A\SDW-G*H4
M2.9J9%_U^(U%F5.2;Z90- &Y:<E2RP0'<&P<G+:^MF*638T\C_,E:"2KHZ(=
MBVP3XIFS80@0QGAM4$ =$^XHAS-21=#HV)MV<X/4!5A0U*NT!YXAK/*+UWM'
M!R_U;!2Z!TPGX.#J8P\I^ C?#$7M<P.BC4+\CP;')ILFI]A&J\&)M96H7V,Z
M*O$:KC#$A8&3.?30SAFB*Z/,1HKX6=<=Q*7)])'M$KL%_I,R9\3Y-6VU!*F&
MH@K<W*"7:[/CDCWTFLA+@SLRXNP_+YL4T#PB==X^?55HS/.O"JAA,MP#KO94
M)PL_GA67IZ!P5$(ZLXRA5R3V<3*1Y>F6W:X79A37SI212?UR]4*B<M1R;\9#
M&:Z_AEF*KLTZDHW;!LN$!L4CX$KL"1 7^B^8'4\5?V9J97-KB&=4KCWIC?<F
MDI/(T@T5E,I:$;&DS-:<M#NL:T"+#L=(): <Z)Q'*U]0(GXW-] ,Y*8!Q)NC
M S=O)Z=HE6!V3<JH  =[L((@"WCN.V-\NF2@.?X@;3A)1,-.0>H+M,J1#]J%
MRHVU[Y_LIA^0 #*@'>83Z,6_)#.,8YPDFVP=R9VDS*WEC/"4^!:> +H)!?8!
M?POOPGDAN%=H=4(=Q$H>CX<=!!&<.UA]N&K77\Y58_3M="..C-C/1I'%3,BZ
MR81FZQ0K66PT&,MR@\%R.MNE7#PC\N5#Y>VCLR5IS-N^=Q4.B"' C8;\NC;8
M1WW8M&C(M )L!6!<5Z7>VEY7$%YQET\4"(&K(KR(;LQEUB1K"6E<IC.!NY-
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M\LLC 5_0+3R:'G?77.+8GS75KZ"ICC0$[ DZ5U)C?;%$@RLZ_Z;3QY(ZST]
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M*#&3@:^3,[HH/"AX]$DI\EX%%HQ%UK<1&59&3B#X"2Q')*@;8IZO7]9?%S1
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M,HPB2QUC&=]=FU=W.RUD['ZR:=DJTUNV;G_XO=LW%T1@H,4+<*ABYC*?+)B
M O'7[;43(AXM6O(*J0!&*BC@L,B?PP%X;.(IC37&*"-<<PF/O,CG^.<?50Z[
M_A+NO:B)JT]'8CE!Q%!0:A2[*+TPK9NQ8;\Y.:_ V"RU(T@5<1B;IHP1G3M0
MQ>7XFB.\6[:E6_<E?\B-R3<_)D'Q8UQKGQR<OC[XW^20LX>ZEG)'MB.[Z!3[
MPQJ0<]B_>$XLXD[2FKLO3=6 4TM$H1A1 ^I2LJ"=X(0'FP+]@;^%(]GPF;$]
M-E)WO/\HJA&BJ'F\D:]@P1!JE7@7P*K^NZH_R+,T8$.^_/?I47(P@V4>9Z7[
M43W.4AVG>7MV"%9*4:@67NM5E=4"Z(#/__=?>!'^XY4.=)K$$O[L%XGH_J.N
M%B!(CLOQT^73[. :14Z)1XJ^P#E(H?-=&B;/KZFNDT774Z-7G&N]<-W=/HHS
M:7)88UB; UE5))S;NU;T^'"MMF+JEAW?'T[+]QL(I>4<(IV<;>9FAOE$X5&(
MYI@13.FE@Y=FI'?[B4*"?.N6..23MQA_^#W&;W$4EL(DR)N+PB3$E0N.S(:'
M0! 04<A#XB,>^N$.D:0:%Z5NDOW9'L9[<AAG]Z\%XN:'RR?!71/]&*%BQ^90
M\1[L== Y:DD+#P/F3:7RNW83?2&/\-HM_[;,O)^PL]K#::UV\\,13:BM=S26
M 5F'@VB3!R^BZ;D99F=+12VFVB]A32.0YI.@"4SG @]VQTT/ E7S,JAPQ[;<
MO0^B@";U>."#^'<=MPW"MNW%J@8/CNPPE"6,@<3@MCLYV[-[RWYL#Z<AV\W/
M;A_=UHT.+PQC18>6HKHB/NKO#=0//VE:KV]\!T;OGPBO[WP&]N/%3,$A2S(A
M T<"$4[.PTE-=I[OZF=T><8:MW[3AB2<CJN&DP>Q-6"N4A[$Y^>1;(P,V_UN
M./#33R"6)EQ1!N<Y:'6/901(43(F@^&^]KQ/MD2QGUT.S1].M[R-Y=#2M%XL
MM@.[;ZQJI'%9GA),"?>(X6(+7229-E+ME5)=P)YK0&QW["T[HCV<EFBWV[$F
M?^UN51#J#!Z#+4O27A&W-P+)>G/9#@ASN_D^%3#LF\<,#/MF"PQ[9'L[UB3K
M(7?)NHFHC3G3-_56>N-=H:."") :+..*O8^ A(Z ^4NX,(1[U<;-Y6/IK4ZV
MO]MG4OIP17KT9&%3RK 39>;R:H0,'5+.M\J;TO&%X2"<L*TBNF57KH?9EFOC
M8[J$MIL.(J7S'1YN8E")T]V$I-RFE<J6E?O3-ZQZR!VK-M^T1Q&>,*JXQ)Y4
M3F(2?4/#R8*;-2>.U.UNNV7'J8?3<FKSO65V3\14@5$6#*=&/G8OWJ_5OD0C
M:+,Q[0=_L]USM^RX]'!:+MUBSZW%,F7)I9Y'R:42PRV%O!E;<JE/W/#H?G<\
MVGPS<B,\#0/NL0W_NK_W]+N]OV,28@[2397&9\)<"P93:)MI8O!1#GN1K4BG
MIM(U'<]Z@<AB5_;P074'H--4)DMEV,GQ^11:C@V T+Y9,\G^# <0SP/UCTD*
ML27'91);=S(6;8-/NZFL_F$VLJ2=D6[/_BW[/3V<AD^;RP%-@-#3V(Q+<+RP
M!5(C%-=/JBOFOT"T7UT532H,9@3VX/2NX>_MZW5#]\A@"?^HN.,3'Y3+BHXY
M9SP=3G7Y/,<XK6H(26@SLIQYNJH6Q<1I?\ !'!>]<MRJ6?+-WCXR.SW;W\5G
MOC?J,SE]\D]/@_8A(;=GZI8-IAY.AZF-SU2, VD=/\/3+MK*:\87:H*6WG!
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M;AI;V%RK#P<KXPRAAWO#,,.J9=D@Y! _J^M''%8-Q8D^;"0K!/6R@7Q=$I)
M6&PT)K'BEJO"$[X4V5G#T'4,R=Y(Q?WSS.]OS& C(,#?'S,0X.];(, CV]N1
M>-CD"XJ'O<NN9[J@/%",' I[4XD2Z@*((Q&!>78="'#T1;09XN'P0Q!L:/['
MD8A8F;;@!YEQ^TTV1*M?YAG<LK:5\V3INL9"9MIH31?EI.EW:+KA#]-V*/;H
M%'VZZ)A0]6H'Q!B8YJ8L'Y+][_?VDGFLT7N]WIV[AC=9$GWWY>A_":?&[RED
M5SZJM0W-QTI#=ZUM O<S!,F;;Y/>$:X<G-Q)R%-D=Z%WMNGV2M;;76#OU9-E
M4>&)L25;S]A=NN7\>)<-SI%I2T[@M+;5;QDG\SN<O(2[C;:UZS'^85@K)MB@
MY'$D[*Q1_1",>5&87L_F2QK<TJ&"V8UCC<6J:]@?XE*M][8X_DEU9?R%4N%<
MML1,)<3%3Y,#*VP:;H-$I15X:KQP@#&)Z1IXL2*[@KV4P .58:3ZM:0V\M1,
M@J+XTC\:1[+1;M(;'SW6!8;! OPR1A4Z]7*8( !=B1L,'4*?[#SJ4HM9WL03
M'N"_7*A2:20NG][A0'U$CKU&XL'PU(72(HD3*5T./&R:ME :)S!QHI2XBT,$
MMY'2X@"6(,VRB7X4'[3A@"0:M<3F^@CWKMFV?=H=VDOJ"[*77L&&G^9C[(_[
M]JI4=7.1SSD(;%S,;A(<-C7Z^:8@DKCNLOHZK.W)W>XP?<ERENFHEU11]%:N
MX)5S1TYG8\K1<(/2'DYV35+G#8,#1RG\!V1%=@X?<P$*20A\DG00B]\2 ^-P
M,/6<(<#MJHR9*,C\A;U[I].\R$DZ[F0P#*?LTXW/Z 3F_G,PUK5P-=S=2'F+
M-Z16Q/O/)T^>][#9[J91=63'2Z.E->Z::Y$APT!F:,)1TN#%T^^^^YL>&\V#
M!)KPA]6B-;NC9^J"4G>[\8:#OIUG81BF!E]+><P)U5E!N3K4<3(NFZ3M;C:<
MLSFR+>[HA&]AZT^?O1@.+BI8DET=\Z'[:VY&>FZL!-@/$"[;-<X4!?@BAS:;
M/0P>+U?U5)ASDJSO>55-L(3'!APG"E507DIMG<E<6B(X-R!&>TS:XWI#,+67
M>GHMC1TEW /;-J@9A>UB22I7"!2'IYGVJ%L<+IP(MG8Z:[D- [D+-"FP;4G<
MC O0=Y?='$MW6/JN)CPM9R,;88$A:),RG^(&4G6];9]V6\TY??":\P9\(K#;
MK(W9X>A"H<VAA_NW@O=W;WU^WJUOG]U@O^>/9+]ONNMM6Y%LWD&8>8"LZ2ZB
M @B4170J:UF!#)SL4:9^7LM'/6UF/"ZS'>=NRZT(N,I)39(3%F4[<<EHC:FY
MCKG@,C:SE>63-?>0XJXDAC4WY9"42\)1)?M?I]_L?9.^>/9-S\!\NOGA8/\[
MUR3L:XSD6(9+R>R3'4[I=J;'1"+ L%F,L=4#@8#HVR?3JGY"_P++(&OR)M6F
M^,I9%NL5S3L,UV LPIUBZ?]D&(MI:]8YW\B;:%HNS>YC' J#RUNV+#16;Q+$
M\+$)3&YG(7,<I\67ILK"O1HH($(4>5@F.P4RZ"(GR@NX#1B!\*_=T%8/C[LE
M'A(>"ZIRAUU1>*=;(8TSQW8J>)T<QD+<Y1=5(2]95Y>X#8.06KA2V<I9,US.
M]O9FSFP)_"49T4B;15!U>+@2F] \NB=JU%D/?*#;7639^J1WNSIIZ"\8X_T
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M1BG^6B=Z\#DPF[A256V[.W HL3."_NW6894@JR&Z/Z); PT-FRC9C6T5'<X
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M#XT9[3TE/C:H*XQGY)B 5=6JTJEL/#J\APM^?[=B%[CVWQ]3Y'B,OY3C@=$
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M\5Q:D@6N>W^V<F&G2E<765$JON0[8[)*'[-%ZDI1)/VZ5+.0>G&*=B8*IYF
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M."[&02QZNR_XXD1UP %Y[J7-^J ;I^@SJ@%\#1EBPXW,_[93,5S*4S'_[K_
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MK@;ZU.TX+<SRX^ZNM!]W=R7\N(^_([ZEA:??QS/ER.&OG3/OC\[E6;O;]?Y
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MZ!B%>67K(4QS-F8P6+BO,@2FQHL"+H.APF(6UH/<VPJ_],)1H=FD8!&H5HL
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MB4=6XOW1S>\%  !B%P  $    &4T,S@U7V5X,S(M,2YH=&W56&UOVS80_F[
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MLULY$K4=_7F"2+22(BB7KH@>$[?^'A? >1 S2D"43;6Z$D3T<[9:G(P[X[5
M+H''2\.&HQ^+S6<RN_QUB7LKE[[X,D"#0+Z!.*,(LA3O$%"DR??#,GY:Q?_P
M:]K.0[ZE?1IO80^C3_V=WI'G+\WIW?H_4$L#!!0    ( &&)1U: G]7E=#L
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MZWGK9HYR'Y#P$WG*[]KC"SOY'JY#!/; =4B*Z^2(]&.SQAF)HB(NV0G/FJZ
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MM\#Q)CJE"V4V"LT*NP&&>Y25N% TAZVR9;TA)GF5\%Y-#CR7 @[+R:^#8["
M(=]'0;>>+U.C#W/%!'8HEJ.#B'[%6ULWQJH+Y/PU!<%&<5LXI]"'!W,$=8$/
MFL<B?L7,WQ,^AF/Q58!]'0Z!C/U$R8!,AJOW"X3YAF"A[9N"A0Z[9[W]=NMX
M]_#@;?=G2Z]%U[6JP.F;9 =G'NI4D_H/Q-G 7C -O.II;I#9:HO8ES.L)% ]
M7XB)GW0>R'26[RZAH#-#HV<#M_*LL18PAAH>W1Q@!LLC]N/+N*L=;W=,_939
M!=3D-'OLY2&M^;8@-Q WA/RB;:P)=A+<)L4?511C++DP04"PT =)7H(T,TC!
M0(:=_]IB/^=AM!UU-_L6.$1 MK(+3C3BGSM4/,3SW ;:-!#@8QB3?U*Q.RFK
M"%X"AH>M_V#?)>DYU@*WB7IVX<Y5SU:-I]M79D3!EI$5>7@Q/>M\)*^V&RE1
M"/_MS>'>S@)N82;NS0ZC)OCID 5\% #=?G QNKQ/>?M']BEO/_B4OROF?SND
M2]>&%@G47,/Y&8ZD37135\"%5@AX(+N*$2 ,K3,_EAG(AF;.?U-6QODVMJ)2
MAZPY&X7TE*%L$J>>LF-6P7%P3QOI&"^J,UR(4X)Y1N^I075Q.!H,&5%]<.&"
M8%D.M:)6I-[5L--N7617J(%V7.QS!#;E--<SG@D3BA6@ (L5Y^) ^+.^U(&J
M)3+(*58X65>$P1;!^IX3+[YQ&,=1U@G!@CE>4Z=Q.>2"TZ#N7NZW6_YMN:EF
M505V.J!5<WS'6.]S\@H$(#]-$XQ^( RJ"7]%2A1=/Q.21X-FR(H9W&KT)TQ3
M"I74 ;'%#DF;@=:$__60UK48:X.]JC%9$&R=SJ*M7>&3L8>0(*@LP8F'#B/L
M* :]/E3*C)R,C'U9V:ML#JJ6?+^M]Y*!U$99A9$=0U$WYB<2PN%W4E+8W;"4
M6:0Y7800!>WY74O!M*'9@9#J(/Q#I2\F=G0+_:%%DJR2W\>%&J+;S&":FK,H
M;:G"IN!$C?#1GP=Z4@IP,<.*I/92.5?@91RIWO[;[LD#4[UMS I3&]NMT[7M
M!F[*X$!*M5W 2[^$&1(%<0"Z:F1ZV+EJ)B07G,2:OY*?^4 &MTH8IVK&$PJ\
M6Z!M SDT\A2)Y9@HSHIP1/UYHN&#2FKX*K*86"_(-)-"?9YUO=*4V[TP@WNU
M4[74PSR%>>*>-5E"SSH=G(M9SBCA\]R*H9M@@8I![!;-!W<G;'Z"F@\";MXF
M[WX%V%-C0;A7DZ":\.OL5)C=4[;37'[O]CR6+/T!AED\+((G87U8PD)32/+P
M:7KMUE_(#,1U7(3T.+:91WX%G=GD$O:B1N7<43M,^U%29/8"6 *>(5+T!^.:
M_;(N$N>VF'@+\)^CZXFU-(Z&^I6:IW58!&<0A/41QV;2(9;78]+A$E9GKG>(
M(2+BL.\)@G/H;W^0R+>O; "L^'\YR,=^Y<8<&HOHI\-@6Z!#, DJ]5?@L7CD
M[FQN"H$.N;I;UA<T,YPLF!#$0\0A"]]RM/':IG68'!4;3YRMDV3T4&.E!V%6
M^<WBDE%^>263WU%Q$&/H/>&9X";4SP2_J8X^D];BLZB.3,8O)!T87X+:V4W
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M:7TE1@%P/4:B";NJ*%9'7BA6S;@X$K9@<,:?"8$QPH,K?L"J_YIFTK&@N"Z
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MT,;CHF*JRHD6#X,,)0<6KXU[*7N*T8$8)5+YP5J3+IFF?^VUN^1\CBGCX/Q
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MF-"+;_$!E4A%NU43JNC8\GK1V,I+L0+LQ["W*0-R@>TW(9V?U?6=EN '5F$
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M/L#F?NZBD5\W$.(W&$;&T[J8G=4>BU]Y.>(;4:KSKK(VF">"Q0D2[:U[SP+
MD0[@:@G X6$5 4!1$X#6[V<_"10G(P@ 3(H ',R@L%^@_U^[7HSPV+^NN+CZ
MF !<O9K@4G3.57U[DP"@%Z?P.&D"< F>[.\[;HR8"CF]_1PMCL?KVM/KBP/0
M9,'(%&Y.Z]+,B2 0N[*RZX/VV5=6X_U*23>6PA4-SLQXEK13B<?+MMJ77XH1
M&3 J.:CB)0 V[X\E)]<GG3ZXIY^\WB, ]4ND]%.M!,".'SSR@R)F$*'HE'>9
MD3IX9/DEL\*V@OU&VJR*Y.4Y1PC=0CI$?*Y;J\I!Z$:'8[KE<47 F[J'2NKV
M-U>H:PC [)*(&3U%ZL_$97R,-P%H7SJSP*C_YR#E,"4 .-P8 9AZ>7KWF<'_
M:R^3RFV:)0T_2!JQV^ZB<F)EL81N.+I&N0^7KN]^TL)^DSVW^7GM?O]"1L>W
MDL.PN<71*?XV7W20<;WN 0[WQS;]8!:F&>^Q]TQ'[KJWXV$W+JY[-"L4)<NW
MT@=\47^]4Z/YJJ0=+#K'_F6H59MI^"' 4TZB 3\2G2:J\)0 "!$ ?* 3 =AL
M1F">DMA'Y"],$8"^'M0)U@4OA/Q_[&JIL.2RDZ3L]9=9@J7PA1!NF_0:@,H2
M5%QLW_^7^%1=,$?TM5:=8&%$*'H$G^-;0*_5&ST6+(^!4RGZNW;J-<6*#T-U
M1R3W4_O47K>>_[H;1&;FU0URDT&3)@SL7"E^+4PC+IDWZ@;K[P/AC]\S#2LQ
M)PV$Q.&CO&$'@X#I_Q[[_AUH_"^];#.Y^GG4WLV8DN)JA"C'\H6=Y(= FXCO
M$3HB&QR5G1QGKP5/3HKKF#[!N79JZUP0'QZM\L_?/,16$I,?1)3V7L2,[;'#
M@Y"X-/?&WZDH![L@;G<4,&;\YI)[P1VR&C[F:8[T.8ADK<Z+BI$VGG)F6?!2
M.S'  OZ/4?*S>% \Q68$8,3W[MGYT]&*D9JS=&+VNLGST[;U,@@D66%0STT
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M4X1DOH_:]O78S462>\]8ZAC<>B&K745.?EAE*=LKWBM@4G+0W[S%#Z=STB$
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M7A$"T"3Z:&'NQ&:L_D&;:TS]!'^^SQP=A>L,M8(!&]FE"&:D"1I<Y- \WX*
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M;KU^M _E:::TU>V'0QXDIVP[^NT>UN@KSMRYJ,-T4>L.\/<,2^\R[9H?4-$
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M\,PU?2[U]'<A\1U&*6/GA\R!\P^)5%"VW?)0[[84!U=5S(3%=Y=FI5H:"[=
M:X$;<T&]KJN:P<,M]YMBLV@GY:XVB),&GXEB8_-:W;N8(< .(=*GMD_#J_R!
ML'F[+'9LJ]9XI.E',95P#67QN!TWT3Z6'!<V;*>7M5/,X&.GDKS12Y?+7DY'
MQ<@-&1EA8_B@8>64/Y]3OX4FRP"NO?(<"(U7/!]0E&4W9[HZFLODD?R]B]PV
M56I4EN/]:Q\1@@C:'5H'\\-33AB70P H-B-;KCR6BF2YR6D3KB_@'BPVL840
MD"!2$PX>5+5M_5BN\;O;/^K*FFY]^MC9*^8@=\_\0L_%4E3H9O"7-9(K'J,D
M%B"-$$_1-0$%AMNH\I\L%3":%2\FMUL85;8G(I;53^!J#W?NZGQT4_W8=B)%
M $2;"EWL&/GO3G@1 (B?!J8JS.-:F1-'<4ZK4%O<[?W/5_>T$J)BJM'LKD93
MH_77R8M&#T)C11LF630"R"&0' GSEJV6Y$QF#/7J#>..> ==FJ#D1RPF-L$^
MDJRF1LHMN2$>@V0)02QS56S#J8,:L<@),%YEST7I<.$ A;_]?0?J#,#&6,]1
M-$QO!\@]T)MK*S*@=KCQ+2,WI'%U^;Y0$5D4 =@*=RBLD9IN\E[-Q!. '*Y!
M2[Y. D >4Z<4)64)?0:0%JN1&!* <D1?-1Z,BY/.P6T?+Q" CJ0D3399$H]H
M(/X) $HXU&7WTL-4!GU(6TU;OZK2_,GII9@Q[VI$JNFCQVZ;,^Q>@>0=8;N\
MBO4?2BJPBS^?=EXO@$H7-D(^E^X\XM'LB=?T'_K)")?X=(O?_+3C%/\TG=?9
MY(92)P"']$B<X!0] >@S-C\F]A##V7@FEW $NK#XA+BIJT-@',3HX(2DF&@)
M.ZH)B56NV#PB-2< T_*(%[[U[12CQ.#.-*]L/3@-;O0_+(KC;Y)"_UO0?ZX@
MES\+.C/U?X%&_V^:EM\UAV"6C=8V9O*ZR7GSPD3Y7&9]*._WQS7F?]'&MC Y
M7.N=Q_>BEKBV*S1.\S ^@"ZDH8-9AITB+Y%-^I<6#M;]<:CE)%>X'1?]"M,>
M:1H<F2$A>FOA+M6+-B^ZS.<(T?NH%C#CNS(6QV\%MRQNPYJ,G7V/AHP,O%_*
MDH4T5RG:)"\D,VV?T6<FY<0$Q<"AVHC'JVVPZW72;@VM\_$/DWF\G$F++2>3
M2YL)P"G(@BM;$!(H\+;TY;9ZT0><] 9EMR,VF(1TZ('-S=%8[ZE6_,.HOES!
M4!B$<R(HO5)\(,3PW'#+[+1&*OMLYZO.8^AS]J\RL@U[I!&VI1AP9EE5Z(9:
M5]QB0.8-SW1,(P&PW1G.$;94*O^]5/&D.?*0U0X#:G5+0PK=DV9:,NT(C:+5
M\,E+:YL4,\P.CW[MP\*(>"KB1162OML@N]OZR'AYDJ="S(>59S8<[!?BV%/]
M,/I]IFOG ;KPWK[+Q;!?RI&>LCR:OPQ>?5N7Z:O:D9A@O=0/WR("N,#@>O[I
M1I4'RF*>?RZP'_)+D^F^0?)RY":ZR(ZX6Y<Z-#H+6)2>"T*8J5R?N?FF8[!'
M>M*_H/>-7?N=MVT,.X^ON36#WW+2*]C+2DS10<6:)"ZWQCRH:8^#T(\_^NSF
M)MK^\\>^A/SI8B+[@\==Q#" !.ZTU0M_3IUEL1F(2EIA&;0D2YR+%1^(N]\\
MMWFQ!T@1VEU_$<S6'OP>S0(.*I I1UYH=1%44OIJDQC"HD;OPKS<]\%G,?%I
M%ET(2P#3X;Z\BCMI<+>RF$IC1SMS[MJ3_;]%8(NY#[$&.[?.%5_J\9+\U&G!
M\WRF,<Q2EK0H0.7#O3D"P'2'FZZ\4ED54TIV(]/7)O.PH*(<8Z3)W?5^*B\6
M?6;B&5B$F[9(=F\Q51"JSMH4:YM<(JA>35;E1C$W#'TBPZ:U9NM)['X>K>?_
MCO4Q[['6E9RZ=85DLCP=,D4QC4F?-AK[KWTML(NC<@4)ANPK['>58F_B O)E
M"_SA"V'MH1NZ%\&"E'8PKU@ER]6$H?R)I7JN.N^N):]O$/4(,AKO3@4-U=7;
MMC.;GTZ7$1B)M%TX+?3$AIY2N@6U,S2,QR'VEHA-;-JL^>&J P$(A!WMA1*K
MV]!7 G##F #@0"Y;V7BZ0C_\LRIBFTXS-:._]B0C&XM(X1B[=!IEE[.VROSO
M$0 %)\0FL0DVRZDBTFSR#4L??)<$UV=,6&42>X/L;,WF7W+\GLN,0N#LK,PE
ME3IES_.L*A$?#[AW+\K)W+,G2GXM,%*[]%O-C52I,INBY?[)7ZI?I&9>G<P[
MK\ MC1A#9C0IQ[PM-43:)JV[J^T6\1CV9VL@^\GBM$]O/@PJ? &KJO8TROWY
M-92_8XCYW_O4]<[;<T<[6")>Y2(CO)?&@,9UKQB*G$VJ%=04]+V3W\XA_7F3
MRWT .NPP-_AX2_G#IYSP.PVDO)N%WHEU54/?^MNJKE%^3H'H/@2#H!BS-O/0
M'.T$]PAG-/*UA<# IU?</THGP>&!5VA6GLJ0<IX-HFU0X&^?A8?KT#]EOJ$5
M?Q=%.E1#F7%G8SJ%NS1#[9FEE9)MHYL,!/FUD[UQ[Q-2HE<(](N7PY&N]8#V
MLN?.P$G64*T>#7);>'71%6KM@D8,=ZPC9FQ7)U72CCG&NA[%8OTY7(D[0RG?
MPO$0><PTY=-VB38A(>@(8Q+]=;>RTU[OQT).*&<M[]9T=':,LH;/<HR K8==
M//.[I+897"DS;4CLI4V:C#[%=L7R3'JD"G$=RDO&!5-[VW(OL1FS9^F9^IT:
M(D\><>'-"Z_Y:V#.6 9&.M=HXT*/L_..]*^FOHH=B_1>LQ']Y&/?F^+O!"F2
MF=]?;U54T)J.UW_9MG38NRT3R]#U\(+,<A2R?13Y28L 9#D<'2)7/5#H.7P]
M_'X6P]XA@Z_M4'>MUP8)INI#8#KX6U+[K&?-QTFXG=,' Q:KWN\_Q&)(>+G3
M:4B*M$UO][APGVN:@?!!HL@F2F]:9,<M^>ZMZI;??GG=B.GGFQJFVW+J"VUC
ME9_%,$&;2DU:\RYQYKE[3V*$RM(?I%69K[3[66-H37ZZW,G)J(P41,OKF,X%
MRJUS3\^-E@^TF(G%<PG8R<E&[;IZBQ* MWKL%<2T8:(TV,#WRQMV(%TDC!SN
M<(Z2DW0<3P3D*6?/<!+[-_N2N9>5O&_:7<TLGQ, ]+?CK,/,*DGA0QQ^#P^_
M>5(\5V=S3*G67CQ*3#E&%<DLMB0!"05AMW2Z_=(X H#4L_!.: X7 &-3Q/B.
MLZR=OR(UFF$9$MZAS7<+7PY26)]7K9 %SBC(0C,#$S/RB47RQ0%LAS<5O'-X
MLHJ+=LW'KNU^+V\>PRN>BM>M$*;W'E =6*BO^[Z[6Q5Y>42SEH63AF1/4JON
MWLP'/OA^ZL7ER,?H9[)SHZ5[)Y;J=?T;;\IJ!GF2[APG-(Q8UB $ 8>[(GG\
M.7+\U_81B^JJK3>K![VJ//!*!&#&R7YJE_HS :C/^OU,K"(?\5VJ"W^$P!31
MKNT0-:- ;?XB .<5^V"XK33\2=96L?F*@<N"^7#W=F!M^.^/+7;P3$.%1-09
M$SY>)@!M2*RQ4=4)J2-JDXA6K-/X_SDS^R\"<U[B=4_\FU>KLTZ_H=B$_<<U
MR?Y#$<7_UN._3H^$V<K/2VM?3%-TVN9JJCL;-E>U"4!3[W!E]]0OJ8>WQJQX
M1IP4,WR@'(E-HQ*5>/M.:XG2CG,+)*_F+\!E]O.&5K3VX_<9Q$VLJN4KK1)Z
MQSU8Y@88A4%*[R_M[?!;7ALS1*W.>V!P.D,+,8:0'X4L5TQ_7#!?8&G35/R0
M"Z.'*@N1@6Y7[A@VD759E;*0%N=*MAA-:-I=+(4_[&'K]@I5YLXC.]LKTZ8I
M:5V1-D1V\BR%5!1N95E.%V7)-FT#-M($*1_=1)B+%E@[.$@?(!KD.NJO>@?;
MZ"#AY8^M:<XMSC-$[>W-9F;10^&03^W9AO5SSW0[R>9IWLSE,;8+Y3_]?(U:
MX:40=(,QE-US=[DZ"6=_]6O-L7@CX_LEUILBB-?5L4\=G\E115E^%<[KQ]\Y
M\6_?^S;5>_I5S9B)/QS#F/=:/?M7<;PK;Z^&G-_NO/NFNF:X&6<\=Z)$&GW,
MD\L]D$Q-F#0[K='LV<'V..D4.VBRN(Q-1B//LZ7W=!U]N[OO7\YZ=\.6W((N
MEX=V:>>D'QR_IZ(1C4 \R'8)(IH5X%:!ER9N]:1P>"9GJJHET2SA2S2UKQEE
MVV05W$=3"0##WM)\A-0/P>:NZ,B:<-GE-N\5N6$(39X?U<ZW2ID=8VY!;M=:
M;AL6Q905_G?X6>E*VP*P".+B1]/7KFUK5B0Q\COPGTM_?"_T;0A++"+RRMBX
M60G]Q_V%4F\ZN48PPY!,Q/F7B C?B?(>JB/==#<AL9PT"$2QHE,!5^@<*Y0A
M4*!5_B3K]2L]9D=,)ZY45U@M69_#WK#GPDA^>?#44Y)ATI*+<-"MHT:$N4B2
MV-?R-&(-L2.6/P<] O#&*?EDEP#,P7'7"XWQ097F!P,$(/H)PB8+[TULH0/[
ML%K[/D2$?CYUL$9,$O.?)5/?4,4I8-,6 B!.E%/C#6^3FN2MY%LI,6\3YV:9
M1FX*?\3K#@R_\E?8LNZNNK^:/.E4I\4^A G6?:^8VQ]0>R)W]-5;YMO3O$'7
M][LXI!](N_#N75T]5,JWE:PQSRK6BH5WZD*&D$H=GHCH\/@+&=6]&Y&UQ?;7
MA>IN*N8[.L=[%[9@8^'GU[BR>>WZ9*AD'ZK,!Y!5U5_)'-9)D3;V$3$1I'9T
M1\N(A@K1N 9EOEXJ[-&IP:2ODA9X4K+W)45]',AG[TYKX'2/KG->SC):D O?
MN+[GIZZ][2?N^3W9:_0'B_3'<)7;-",F-<ZN8VSG<WB&(X1V.[,=?.)G"L<;
MR/S(8MA+OX;R-V@\L^&-:5KOBWY4$6?A)S:PEO#T'A^/*67T5]&0A4H:Q/D*
MCR(-1R>>\,*"^:25>SZLJVB5;@NU[?/HJXKUH3F E$\%.[QYG>R*[1YC_,77
MGU\W\/RL/JOA^8*71U-C+\7%?39Q6S#IVHMK]N$\+?WYL^H=+$%]T$LK?J1(
MX_O8GCO(T:(U-;KGO8NO )-;/)#,=#:JO=W<W,C 7Q]6]:4J:^\\LX)[=MB<
M32;S; 2R+&3?G'M??Z5ZP*,#;5HFZ)P4+,$W]KE1Q3D4\FCN+>\2I_MLAMSC
MRF>%+:J4'5'??CA;UJV-:P2:QU*WV&0U*X^9VTDRK\T[/)GT:'';>7G_^5EN
MFZCY0$M&ZN*PW(0[M3Y&I'EMLSPO1;?#+]O>H)G[ZK:Z0_7$!\#<8+%8;1E*
M8NBDKEAHZ8,PCZHT\*)?17<F/+MQLTTN)J,(XAT;_JK\,_FOK6+F!USBN#<B
MD 6Z:<PP=+=5TW*6,AZ3]LOIN;H?3Y[;&>"":D@&.MZ2_=8>5'<"I)?U8)+7
MH/$8RO#L691/A!M,DG?I#B 4CG"'6E#NI9LQBLEX2PD\/7N3C2[^B=\S!XM_
MXTV.?V60RIL.)BCU.WOPAN<8 #P7I]-C886NX*TJ)]@2K3L!0.A]@86!.,X-
MBI^T$H#O0W7* SKQ/RB<XN:V>:UWW-ZDDV;2VN^5,-_UR)-5-9VJF9_#>-@.
M:H5\KK+\0>0$SJ.([QQH/+Y0&'>]R_R(U(0 3 T6<:"-*ZICYM_W4,7S41[4
MBA^ H!OLWNSRNG:2E1[58(<T=%6,Y"%R\K(7XNIB+9/YG1-D:[J+2%']U#3R
M!C$W:XDY?<,OZ_BH'-$T44Y,;86^DQ.CZ<(*8P.G=7I#LF!H=GOY^J]@'Y9&
M^=(.G+VWY-B5$LE&17^'"V(",4_N206&QNU)0,^>W0=/-EJNHBKKYSVG_F0R
ML;Y59NV":@@ *M]$;%7/P7Y+OKQ[B6[Q4316;SYJYR>-SZ:FJ7,G=V*F7K4A
MM.?3,O(Z,\D"LEE!9EK[Z 5X'N%'6SR,]SB 5)YJ:XM8_)O< D-_+:167<R/
MX3O5/N^Y!5+ZX:2\"0W3K#O[@VN*73QU8J\3+>ANMZIPG[/L'?B)5DP?I*9W
M(-_SULB&\"2 5%-A=8QQR5$!MM[GH=$?[>M&YI"%?1?1V5.W?;\FMVA]G R(
M[U-3S95MNHZ#2<G-9;JN&ZG.FNH9/"_%>J2*][?B9& Q#A$5/W$78D=S)F95
M>=+#]G<:+?I5/(,!-S%:LY$<_,B6GL]/87;OF1G>-Z35Q:+?LW!'./!A9G%E
M#@& H82WY;/6>]Q9",!S(Q<<=2C.[MS7PB0!J*@HY..Q(S2PXAMO)/1J/-=Q
M0&<T?'Q;T^S9[IKXX0 \PI_[;>G'B23K\P9-;@"932YO9GU3V;XN$6_;T7BK
M8U_$S@$&><CNM;](]/JMNBGL95KLH)-2JV]FHN7U]<V711 B79U:UV*S>B8#
M4E!WSVVMI[-X;C[!I:F"A-)HLGL7("]X(Y7K^HO>E ]NH./O$ !],2GF#?.&
MAV<<C"0$[MII)";B"$!WZNLP9>JVHLIM @!QP3.MYYZ0;" V5_J)5<)S /_L
M ':PY_#-J_@@%*V\A]_"K0[C>YH)@/!L'^_Q/3K<5+""\;\_:>F/.<W_/>7_
M7U.,F8YRHIA$C-<M,%6ONUU?7H]=73W0-+=/L1[Q*$<PZ;BS*4WJ'4+J_Q<,
M ^_\@3:75U*]*ZNKHCI(HTM5&_@NT H>S:<GA.!,EWL*#-6<<0=)FN7O6JOG
M#NPON/<=^V-B,O=@]]_BD)O6 8&HG>(:]F'<]3'-(]+Q4Z#-QC/M_:'L,,@K
MWV!B:E3CN.XC)9-&3NFW;5\K3$P()@]5N;LH7&- 8;CH\HJ![:5(G6^PE\WJ
M.OPG'P)R//*'U"K<]=4_2?TG%PQ3>9CRC_+]XKZ@G*G%3/:YB(7V9)=<L=M.
MW[A"V$EBVR<(<L7!GTV>WGM^O5VV@V4V^6]2\2CSP^'Q&#2>::&(!-_VI7')
MOW4Q@2CW[7+V[S6*J#T64];7G87/&QEW])8IOXXKRZR&VD!G\UL_W3D[?B J
MSQW%AHM^$==Y&&C68)7.MIM[DJ5T"&,27C]/[$"PD.^79XM2!RC2;K[JJK)U
M6ZYU^>#ZXYUF^*B:E]BX<.A[AKM W$&1"@ HIM-<"TO0_OPH-]0SI;"O^Q#"
MEK?DGAD:%+2L)^21)O]Q0[KCVV=.#NUYT8<:BO[;Y-"0=,_EOSHG!9OW02)8
MZ8V*^5DE)K6=3I96P2S&I[\2K+Y0%:55.=G<$E\=*'2];[\O.AHVI!\ING:G
M;9,'[S)).HYKSH7%?G2IN&RXMJBRD9*IJEM790)<M'RR1LF6<'B_Y**P,_R@
MQ/MH'R5W'#?1B=%73_'L>O-MSG--_"UZ.-<H!]1"?>Z7<Y(P33?3\ETUJND-
M;8.XOIM)ED$K#KU5_PQBFFOCL&V\8-\?07S#_\$ *1,K5>UKH-N4@O-IYV:$
M@2+/DHNK<_R2"YFJ$(9SU/^S;^59'\_3V<O](8*1; _K8FY]*N8)7SO+FS1S
M'"CH(-9BCF@$JS339/DX/GYYV>Y-#4F7P)G/7F1'/_N-E:@&[K$]LGH= J$I
MN $$!M<4DRQ=.CH79HFJMMB1PKBD%W T'&6>Y'\JSLQG;G(6]3+M>YO#KW%>
M6R\@.(*OH.=,!-^;OV=035VP%[&38QS<&T2-<H6=Z7_(_NNA/&:R6AAK* <Z
MH8PF /YP4WTD 9A7'H2-FY]0.[0*5O!?YXH?\0F\W?M2[0TO@ X9_>I_CI71
M3E;5(7"=0QG&(*>K8[%;9=5WRC429@C T:7+>&Q,,IY),Y0 +)FX',_*S0\8
M#%3EB\7VOQIM5-P^?!$&TV@?CPB>>E"R_2Q=A=LNR=-]9]T:0IG0>7B3V'A_
MS2]>>8I*/%F;.UHW7S1WDX=A#17!!."M*VHS;.DORU1W>H3Y5TEU;Y7'JK!?
M?$AA^%ET/2K+<?8]:W10;<RT!H/]W33_2M#U=#:B5::P/&V\_D')WZ3*$8 _
MB5V&S5AA$?@7;<3U(44<WXXFN:L-T8=&CSA'<]UCX0\F I"2CRH<+K_\LC/G
MNO_,@@JP^"BF1 _G=667%^+S%M#'FA/9D?W8+%%=VG]3W1K>G[O+\08;IN\9
MGN^<YVI*'%?NW@;=1+K'))Y[FS=F9M1+^MR&K_.BK?YB4TAFRQ/7J9VW#_,0
MUXY'H$Z_/6'^;XJN:X<,12&-!HX50VT.RF#KYT^&QY$:?[D%^:?)J]UN"K8=
M>]G$V[,FFX]OH8C\:P#U)Q]D_WD#=]B01F(*MOB^M[].UF#EUP[,W13D_WS#
MG[U7+$J4"QE"KAUQ$*G=?T 1FX,2_/?BB8".W<U_STQ8V9+GOR&\O!S&BG4Q
M_!G?N?MQ;5(#8I>M7C UT;'DT+ZM8-^;]<CCT]0=:VNZ)!\:1KB+FQ_)Z@/H
M60[]+SNU LQ'XUVW<07(=Z@R"0)PB#G]/V"NX2\B'A.KS\Z<$['MU<<)7&?J
M7=7L7R]T<>Z9:+%E7(1<1NZUJV6JFQ=GO$IUXD74'?&U2J3I'4>@?J4B<-@Q
MQ%3BZ4M'?Y;(:!]A\F-#T6!?@ #\638?OIO89:/;QO"X8JSN)[[%Y"<+2(OB
M_<=9!$!1:NI@ =&$7.N!X?V=4)O?B#8;O8NQ\Z+Y;S'_5XI)E#CF2X=Z>BZM
M=EA'G8'=+;O#]F.#K73MHM8=U9MW+MXG^3O'.<WPS3<#_K(^7AZ/DV/;WI33
M1L&Z04\"W+'ZZ<+13Y755Z<C'YNL=Y K!RBBC384.=F\+^OT'5PB $I&&&-J
M"V/85091J7"Y[GXJMZ:O4?7/[;7='(P/''+CYAXS+FA\BO U_AS@W]N)LWNG
MG)/5L+]"TBCX$5#,<GN!*0IK#<9RC">R/&2D,"_N;'7[ONHY967L%_8YK:LZ
M:N\P,7C;E\U]\KV39Z^7F"9;1*_7-\9M;J=:'UG0!YH U=G:^GS:!<3I9Y"1
MJP_PU@?"VW):<TY4)5K3D18]WX$4F&9\ I[!B4KTP72D8TBP2$I?[OBJ2<>0
MX*CW54L^VQ"AB3?!+&?0'W>7==<]9*XG[5&J-*$%6)Y(48%?4V7ZM)L]WX$/
M<N&*-Q&+8.,LCU/Y?5@-'(S8$UEG+6;A[MC:!5[IW_-Z6KGU,K4@A,?*FBP&
M'=9'"I'=*Q:91$V",SPF0:COCF;[IF:SS/,"]'17+C'#O*-(@T5D#SZVS%B>
MU] 9<!G2W!.F#G^U\O&GG; * 8C[Q3.4^CT%,</R/8XDBH%[)6M5$7V.ZZ 6
MO)5K<L_&@6U3^OFNK@H%@VB&*YBE*W UJ.,('=&#_[$E65&<3#TOKASA7ZN_
MPZ30>BMI!LZ-D&I8S%&W:3RVV-GK*T\DMZ*G\.SX1J[GDLS]S!M= HU+W;%D
M'7)J)-;DJ45?[40.JVQ)]!91C7.ELPJ\2O5,R9G4 U$O)6.9,UCNIL]E9 XJ
MX1E0M 3@>XK-X>E[R"8'D<Z[-7MA;0GN:,,[SG%M&H$W*-FS.=FHGBGD4_H2
M .] CQ6MIELZ<_RY"'V\3;+Q)9F?KQX.?KUTR'Z XPT\A6&QOAU-_!7D7WS[
M1'[XN'DG^V\"BG_F^9QLXKKK:_6[-LSGO::V,HCEX'D7K >&C8#-R!,5/J%(
M0J0B,(P-F^:;M+W1JR<SA_U[ F:GX2%"+,C"-8BX*423URF,,P@2 ")<SO(1
M&^=-8D.Q>]40?_H^MC[I5T0=3$[ZE*K!_[9B\VJ%?_T"'AY  "BF3JN16AF.
MF)EAV?_""32_VY/?>P[6SD$?H'9HBP:WCY/_?AN?!MQ-SCK]CECQ7[.QS!(#
M5BO+.@$U2U6Z7&5\3_^<^4 @I=6G[3<GW,K6%&AE8AF9!NRM@]X-9N /\-9P
M=D/Y_( N'-)94;BNF^?IF%L426QD=CMT_5#16?'5%%:MF"1-SH29],!\&;Z(
MQM9KR.SVN*7J4'Y8CKLI.:OB(RLD57Q\;4V@ZQ[3;+V],[OR3)R97V-_?>B;
MTL1" @!,(EBGR.\7)3A;=TY^6'M!^C_:>_-PJMKV;WR)TDB2(=.N$*&DC!DV
ME2DB(67:B3*%9!Z7"!%VJ&0N0A(R$]GFF6TJ&;=Y9IMM]MYK_];NOK_/W?T<
MW^?Y/N]Q_-[C^/W>X_UC'8=EK>N\SNDZS\]Y[>NZ5C%C#';RK%'#]IXQO^Z)
MM0NN)0-:XXX-*FT,/@MQUF.#Y1UH[DL5]U.L[S?QV%AL< ;=D A('5SEG[!U
M(S'$0,SEU30":@$=PS7DSTN#"\FB,EN-$ZHD@;X]=ZJ[S=>:>,R(.DWR*Y).
MA$B"@5!/K;_W[,KEQ(G0P/3G@/?/%4_OVKBTI^^I]+*V20P%$"M+I[J4U:H#
M^UI5N;3<>G1!A$)A ^'%DV-R5EVL,NLTY=)<J^CH)(77385Y%FB)BY?#:V%:
MP2?6S1LUE]D_W3G(C3EFJH !JY88ZSR>Y3,N.J]5*=PE&O!M-?4W3H,<STD:
M94<#R"\0\>6OB6:#:./%A:70"8X[VW;KS KQ03;[XD28IQN?XAY_NNO#@ L1
MO5 'B[E(TGJI]6ZVMKGQW%;N6RY73K&^D13$\0PF&;LC<FWA[TP?JWHG)OBJ
ME*K$G4=Z)FSL!$LP:[ AOVE=)M6&%L68$7WYY!J9<"NRZZNW;II3@!".4?0(
MF+8Q4]*,Y2E-IP U?2_%RSH;.AG?^/8USX21$ASGXM8;XD1HIQL#.I>/-[R1
M'_2NPZ:/Q8']I;ZXYYC"/&X*0-LY.-Z;PL^KI'M&:]1!FK:8H0,40H[9(^30
MBY<F)X*(!NT)GG:-*,_UAW$BENV:GLLLB'B>4;FZYEDI!ILW=X.6""'3=Y(H
MP-.Y@/&A]&/@%X-VV(P%4XU]EJB:) 61LB@Q<O#:4;G:K4HE_-."Y#9?EFE;
M\3L"[;_D<J>RE\ZH_=9)=<N>LV0<,? '+>%5TUOYEE=NUI+OL'GS>,&R;*8A
M6=+[>8:/:"3@]ZW#O14D=U>,:O"HK3/S?AR2SCB0TN#]<[5'-E!T<4C*H0[\
MDQ!BI1#7_O+(48][W,%+QM&#O):(6)(U<LQ:>W*&>$1N&.>VE'Q>WJD@MU@8
M2Y>W?&CZC+9=K?B8^#6J 7N788 &UUBGH>ZZ;1*C,N(X5\>[V=3FJB&<S<[3
M1FG."Q[;'U AV_L$SJ6H\#7]W#MV<G=R<6)-8F;<JI0\[]0SS=53U^5$[)W(
M;9-.(R<&+Q'01 UFV(;4^B :(<PAY 05D$4SY"NUW#?KI;VO)U1@5L_<>(<0
M(>>^D9EP:V[DB<VANW$4V,D;W9 -5.-'N^+$I#SM3_P7,56J0Z2NGIEIOO55
MQ-0>-B%#I^R]Q9FU3.28^77[_5 3BI=+:J#RT43/P\M$&'0\OF]5/-..YBF'
MB;TXZ1$2W6G/U0UA:[=(JN34YW@"=RGAA;,9WVR71WD0VU*PO4+Y9>CXZBJ#
M$]]5XFFDR--I1!%7)M6.=>B:TL"X\Z 7@MO7K%[N!BO-NGGUK!N#-6@):XP7
MZJ3Z?)?OR6&F\\[N3Q'SJZX>,QBJ/!D9Z&7&2(R:EM&QI:\=74E9KSA+9Q(,
MV//KH^3JFN:E#H<ZECWE/=^C6NAVF'%L<^O#"COLK3_,8.9XZBV][#X:IGW_
MT"S.F)@3?'(B8+=WLXV 5/[6_;[\S>('T/IQZQZG$EK.MW!87:V:>]K;=\.4
M6^UC\\?RU.$, <$,_H<P1E(R^T_Q$>)%D4I7A8239_'*T'%!N<P@_?PJIYV^
M!#3/2'X6XV'K#Q=/T##QW'1Q>%?OAF!ZG5S-]EY)P-F;)GK[1T4RT71,Y[8P
M?5A=_*E[V:]O 2=W9ZPV\ NF'7O"!*XO2[GAYZ;=?^[V!!J=O6M4DAO9Q<B%
M>^4&IR74C8%D]QW5B$NDYRG:7+BZ,43-[OV\>WX>8)TG8^Z^LOY-4?G$>,V7
M7!?K2IL4'>?+FGC]Q6Y$D=1E6Q[9Y_=\'@7VL5L&!$XZ;>9\#\H@);_X!9(D
MD,DKJ$EG\\:8#%<YT712_G[T,IK!4[0OH!ZQDH0R1ZZ\F,-X1)-UB*VMC!\_
MTW[N4-%*FBHYH%YKEE9[9 ;MN./5S6WZ)%_T)]<!EE: <X_*3:D(:?Q.G$*V
M]@[;K^15H+M#W=.IJB05@;?K<QYA[^YR8VE&ERZ0T%,WX?C4& ,%+@E !(G6
M9M[FC$9[.TMKIGP^EXZNCBNK"5PS='%9DS<H@-P#N- [8EC3M8"HIP"QC"Q&
M'S P4?B_AWA0NVR%R<31[R\8N8?F.0*+7AGNB\C7/MV0]G+TF".6I<:#&<2>
M /$!AJ8\1QS&32Y:1TZ$RG[L'W[E]^Y"\YE7*X5Z1CHDU$X$^Z<.=1G?0R2T
M3HF/UK*UF7]/3<<JES0-01J[[?O:HM_VG<7<"'MC+A9&!C]<7GU%#;JP1NV.
M\#[^S(.2VO=899]C#S?(X=LN*./R/?LJVV'5@1 N9ZZ ".F)(O>2UYNH %CE
M_86&79 P*53A=)\$XHCJHVU#A:<7AUCWW[LM/1@V<]+S!QM)Q .<->V&^=4E
M[%H)]#A[V<J\+V6=5O3MT!@U>ZS-O6HL&BE%6HV!539O9J6;J7[=L<]T(3=S
M:CSK>X9^P[&>21B)%\"C&BU*/C2@35ZQ^NUOV["U,Q0@Z2(%P.V+:8J'W%LI
M@#?'[&X: X[J$8S9?=1MLK*BA#MK,)CY]H'Z'OKWFU+<:8>="5&8ZE^$T)]N
M+A%@@/,_-\;^V=C:.P0S$X;9KDZ=?R7K*PJC*A<B=(@4T0JQRF$V1*V1\)._
M_LR1^@>G<O]CNRQ#L,[(LD)M\QR]MH:,@KHA^YKB9C47VF:4]&?;K,NND2!<
MDUM:V_'>.%75\A)85E_<J[GRUM? Q2&> EQ\_Z+.25@6HPRI8I33K4K>/!:_
MS<IL9.Y])_#@Z#:76R8%R"^<D-7>.H22J3XB$%7^G)=>@.>U1BW'07<GY8AJ
M2X^WQY87W8<\E[B#BQX9M-]05H<CS=R]R?&$U[&J1+;K:][)BZU(8=>EI"M+
M6,T);FM<_V6W>"Y,_U:EQ3TZD/_).V=@(DR_1>B08#C;=;W(?;$/634==/:,
M?7ERJ5&<FU/C0;C1C0)AQ-"^O37K2=(3<=^4 5VHN<>[F0_"%N($3ZNL&9QG
M-$YPBK/N<D[=_WSNC>E-NVJYP"J%TD;#7^^V]%2L(K=\<N-2]VCSN]&$N31F
M'*].L19FOB9>?HKSZ%WEK_<B>WA9?$.!-#(ZG34\(M[RK1]3\BE?3:XPQT;Q
M(PB-?5?$!R\\8'^Y<VA]/<E])JY<&="Y?":J2\0N_2Y[9]0GNQY:^<=B6E2N
MIN.)"CWM9O[0]65>]@7T]3)EX"94UWU-172Q7%2D>#S94M.RCWU!"VKJD6N:
MA#H*<>PTG$W&'[DO.-:;I/A1=: ?J1)KP:I=27<H:$9NM9U>N3N6B2'6XC:R
M]/"A0'PCE_Z\X)Z8+978:76!+9>,V).G!IN,O\@_<>RPQOR,4W^N3(YY,!4T
MQ+PX%[8[P6U#/DZC:7W9*O8AAT]&W+N](+\;L$]:>B/]"+/ZG0&)[L5G]DH/
M6.<"(F+9LS9N[N5-M;9HT(I_J'F5"1KSU7)JY')2[-JHZK[0\VA=\/3525%L
M='22S'1.E^)QK9 /A1I,/2)A-NIZD@M^VL:'=3'YSG@Y+#G9=H8I@.HJ#9<G
M>D)A#>APG(DZ+7;D8FOKN=*,_AZZW5]NP.$0RY7<OQ4_#JB,7)\"9FD:V;->
MW=S+E&IMDR_8\Z@J&O]T#VEH!NXN(&5.,S+5^LT#WH[Z"^?9Y!(<ZTU3_,Y2
M (NYRD=1%,!RP"-J#S?I=2MM+W.$TS5#K<3]2JS)MNRJZVR/A"1+MH.Y$)YE
M_]E.H=\O2]NOL5V%LNW*]X_%NV\OG@O'A7L0"$7.6ON>'=A*H "K$C\)$]"U
M;".H%#$MW/#NQ_MBYR3D!>TBFKG LYPG>9.>J$DLW+NP,=_SY)4]?I='"\ET
MZ[4R>TL++G, _4)*^5 XW7%:_HKUIX0E. #4C]! 5:.)[W8:H^>V/?LX!H;?
M'S17-__)=C23DWU12&]]^XD/XW'0;B#I3IN6VI4+AQ4SZ0*2M&5.<#FUNY*O
MHTE$.*XGH$S@Z@2)A-.%A:_(</!^9RX9Z8,/901Z.*W!,=L1;]SJ26+&$>+T
MZ"XB)G2LYU;AM><G<NZFWC4?41P.1KAS#S'-[?;F+=S.G J^U)3'OF4!J!M[
MU\UTFEMCE=J1'[LH0#*8O/-BX3MF9@:N#!_B6/ WQ1P87Q_:#HD-4L"('L<1
MC R4:"F V9'/C[-G$I@77?O8R+F//A%-'\I.WGMZ)6M9L=3A[8H8C$T#^8L+
M'%A>%U5$7O)@=PP(7S[11)^4?$'."8YXXN ,;KSV5S>CF*8ES-BCX:5S9'_)
M@,)DZ5&$=OF/&(BU"!\[!2=5!>\V2\N$_L8>.T?<RDNCL3SFW%B!^#.<?)(W
M$YR:^!F<L!)Z\Y(S-\OCVV./N8?2ARL^X OH<2O)/D2K"OE (CR72T@D$M,P
MXPLIS0,F=$?WJ3,GT><.OZ\4,7E?.RNK)666SHM&E7>7-KN46_]07!!4.4+,
MBS 241J.#,#*'7WBGJ%0\F K*U-36VC8.XIVS2YLAC>SN9F^1$EC7H\J!HP,
MP+_,HB!LFI2$$)@:KLONZ5O>^$@!QAS@I*]XAP*LG*0Z56-EGLV*9MA:8;[*
MI^Y77"^U%&X..0[YZH>4>J([/DD?9'3WM=! F-@AFS8P!*,>L),52=J/I)[+
M60+70.]$0,)1D!"W?J.VU]?9GB=U/0L&MQ1 =%I[*TA@!\/;_<\=BH,U(_&0
M7QX%&%6B ..V[5*,.CM=93ZJ,ZI;OIP[X 48R8)2DYXHTKDYS.PA!$2'@,Z@
M?^_9(WUL'GGY5S-R<C"$:D,6BB';=WAB8,3BZ;"[A[H=F1ZNUV OW\!M[*7N
M_V2D ,RFUM1.5*8V$8F(?H+#%*F6>)69A(N< _\FR1O<>&]46UYEY,%]TB/;
MUP1W$X,J,$]VT1WIQ251RP[G3QYHN!M2D[+]4#[XFV8^22*YW"%>2";HS'PW
MIIEGD (<\,$FLU]^I*!.ZW4HNI3+Z6D!G2^OPO>CJZ]G(ZX,Z.U10HL<RE?:
M;%XCD,*?O+G8/[=K+%:<>C@R1T^S.Z?;\R6#EV6:5M]M"(R<J9\Q5S!=+6?O
M<.S+0%X?W<T^1 &J9:$24]P*0TB%K2O=G>[W?!3@,P700(HB:]><&G/.,D:<
MOQ:%7OQ8\04N2WN?-!:/%:"KDAO*S,&'7>(IR[0<+S^/*Q4R=S+'F9L,.H0K
M=+'.*8KEK,;0/T6C:N)J;D*QHFRH7=6;(W+E1S,YKITQ3L@=Z.B4=9K:))W5
M1J>S :!%1F2$T1)2TG&N@-MGUU>_B;/<?/K^..\4^+D6'9W@-(?EZA7UL,G[
M$.ZT/WR-*2S@2$2I_/P;1D;R1=-+3&3>7'@H!CJ?NC\@;FJO\ITMV)I[S=5Q
MYZ;OZ38>44)T>C=]G._WEH3UPD<SJ_6.6+G3EL]:_/7H"KV"I@"+21<N?=?R
MXC5O7*'RE/T@QGTPJ12K^5V$%;%K46'/NZMJ!_O :<?I&14MY/=Q/-X)-SF!
MSA:K/*/%>^6KR$,MMP //_D+KDX[!\?CK,(RV=XFF?OI7%J_(']!=CHK_NT)
M[A]6+6>DOI@%8C63OFO0!L':X Z!(D>20SH$',EA<@G<V5NY;Q,<(PMHDYUT
M$*&Z^YW(04GV^/(M; Q/67_?("+\L;;C?J;HBS0"0[+!V [IS>E4:W,<GU>?
M][T8XS4_EZ8EM&>:7RVH&8.N!]4V$ 3#,'Y%9^WAEU(E V7TE?LZ0#&"GOEX
M13G"]=G[!DD:C^K-YO[&!5/WOJ//GU7:>%@L,9;:"?0H%(8MS.QW(G9?Y(5.
MBR4E>CKIDY,#H;>80C%4M_R1RG/2=U;?[]'>Q6Y4)FSMR$S,J<.*>;P3Q;C(
M^X5V*KEH3?M1>(*OY6JNQ*6ZKD+_:V*9-&]Y:.1IQ.%RMZ$\: X0E*W4VB=O
M\P;U#-;!!2JK\.A_XJ$83N<1*X,J]B[=75P@Z 6,-U]Z2@[R3G@"%^@%Z!NE
M"WB(95I#B)L"2)-QN)EEIP@?F0R/51%;7K6GB%-WDCBY'WMU_>*4 OQB]:RO
M<,O]^\[\QRSL]JS[RU*K^0PXRG[WZ3*_RJG&8T9$"6.E80'Z6*:)O=>[6/?H
MT^6#1ZF>,*=8&MRR[MV[MFV'*[7#IOM0*V$P'3' GCO'\U)!2$TSMK.!?A>S
M@?F&!:,C% HSQA-&;K%T=C9'EW*VT5 G-)H,$D.8V]2V&2\J'CSO<<_SGEN[
MT- 5G:'K@>8-6X<O? OR.?L;33B0'%(*6T3F@4X!197?UYDC+DK><\+?0##/
M7(@F/_^[&WC@!T[IJUQ\=U=A3.3"<.GF=!JS"E\44LRMX8 +5I#>..)GZCP[
M:BYX*TAX5_4=.B3JA#GB9VWK28_PK9P_YVV.OU@]_R3*4EFQEA,H'UWOT.J0
MWNT#SF?77=&5\[TK>W694WT#FWV=']UQ%(^2#GN^OLX4MK'0$X>Z64,!-$$4
M;#0\8UWL5F,XBQ1BTV]X168)#A'=R; 8'+HB 41N;VJ,^-[*T\\I3<).&!\<
M-BJ\(9C$R_'R1&W8'D^+K<R];4!#NM6ZX#ZQ4N\=Z8F^Y.LH'=AU?Y%>!L?N
M#^V<#.<0E7(3WJHM^24WRTE"\-E$I6ZVWR;=<"3A0*.W!UX>2&TS;I)B_!4A
MLF67WK0>:X)]^N?+'&.SYPL!(S&]CW$]B+Y59+>L"R'0^?Z3 ?$KFN&?1 _0
MN<$#8-)&>75C6HVF^^:IQCB<#5^&W!*G@KW,DO'-)":9@'9M&15-KZ#17P-!
ML:+X0NQM9^<A9D&W!VAE]GEML]YN=RZIC8:\G\ES//49\Y)QV5$F_9K\@6LT
M7$=5;RI-,@UQ%!GCGA7*?A.2#5E.!X:.U@SOV^.X_7:"'PML 31X$W[WU\?-
MSZ0LHY\DI/U]5H/%= O"WB@A*B_U2G9.GM\Q%FQ>BKYBT$7K^CTBP3A*+CA$
M%10[!)X6.O<53=HJH@#4;:OU^@B"1H4,!5 :EH73$QMU=?JS\MKD#>X>S,HI
ML"&W'UM C.7IYNX;>3'H@MA9HNY.BJ<>@F*?2@'DLT%\#[BJKPH=PS. G6Y:
M%* J\->)N^=79LCTSGC2?M1J*I7$6R\U-Y2GJ%TO.%.42]YU@(3"_Q>X0%LJ
M8)?-EDX-^\Q^*]&!2](?F.TY#.&3Y#QR?: /(DM1 !8]\&^=_A-'\@E$9%EP
M8;#+=LK6L"KD90B7JG"N'?\X" ,1K"V*N($CZ>O\4Z__Q-.6TR(T_;]=%7H_
M^FYO%S<[VHH[*9UL4>?<=YNG3J^(DU7O=TXY?^\_R_GFWC,1.Z^R6JWT-O>Q
M5E. QD_(?"P%N$D!B"L@X=,$='X)%NU)E6S^J4K%MF^* _VY8AP/D^6>#>",
MY1B=OUSKJ&;W9Q.P7NCMLSLL6A@L)1$A1,BU5# U2B)OW:4 \PBX*QBZL*CV
M6U* CR#UDR_Z[IRS7SZL-IP_;V+I$B%YY<3-5T?>R#?*YU4IO!I[?Z7R:M'W
MVGJ1ES77CQXLSQEG\)'F[>7HFT?B2,C16!\O8C*:1#M2V8HD7Z4 ^&JJ)8@B
M%&"3\8\OI(3F)K4'?O%KG38U7YR>Y*ZU[QQTG2&.0!7W,Z+5B@Y7"WQM*C<R
M*VO0<IV<X"(OOX)2R12@%MI?^8V,;81H\)@'R=!["K ]"N,\/9\WX&XP;&_J
M!WH, M ,GUH6^(?2-.NNZ#VM//?Y:I3["6%TU:Z^4YI1%*MP5@A="%]D"V:^
M2NL]VJGZ!)?S9MHF @\A5E0W\<N^R!7&=PK_FFOZZ%J/\CC!\P\LU$)41!CF
MI"X&8FD3,^0;K[=K,)$_%F/Y(-3KZ6,,[!#>EWXM_8L4$0PF,<FY5#9.4 !@
M5WBQ@ +T(B$2 A)"_V[!%>;4JF/[I-AHL6\D]$5HA;[H-BVKX.V_"Q$\V!SC
MUC1/:,<43C@;G7B]/BCKN-.]B]ZF (P$WMWM;22"0%]!_DT#.G\S* H)5Y,U
MSEO?C$(&I"<\^,,N# $^60%#7#R.?3Q%%ZUNMKMW-3H^^=)XJ9&WC,[O4X9\
M,+]?ZA]F#.[#E!%@-Y=?^%=L[RPW7E]/<\])>R.EWB9@.\&I$UN&7'ZZTY/Z
M)3_JN"/_6'.\K,5M.I7WI=(S,AF;C%0U*V]2@#_T_&^\(['H$$OA4XN(NQ'&
M9QD>*UH8 !%U%@&$VZ[3$!'$J<2U#OZAV&K1/+)/8P_J7[I#6WD\$1X;/AQ2
M4MN#T*XX!2A(7J< *'?02G02JIR8R_U=GM\MGS5MTD[>H@"5X48]YSAO8B+V
MO;F&WOO!1>X3392'-,QLMX>7X2]2(M5(*A=P#?D[&UE[NRW-?^:H,)SB11(V
MW0^Y>^HXG&5NZF,Z(%4G'V_#-'\ ,O^1B RNDV)D__HJ1:@%'PE]ME!385SY
M0GJ>N1L*@;70 90IV/S+!,36B@:Y01%/#P%J0'JPO#1BE^3CG4H5$;N04GNN
MJT3C1<+G/:ZR 99^UR?"Q#J F3//-\AGIFWWVSDLFTRCMW>DUX8BGS9MR[G!
M#K^7A/.#*BE S*J"WQI>#"W9RI.D3C7#&OXB8[QE9,^V )KD6?G$O_V:P3GG
M];.AHA?$GYP],?M)52YZD/>;IOB[[;GC3C>VG ZVU+\]L/\LAL:I>8)[C@)8
MYDZ3]I+?_:(<O(:7(2\ERX-//."0!9/>3]N>7S5'C/[%=<'<T5J[&8_MJ\Y(
M*V,_UQP]%H7L=2_7S<_#5QCSYME8Y_C2S)]\,AZ-Q%]I[1E ^<E5YQ80DJ\_
M^M:L8)>D#0K".M:G'^"<09588\JG&G#E@\GQH3L93J /!I]J@@HL$D](O#S^
M0X8]<U#P^3&#'$2$:EG*7:?KL.0B]<@"0M(/^Y]"30X;51F!]RNX/+E[\9=U
M>)6WVF7=IZ+-L+F\+AX^]6EYBD$#>UY$94WET'?>+\CP1UQHGFRL6$'=:R;9
M(C-!KQ5Q> B"S'U0;P/RTM+NPRK'<@=@U])%=NG83BC&KJ>DZ6*J=2LMG%^F
M*\[;VCX.E'M>;"GKG1>V.UZ0$72R^IEZF;MNH86/_%D?C3:%<C*N;O>P<9E*
M_5:<OL)V:PW9UT;7Z>3/:0IP@Q-:L%L81,=56L>Q^]T[';:/6"4XL[!P=UV9
M%5CK.;2MTM78C<[<"3<7[=Q-QKZ\U+@U+"L<U?IE%:WS-7I)^XN:P\9P695=
MA66/;-9D&9-<S:"!DXOT)-GF3DK8.]0YR1GI ;$XE.ZZ\(*IZH\]'MY8$=.Y
M$?/#2S^?>&T,WV 3Z7K#-F"M+"W@0(M<$=IQ%>QQ]WE1X?SH"9*CZ/C10*'3
M:.MYR3".M*>8 =+AD<LXRU6%6*F+]E<<"I>Z?7 Q;Y8:V]L15F"B[V Z*:%T
M<-O+:=T1)5-_6-5,3/4U$2.XXYOTVE7P5"OBC!QF1):^?7,SZRZXC=EC:@;K
M9'O"N9KU*I@>*"?,,CK1N9SAL;83SC8HOD1HOA&L\$W*($C5SE[OE/_IU)=I
M^^C'#%+\$9?:ULQ'5 XMGMA8T,L?).=6Q<2";JORZ6)NXC:K6(M9WP61:^C:
MZ0P/@QV!ML+F!>(;ZI#O\!;[C$T9&;P[V'BBH"R!=_!I0-D7*8'2!K59%>U]
MW[1*LSJ=+5LZ!E@F#+F:TB9QYCP/TN7EJ$TSO;-(,VV%V-PH.'L;I^1)GO60
M^MD8:QDPV P# +00$3UBZ-BS?:X1DC>P>G?05'\;65$XD[MLE$SR1)\A @X%
M54N3)7# IC[UU8>61AZD^WC_HDQG4/OA34 "!<B$*>5T*;+\CHI4?@<[GX:/
MTYCR5QQCO*QV0O[81<;Y&W=20@%!^!(.([P,.1_]H?%T5JK-C_F6VI/^6DHY
M':7XYYBU(W#@6A2S([7;!4-"4/G;/H@3*N=$K8020,@OS@VB%2# P&E_+G6A
MQ($,</0B&&C;I;,D,$R>(DJ[HAPC_^DAXO>6M[]Y#"I-:&25==C;W5K>DLUR
M9=['.AM6V^HR<;"%EU_EB<:Z:F&RVW9P0?"#;6X'TNE*.'.].Y-( ?R:H>-@
MC3!U:<<>:QSA</*8L5T"CT2%I)TC]U3".=J!H;-E>R<\-$K> L21NVM^CR)H
M5YQTZY).)^OT;!ZYC=,)%[@;YZ7&W6_&VZJGD]>[YTJYQ:1W8ZC\!R*F0CY!
M5K1TG@*,L5 7F="(XTG[M*D[\%'4Y1_,5&QG00$.3F[@#[L'ZT'M9=]=LF^U
M+&B57U+G:"X[;RY4SN:_[TIX=G6K@WQU-O<Q>0LC&UL7.^<M4=G\ ^F1 FND
MHAWSO;$%I3P:3Z/4JE('M,N)M?VU^<1P#$'9&T[)BC=@S$D33:(N5C&@+E:A
M@R'I"63-E\(L$R.M[X7LRPC=6-,?3AZQ'&KF;O=:/D1'&4S?U'*G_5%^_2\!
MFOZI=6K92J5?<?Z7+O&5*\?V%VMKI]GU&J!6YZ3(3@Y35S)EEZ$5YS&[F"$G
MY!%P,GD.M8R!PFSF%UX18*3)1P&N4P 7F)BY@8$^BI"_:=$)'?<YJJ/,$IG9
MYCY3>XN0JN;?(5R:'2=3ES9U2VE'K7'!F(/$U\O&Z4)4*EQF5QG=W5PP0=07
MJLLA,_@"7W.0:8^;U!W)3F"8KOAJPL%N*I?=\WGMV?.&:O^<X\OF$<2O]^X=
MW'P<FI%OG)_?EX859A/R_;ZN@M?*N(\YZ')-Y=HJ]]>L\S]N<NV1O[PQ"3GC
M"'H#+^?&.4W?5RZX<-'V?<S1M&(:77R]S-DFR,I:121Z\#D^;1Y_Z_Q"53HP
MIT4M7YWK\[[O^QV#)C(;2_3'O\K84 #D:(2O#:J94/"% @1J9WKPJ)+X)$>T
MG*:6[,HV&QRU4(&&^5F?"%%#]#+W:$F-O:2A/K[=(_&F;T]]:QA\%E@K+<WW
MI>KDO>+C7*X=@AQ',EX?#K)6NQ#+1Q-,;R-Y8,"5O/Q6[G"7#0;&%%'!$J*3
M)*U<B$4A@P)<92G1]/DQA\64D=H/K23KJFD*CPL_"(FXOO?>!_(EXP0%A+^M
M>\;=J8%;ETZOOGHH0#MT5%KA7;=H<)=O"[^'1COKP;.TS(^O6"962/F.1@@6
MH69(1YUN0=KUB=8$[<P+ "&H-]!N0FA(*M>T<F-B)?>V*&?RL2I39"E.P6!N
MW='40HDNX*52=4I6_VT(K&9>@AU/8!Q[ W%P\QX7X[$JVN)I!++-1[N]^8-V
MX.4/CSXG\9;<*JVF:1!+<-M&)GHD'O<2PF$))[=>@=&KEFDE-3XW6ME6CQ2P
MLC_*X@J;H4\VM>8<.Y\RVS1RLNB!TYN]=X(4,I(\#ZX;"FZY8))7E/[JKT@Q
M2G#U2#K?O397274@;$;A&;HA'E%C=YU5E^VYW<U,_NM9ARUS9'+%4] /C'8H
M !U/-WK-5V2C!!93@SV<I/2PA1TCEL<?<5$=*_"4>KK]NV]PQ)B*(1.1$Z:.
MRCP=)>O0?ODTQ"3I[BP%6/DH"L[*//BU^91Z4)__-A3P!D7=?AKN47^<G.@P
M0Z(=T('UF(3^^U-!>*#2TN3T^]4>IK-KVI#KB^]2+<@F40!_1FO5'22KYSV"
M[J=]A^54[=F/O//;H>W)U=I[P9NOET62\:CAWFKV_3^KYR]OUWL4'?]&[>2H
MUW4D['8]1F.FG^<_C?#[/6OH=".5SJ'CPW3OPZ+5M'6YAPY(FOGKW#F&I#6U
M5N9I^4N..5HX3MU*-2TXJ,;WZ!&7,_X6LB;QMOHM@U7N<K5DEY\RPALRXQ4=
MH?*_]Z1=\^V./V/(R5/)'F,[#JAO?2.QHC4F*AZ'H]W]?ZC*W_T>@@R1F"[4
M6<P"D:,!_ZT.'EE!#"\TBLM*7AAU&^K?ZAC36@SX#OD"6XT2DRR]!%W=UO"+
M1GJ1=[6:6<5><ZLYZ'_,O%Z.0HP:"W5ICY*TUAP8+AFJ"JXRO#QT25A&]\M&
M%2HY-W?L1G3UIVT\L+HOB<WZ+ ]VQ&<H+)PLNS%W9WW0:&EPR]TUX&7EG0;?
MUXER8@ZX*54,<5 %O%S;KP^!58,#W9!VW: #[><W:%$2W\#MJ<>'Z'8 WO<[
MN[VWO&5"EL_U0<?"Y?A"/Z!%[!]1 *>9N:37+5@'8.\U,3L!OD?LG^?&7IS<
MT9GRG1N0WKVUY0(FKR"*TDC)(3\1@:M-,9P5!AD.Z/2?I::/W7S727'^J&<K
M[&8@06-C%"'[MDXR 3%&GGH<7<O63OPPD]LBL_O#N;,^S$/]::<=URWG>6I\
MN96IL8-D[N8<_5[V->[2./&"GIC>FLHJ&L]X*2/[-.G44[MK 0T<CK);;]:"
M.A*1/UQRA=Z(KTL],D[*X(KSODFE%C;#J7+6ZW(REL"&U=X!F7_TC(GL689+
MCC&1?,'Y_2@^AT<1.*0F]"K/6S3,J 5V\C?6:2\CKJ&$9HBX"E)6ZT2H?'5%
M8=.L:UAHR7&Q>V@A.9Y4J^E"O4]4!LV%"C'1J_+BWI(A"AW@F%!/<9/"?7/B
MT.@B/-J:,WO&QD5*#E"  Y*);ZN%*E'" 200J>DR9^IX7.QH:@LZ(EEP8LX@
M)4@D>NJ,4>: S.[W3_K4'[,>+E!/%@%#1L :AF,_9 SJ!FYKL%A:[#!JTJQO
M;I*$Q@EG;Q-J*D_UM+QN2<>.(&)X";MN<]VETMFC0FS-+^R=P@-.9*U>95V!
M]+PHP+="R_4L/3@M8;%5P8;!)"))6W>E)/A<X4_6-?4E?,[/XM:WT0=#'TOF
M"O1$)Z_DO*G(K>7XUA ..EC;<MG9N4D;E-!:B_SDC/YR\G!DIY^G2ZY>KBB+
MUN./.\,XI^\UO<_F<I0MONX]KF,\HZBC?!SX[RX#[E4V2.DKDAQT#A.;TU"*
M>UYW/B:UX"CP?2F$;Y3AAMU50M;N\@,4P6%WT55/'[4DCX3 ; Q^#1XYB %/
M$(X51B!NB@)PM+[>$I\V:?VW[\B@[DV;=,A"S%G/BP[M_Q!RI**/^5"&&')7
M_.'M4*XOH\=:FQ\]9A"R0]9Q+$T%!<IRNB]+G#!PJ7@3Z,3:N3Q_+>,@V\EC
M,OSN)W)"#XAK/(B]']=\V_*BFES]SMN$*(]-/DCB J9GWY#)P)%4FW'E44\&
MGT"NW"].YV?81Z1[Z71(N[9J44,'Y"KRVZ<Z\O;W3#<]R4U8'PSC< LF66?:
MQ/Q8'4HK5?VJ]CS$0W"UI6JEO<FJ?/2EEIYC4C9?Y\1!7A^9*Y6; S?-OEIX
M$7N4.I]U:>;?^1PIJQ9HH1-D5EA"GTD7UM5"I+^X;-.E#Q9N4( =B+JMH142
M!ZWALG&=;$<!P!B2U91/0*S;.;U_H!:=OSVV$4[4JAIHV[M9?%V*5(32SI9@
M\WDVF5T6O-('J4.OH048A3;DY)1I!V'6M#=RMU$40$7"Q05&-2]$;RLSCJEV
MP2:_RY& "Y>[)!7J7.ZEYL#Z?3SAQO3%-[/[)^@\^YCA !BMVYI,4&>[Z+,^
MA6G?W"G+QKS044<&;Q#,L+'\NZ?]')MOLTR5#%PR5">6G;=4B1,/.S7U_>EN
MV)1:KNXACHBXJ=<ELQ[NF;KZ"'&'$MUB[6>&899GQP5[-UOJ8*SV,,WA65Q\
MEK![.+O,4%7#I-@F4NI,:4SWJ8=.>Q?CC[9\D"6U-;.;E_1:\BHD]&:E#$J^
MYR_[EL@;XE\1'V ^Y13=@W!VW,R),,1@"5RD7G@H7\83=+>K)FU7)A/[UXQR
M<T<6M+2?>;ZR^XID.BWUJ:%J%_3J+NUZ]]QNV]2X)9K/?JT!877KQ)ZPA$W&
MY):4TAZ[[.SL!U'SDSOS[P)EB\7T[1U[:-#<6GNYBN#HR$!%2XDE)*$CBL?
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M@Q9%7#^'6 DB"$!^U)_<'F2"8\P_P%G'7@Q^@#KSE50 U^\1:?"C[C\IG*,
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M*MJ2/+/]92MY&/6$^>_LJVYI!R-G6>@A6C1T_DVH?/)V\DCM .CBTZ2]F,P
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M];?-(U+AAP>-Z+QZKL723;S;3 D%;A&N_%R*>SSY3VX.4OK_'U!+ P04
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M(HY44@5DQ*6L%P794XQ&TL6JA!T%\M+Z13E&E%0R*(N9A@T1^&\0Q2^QBL
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M[!)DD5^\SK0[N6+B!57%=]U'[A3X.]UH1-("">]"0)\28Y=Y*/5XB9BXN9&
M)U-F%M-D)&T,VUR@^0^<E$U4]'9U4*$]8Q2B-LU)?3+5"^5X]"7PR\N5N,H8
M/=\?&R;OCI6>O\_<S'81$*D<<5K/24KP262CX;PBUK-ZP3].D=6F&]9?LMH7
M1D'08Q@U<^BJ5&A* @X(>+N*SACWT=,EQ7UTO=]7N=XFAU"6D)U5=PK$+<N:
M;,!Q<.C,P2ZCLN#Z]UZY-%%7NG@;$]8>J_K#05(E=3*I#Z3TK0HP%R$AH<]I
MRDZ;\%P=P5<]C@D5TK5%%VSG3\+RF[/P<ZN2&\(,K>]>:5,.*K<TL=USQQ>>
M N KBJR"TV$(^+WMI<>0X$_$IA"2WK>? +.VQI(*O%M?#DW:KG=&O,K15Z57
M;"4:KM-P1NKP[7Q,RT2.7)^:-@B1:U!)D+!Y82&8)2D+;K'\48[[YW+"V493
MNH2U)4'YL1_3Y/;Y8G<]*#1#;3V8"3AD7K/.1(&I!O1A2XW37;SV67P:2T%M
MW\=UB=O]"K!6!^JL5:M@8@XY2C\9M7R C_2-HLK!=4%E:;*'=S"<8=:!TA4S
MV6X=K@S2+Y$N12#+DQC+]\VT=<T/D)@>BKCCZ=7Y'?G[WG&!9$09>QN-XB5F
MJVD"EQ]^IPMEN*T^9Y]$.>A*$\CQ,$A4FL;2.QOBXO'./BVU=DA@)G[3T,GC
M4:&TA@R)UQ?+0(!U/-5WI[E .5;&1H<.T$7 AG/N%U112;6#A,E.#\6XJYJ
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MPCUM:[\SY)95<^IXT>F5TY)P:F?08I/M%+0I1V_TAQ5,.=!,6YJ7I=!L\'7
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M+923LYGTM1O>,CWRUW7/68B P,^",(&X@%*[>2D63P[6TJQ$ N2O^\H$EJ>
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M10V2*OT^__X_-M+3B?\"4$L! A0#%     @ 88E'5C7AFG3="0  WUD  !$
M             ( !     &%V>&PM,C R,C$R,S$N>'-D4$L! A0#%     @
M88E'5BO"CB_F"0  W&\  !4              ( !# H  &%V>&PM,C R,C$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( &&)1U;5>:]7/!(  &$D 0 5
M      "  244  !A=GAL+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !A
MB4=6&(/(4 0T  #\Z ( %0              @ &4)@  879X;"TR,#(R,3(S
M,5]L86(N>&UL4$L! A0#%     @ 88E'5KLGGJ6/(@  /S\" !4
M     ( !RUH  &%V>&PM,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( &&)
M1U:_ZU48K?<  /ZT!P .              "  8U]  !E-#,X-5\Q,"UQ+FAT
M;5!+ 0(4 Q0    ( &&)1U;EG7ZUPJH   .J!  0              "  69U
M 0!E-#,X-5]E>#$P+3$N:'1M4$L! A0#%     @ 88E'5KX4B1(_!P  R1\
M !               ( !5B " &4T,S@U7V5X,S$M,2YH=&U02P$"% ,4
M" !AB4=63")I;RT'   #'P  $               @ '#)P( 930S.#5?97@S
M,2TR+FAT;5!+ 0(4 Q0    ( &&)1U;B_='-[P4  &(7   0
M  "  1XO @!E-#,X-5]E>#,R+3$N:'1M4$L! A0#%     @ 88E'5H"?U>5T
M.P  Y$ !  \              ( !.S4" &4T,S@U7V5X-"TQ+FAT;5!+ 0(4
M Q0    ( &*)1U;=OX_1RH4  *^F   -              "  =QP @!I;6%G
M95\P,#$N:G!G4$L! A0#%     @ 8HE'5G%P!8"/7   SVX   T
M     ( !T?8" &EM86=E7S P,BYJ<&=02P4&      T #0 R P  BU,#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
